WO2006087543A1 - Antibacterial piperidine derivatives - Google Patents

Antibacterial piperidine derivatives Download PDF

Info

Publication number
WO2006087543A1
WO2006087543A1 PCT/GB2006/000529 GB2006000529W WO2006087543A1 WO 2006087543 A1 WO2006087543 A1 WO 2006087543A1 GB 2006000529 W GB2006000529 W GB 2006000529W WO 2006087543 A1 WO2006087543 A1 WO 2006087543A1
Authority
WO
WIPO (PCT)
Prior art keywords
methyl
amino
alkyl
compound
formula
Prior art date
Application number
PCT/GB2006/000529
Other languages
French (fr)
Other versions
WO2006087543A8 (en
Inventor
Greg Basarab
Brian Dangel
Paul Robert Fleming
Michael Barry Gravestock
Oluyinka Green
Sheila Irene Hauck
Pamela Hill
Kenneth Gregory Hull
George Mullen
Brian Sherer
Fei Zhou
Haihong Ni
Original Assignee
Astrazeneca Ab
Astrazeneca Uk Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36218455&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2006087543(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to KR1020137019849A priority Critical patent/KR101422432B1/en
Priority to MX2007010072A priority patent/MX2007010072A/en
Priority to AU2006215399A priority patent/AU2006215399B2/en
Priority to CA2598423A priority patent/CA2598423C/en
Priority to NZ561613A priority patent/NZ561613A/en
Priority to US11/816,612 priority patent/US8399489B2/en
Priority to EP06709766.7A priority patent/EP1853586B1/en
Application filed by Astrazeneca Ab, Astrazeneca Uk Limited filed Critical Astrazeneca Ab
Priority to CN2006800130583A priority patent/CN101163693B/en
Priority to BRPI0607756-0A priority patent/BRPI0607756A2/en
Priority to ES06709766T priority patent/ES2430569T3/en
Priority to JP2007514146A priority patent/JP4058106B2/en
Publication of WO2006087543A1 publication Critical patent/WO2006087543A1/en
Priority to IL185306A priority patent/IL185306A/en
Priority to NO20074703A priority patent/NO20074703L/en
Publication of WO2006087543A8 publication Critical patent/WO2006087543A8/en
Priority to HK08102716.1A priority patent/HK1114376A1/en
Priority to US13/759,323 priority patent/US20130150366A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Definitions

  • the present invention relates to compounds which demonstrate antibacterial activity, processes for their preparation, pharmaceutical compositions containing them as the active ingredient, to their use as medicaments and to their use in the manufacture of medicaments for use in the treatment of bacterial infections in warm-blooded animals such as humans.
  • this invention relates to compounds useful for the treatment of bacterial infections in warm-blooded animals such as humans, more particularly to the use of these compounds in the manufacture of medicaments for use in the treatment of bacterial infections in warm-blooded animals such as humans.
  • bacterial pathogens may be classified as either Gram-positive or Gram-negative pathogens.
  • Antibiotic compounds with effective activity against both Gram-positive and Gram-negative pathogens are generally regarded as having a broad spectrum of activity.
  • the compounds of the present invention are regarded as effective against both Gram-positive and certain Gram-negative pathogens.
  • Gram-positive pathogens for example Staphylococci, Enterococci, Streptococci and mycobacteria
  • Staphylococci Enterococci
  • Streptococci mycobacteria
  • MRSA methicillin resistant staphylococcus aureus
  • MRCNS methicillin resistant coagulase negative staphylococci
  • penicillin resistant Streptococcus pneumoniae and multiple resistant Enterococcus faecium.
  • Gram-positive pathogens is vancomycin.
  • Vancomycin is a glycopeptide and is associated with various toxicities, including nephrotoxicity.
  • antibacterial resistance to vancomycin and other glycopeptides is also appearing. This resistance is increasing at a steady rate rendering these agents less and less effective in the treatment of Gram-positive pathogens.
  • agents such as ⁇ -lactams, quinolones and macrolides used for the treatment of upper respiratory tract infections, also caused by certain Gram negative strains including H. influenzae and M.catarrhalis. Consequently, in order to overcome the threat of widespread multi-drug resistant organisms, there is an on-going need to develop new antibiotics, particularly those with either a novel mechanism of action and/or containing new pharmacophoric groups.
  • DNA gyrase is a member of the type II family of topoisomerases that control the topological state of DNA in cells (Champoux, J. J.; 2001. Ann. Rev. Biochem. 70: 369-413). Type II topoisomerases use the free energy from adenosine triphosphate (ATP) hydrolysis to alter the topology of DNA by introducing transient double-stranded breaks in the DNA, catalyzing strand passage through the break and resealing the DNA.
  • ATP adenosine triphosphate
  • DNA gyrase is an essential and conserved enzyme in bacteria and is unique among topoisomerases in its ability to introduce negative supercoils into DNA.
  • the enzyme consists of two subunits, encoded by gyrA and gyrB, forming an A 2 B 2 tetrameric complex.
  • the A subunit of gyrase (GyrA) is involved in DNA breakage and resealing and contains a conserved tyrosine residue that forms the transient covalent link to DNA during strand passage.
  • the B subunit (GyrB) catalyzes the hydrolysis of ATP and interacts with the A subunit to translate the free energy from hydrolysis to the conformational change in the enzyme that enables strand-passage and DNA resealing.
  • topoisomerase IV Another conserved and essential type II topoisomerase in bacteria, called topoisomerase IV, is primarily responsible for separating the linked closed circular bacterial chromosomes produced in replication. This enzyme is closely related to DNA gyrase and has a similar tetrameric structure formed from subunits homologous to Gyr A and to Gyr B. The overall sequence identity between gyrase and topoisomerase IV in different bacterial species is high. Therefore, compounds that target bacterial type II topoisomerases have the potential to inhibit two targets in cells, DNA gyrase and topoisomerase IV; as is the case for existing quinolone antibacterials (Maxwell, A. 1997, Trends Microbiol. 5: 102-109).
  • DNA gyrase is a well- validated target of antibacterials, including the quinolones and the coumarins.
  • the quinolones e.g. ciprofloxacin
  • ciprofloxacin are broad-spectrum antibacterials that inhibit the DNA breakage and reunion activity of the enzyme and trap the GyrA subunit covalently complexed with DNA (Drlica, K., and X. Zhao, 1997, Microbiol. Molec. Biol. Rev. 61: 377-392).
  • Members of this class of antibacterials also inhibit topoisomerase IV and as a result, the primary target of these compounds varies among species.
  • quinolones are successful antibacterials, resistance generated primarily by mutations in the target (DNA gyrase and topoisomerase IV) is becoming an increasing problem in several organisms, including S. aureus and Streptococcus pneumoniae (Hooper, D. C, 2002, The Lancet Infectious Diseases 2: 530-538).
  • quinolones as a chemical class, suffer from toxic side effects, including arthropathy that prevents their use in children (Lipsky, B. A. and Baker, C. A., 1999, Clin. Infect. Dis. 28: 352-364).
  • cardiotoxicity as predicted by prolongation of the QT 0 interval, has been cited as a toxicity concern for quinolones.
  • cyclothialidines Another natural product class of compounds that targets the GyrB subunit is the cyclothialidines, which are isolated from Streptomyces filipensis (Watanabe, J. et al 1994, J. Antibiot. 47: 32-36). Despite potent activity against DNA gyrase, cyclothialidine is a poor antibacterial agent showing activity only against some eubacterial species (Nakada, N, 1993, Antimicrob. Agents Chemother. 37: 2656-2661).
  • Synthetic inhibitors that target the B subunit of DNA gyrase and topoisomeraseIV are known in the art.
  • coumarin-containing compounds are described in patent application number WO 99/35155
  • 5,6-bicyclic heteroaromatic compounds are described in patent application WO 02/060879
  • pyrazole compounds are described in patent application WO 01/52845 (US patent US6,608,087).
  • R 1 is selected from hydrogen, nitro, hydroxy, halo, cyano, C 1-4 alkyl, C 1-4 alkoxy, C 2 -4alkenyl, C 2-4 alkynyl, d ⁇ alkanoyl, Ci -4 alkylS(O) a wherein a is 0 to 2 and C3 -6 cycloalkyl; wherein R 1 may be optionally substituted on carbon by one or more halo or cyclopropyl; R 2 is selected from hydrogen, nitro, hydroxy, halo, cyano, Ci -4 alkyl, C 1-4 alkoxy,
  • W is -O-, -N(R 6 )- or -C(R 7 )(R 8 )-;
  • X is a direct bond, -CH 2 -, -C(O)- or S(O) q - (wherein q is 1 or 2);
  • Ring A is carbocyclyl or heterocyclyl; wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R 9 ;
  • R 4 and R 5 are substituents on carbon and are independently selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, sulfo, formyl, ureido, hydroxyiminomethyl, C 1-4 alkoxyiminomethyl, iV-hydroxyformamido, C 1-4 hydrazino, hydrazinocarbonyl, JV-hydroxyethanimidoyl, amino(hydroxyimino)methyl, C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 1-4 alkoxy, C 1-4 alkanoyl, C ⁇ alkanoyloxy,
  • C 1-4 alkylsulphonyl C 1-4 alkoxycarbonyl, carbamoyl, N-(C 1-4 alkyl)carbamoyl, N, N-(C 1 -4 alkyl)carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulphonyl;
  • R 10 , R 11 , R 14 and R 15 are independently selected from a direct bond, -O-, -N(R 18 )-, -C(O)-, -N(R 19 )C(O)-, -C(O)N(R 20 )-, -S(O) P -, -SO 2 N(R 21 )- or -N(R 22 )SO 2 -; wherein R 18 , R 19 , on o 1 oo R , R and R are independently selected from hydrogen or C h alky! and p is 0-2;
  • R 16 is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, carboxy, carbamoyl, mercapto, sulphamoyl, methyl, ethyl, ethenyl, ethynyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, iV-methyl-N-ethylamino, acetylamino, N-methylcarbamoyl, iV-ethylcarbamoyl, N, N-dimethylcarbamoyl, N, N-diethylcarbamoyl, N-methyl-N-ethylcarbamoyl, methylthio, ethylthio, methylsulphinyl, ethylsulphinyl, me
  • the present invention also provides a compound of formula (IA):
  • R 1 is selected from hydrogen, nitro, hydroxy, halo, cyano, Q ⁇ alkyl, C 1-4 alkoxy, C2-4alkenyl, C 2-4 alkynyl, C 1-4 alkanoyl, C 1-4 alkylS(O) a wherein a is 0 to 2 and C 3-6 cycloalkyl; wherein R 1 may be optionally substituted on carbon by one or more halo or cyclopropyl; R 2 is selected from hydrogen, nitro, hydroxy, halo, cyano, C 1-4 alkyl, C 1-4 alkoxy,
  • Ring A is carbocyclyl or heterocyclyl; wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R 9 ;
  • R 4 and R 5 are substituents on carbon and are independently selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, sulfo, formyl, ureido, hydroxyiminomethyl, N-hydroxyformamido, hydrazinocarbonyl, JV-hydroxyethanimidoyl, amino(hydroxyimino)methyl, C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 1-4 alkoxy, Ci -4 alkanoyl, C 1-4 alkanoyloxy, 7V-(C 1-4 alkyl)amino, ⁇ -(Cmalkyl ⁇ amino, JV-
  • R 9 , R 13 and R 17 are independently selected from Ci -4 alkyl, C 1-4 alkanoyl, C 1-4 alkylsulphonyl, Ci -4 alkoxycarbonyl, carbamoyl, JV-(C 1 -4 alkyl)carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulphonyl;
  • R 10 , R 11 , R 14 and R 15 are independently selected from a direct bond, -O-, -N(R 18 )-, -C(O)-, -N(R 19 )C(O)-, -C(O)N(R 20 )-, -S(O) P -, -SO 2 N(R 21 )- or -N(R 22 )SO 2 -; wherein R 18 , R 19 , R 20 , R 21 and R 22 are independently selected from hydrogen or C 1-4 alkyl and p is 0-2;
  • R 16 is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, carboxy, carbamoyl, mercapto, sulphamoyl, methyl, ethyl, ethenyl, ethynyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, iV-methyl-iV-ethylamino, acetylamino, iV-methylcarbamoyl, iV-ethylcarbamoyl, N, iV-dimethylcarbamoyl, ⁇ iV-diethylcarbamoyl, iV-methyl-iV-ethylcarbamoyl, methylthio, ethylthio, methylsulphinyl, eth
  • the present invention also provides a compound of formula (IB):
  • R 1 is selected from hydrogen, nitro, hydroxy, halo, cyano, Ci -4 alkyl, C 1-4 alkoxy, C 2-4 alkenyl, C 2 - 4 alkynyl, C 1-4 alkanoyl, C 1-4 alkylS(O) a wherein a is 0 to 2 and C3 -6 cycloalkyl; wherein R 1 may be optionally substituted on carbon by one or more halo or cyclopropyl; R 2 is selected from hydrogen, nitro, hydroxy, halo, cyano, C 1-4 alkyl, C 1-4 alkoxy,
  • Ring A is carbocyclyl or heterocyclyl; wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R ;
  • R and R 5 are substituents on carbon and are independently selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, sulfo, formyl, ureido, hydroxyiminomethyl, JV-hydroxyformamido, hydrazinocarbonyl, N-hydroxyethanimidoyl, amino(hydroxyimino)methyl, C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 1-4 alkoxy, C 1-4 alkanoyl, Ci -4 alkanoyloxy, iV-(C 1-4 alkyl)amino, ⁇ N-(C 1-4 alkyl) 2 amino, C 1-4 alkanoylamino, N-(Ci -4 alkyl)carbamoyl, N, N-(C i .
  • R 6 , R 7 and R 8 are independently selected from hydrogen or C 1-4 alkyl; n is 1-4; wherein the values of R 4 may be the same or different; m is 0-4; wherein the values of R 5 may be the same or different;
  • R 12 is selected from azido, halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, Q ⁇ alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 1-4 alkoxy, C 1-4 alkanoyl, Ci -4 alkanoyloxy, N-(C 1-4 alkyl)amino, N,N-(Ci -4 alkyl) 2 amino, C 1-4 alkanoylamino, N-(Ci -4 alkyl)carbamoyl, N,N-(Ci -4 alkyl) 2 carbamoyl, C 1-4 alkylS(O) a wherein a is 0 to 2, Ci -4 alkoxycarbonyl, N-(Ci_ 4 alkyl)sulphamoyl, N 5 N-(C i -4 alky l) 2 sulphamoy 1,
  • R 9 , R 13 and R 17 are independently selected from C h alky I 5 C 1-4 alkanoyl, C 1-4 alkylsulphonyl, C 1-4 alkoxycarbonyl, carbamoyl, JV-(C 1-4 alkyl)carbamoyl, A ⁇ iV-(C 1-4 alkyl)carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulphonyl; R 10 , R 11 , R 14 and R 15 are independently selected from a direct bond, -O-, -N(R 18 )-,
  • R 18 , R 19 , R 20 , R 21 and R 22 are independently selected from hydrogen or C 1-4 alkyl and p is 0-2;
  • R 16 is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, carboxy, carbamoyl, mercapto, sulphamoyl, methyl, ethyl, ethenyl, ethynyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, iV-methyl-iV-ethylamino, acetylamino, iV-methylcarbamoyl, iV-ethylcarbamoyl, ⁇ iV-dimethylcarbamoyl, i ⁇ iV-diethylcarbamoyl, iV-methyl-iV-ethylcarbamoyl, methylthio, ethylthio, methylsulphinyl, eth
  • the present invention also provides a compound of formula (IC):
  • R 1 is selected from hydrogen, nitro, hydroxy, halo, cyano, Ci -4 alkyl, Ci -4 alkoxy, C 2-4 alkenyl, C 2-4 alkynyl, C 1-4 alkanoyl, C 1-4 alkylS(O) a wherein a is 0 to 2 and C 3-6 cycloalkyl; wherein R 1 may be optionally substituted on carbon by one or more halo or cyclopropyl; R 2 is selected from hydrogen, nitro, hydroxy, halo, cyano, Ci -4 alkyl, Ci -4 alkoxy, C 2-4 alkenyl, C 2-4 alkynyl, Ci -4 alkylS(O) a wherein a is 0 to 2 and C 3-6 cycloalkyl; wherein R 2 may be optionally substituted on carbon by one or more halo or C 3-6 cycloalkyl;
  • Ring A is carbocyclyl or heterocyclyl; wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R 9 ;
  • R 4 and R 5 are substituents on carbon and are independently selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, sulfo, formyl, ureido, hydroxyiminomethyl, N-hydroxyformamido, hydrazinocarbonyl, N-hydroxyethanimidoyl, amino(hydroxyimino)methyl, Ci.
  • R 12 is selected from azido, halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, Ci -4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 1-4 alkoxy, Ci -4 alkanoyl, C 1-4 alkanoyloxy, N-(Ci -4 alkyl)amino, N,N-(Ci -4 alkyl) 2 amino, Ci ⁇ alkanoylamino, N-(C 1-4 alkyl)carbamoyl, N,N-(C 1-4 alkyl) 2 carbamoyl, Ci -4 alkylS(O) a wherein a is 0 to 2, Ci -4 alkoxycarbonyl, N-(C 1-4 alkyl)sulphamoyl,
  • R 9 , R 13 and R 17 are independently selected from C 1-4 alkyl, C 1-4 alkanoyl, C 1-4 alkylsulphonyl, C 1-4 alkoxycarbonyl, carbamoyl, iV-(C 1-4 alkyl)carbamoyl, N,JV-(C 1-4 alkyi)carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulphonyl;
  • R 10 , R 11 , R 14 and R 15 are independently selected from a direct bond, -O-, -N(R 18 )-, -C(O)-, -N(R 19 )C(0)-, -C(O)N(R 20 )-, -S(0) p -, -SO 2 N(R 21 )- or -N(R 22 )SO 2 -; wherein R 18 , R 19 , R 20 , R 21 and R 22 are independently selected from hydrogen or C 1-4 alkyl and p is 0-2;
  • R 16 is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, carboxy, carbamoyl, mercapto, sulphamoyl, methyl, ethyl, ethenyl, ethynyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, N-methyl-JV-ethylamino, acetylamino, iV-methylcarbamoyl, iV-ethylcarbamoyl, N,iV-dimethylcarbamoyl, ⁇ iV-diethylcarbamoyl, iV-methyl-JV-ethylcarbamoyl, methylthio, ethylthio, methylsulphinyl, ethyls
  • the present invention also provides a compound of formula (ID):
  • R 1 is selected from hydrogen, nitro, hydroxy, halo, cyano, C 1-4 alkyl, Ci -4 alkoxy, C 2-4 alkenyl, C 2-4 alkynyl, C 1-4 alkanoyl, C 1-4 alkylS(0) a wherein a is 0 to 2 and C 3-6 cycloalkyl; wherein R 1 may be optionally substituted on carbon by one or more halo or cyclopropyl;
  • R and R 5 are substituents on carbon and are independently selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, sulfo, formyl, ureido, hydroxyiminomethyl, N-hydroxyformamido, hydrazinocarbonyl, iV-hydroxyethanimidoyl, amino(hydroxyimino)methyl, C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 1-4 alkoxy, C 1-4 alkanoyl, C 1-4 alkanoyloxy, N-(C 1-4 alkyl)amino, N,N-(C 1-4 alkyl) 2 amino, C i -4 alkanoylamino, N-(Cj -4 alkyl)carbamoy 1, N, N-(C i -4 alkyl) 2 carbamoy 1, N-(
  • R 10 , R 11 , R 14 and R 15 are independently selected from a direct bond, -O-, -N(R 18 )-, -C(O)-, -N(R 19 )C(O)-, -C(O)N(R 20 )-, -S(0) p -, -SO 2 N(R 21 )- or -N(R 22 )SO 2 -; wherein R 18 , R 19 , R , R and R are independently selected from hydrogen or C 1-4 alkyl and p is 0-2;
  • R 16 is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, carboxy, carbamoyl, mercapto, sulphamoyl, methyl, ethyl, ethenyl, ethynyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, iV-methyl-iV-ethylamino, acetylamino, JV-methylcarbamoyl, iV-ethylcarbamoyl,
  • the present invention also provides a compound of formula (IE):
  • R 1 is selected from hydrogen, nitro, hydroxy, halo, cyano, Ci -4 alkyl, Q ⁇ alkoxy, C 2-4 alkenyl, C 2-4 alkynyl, C 1-4 alkanoyl, C 1-4 alkylS(O) a wherein a is 0 to 2 and C 3-6 cycloalkyl; wherein R 1 may be optionally substituted on carbon by one or more halo or cyclopropyl; R 2 is selected from hydrogen, nitro, hydroxy, halo, cyano, C] -4 alkyl, Ci -4 alkoxy, C 2-4 alkenyl, C 2-4 alkynyl, Ci -4 alkanoyl, C 1-4 alkylS(O) a wherein a is 0 to 2 and C 3-6 cycloalkyl; wherein R 2 may be optionally substituted on carbon by one or more halo or C 3-6 cycloalkyl;
  • X is a direct bond, -CH 2 -, -C(O)- or S(O) q - (wherein q is 1 or 2);
  • Ring A is heterocyclyl; wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R 9 ;
  • R 4 is a substitutent on carbon selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, sulfo, formyl, ureido, hydroxyiminomethyl, N-hydroxyformamido, hydrazinocarbonyl, N-hydroxyethanimidoyl, amino(hydroxyimino)methyl, Q ⁇ alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 1-4 alkoxy, Ci -4 alkanoyl, C 1-4 alkanoyloxy, N-(C 1 -4 alkyl)amino, N " ,N-(C 1-4 alkyl) 2 amino, C 1-4 alkanoylamino, N-(C 1-4 alkyl)carbamoyl, N,N-(Ci -4 alkyl) 2 carbamoyl, N-(C 1-4 alk
  • R 6 , R 7 and R 8 are independently selected from hydrogen or C 1-4 alkyl
  • R 12 is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C 1-4 alkyl, C 2-4 alkenyl, C 2 - 4 alkynyl, Ci -4 alkoxy, C 1-4 alkanoyl, C 1-4 alkanoyloxy, N-(C 1-4 alkyl)amino, N,N-(C 1-4 alkyl) 2 amino, C 1-4 alkanoylamino, N-(C 1-4 alkyl)carbamoyl, N,N-(C 1-4 alkyl) 2 carbamoyl, C 1-4 alkylS(O) a wherein a is 0 to 2, C 1-4 alkoxycarbonyl, N-(Ci -4 alkyl)sulphamoyl, N 5 N-(C i -4 alkyl) 2 sulphamoyl, C 1-4 al
  • R 10 , R 11 , R 14 and R 15 are independently selected from a direct bond, -O-, -N(R 18 )-, -C(O)-, -N(R 19 )C(O>, -C(O)N(R 20 )-, -S(0) p -, -SO 2 N(R 21 )- or -N(R 22 )SO 2 -; wherein R 18 , R 19 , R 20 , R 21 and R 22 are independently selected from hydrogen or C 1-4 alkyl and p is 0-2;
  • R 16 is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, carboxy, carbamoyl, mercapto, sulphamoyl, methyl, ethyl, ethenyl, ethynyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, Af-methyl-JV-ethylamino, acetylamino, iV-methylcarbamoyl, iV-ethylcarbamoyl,
  • the present invention also provides a compound of formula (IF):
  • R 1 is selected from hydrogen, nitro, hydroxy, halo, cyano, Ci -4 alkyl, Ci- 4 alkoxy, C 2-4 alkenyl, C 2-4 alkynyl, C 1-4 alkanoyl, C 1-4 alkylS(O) a wherein a is 0 to 2 and C 3-6 cycloalkyl; wherein R 1 may be optionally substituted on carbon by one or more halo or cyclopropyl; R 2 is selected from hydrogen, nitro, hydroxy, halo, cyano, C] -4 alkyl, Ci -4 alkoxy, C 2-4 alkenyl, C 2-4 alkynyl, d ⁇ alkanoyl, Ci -4 alkylS(O) a wherein a is 0 to 2 and C 3-6 cycloalkyl; wherein R 2 may be optionally substituted on carbon by one or more halo or C 3-6 Cy cloalkyl;
  • X is a direct bond, -CH 2 -, -C(O)- or S(O),- (wherein q is 1 or T);
  • R 4 is a substitutent on carbon selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, sulfo, formyl, ureido, hydroxyiminomethyl, iV-hydroxyformamido, hydrazinocarbonyl, N-hydroxyethanimidoyl, amino(hydroxyimino)methyl, C ⁇ alkyl, C 2 - 4 alkenyl, C 2-4 alkynyl, C 1-4 alkoxy, Ci -4 alkanoyl, C 1-4 alkanoyloxy, N-(C 1-4 alkyl)amino, 7V,7V-(C 1-4 alkyl) 2 amino, C 1-4 alkanoylamino, JV
  • R 5a and R 5b are substituents as defined for R 4 or taken together with the carbons to which they are attached form a 6-membered carbocyclyl ring substituted by one or two groups which may be the same or different and which are selected from R 14 ;
  • R 6 , R 7 and R 8 are independently selected from hydrogen or C 1-4 alkyl;
  • R 12 is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C 1-4 alkyl, C2- 4 alkenyl, C 2 - 4 alkynyl, C 1-4 alkoxy, C ⁇ alkanoyl, C 1-4 alkanoyloxy, N-(C 1-4 alkyl)amino, N,N-(C 1-4 alkyl) 2 amino, C 1-4 alkanoylamino, N-(CMalkyl)carbamoyl, N,N-(C 1- 4alkyl) 2 carbamoyl, C 1- 4alkylS(0) a wherein a is 0 to 2, Ci- 4 alkoxycarbonyl, N-(Ci-4alkyl)sulphamoyl, N,N-(Ci 4 al
  • R 9 , R 13 and R 17 are independently selected from C ⁇ alkyl, d ⁇ alkanoyl, C 1 _ 4 alkoxycarbonyl, carbamoyl, JV,JV-(C 1 . 4 alkyl)carbamoyl 5 benzyl, benzyloxycarbonyl, benzoyl and phenylsulphonyl; B2006/000529
  • R 10 , R 11 , R 14 and R 15 are independently selected from a direct bond, -0-, -N(R 18 )-, -C(O)-, -N(R 19 )C(O)-, -C(O)N(R 20 )-, -S(0) p -, -SO 2 N(R 21 )- or -N(R 22 )SO 2 -; wherein R 18 , R 19 , R 20 , R 21 and R 22 are independently selected from hydrogen or C 1-4 alkyl and p is 0-2;
  • R 16 is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, cafboxy, carbamoyl, mercapto, sulphamoyl, methyl, ethyl, ethenyl, ethynyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, JV-methyl-iV-ethylamino, acetylamino, iV-methylcarbamoyl, TV-ethylcarbamoyl, ⁇ dimethylcarbamoyl, N,iV " -diethylcarbamoyl, 7V-methyl-iV-ethylcarbamoyl, methylthio, ethylthio, methylsulphinyl, ethylsul
  • the invention also provides a compound which is 2-((3 ⁇ 4i?)-4- ⁇ [(3,4-dichloro-5-memyl-lH- ⁇ yrrol-2-yl)carbonyl]amino ⁇ -3- fluoropiperidin-l-yl)-l,3-thiazole-5-carboxylic acid;
  • the invention also provides a pharmaceutical composition that comprises a compound of formula I, IA, IB, IC, ID, or IE or a pharmaceutically-acceptable salt thereof, and a pharmaceutically-acceptable diluent or carrier.
  • the invention also provides a method of treating a bacterial infection in a warm-blooded animal, such as a human being, in need of such treatment, which comprises administering to said animal an effective amount of a compound of formula I, IA, IB, IC, ID, or IE, or a pharmaceutically-acceptable salt thereof.
  • the invention also provides a method for inhibiting bacterial DNA gyrase in a warm-blooded animal, such as a human being, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula I, IA, IB, IC, ID, or IE or a pharmaceutically acceptable salt.
  • the invention also provides a compound of formula I, IA, IB, IC, ID, or IE and pharmaceutically acceptable salts thereof for use as a medicament.
  • Theinvention also provides the use of a compound of formula I, IA, IB, IC, ID, or IE, or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for use in the production of an anti-bacterial effect in a warm-blooded animal such as a human being.
  • the invention also provides the use of a compound of formula I, IA, IB, IC, ID, or IE, or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for use in the treatment of a bacterial infection in a warm-blooded animal such as a human being.
  • the present invention also provides a process for preparing compounds of formula (I) or pharmaceutically-acceptable salts thereof, comprising:
  • alkyl includes both straight and branched chain alkyl groups.
  • Ci -4 alkyl includes methyl, ethyl, propyl, isopropyl and t-butyl.
  • references to individual alkyl groups such as propyl are specific for the straight chain version only. An analogous convention applies to other generic terms.
  • a “heterocyclyl” is a saturated, partially saturated or unsaturated, mono or bicyclic ring containing 4-12 atoms of which at least one atom is chosen from nitrogen, sulphur or oxygen, which may, unless otherwise specified, be carbon or nitrogen linked, wherein a -CH 2 - group can optionally be replaced by a -C(O)- and a ring nitrogen and / or a ring sulphur atom may be optionally oxidised to form the N- or S-oxide(s).
  • a “heterocyclyl” is a saturated, partially saturated or unsaturated, monocyclic ring containing 5 or 6 atoms of which at least one atom is chosen from nitrogen, sulphur or oxygen, it may, unless otherwise specified, be carbon or nitrogen linked, a -CH 2 - group can optionally be replaced by a -C(O)-and a ring sulphur atom may be optionally oxidised to form the S-oxides.
  • a “heterocyclyl” is an unsaturated, carbon-linked, monocyclic ring containing 5 or 6 atoms of which at least one atom is chosen from nitrogen, sulphur or oxygen.
  • heterocyclyl examples and suitable values of the term "heterocyclyl” are morpholino, piperidyl, pyridyl, pyranyl, pyrrolyl, pyrazolyl, isothiazolyl, indolyl, quinolyl, thienyl, 1,3-benzodioxolyl, thiadiazolyl, piperazinyl, thiazolidinyl, pyrrolidinyl, thiomorpholino, pyrrolinyl, homopiperazinyl, 3,5-dioxapiperidinyl, tetrahydropyranyl, imidazolyl, pyrimidyl, pyrazinyl, pyridazinyl, isoxazolyl, iV-methylpyrrolyl, 4-pyridone, 1-isoquinolone, 2-pyrrolidone, 4-thiazolidone, pyridine-iV-oxide and quinoline-iV-oxide
  • a “carbocyclyl” is a saturated, partially saturated or unsaturated, mono or bicycHc carbon ring that contains 3-12 atoms; wherein a -CH 2 - group can optionally be replaced by a -C(O)-.
  • Particularly “carbocyclyl” is a monocyclic ring containing 5 or 6 atoms or a bicyclic ring containing 9 or 10 atoms.
  • Suitable values for "carbocyclyl” include cyclopropyl, cyclobutyl, 1-oxocyclopentyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, phenyl, naphthyl, tetralinyl, indanyl or 1-oxoindanyl.
  • a particular example of “carbocyclyl” is phenyl.
  • An example of "C 1-4 alkanoyloxy” is acetoxy.
  • Examples of "C 1-4 alkoxycarbonyl” include methoxycarbonyl, ethoxycarbonyl, n- and t-butoxycarbonyl. Examples of
  • Ci- 4 alkoxycarbonylamino include methoxycarbonylamino, ethoxycarbonylamino, n- and t-butoxycarbonylamino.
  • Examples of “C ⁇ alkoxy” include methoxy, ethoxy and propoxy.
  • Examples of “C ⁇ alkanoylamino” include formamido, acetamido and propionylamino.
  • Examples of "C 1-4 alkylS(O) a wherein a is 0 to 2” include methylthio, ethylthio, methylsulphinyl, ethylsulphinyl, mesyl and ethylsulphonyl.
  • Examples of "C 1-4 alkanoyl” include propionyl and acetyl.
  • Examples of 'W-(Ci -4 alkyl)amino include methylamino and ethylamino.
  • Examples of "N 1 N-(Ci -4 alkyl) 2 amino” include diW-methylamino, di-(7V-ethyi)amino and W-ethyl-N-methylamino.
  • Examples of “C 2-4 alkenyl” are vinyl, allyl and 1-propenyl.
  • Examples of “C 2-4 alkynyl” are ethynyl, 1-propynyl and 2-propynyl.
  • Examples of 'W-(C 1-4 alkyl)sulphamoyl are N-(methyl)sulphamoyl and W-(ethyl)sulphamoyl.
  • Examples of "A ⁇ N-(Ci -4 alkyl)2Sulphamoyl” are W,N-(dimethyl)sulphamoyl and N-(methyl)-W-(ethyl)sulphamoyl.
  • Examples of "W-(Ci -4 alkyl)carbamoyl” are methylaminocarbonyl and ethylaminocarbonyl.
  • Examples of "NW-(C 1 -4 alkyl)2carbamoyl” are dimethylaminocarbonyl and methylethylaminocarbonyl.
  • Examples of "JV-(C 1-4 alkoxy)carbamoyl” are methoxyaminocarbonyl and isopropoxyaminocarbonyl.
  • Examples of 'W-(C 1 ⁇ alky I)-JV-(C i -4 alkoxy)carbamoyl” are W-methyl-N- methoxyaminocarbonyl and N-methyl-N-ethoxyaminocarbonyl.
  • Examples of “C 3-6 cycloalkyl” are cyclopropyl, cyclobutyl, cyclopropyl and cyclohexyl.
  • Examples of “W-(Ci -4 alkyl)ureido” are JV'-methylureido and W'-isopropylureido.
  • Examples of "W, W'-(C 1 . 4 alkyl) 2 ureido” are N 1 N'- dimethylureido and iV'-methyl-W'-isopropylureido. Examples of
  • 'W'-(Ci. 4 alkyl)hydrazinocarbonyl are W-methylhydrazinocarbonyl and N- isopropylhydrazinocarbonyl.
  • Examples of "W',iV-(C 1 , 4 alkyl) 2 hydrazinocarbonyr' are N 1 N'- dimethylhydrazinocarbonyl and N'-methyl-W-isopropylhydrazinocarbonyl.
  • Examples of include methylsulphonylamino, isopropylsulphonylamino and t-butylsulphonylamino.
  • Examples of “Ci ⁇ alkylsulphonylaminocarbonyl” include methylsulphonylaminocarbonyl, isopropylsulphonylaminocarbonyl and t-butylsulphonylaminocarbonyl.
  • Examples of “Ci -4 alkylsulphonyl” include methylsulphonyl, isopropylsulphonyl and t-butylsulphonyl.
  • a compound of formula (I) may form stable acid or basic salts, and in such cases administration of a compound as a salt may be appropriate, and pharmaceutically acceptable salts may be made by conventional methods such as those described following.
  • Suitable pharmaceutically-acceptable salts include acid addition salts such as methanesulfonate, tosylate, ⁇ -glycerophosphate, fumarate, hydrochloride, citrate, maleate, tartrate and (less preferably) hydrobromide. Also suitable are salts formed with phosphoric and sulfuric acid.
  • suitable salts are base salts such as an alkali metal salt for example sodium or potassium, an alkaline earth metal salt for example calcium or magnesium, an organic amine salt for example triethylamine, morpholine, iV-methylpiperidine, iV-ethylpiperidine, procaine, dibenzylamine, A ⁇ /V-dibenzylethylamine, tris-(2-hydroxyethyl)amine, tromethamine, TV-methyl d-glucamine and amino acids such as glycine or lysine.
  • a preferred pharmaceutically-acceptable salt is the sodium salt. However, to facilitate isolation of the salt during preparation, salts which are less soluble in the chosen solvent may be preferred whether pharmaceutically-acceptable or not.
  • a compound of the formula (I) or a salt thereof may exhibit the phenomenon of tautomerism and that the formulae drawings within this specification can represent only one of the possible tautomeric forms. It is to be understood that the invention encompasses any tautomeric form which inhibits DNA gyrase and/or topoisomeraseIV and is not to be limited merely to any one tautomeric form utilised within the formulae drawings.
  • the formulae drawings within this specification can represent only one of the possible tautomeric forms and it is to be understood that the specification encompasses all possible tautomeric forms of the compounds drawn not just those forms which it has been possible to show graphically herein. The same applies to compound names.
  • the present invention encompasses any racemic, optically-active, polymorphic or stereoisomeric form, or mixtures thereof, which form possesses properties useful in the inhibition of DNA gyrase and/or topoisomeraselV, it being well known in the art how to prepare optically-active forms (for example, by resolution of the racemic form by recrystallization techniques, by synthesis from optically-active starting materials, by chiral synthesis, by enzymatic resolution, by biotransformation, or by chromatographic separation using a chiral stationary phase) and how to determine efficacy for the inhibition of DNA gyrase and/or topoisomeraselV by the standard tests described hereinafter.
  • R 1 is Ci -4alkyl.
  • R 1 is methyl.
  • R 1 is halo.
  • R 1 is hydrogen.
  • R 2 is C 1-4 alkyl.
  • R 2 is methyl.
  • R 2 is halo.
  • R 2 is fluoro or chloro.
  • R 2 is hydrogen.
  • R 2 is chloro.
  • R 3 is C 1-4 alkyl.
  • R 3 is methyl.
  • R 3 is halo.
  • R 3 is fluoro or chloro.
  • R 3 is hydrogen.
  • R 3 is
  • R 3 is chloro.
  • W is -O-.
  • W is -N(R 6 )-.
  • W is -NH-.
  • W is -C(R 7 )(R 8 )-.
  • X is a direct bond.
  • X is -CH 2 -.
  • X is -C(O)-.
  • X is S(O) q - (wherein q is 1 or 2).
  • Ring A is carbocyclyl. Ring A is heterocyclyl; wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R 9 . Ring A is heterocyclyl. Ring A is thiazolyl, quinolinyl, benzothiazolyl, pyrimidinyl or pyridinyl. Ring A is thiazol-2-yl, quinolin-4-yl, benzothiazol-2-yl, pyrimidin-4-yl, pyridin-2- yl or pyridin-4-yl.
  • R is a substituent on carbon and is selected from halo, hydroxy, carboxy, Ci -4 alkyl,
  • R 12 is selected from hydroxy, C2-4alkenyl, C 1-4 alkoxy, N-(C 1-4 alkyl)amino and R 11 is -C(O)-.
  • R 4 is a substituent on carbon and is selected from fluoro, hydroxy, carboxy, methyl, methoxy, propoxy, iV-ethylcarbamoyl, N,N-dimethylcarbamoyl, iV-methyl-iV-methoxy carbamoyl, methoxycarbonyl or morpholino-R 11 -; wherein R 4 may be optionally substituted on carbon by one or more R 12 .
  • R 12 is selected from hydroxy, ethenyl, methoxy, ⁇ -methylamino or ⁇ , ⁇ -dimethylamino; and R 11 is -C(O)-.
  • R 4 is a substituent on carbon and is selected from methoxy, hydroxy, methoxycarbonyl, fluoro, allyloxy, propoxy, N, JV-dimethylcarbamoyl, morpholinocarbonyl, iV-ethylcarbamoyl, N-(2-hydroxyethyl)carbamoyl, dimethylaminomethyl, N-methyl-N-methoxycarbamoyl, methoxymethyl, methylaminomethyl and carboxy.
  • R 4 is a substituent on carbon and is selected from methoxy, hydroxy, methoxycarbonyl, fluoro, allyloxy, propoxy, ⁇ N-dimethylcarbamoyl, morpholinocarbonyl, iV-ethylcarbamoyl, N-(2-hydroxyethyl)carbamoyl, dimethylaminomethyl, iV-methyl-N-methoxycarbamoyl, methoxymethyl, methylaminomethyl, carboxy, N-methyl-N- methoxyxcarbamoyl, ⁇ -hydroxyethylcarbamoyl, hydroxymethyl, (methylthio)methyl, (methylsulfmyl)methyl, (methylsulfonyl)methyl, benzyloxy, propynyloxy, methoxyethoxy, methoxypropoxy, chloro, methyl, cyclopropylmethoxy, thiazolylmethoxy, ethoxy,
  • R 4 is halo, particularly fluoro.
  • R 5 is a substituent on carbon and is selected from halo, carboxy, carbamoyl, d. 4 alkyl, Ci- 4 alkoxy, TV-(C 1-4 alkyl)carbamoyl, TV-(C 1-4 alkoxy)carbamoyl or C 1-4 alkoxycarbonyl; wherein R 5 may be optionally substituted on carbon by one or more R 12 .
  • R 12 is selected from C 1-4 alkoxy or carbocyclyl-R 14 -; and R 14 is a direct bond.
  • R 5 is a substituent on carbon and is selected from chloro, carboxy, carbamoyl, methyl, methoxy, TV-(isopropyl)carbamoyl, TV-(methoxy)carbamoyl, methoxycarbonyl or ethoxycarbonyl; wherein R 5 may be optionally substituted on carbon by one or more R 12 .
  • R 12 is selected from methoxy or phenyl-R 14 -; and R 14 is a direct bond.
  • R 5 is a substituent on carbon and is selected from chloro, carboxy, carbamoyl, methyl, methoxymethyl, methoxy, TV-(I -methyl- l-phenylethyl)carbamoyl, TV-(methoxy)carbamoyl, methoxycarbonyl or ethoxycarbonyl.
  • R 5 is a substituent on carbon and is selected from chloro, carboxy, carbamoyl, methyl, methoxymethyl, methoxy, TV-(I -methyl- 1 -phenylethyl)carbamoyl,
  • R 5 is carboxy
  • R 6 is hydrogen
  • n 1.
  • n 1 or 2; wherein the values of R 5 may be the same or different, m is 1. m is 2.
  • R 2 is selected from halo.
  • R 3 is selected from hydrogen or halo
  • W is -N(R 6 )-;
  • X is a direct bond; Ring A is heterocyclyl;
  • R 4 is a substituent on carbon and is selected from halo, hydroxy, carboxy, C 1-4 alkyl, C 1-4 alkoxy, iV-(C 1-4 alkyl)carbamoyl, ⁇ iV-(C 1-4 alkyl) 2 carbamoyl, iV-(C 1-4 alkyl)-iV-(Ci -4 alkoxy)carbamoyl, C 1-4 alkoxycarbonyl or heterocyclyl-R 11 -; wherein R 4 may be optionally substituted on carbon by one or more R 12 ; R 5 is a substituent on carbon and is selected from halo, carboxy, carbamoyl, C ⁇ alkyl,
  • R 5 may be optionally substituted on carbon by one or more R 12 ;
  • R 6 is hydrogen
  • R 11 is -C(O)-;
  • R 12 is selected from hydroxy, C 2-4 alkenyl, Ci -4 alkoxy, N-(C 1-4 alkyl)amino,
  • R 14 is a direct bond; n is 1 ; and m is 1 or 2; wherein the values of R 5 may be the same or different; or a pharmaceutically acceptable salt thereof.
  • R 1 is selected from methyl; R is fluoro or chloro;
  • R 3 is selected from hydrogen, fluoro or chloro; W is -NH-; X is a direct bond;
  • Ring A is thiazolyl, quinolinyl, benzothiazolyl, pyrimidinyl or pyridinyl;
  • R 4 is a substituent on carbon and is selected from methoxy, hydroxy, methoxycarbonyl, fluoro, allyloxy, propoxy, ⁇ iV-dimethylcarbamoyl, morpholinocarbonyl, iV-ethylcarbamoyl, JV-(2-hydroxyethyi)carbamoyl, dimethylaminomethyl, iV-methyl-iV-methoxy carbamoyl, methoxymethyl, methylamhiomethyl and carboxy;
  • R 5 is a substituent on carbon and is selected from chloro, carboxy, carbamoyl, methyl, methoxymethyl, methoxy, N-(I -methyl- l-phenylethyl)carbamoyl, iV-(methoxy)carbamoyl, methoxymethyl)ethyl]amino ⁇ carbamoyl, methoxycarbonyl or ethoxycarbonyl; n is 1 ; and m is 1 or 2; wherein the values of R 5 may be the same or different; or a pharmaceutically acceptable salt thereof.
  • R 3 is selected from hydrogen, fluoro or chloro
  • W is -NH-
  • Ring A is thiazolyl, quinolinyl, benzothiazolyl, pyrimidinyl or pyridinyl;
  • R 4 is a substituent on carbon and is selected from methoxy, hydroxy, methoxycarbonyl, fluoro, allyloxy, propoxy, N,N-dimethylcarbamoyl, morpholinocarbonyl, iV-ethylcarbamoyl, iV-(2-hydroxyethyl)carbamoyl, dimethylaminomethyl, JV-methyl-JV-methoxycarbamoyl, methoxymethyl, methylaminomethyl, carboxy, JV ⁇ methyl-JV- methoxyxcarbamoyl, N-hydroxyethylcarbamoyl, hydroxymethyl, (methylthio)methyl, (methylsulfmyl)methyl, (methylsulfonyl)methyl, benzyloxy, propynyloxy, methoxyethoxy, methoxypropoxy, chloro, methyl, cyclopropylmethoxy, thiazolylmethoxy, eth
  • R 5 is a substituent on carbon and is selected from chloro, carboxy, carbamoyl, methyl, methoxymethyl, methoxy, JV-(I -methyl- l-phenylethyl)carbamoyl, JV-(methoxy)carbamoyl, methoxycarbonyl or ethoxycarbonyl, JV-methoxycarbamoyl, formyl, (methoxyimino)methyl, isopropoxycarbonyl, ethoxy, morpholinocarbonyl, hydroxy- 1-methylethyl, amino, methoxy carbonylamino, methylsulfonylamino, JV-(I -methyl- l-phenylethyl)carbamoyl, JV-2- morpholin-4-ylethylcarbamoyl, piperidinocarbonyl, N-methylcarbamoyl, JV-2- hydroxyethylcarbamoyl
  • R 1 is selected from hydrogen, halo, cyano, or C 1-4 alkyl
  • R 2 is selected from hydrogen, halo, cyano, or C 1-4 alkyl
  • X is a direct bond, -CH 2 -, -C(O)- or S(0) q - (wherein q is 1 or 2);
  • Ring A is carbocyclyl or heterocyclyl; wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R 9 ;
  • R 4 and R 5 are substituents on carbon and are independently selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, sulfo, formyl, ureido, hydroxyiminomethyl, CMalkoxyiminomethyl, iV-hydroxyformamido, C 1-4 hydrazino, hydrazinocarbonyl, JV-hydroxyethanimidoyl, amino(hydroxyimino)methyl, C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 1-4 alkoxy, d- 4 alkanoyl, C 1-4 alkanoyloxy, iV-(Cj -4 alkyl)amino, ⁇ iV-(Ci -4 alkyl)2amino, C 1-4 alkanoylamino, iV-(C 1-4 alkyl)car
  • Ci. 4 aIkarLoyl C 1-4 alkanoyloxy, N-(Ci -4 alkyl)ainino, N 5 N-(C 1-4 alkyl) 2 ainino, wherein a is 0 to 2, C 1-4 alkoxycarbonyl, N-tC M alkyOsulphamoyl, N,N-(Ci- 4 aIkyl) 2 Sulphamoyl 5 C 1-4 alkylsulphonylamino, C M alkoxycarbonylamino, carbocyclyl-R 14 - or heterocyclyl-R 1 ?-; wherein R 12 independently of each other may be optionally substituted on carbon by one or more R 16 ; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R 17 ;
  • R 9 , R 13 and R 17 are independently selected from C 1-4 alkyl, C 1-4 alkanoyl, C 1-4 alkylsulphonyl, carbamoyl, iV-(C 1-4 alkyl)carbamoyl, JV,JV-(C 1-4 alkyl)carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulphonyl;
  • R 10 , R 11 , R 14 and R 15 are independently selected from a direct bond, -O-, -N(R 18 )-, -C(O)-, -N(R 19 )C(O)-, -C(O)N(R 20 )-, -S(O) P -, -SO 2 N(R 21 )- or -N(R 22 )SO 2 -; wherein R 18 , R 19 , R , R and R are independently selected from hydrogen or C ⁇ alkyl and p is 0-2;
  • R 16 is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, carboxy, carbamoyl, mercapto, sulphamoyl, methyl, ethyl, ethenyl, ethynyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, iV-methyl-N-ethylamino, acetylamino, JV-methylcarbamoyl, JV ⁇ eth.ylcarbam.oyl, ⁇ N-dmethylcarbamoyl, N,iV-diethylcarbamoyl, iV-methyl-iV-ethylcarbamoyl, methylthio, ethylthio, methylsulphinyl, ethylsul
  • R 4 is a substituent on carbon and is selected from methoxy, hydroxy, methoxycarbonyl, fluoro, allyloxy, propoxy, JV, JV-dimethy lcarbamoy 1, morpholinocarbonyl, N-ethylcarbamoyl, JV-(2-hydroxyethyl)carbamoyl, dimethylaminornethyl, JV-methyl-JV-methoxycarbamoyl, methoxymethyl, methylaminomethyl, carboxy , JV-methyl-JV- methoxyxcarbamoyl, N-hydroxyethylcarbamoyl, hydroxymethyl, (methylthio)methyl, (methylsulfinyl)methyl, (methylsulfonyl)methyl, benzyloxy, propynyloxy, methoxyethoxy, methoxypropoxy, chloro, methyl, cyclopropylmethoxy,
  • Ring A is heterocyclyl; wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from C 1-4 alkyl, C 1-4 alkylsulphonyl, C 1-4 alkoxycarbonyl, carbamoyl, N-(C 1-4 alkyl)carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulphonyl.
  • Y is N-H, N-Ci -4 alkyl, S, or O;
  • R 5a is H or as defined for R 5 ;
  • R 5b is H or as defined for R 5 ; or R 5a and R 5b taken together with the carbons to which they are attached form a 6- membered carbocyclyl ring substituted by one or two groups selected from R 1 which may be the same or different;
  • R 14 is selected from a direct bond, -O-, -N(R 18 )-, -C(O)-, -N(R 19 )C(O)-, -C(O)N(R 20 )-, -S(O)p-, -SO 2 N(R 21 )- or -N(R 22 )SO 2 -; wherein R 18 , R 19 , R 20 , R 21 and R 22 are independently selected from hydrogen or C 1-4 alkyl and p is 0-2.
  • Particular compounds of the invention are the compounds of the Examples, each of which provides a further independent aspect of the invention.
  • the present invention also comprises any two or more compounds of the Examples.
  • the present invention provides a process for preparing a compound of formula (I) or a pharmaceutically-acceptable salt thereof.
  • the present invention also provides that the compounds of the formula (I) and pharmaceutically-acceptable salts thereof, can be prepared by a process as follows (wherein the variables are as defined above unless otherwise stated)
  • R a is cyano and R b is dimethyamino or diethylamino; or R a and R b are independently selected from C 1-4 alkylthio; or R a and R b together form 1,3-dithianyl or 1,3-dithiolanyl; into a compound of formula (I) ;
  • L is a displaceable group. Suitable values for L include halo, for example chloro and bromo, pentafluorophenoxy and 2,5-oxopyrrolidin-l-yloxy. D is a displaceable group. Suitable values for D include halo, for example chloro, bromo and iodo, tosylate and mesylate.
  • M is an organometallic group
  • suitable values for M include organocuprates, for example CuLi, organozincs, Zn, or a Grignard reagent for example MgG where G is halo for example chloro.
  • Specific reaction conditions for the above reaction are as follows.
  • R a is cyano and R b is dimethyamino or diethylamino; in the presence of a base for example sodium hydroxide, in a suitable solvent for example aqueous methanol at room temperature.
  • R a and R b are independently selected from Ci -4 alkylthio; or R a and R b together form 1,3-dithianyl or 1,3-dithiolanyl; in the presence of a reagent such as a mercury, copper or silver salt for example Hg(C10 4 ) 2 , CuCl 2 or AgNO 3 ZAg 2 O in the presence of a suitable solvent for example methanol, acetone or ethanol from a temperature ranging from room temperature to reflux.
  • a suitable solvent for example methanol, acetone or ethanol from a temperature ranging from room temperature to reflux.
  • Pg is a hydroxy protecting group as defined hereinbelow; and D is a displaceable group as defined hereinabove.
  • FGI Functional Group Interconversion
  • Process b) Compounds of formula (III) and (IV) may be reacted together may be reacted together in the presence of a coupling reagent, for example dicyclohexylcarbodiimide or EDC, in a suitable solvent, for example dichloromethane, THF or diethylether.
  • a coupling reagent for example dicyclohexylcarbodiimide or EDC
  • a suitable solvent for example dichloromethane, THF or diethylether.
  • Standard peptide coupling reagents known in the art can be employed as suitable coupling reagents, or for example carbonyldiimidazole and dicyclohexyl-carbodiimide, optionally in the presence of a catalyst such as dimethylaminopyridine or 4-pyrrolidinopyridine, optionally in the presence of a base for example triethylamine, pyridine, or 2,6-di- ⁇ /&y/-pyridines such as 2,6-lutidine or 2,6-di-/er/-butylpyridine.
  • Suitable solvents include dimethylacetamide, dichloromethane, benzene, tetrahydrofuran and dimethylformamide.
  • the coupling reaction may conveniently be performed at a temperature in the range of -40 to 40°C.
  • Suitable activated acid derivatives include acid halides, for example acid chlorides, and active esters, for example pentafluorophenyl esters.
  • the reaction of these types of compounds with amines is well known in the art, for example they may be reacted in the presence of a base, such as those described above, and in a suitable solvent, such as those described above.
  • the reaction may conveniently be performed at a temperature in the range of -40 to 4O 0 C.
  • R a OC(O) is an ester group.
  • Suitable values for R a include C 1-6 alkyl.
  • Deprotection of the R a carboxy protecting group may be achieved under standard conditions, for example acid or base hydrolysis, such as those conditions give hereinbelow.
  • FGI Functional Group Interconversion
  • Process g Compounds of formula (X) and (XII) may be coupled together under the conditions outlined in Process c).
  • Introduction of substituents into a ring may convert one compound of the formula (I) into another compound of the formula (I).
  • Such reactions and modifications include, for example, introduction of a substituent by means of an aromatic substitution reaction, reduction of substituents, alkylation of substituents , oxidation of substituents, esterification of substituents, amidation of substituents, formation of heteroaryl rings.
  • aromatic substitution reactions include the introduction of alkoxides, diazotization reactions followed by introduction of thiol group, alcohol group, halogen group.
  • modifications include; oxidation of alkylthio to alkylsulphinyl or alkylsulphonyl.
  • the skilled organic chemist will be able to use and adapt the information contained and referenced within the above references, and accompanying Examples therein and also the Examples herein, to obtain necessary starting materials, and products.
  • the necessary starting materials for the procedures such as those described above may be made by procedures which are selected from standard organic chemical techniques, techniques which are analogous to the synthesis of known, structurally similar compounds, or techniques which are analogous to the above described procedure or the procedures described in the examples. It is noted that many of the starting materials for synthetic methods as described above are commercially available and/or widely reported in the scientific literature, or could be made from commercially available compounds using adaptations of processes reported in the scientific literature. The reader is further referred to Advanced Organic Chemistry, 4 th Edition, by Jerry March, published by John Wiley & Sons 1992, for general guidance on reaction conditions and reagents.
  • a suitable protecting group for a hydroxy group is, for example, an acyl group, for example an alkanoyl group such as acetyl, an aroyl group, for example benzoyl, a silyl group such as trimethylsilyl or an arylmethyl group, for example benzyl.
  • an acyl group such as an alkanoyl or an aroyl group may be removed, for example, by hydrolysis with a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide.
  • a silyl group such as trimethylsilyl may be removed, for example, by fluoride or by aqueous acid; or an arylmethyl group such as a benzyl group may be removed, for example, by hydrogenation in the presence of a catalyst such as palladium-on-carbon.
  • a suitable protecting group for an amino group is, for example, an acyl group, for example an alkanoyl group such as acetyl, an alkoxycarbonyl group, for example a methoxycarbonyl, ethoxycarbonyl or t-butoxycarbonyl group, an arylmethoxycarbonyl group, for example benzyloxycarbonyl, or an aroyl group, for example benzoyl.
  • the deprotection conditions for the above protecting groups necessarily vary with the choice of protecting group.
  • an acyl group such as an alkanoyl or alkoxycarbonyl group or an aroyl group may be removed for example, by hydrolysis with a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide.
  • a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide.
  • an acyl group such as a t-butoxycarbonyl group may be removed, for example, by treatment with a suitable acid as hydrochloric, sulphuric or phosphoric acid or trifluoroacetic acid and an arylmethoxycarbonyl group such as a benzyloxycarbonyl group may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon, or by treatment with a Lewis acid for example boron tris(trifluoroacetate).
  • a suitable acid as hydrochloric, sulphuric or phosphoric acid or trifluoroacetic acid
  • an arylmethoxycarbonyl group such as a benzyloxycarbonyl group
  • a suitable alternative protecting group for a primary amino group is, for example, a phthaloyl group which may be removed by treatment with an alkylamine, for example dimethylaminopropylamine or 2-hydroxyethylamine, or with hydrazine.
  • a suitable protecting group for a carboxy group is, for example, an esterifying group, for example a methyl or an ethyl group which may be removed, for example, by hydrolysis with a base such as sodium hydroxide, or for example a ⁇ -butyl group which may be removed, for example, by treatment with an acid, for example an organic acid such as trifluoroacetic acid, or for example a benzyl group which may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon.
  • the protecting groups may be removed at any convenient stage in the synthesis using conventional techniques well known in the chemical art, or they may be removed during a later reaction step or work-up.
  • an optically active form of a compound of the invention When an optically active form of a compound of the invention is required, it may be obtained by carrying out one of the above procedures using an optically active starting material (formed, for example, by asymmetric induction of a suitable reaction step), or by resolution of a racemic form of the compound or intermediate using a standard procedure, or by chromatographic separation of diastereoisomers (when produced). Enzymatic techniques may also be useful for the preparation of optically active compounds and/or intermediates. Similarly, when a pure regioisomer of a compound of the invention is required, it may be obtained by carrying out one of the above procedures using a pure regioisomer as a starting material, or by resolution of a mixture of the regioisomers or intermediates using a standard procedure.
  • Assays were performed in multiwell plates in lOO ⁇ l reactions containing: 50 mM TRIS buffer pH 7.5, 75 mM ammonium acetate, 5.5 mM magnesium chloride, 0.5 mM ethylenediaminetetraacetic acid, 5% glycerol, 1 mM 1,4-Dithio-DL-threitol, 200 nM bovine serum albumin, 16 ⁇ g/ml sheared salmon sperm DNA, 4 nM E. coli GyrA, 4 nM E. coli GyrB, 250 ⁇ M ATP, and compound in dimethylsulfoxide.
  • Reactions were quenched with 150 ⁇ l of ammonium molybdate/malachite green detection reagent containing 1.2 mM malachite green hydrochloride, 8.5 mM ammonium molybdate tetrahydrate, and 1 M hydrochloric acid. Plates were read in an absorbance plate reader at 625 nm and percent inhibition values were calculated using dimethylsulfoxide (2%)-containing reactions as 0% inhibition and novobiocin-containing (2 ⁇ M) reactions as 100% inhibition controls.
  • Compounds of the Examples generally have IC 5O values of ⁇ 20 ⁇ g/ml.
  • Bacterial Susceptibility Testing Methods Compounds were tested for antimicrobial activity by susceptibility testing in liquid media. Compounds were dissolved in dimethylsulfoxide and tested in 10 doubling dilutions in the susceptibility assays. The organisms used in the assay were grown overnight on suitable agar media and then suspended in a liquid medium appropriate for the growth of the organism. The suspension was a 0.5 McFarland and a further 1 in 10 dilution was made into the same liquid medium to prepare the final organism suspension in 100 ⁇ L. Plates were incubated under appropriate conditions at 37 degrees C for 24 hrs prior to reading. The Minimum Inhibitory Concentration was determined as the lowest drug concentration able to reduce growth by 80% or more.
  • Example 48 had an MIC of 0.13 ⁇ g/ml against Streptococcus pneumoniae. Other examples areprovided in the following table.
  • a compound of the formula (I), or a pharmaceutically-acceptable salt thereof for use in a method of treatment of the human or animal body by therapy.
  • a method for producing an antibacterial effect in a warm blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of the present invention, or a pharmaceutically-acceptable salt thereof.
  • a method for inhibition of bacterial DNA gyrase and/or topoisomeraseIV in a warm-blooded animal, such as a human being, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof as defined hereinbefore.
  • a method of treating a bacterial infection in a warm-blooded animal which comprises administering to said animal an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof as defined hereinbefore.
  • a further feature of the present invention is a compound of formula (I) and pharmaceutically acceptable salts thereof for use as a medicament.
  • the medicament is an antibacterial agent.
  • a compound of formula (I), or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for use in the production of an anti-bacterial effect in a warm-blooded animal such as a human being.
  • a compound of formula (I), or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for use in inhibition of bacterial DNA gyrase and/or topoisomeraseIV in a warm-blooded animal such as a human being.
  • a compound of formula (I), or a pharmaceutically acceptable salt thereof for use in the production of an anti- bacterial effect in a warm-blooded animal such as a human being.
  • a compound of formula (I), or a pharmaceutically acceptable salt thereof for use in the treatment of a bacterial infection in a warm-blooded animal such as a human being.
  • a compound of the formula (I) or a pharmaceutically-acceptable salt thereof for the therapeutic (including prophylactic) treatment of mammals including humans, in particular in treating infection, it is normally formulated in accordance with standard pharmaceutical practice as a pharmaceutical composition.
  • the present invention provides a pharmaceutical composition that comprises a compound of the formula (I) or a pharmaceutically-acceptable salt thereof, and a pharmaceutically-acceptable diluent or carrier.
  • a pharmaceutical composition that comprises a compound of formula (I) as defined hereinbefore or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable excipient or carrier for use in producing an anti-bacterial effect in an warm-blooded animal, such as a human being.
  • a pharmaceutical composition that comprises a compound of formula (I) as defined hereinbefore or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable excipient or carrier for use in inhibition of bacterial DNA gyrase and/or topoisomeraseIV in an warm-blooded animal, such as a human being.
  • a pharmaceutical composition that comprises a compound of formula (I) as defined hereinbefore or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable excipient or carrier for use in the treatment of a bacterial infection in an warm-blooded animal, such as a human being.
  • compositions of the invention may be in a form suitable for oral use (for example as tablets, lozenges, hard or soft capsules, aqueous or oily suspensions, emulsions, dispersible powders or granules, syrups or elixirs), for topical use (for example as creams, ointments, gels, or aqueous or oily solutions or suspensions), for administration by inhalation (for example as a finely divided powder or a liquid aerosol), for administration by insufflation (for example as a finely divided powder) or for parenteral administration (for example as a sterile aqueous or oily solution for intravenous, subcutaneous, intramuscular or intramuscular dosing or as a suppository for rectal dosing).
  • oral use for example as tablets, lozenges, hard or soft capsules, aqueous or oily suspensions, emulsions, dispersible powders or granules, syrups or elixir
  • compositions of the invention may be obtained by conventional procedures using conventional pharmaceutical excipients, well known in the art.
  • compositions intended for oral use may contain, for example, one or more colouring, sweetening, flavouring and/or preservative agents.
  • Suitable pharmaceutically acceptable excipients for a tablet formulation include, for example, inert diluents such as lactose, sodium carbonate, calcium phosphate or calcium carbonate, granulating and disintegrating agents such as corn starch or algenic acid; binding agents such as starch; lubricating agents such as magnesium stearate, stearic acid or talc; preservative agents such as ethyl or propyl p-hydroxybenzoate, and anti-oxidants, such as ascorbic acid. Tablet formulations may be uncoated or coated either to modify their disintegration and the subsequent absorption of the active ingredient within the gastrointestinal tract, or to improve their stability and/or appearance, in either case, using conventional coating agents and procedures well known in the art.
  • inert diluents such as lactose, sodium carbonate, calcium phosphate or calcium carbonate
  • granulating and disintegrating agents such as corn starch or algenic acid
  • binding agents such as starch
  • lubricating agents
  • Compositions for oral use may be in the form of hard gelatin capsules in which the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules in which the active ingredient is mixed with water or an oil such as peanut oil, liquid paraffin, or olive oil.
  • an inert solid diluent for example, calcium carbonate, calcium phosphate or kaolin
  • water or an oil such as peanut oil, liquid paraffin, or olive oil.
  • Aqueous suspensions generally contain the active ingredient in finely powdered form together with one or more suspending agents, such as sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethylcellulose, sodium alginate, polyvinyl-pyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents such as lecithin or condensation products of an alkylene oxide with fatty acids (for example polyoxethylene stearate), or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol
  • the aqueous suspensions may also contain one or more preservatives (such as ethyl or propyl p-hydroxybenzoate, anti-oxidants (such as ascorbic acid), colouring agents, flavouring agents, and/or sweetening agents (such as sucrose, saccharine or aspartame).
  • preservatives such as ethyl or propyl p-hydroxybenzoate, anti-oxidants (such as ascorbic acid), colouring agents, flavouring agents, and/or sweetening agents (such as sucrose, saccharine or aspartame).
  • Oily suspensions may be formulated by suspending the active ingredient in a vegetable oil (such as arachis oil, olive oil, sesame oil or coconut oil) or in a mineral oil (such as liquid paraffin).
  • the oily suspensions may also contain a thickening agent such as beeswax, hard paraffin or cetyl alcohol. Sweetening agents such as those set out above, and flavouring agents may be added to provide a palatable oral preparation.
  • These compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid.
  • Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water generally contain the active ingredient together with a dispersing or wetting agent, suspending agent and one or more preservatives.
  • compositions of the invention may also be in the form of oil-in-water emulsions.
  • the oily phase may be a vegetable oil, such as olive oil or arachis oil, or a mineral oil, such as for example liquid paraffin or a mixture of any of these.
  • Suitable emulsifying agents may be, for example, naturally-occurring gums such as gum acacia or gum tragacanth, naturally-occurring phosphatides such as soya bean, lecithin, an esters or partial esters derived from fatty acids and hexitol anhydrides (for example sorbitan monooleate) and condensation products of the said partial esters with ethylene oxide such as polyoxyethylene sorbitan monooleate.
  • the emulsions may also contain sweetening, flavouring and preservative agents.
  • Syrups and elixirs may be formulated with sweetening agents such as glycerol, propylene glycol, sorbitol, aspartame or sucrose, and may also contain a demulcent, preservative, flavouring and/or colouring agent.
  • sweetening agents such as glycerol, propylene glycol, sorbitol, aspartame or sucrose, and may also contain a demulcent, preservative, flavouring and/or colouring agent.
  • compositions may also be in the form of a sterile injectable aqueous or oily suspension, which may be formulated according to known procedures using one or more of the appropriate dispersing or wetting agents and suspending agents, which have been mentioned above.
  • a sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example a solution in 1,3-butanediol.
  • Compositions for administration by inhalation may be in the form of a conventional pressurised aerosol arranged to dispense the active ingredient either as an aerosol containing finely divided solid or liquid droplets.
  • Conventional aerosol propellants such as volatile fluorinated hydrocarbons or hydrocarbons may be used and the aerosol device is conveniently arranged to dispense a metered quantity of active ingredient.
  • the amount of active ingredient that is combined with one or more excipients to produce a single dosage form will necessarily vary depending upon the host treated and the particular route of administration.
  • a formulation intended for oral administration to humans will generally contain, for example, from 0.5 mg to 2 g of active agent compounded with an appropriate and convenient amount of excipients which may vary from about 5 to about 98 percent by weight of the total composition.
  • Dosage unit forms will generally contain about 1 mg to about 500 mg of an active ingredient.
  • the pharmaceutical composition of this invention may also contain or be co-administered (simultaneously, sequentially or separately) with one or more known drugs selected from other clinically useful antibacterial agents (for example, macrolides, quinolones, ⁇ -lactams or aminoglycosides) and/or other anti-infective agents (for example, an antifungal triazole or amphotericin).
  • drugs selected from other clinically useful antibacterial agents (for example, macrolides, quinolones, ⁇ -lactams or aminoglycosides) and/or other anti-infective agents (for example, an antifungal triazole or amphotericin).
  • drugs for example, macrolides, quinolones, ⁇ -lactams or aminoglycosides
  • other anti-infective agents for example, an antifungal triazole or amphotericin.
  • carbapenems for example meropenem or imipenem, to broaden the therapeutic effectiveness
  • the size of the dose required for the therapeutic or prophylactic treatment of a particular disease state will necessarily be varied depending on the host treated, the route of administration and the severity of the illness being treated.
  • a daily dose in the range of 1-50 mg/kg is employed.
  • the daily dose will necessarily be varied depending upon the host treated, the particular route of administration, and the severity of the illness being treated. Accordingly the optimum dosage may be determined by the practitioner who is treating any particular patient.
  • compounds of formula (I) and their pharmaceutically acceptable salts are also useful as pharmacological tools in the development and standardisation of in- vitro and in- vivo test systems for the evaluation of the effects of inhibitors of DNA gyrase in laboratory animals such as cats, dogs, rabbits, monkeys, rats and mice, as part of the search for new therapeutic agents.
  • each intermediate was purified to the standard required for the subsequent stage and was characterised in sufficient detail to confirm that the assigned structure was correct; purity was assessed by HPLC, TLC, or NMR and identity was determined by infra-red spectroscopy
  • DMF is N,N-dimethylformamide
  • DMA is N,N-dimethylacetamide
  • TLC is thin layer chromatography
  • HPLC high pressure liquid chromatography
  • DMSO is dimethylsulfoxide
  • CDCl 3 is deuterated chloroform; MS is mass spectroscopy; APCI is atmospheric pressure chemical ionisation; EtOAc is ethyl acetate; MeOH is methanol; DIEA is diisopropylethlamine; TFA is trifluoroacetic acid; HATU is
  • Smith Microwave Synthesizer refers to an equipment that uses microwave energy to heat organic reactions in a short period of time; it was used according to the manufacturers instruction and was obtained from Personal Chemistry Uppsala AB;
  • Example 42 is the Final compound in the synthesis which started from
  • the title compounds were prepared using a Smith Microwave Synthesizer by subjecting the reaction mixture to single-mode microwave at 150 0 C for 30 minutes (min.) or until the reaction is complete as judged by LCMS 5 using polar aprotic solvent such as DMA, NMP or l-butyl-3 -methyl imidazolium-tetrafluoroborate as reaction solvents.
  • polar aprotic solvent such as DMA, NMP or l-butyl-3 -methyl imidazolium-tetrafluoroborate as reaction solvents.
  • Cis( ⁇ )methyl-2-(4- ⁇ [(4-chloro-5-methyl-l//-pyrrol-2-yl)carbonyl]amino ⁇ -3- methoxypiperidin- 1 -yl)-4- ⁇ [( 1 -methyl- 1 -phenylethyl)amino]carbonyl ⁇ - 1 ,3 -thiazole-5- carboxylate (Example 21; 0.058 g, 0.1 mmol) was dissolved in equal volumes of TFA and DCM.
  • Cis( ⁇ )methyl 2-(4- ⁇ [(3,4-dichloro-5-methyl-lH- ⁇ yrrol-2-yl)carbonyl]amino ⁇ -3- methoxypiperidin-l-yl)-l,3-thiazole-5-carboxylate (Example 1; 200 mg) was dissolved in THF (50 ml). 2N LiOH (100 ml) was added and the mixture was heated at 50 0 C for 18 h. The reaction mixture was cooled to ambient and acidified with 20% aqueous citric acid. The aqueous phase was extracted with EtOAc and the organic phase was washed with water, brine, dried over Na 2 SO 4 .
  • Cis( ⁇ )2-(4- ⁇ [(3,4-dichloro-5-methyl-lH- ⁇ yrrol-2-yl)carbonyl]amino ⁇ -3- methoxypiperidin-l-yl)-l,3-thiazole-5-carboxylic acid (Example 35; 100 mg) was dissolved in anhydrous DMA (2 ml).
  • Example 72 was prepared by the procedure described in Example 72 from the starting material (SM) indicated.
  • Cis( ⁇ )2-(4- ⁇ [(3 ,4-dichloro-5-methyl- 1 H-pyrrol-2-yl)carbonyl]amino ⁇ -3 - methoxypiperidin-l-yl)-l,3-thiazole-5-carboxylic acid (Example 35; 100 mg) was suspended in anhydrous DCM.
  • BBr 3 / DCM (15 ml) was added and the mixture was heated at 40 0 C for 18 h.
  • the reaction mixture was cooled to -50 °C and water was added.
  • the mixture was extracted with EtOAc and the organic phase was washed with water, dried over Na 2 SO 4 .
  • Example 74 was prepared by the procedure described in Example 74 from the starting material (SM) indicated.
  • Cis( ⁇ )3,4-dicholoro-N-[3-methoxy-l-(2-methylquinolin-4-yl)piperidin-4-yl]-5- methyl-lH-pyrrole-2-carboxamide (Example 29; 170 mg) was dissolved in pyridine (5 ml). Selenium dioxide (211 mg) was added and the mixture was heated at 130 °C for 3 h. The brown solution was cooled to room temperature, diluted with water and filtered through a bed of celite. The filtrate was extracted with EtOAc, washed with water and dried over Na 2 SO 4 , concentrated in vacuo.
  • Methyl 2-bromothiazole-5- carboxylate (1.43 g) was added followed by N,N-diisopropylethylamine (3.6 ml) at room temperature. The reaction was heated to 55 °C for 14 h cooled to room temperature. The reaction mixture was diluted with EtOAc (250 ml) and washed with a saturated aqueous ammonium chloride solution (125 ml), followed by a saturated aqueous sodium chloride solution (100 ml). The EtOAc solution was dried over anhydrous MgSO 4 and concentrated in vacuo. The crude product was purified by silica gel chromatography using 0-10% CH 3 OH in DCM.
  • the recovered product was recrystallised from EtOAc to further enhance the diastereomeric excess, increasing it from a 90:10 cis:trans mixture to a 96:4 cis:trans mixture (by HPLC analysis).
  • the recrystallised product was carried on to the next reaction (2 g).
  • Examples 79-82 The following compounds were synthesized by an analogous method to Example 78 from Example 77 and the starting materials given in the table below.
  • Cis( ⁇ )methyl 2-chloro-6-(4- ⁇ [(4-chloro-5-methyl- lH-pyrrol-2-yl)carbonyl]amino ⁇ -3 - methoxypiperidin-l-yl) ⁇ yrimidine-4-carboxylate (Example 23; 0.12g, 0.27 mmol) was dissolved in 0.5 M sodium methoxide in MeOH (5.4 ml, 2.7 mmol) and heated in the microwave for 1.5 h at 85 °C.
  • reaction mixture was acidified with IN HCl and the product was extracted with EtOAc, dried with MgSO 4 and concentrated to a solid which was purified by reverse phase chromatography (gradient elution from 20-50% CH 3 CN in water with 0.5%TFA). Freeze drying yielded product as a white solid.
  • N-Chlorosuccinimide (0.67 g, 5.08 mmol) was added to a solution of ethyl 5-methyl- lH-pyrrole-2-carboxylate (Intermediate 3; 0.65 g, 4.23 mmol) in chloroform (20 ml). The reaction was warmed to 40 0 C and stirred for 4 h, then poured to a beaker containing 2 N NaOH (20 ml) at 0 0 C. The layers were separated and the aqueous layer was extracted with chloroform (x3). The combined organic extracts were dried over magnesium sulfate and concentrated.
  • Methyl-4-hydroxy-l,2,5,6-tetrahydropyridine-3-carboxylate-hydrochloride 25 g was suspended in DCM (250 ml).
  • DIEA 41.6 g was added in a single portion and the resultant homogeneous solution was cooled to 0 0 C.
  • a DCM solution of di-tert-butyl dicarbonate (29.5 g, 1.05 moles) was added dropwise over a 1 h period. After the addition, the reaction was warmed to room temperature and stirred overnight. The reaction mixture was concentrated to one-half the volume and washed with water, brine, dried over Na 2 SO 4 , filtered and concentrated in vacuo to an oil.
  • Diisopropylamine (4.2 ml) was dissolve in anhydrous THF (100 ml) was cooled to - 78°C and to this was added n-butyl lithium (12 ml) slowly. The solution was slowly warmed to 0 °C and then cooled back to -78°C.
  • a solution of TV-(I -methyl- 1 -phenylethyl)-2- (methylthio)-l,3-thiazole-4-carboxamide (Intermediate 13; 2.8 g) in anhydrous THF was added slowly maintaining the temperature below -70°C.
  • 3,4-Difluoro-lH-pyrrole was prepared as described in Eric K. Woller et al., J Org. Chem., 1998 63(16), 5706-5707) and references therein.
  • A-BuOK was added (100 g) under N 2 . After the addition was complete ( ⁇ 0.5 h), the reaction mixture was stirred at room temperature for another 0.5 h. It was cooled to 0 °C and quenched with ice water (300 ml).
  • the title compound can be prepared as described in Lee, C. et al. Synth. Comm. 2001, 25 31(7), 10881-10890 and / or WO 94/12494or from Intermediate 157 by the following procedure;
  • Cis( ⁇ )ethyl 4- ⁇ [(benzyloxy)carbonyl]amino ⁇ -3-methoxypiperidine-l -carboxylate (Intermediate 22; 6.2 g) were separated into its enantiomers by chiral chromatography over a Chiralcel OJ column (eluant: hexanes/MeOH/EtOH;70/15/15;0.1% diethylamine). The 5 fractions corresponding to the first chromatographic peak (Cis(-)isomer) were collected and evaporated yielding the title compound as a white solid (2.62 g).
  • Cis( ⁇ ) ethyl 4-amino-3-methoxypiperidine-l- carboxylate (Intermediate 21; 317 mg) was added and the mixture was stirred at ambient for 18 h. The mixture was diluted with EtOAc and washed with water, IN HCl, bicarbonate buffer, water, brine and dried over Na 2 SO 4 . The solution was concentrated in vacuo to give the title compound as a brown solid (503 mg).
  • Cis( ⁇ )ethyl-4- ⁇ [(3,4-dichloro-5-methyl-lH-pyrrol-2-yl)carbonyl]amino ⁇ -3- methoxypiperidine-1-carboxylate (Intermediate 37; 3.85 g) was suspended in anhydrous CH 3 CN. Iodotrimethylsilane (2.2 ml) was added slowly. The reaction was heated to reflux for several hours until complete by LCMS. The crude reaction mixture was diluted with water and acidified with IN HCl to pH 3. The solution was extracted with EtOAc. The aqueous layer was basified with 50% NaOH to pH 10.
  • Cis( ⁇ )tert-butyl-4-(benzylamino)-3-fluoropiperidine- 1 -carboxylate (Intermediate 82; 2.2 g) was separated into the title compounds using chiral HPLC, in a manner analogous to Intermediate 23 and Intermediate 24 over a Chiralpak AD column (eluent: hexanes / MeOH / EtOH; 90 / 2.5 / 2.5; 0.1% diethylamine). The fractions corresponding to the first chromatographic peak (Cis(+) isomer; Intermediate 57) were collected and evaporated yielding the title compound as a white solid (942 mg).
  • reaction was monitored by GC/MS and additional NH 4 OAc (2.5 equiv.) and NaCNBH 3 (0.25 equiv.) were added until reaction was completed.
  • the solid residue was dissolved in water, and extracted with Et 2 O.
  • the pH of the aqueous phase was adjusted to 8-9 with solid KOH, solution W
  • Cis(d )l-fert-butyl-3-methyl-4- ⁇ [(3,4-dichloro-5-methyl-l/f-pyrrol-2- yl)carbonyl]amino ⁇ -piperidine-l,3-dicarboxylate (Intermediate 46; 4.26 g) and LiBPI 4 (321 mg) were combined in dry THF (20 ml). MeOH (600 ⁇ l) was added in a single portion. The reaction was heated to reflux for 1 h. The mixture was cooled to room temperature, diluted with EtOAc and washed with 0.5% HCl.
  • Cis-te ⁇ bu1yl-4- ⁇ [(3,4-dicWoro-5-methyl-lH ' -pyrrol-2-yl)carbonyl]amino ⁇ -3-( ⁇ [(4- methylphenyl) sulfonyl] oxy ⁇ methy l)piperidine- 1 -carboxylate (Intermediate 72 ; 325 mg) was dissolved in 5 ml of a 30wt% MeOH solution containing NaOMe and an additional 5 ml of dry MeOH. The homogeneous reaction was stirred at room temperature for 2 days. Upon reacting, solids began to precipitate from solution.
  • the reaction was acidified to pH 3 with 2N HCl 9 ⁇ 7 ml), and was concentrated in vacuo.
  • the resultant mixture was dissolved in EtOAc (125 ml) and a saturated aqueous sodium chloride solution (40 ml), followed by the addition of 2N HCl ( ⁇ 1 ml) to acidify the aqueous layer to pH 1.
  • the phases were separated and the aqueous layer was washed with EtOAc (2 x 60 ml).
  • the combined EtOAc layers were dried over anhydrous MgSO 4 and concentrated in vacuo.
  • Cis( ⁇ )ethyl-3 -(allyloxy)-4- [(fert-butoxycarbonyl)amino]piperidine- 1 -carboxylate (Intermediate 27; 528 mg) was dissolved in MeOH (20 ml). 10% Pd-C (100 mg) was added and the mixture was evacuated and replaced with H 2 gas twice. The mixture was stirred under an atmosphere of H 2 gas for 12 h. The catalyst was removed over a bed of celite and solvent was removed in vacuo to give the title compound as an oil (445 mg).
  • CisC ⁇ Vethyl 5-amino-2-(4- ⁇ [r3,4-dichloro-5-methyl-lH-pyrrol-2-yl)carbonyllamino>-3- methoxypiperidin- 1 -vDisonicotinate A solution of SnCl 2 dihydrate (870 mg, 3.8 mmol) in 5 ml concentrated HCl was added to a solution of 436 mg (0.87 mmol) of Cis( ⁇ )-ethyl 2-(4- ⁇ [(3,4-dichloro-5-methyl-lH- pyrrol-2-yl)carbonyl]amino ⁇ -3-methoxypiperidin-l-yl)-5-nitroisonicotinate (Example 308) in 30 ml acetic acid.
  • Methylchlorofomate (15 ⁇ l, 0.19 mmol) was added to a solution of 60 mg (0.13 mmol) of Cis( ⁇ )-ethyl 5 -amino-2-(4- ⁇ [(3 ,4-dichloro-5-methyl- 1 H-pyrrol-2-yl)carbonyl] amino ⁇ -3 - methoxypiperidin-l-yl)isonicotinate (Example 194) in 3 ml pyridine. After stirring at room temperature overnight, 7 ⁇ l more methylchloroformate was added. Solvent was removed and the residue was partitioned between EtOAc and NaHCO 3 (aqueous). The EtOAc was separated and washed with water and brine.
  • Methanesulfonyl chloride (16 ⁇ l, 21 mmol) was added to 66 mg (0.14 mmol) of Cis( ⁇ )-ethyl 5-amino-2-(4- ⁇ [(3,4-dichloro-5-methyl-lH- ⁇ yrrol-2-yl)carbonyl]amino ⁇ -3- methoxypiperidin-l-yi)isonicotinate (Example 194) in 3 ml pyridine. After stirring for 1 h, 5 ⁇ l more methanesulfonyl chloride was added. Stirred at room temperature overnight. Solvent was removed, and the residue was partitioned between EtOAc and Na 2 CO 3 (aqueous).
  • Example 198 The following Examples were prepared by the procedure described in Example 198 from the starting materials (SM) indicated.
  • Example 201 The following Examples were prepared by the procedure described in Example 201 from the starting materials (SM) indicated.
  • Cis( ⁇ )-2-((35,4i?)-4- ⁇ [(3,4-dichloro-5-methyl-lH " -pyrrol-2- yl)carbonyl]amino ⁇ -3-methoxypiperidin- 1 -yl)-5-(ethoxycarbonyl)- 1 ,3-thiazole-4-carboxylic acid (0.062g, 0.12mmol, Example 188), dimethylamine (O.O ⁇ mL, 2M solution in THF 5 Aldrich), HATU (0.05g, 0.13mmol) and triethylamine (0.018mL, 0.13mmol) was stirred
  • Cis( ⁇ )-ethyl 2-(4- ⁇ [(3,4-dichloro-5-methyl-l#-pyrrol-2- yl)carbonyl]amino ⁇ -3-methoxypiperidin-l-yl)-4-formyl-l,3-thiazole-5-carboxylate (0.10g, 0.2mmol, Example 252), sodium acetate (0.04Ig 5 0.5mmol) and hydroxylamine hydrochloride (0.028g, 0.4mmol) were heated to reflux in absolute ethanol for 3 hours.
  • Examples 257-381 The following Examples were synthesized by an analogous method to Example 35 from the starting materials (SM) given in the table below.
  • Cis( ⁇ )-5-(aminocarbonylV2-(4- ⁇ ⁇ (3 ⁇ -dichloro-S-methyl- lH-pyrrol-2-yl)carbonyl]amino ⁇ -3- methoxypiperidin- 1 -vD- 1 ,3 -thiazole-4-carboxylic acid A solution of 55 mg (23 mmol) of Cis( ⁇ )- 3,4-dichloro-7V-[3 ⁇ methoxypiperidin-4-yl]-
  • Examples 384-385 The following Examples were synthesized by an analogous method to Example 383 ; -'' from the starting materials (SM) given in the table below.
  • reaction was complete by LCMS analysis.
  • the reaction mixture was diluted with water and acidified withlN HCl. After concentrating to remove methanol, the resulting white precipitate was filtered, washed with water and dried (0.07Ig).
  • Example 417 sodium 2-((3 l S'.4i?V4-([f3.4-dichloro-5-methyl-lH-pyrrol-2-vncarbonyllaminol-3- methoxypiperidin-l-ylV4-- ⁇ ' r(2-methoxyethyl)amino]carbonvU-l,3-thiazole-5-carboxylate
  • the mixture was stirred for 1 h and then concentrated under reduced pressure to provide the crude salt (230 mg).
  • the salt was dissolved in acetone/water (50 ml; 48:2) and acetone was added slowly to the stirred mixture until it became cloudy. Stirring was continued and more acetone was added very slowly over 20 min. The mixture was stored at 4 °C overnight. The solid was collected by filtration and air dried for 24 h to provide the salt (160 mg).
  • the crude salt (80 mg) was dissolved in ethyl acetate/ methanol (8 ml; 50:50) and ethyl acetate was added slowly to the stirred solution until it became cloudy. Stirring was continued and additional ethyl acetate (-15 ml) was added slowly to the mixture. The mixture was stored at 4 °C overnight. The solid was collected by filtration and air dried for 24 h to provide the salt (64 mg).
  • Cisr ⁇ Vethyl (4- ⁇ rG.4-dichloro-5-methyl-liJ r -pyrrol-2-v ⁇ carbonyllamino>-3- methylpiperidine- 1 -carboxylate
  • Ethyl 2-amino-5-methyl-l,3-thiazole-4-carboxylate (Intermediate 178, 3 g; 16.1 mmol) and anhydrous CuCl 2 (3.25 g; 24.2 mmol; 1.5 equiv.) were combined in dry acetonitrile (28 ml), t-butyl nitrite (90% tech; 2.77 g; 24.2 mmol; 1.5 equiv.) was added drop wise. The suspension was stirered at room temperature for 12 hours and monitored by LC/MS. The acetonitrile was removed in vacou and the solid was redissolved in CHCl 3 and H 2 O. The aqueous layer was acidified with 2N HCl and the phases were separated.
  • N-Chlorosuccinimide (1.77 g, 13.25 mmol) was added to a solution of ethyl 3,5- dimethyl-2-pyrrole carboxylate (2.11 g, 12.62 mmol) in chloroform (45 mL). The reaction mixture was stirred at room temperature for 24 h and then poured into 2 N NaOH. The organic layer was washed with water and brine, dried over sodium sulfate, filtered, and concentrated under reduced pressure to give a crude solid. The crude solid was dissolved in hot MeOH, cooled to room temperature, and the precipitate was collected by filtration (493 mg, 19%). MS (ES) MH + : 174 for C 9 H 12 ClNO 2 .
  • Et 3 N (5.5 ml, 39 mmol) was added slowly to a solution of 2.0 g (13 mmol) of ethyl A- methyl-l/J-pyrrole-2-carboxylate and 3.1 ml SO 2 Cl 2 in 30 ml CH 2 Cl 2 cooled in an ice water bath. The mixture was warmed to room temperature with stirring overnight. After treatment with aqueous NaHSO 3 , the CH 2 Cl 2 was removed and the aqueous residue was diluted with water and extracted twice with EtOAc. The EtOAc extracts were washed with brine, dried (MgSO 4 ) and concentrated. The solid residue was twice recrystallized from 50% aqueous EtOH to afford 1.38 g of product as a white solid.
  • Methyl 4-oxopiperidine-3-carboxylate hydrochloride (13.0 g) was suspended in anhydrous DCM (100 niL) under an argon atmosphere.
  • DIEA 29.2 mL was added slowly via syringe, producing a slightly cloudy solution.
  • the reaction was cooled to O 0 C, and ⁇ i-tert- butyl dicarboxylate (16.1 g) was added, resulting in an exothermic reaction.
  • the reaction mixture was left stirring overnight , slowly warming to room temperature.
  • the reaction mixture was then concentrated in vacuo and partitioned between EtOAc (500 mL) and saturated aqueous NH 4 Cl (350 mL).
  • Ethyl 4-azido-3 -(2-tgrt-butoxy-2-oxoethoxy)piperidine- 1 -carboxylate Ethyl 4-azido-3-hy droxypiperidine- 1 -carboxylate (Intermediate 238, 1.71 g) was dissolved in anhydrous THF (15 mL) and cooled to 0°C. Sodium hydride (60% in mineral oil) (0.42 g) was added as a shot, stirred for twenty minutes at 0°C, followed by the slow addition of tert-butyl bromo acetate (0.86 mL) via syringe, and stirred for an additional two hours at O 0 C.
  • Diisopropylamine (5.3 ml) was dissolve in anhydrous THF (100 ml) was cooled to - 5 78 0 C and to this was added n-butyl lithium (15 ml) slowly. The solution was slowly warmed to 0 °C and then cooled back to -78 0 C.
  • a solution of TV-(I -methyl- 1-pheny lethyl)-2- (methy ItMo)-1, 3 -thiazole-4-carboxamide (Intermediate 13; 3.7 g) in anhydrous THF was added slowly maintaining the temperature below -70 0 C.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Compounds of formula (I) and their pharmaceutically acceptable salts are described: Formula (I). Processes for their preparation, pharmaceutical compositions containing them, their use as medicaments and their use in the treatment of bacterial infections are also described.

Description

ANTIBACTERIAL PIPERIDINE DERIVATIVES
BACKGROUND OF THE INVENTION
The present invention relates to compounds which demonstrate antibacterial activity, processes for their preparation, pharmaceutical compositions containing them as the active ingredient, to their use as medicaments and to their use in the manufacture of medicaments for use in the treatment of bacterial infections in warm-blooded animals such as humans. In particular this invention relates to compounds useful for the treatment of bacterial infections in warm-blooded animals such as humans, more particularly to the use of these compounds in the manufacture of medicaments for use in the treatment of bacterial infections in warm-blooded animals such as humans.
The international microbiological community continues to express serious concern that the evolution of antibiotic resistance could result in strains against which currently available antibacterial agents will be ineffective. In general, bacterial pathogens may be classified as either Gram-positive or Gram-negative pathogens. Antibiotic compounds with effective activity against both Gram-positive and Gram-negative pathogens are generally regarded as having a broad spectrum of activity. The compounds of the present invention are regarded as effective against both Gram-positive and certain Gram-negative pathogens.
Gram-positive pathogens, for example Staphylococci, Enterococci, Streptococci and mycobacteria, are particularly important because of the development of resistant strains which are both difficult to treat and difficult to eradicate from the hospital environment once established. Examples of such strains are methicillin resistant staphylococcus aureus (MRSA), methicillin resistant coagulase negative staphylococci (MRCNS), penicillin resistant Streptococcus pneumoniae and multiple resistant Enterococcus faecium. The preferred clinically effective antibiotic for treatment of last resort of such resistant
Gram-positive pathogens is vancomycin. Vancomycin is a glycopeptide and is associated with various toxicities, including nephrotoxicity. Furthermore, and most importantly, antibacterial resistance to vancomycin and other glycopeptides is also appearing. This resistance is increasing at a steady rate rendering these agents less and less effective in the treatment of Gram-positive pathogens. There is also now increasing resistance appearing towards agents such as β-lactams, quinolones and macrolides used for the treatment of upper respiratory tract infections, also caused by certain Gram negative strains including H. influenzae and M.catarrhalis. Consequently, in order to overcome the threat of widespread multi-drug resistant organisms, there is an on-going need to develop new antibiotics, particularly those with either a novel mechanism of action and/or containing new pharmacophoric groups.
Deoxyribonucleic acid (DNA) gyrase is a member of the type II family of topoisomerases that control the topological state of DNA in cells (Champoux, J. J.; 2001. Ann. Rev. Biochem. 70: 369-413). Type II topoisomerases use the free energy from adenosine triphosphate (ATP) hydrolysis to alter the topology of DNA by introducing transient double-stranded breaks in the DNA, catalyzing strand passage through the break and resealing the DNA. DNA gyrase is an essential and conserved enzyme in bacteria and is unique among topoisomerases in its ability to introduce negative supercoils into DNA. The enzyme consists of two subunits, encoded by gyrA and gyrB, forming an A2B2 tetrameric complex. The A subunit of gyrase (GyrA) is involved in DNA breakage and resealing and contains a conserved tyrosine residue that forms the transient covalent link to DNA during strand passage. The B subunit (GyrB) catalyzes the hydrolysis of ATP and interacts with the A subunit to translate the free energy from hydrolysis to the conformational change in the enzyme that enables strand-passage and DNA resealing.
Another conserved and essential type II topoisomerase in bacteria, called topoisomerase IV, is primarily responsible for separating the linked closed circular bacterial chromosomes produced in replication. This enzyme is closely related to DNA gyrase and has a similar tetrameric structure formed from subunits homologous to Gyr A and to Gyr B. The overall sequence identity between gyrase and topoisomerase IV in different bacterial species is high. Therefore, compounds that target bacterial type II topoisomerases have the potential to inhibit two targets in cells, DNA gyrase and topoisomerase IV; as is the case for existing quinolone antibacterials (Maxwell, A. 1997, Trends Microbiol. 5: 102-109). DNA gyrase is a well- validated target of antibacterials, including the quinolones and the coumarins. The quinolones (e.g. ciprofloxacin) are broad-spectrum antibacterials that inhibit the DNA breakage and reunion activity of the enzyme and trap the GyrA subunit covalently complexed with DNA (Drlica, K., and X. Zhao, 1997, Microbiol. Molec. Biol. Rev. 61: 377-392). Members of this class of antibacterials also inhibit topoisomerase IV and as a result, the primary target of these compounds varies among species. Although the quinolones are successful antibacterials, resistance generated primarily by mutations in the target (DNA gyrase and topoisomerase IV) is becoming an increasing problem in several organisms, including S. aureus and Streptococcus pneumoniae (Hooper, D. C, 2002, The Lancet Infectious Diseases 2: 530-538). In addition, quinolones, as a chemical class, suffer from toxic side effects, including arthropathy that prevents their use in children (Lipsky, B. A. and Baker, C. A., 1999, Clin. Infect. Dis. 28: 352-364). Furthermore, the potential for cardiotoxicity, as predicted by prolongation of the QT0 interval, has been cited as a toxicity concern for quinolones.
There are several known natural product inhibitors of DNA gyrase that compete with ATP for binding the GyrB subunit (Maxwell, A. and Lawson, D.M. 2003, Curr. Topics in Med. Chem. 3: 283-303). The coumarins are natural products isolated from Streptomyces spp., examples of which are novobiocin, chlorobiocin and coumermycin Al. Although these compounds are potent inhibitors of DNA gyrase, their therapeutic utility is limited due to toxicity in eukaryotes and poor penetration in Gram-negative bacteria (Maxwell, A. 1997, Trends Microbiol. 5: 102-109). Another natural product class of compounds that targets the GyrB subunit is the cyclothialidines, which are isolated from Streptomyces filipensis (Watanabe, J. et al 1994, J. Antibiot. 47: 32-36). Despite potent activity against DNA gyrase, cyclothialidine is a poor antibacterial agent showing activity only against some eubacterial species (Nakada, N, 1993, Antimicrob. Agents Chemother. 37: 2656-2661).
Synthetic inhibitors that target the B subunit of DNA gyrase and topoisomeraseIV are known in the art. For example, coumarin-containing compounds are described in patent application number WO 99/35155, 5,6-bicyclic heteroaromatic compounds are described in patent application WO 02/060879, and pyrazole compounds are described in patent application WO 01/52845 (US patent US6,608,087).
We have discovered a new class of compounds which are useful for inhibiting DNA gyrase and topoisomerase IV.
SUMMARY OF THE INVENTION
Therefore the present invention provides a compound of formula (I):
Figure imgf000004_0001
(I) wherein:
R1 is selected from hydrogen, nitro, hydroxy, halo, cyano, C1-4alkyl, C1-4alkoxy, C2-4alkenyl, C2-4alkynyl, d^alkanoyl, Ci-4alkylS(O)a wherein a is 0 to 2 and C3-6cycloalkyl; wherein R1 may be optionally substituted on carbon by one or more halo or cyclopropyl; R2 is selected from hydrogen, nitro, hydroxy, halo, cyano, Ci-4alkyl, C1-4alkoxy,
C2-4alkenyl, C2-4alkynyl, C1-4alkanoyl, C1-4alkylS(O)a wherein a is 0 to 2 and C3-6cycloalkyl; wherein R2 may be optionally substituted on carbon by one or more halo or C3-6cycloalkyl;
R3 is selected from hydrogen, nitro, hydroxy, halo, cyano, -C=N-OR' wherein R' is H or C1-4alkyl, C1-4alkyl, C1-4alkoxy, C2-4alkenyl, C2-4alkynyl, C1-4alkanoyl, C1-4alkylS(O)a wherein a is 0 to 2 and C3-6cycloalkyl; wherein R3 may be optionally substituted on carbon by one or more halo or C3-6cycloalkyl;
W is -O-, -N(R6)- or -C(R7)(R8)-;
X is a direct bond, -CH2-, -C(O)- or S(O)q- (wherein q is 1 or 2);
Ring A is carbocyclyl or heterocyclyl; wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R9;
R4 and R5 are substituents on carbon and are independently selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, sulfo, formyl, ureido, hydroxyiminomethyl, C1-4alkoxyiminomethyl, iV-hydroxyformamido, C1-4hydrazino, hydrazinocarbonyl, JV-hydroxyethanimidoyl, amino(hydroxyimino)methyl, C1-4alkyl, C2-4alkenyl, C2-4alkynyl, C1-4alkoxy, C1-4alkanoyl, C^alkanoyloxy,
N-(C1-4alkyl)amino, λζiV-(C1-4alkyl)2amino, Ci-4alkanoylamino, iV-(Ci-4alkyl)carbamoyl, N,iV-(C1-4alkyl)2carbamoyl, iV-(C1-4alkoxy)carbamoyl, iV'-(C1-4alkyl)ureido, iV'N-(Ci-4alkyl)2ureido, N-(C1-4alkyl)-iV-(C1-4alkoxy)carbamoyl, C1-4alkylS(O)a wherein a is 0 to 2, Ci-4alkoxycarbonyl, Ci-4alkoxycarbonylamino, iV-(C1-4alkyl)sulphamoyl, ΛζiV-(C1-4alkyl)2Sulphamoyl, C1-4alkylsulphonylamino, C1-4alkylsulphonylaminocarbonyl, N'-(C1-4alkyl)hydrazinocarbonyl, iV',iV'-(Ci-4alkyi)2hydrazinocarbonyl, carbocyclyl-R10- or heterocyclyl-R11 — ; wherein R and R5 independently of each other may be optionally substituted on carbon by one or more R ; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R13; R6, R7 and R8 are independently selected from hydrogen or Ci-4alkyl; n is 1-4; wherein the values of R4 may be the same or different; m is 0-4; wherein the values of R5 may be the same or different; R12 is selected from azido, halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, Ci-4alkyl, C2-4alkenyl, C2-4alkynyl, C1-4alkoxy, Ci-4alkanoyl, Ci-4alkanoyloxy, N-(Ci-4alkyl)amino, N5N-(C i-4alkyl)2amino, C1-4alkanoylamino, N-(Ci-4alkyl)carbamoyl, N,N-(Ci-4alkyl)2carbamoyl, C1-4alkylS(O)a wherein a is 0 to 2, C1-4alkoxycarbonyl, N-(C1-4alkyl)sulphamoyl,
N,N-(C1.4alkyl)2sulphamoyl, C1-4alkylsulphonylamino, C1-4alkoxycarbonylamino, carbocyclyl-R14 — or heterocyclyl-R15 — ; wherein R12 independently of each other may be optionally substituted on carbon by one or more R16; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R17; R9, R1 and R17 are independently selected from Cj-4alkyl, C1-4alkanoyl,
C1-4alkylsulphonyl, C1-4alkoxycarbonyl, carbamoyl, N-(C1-4alkyl)carbamoyl, N, N-(C1 -4alkyl)carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulphonyl;
R10, R11, R14 and R15 are independently selected from a direct bond, -O-, -N(R18)-, -C(O)-, -N(R19)C(O)-, -C(O)N(R20)-, -S(O)P-, -SO2N(R21)- or -N(R22)SO2-; wherein R18, R19, on o 1 oo R , R and R are independently selected from hydrogen or Chalky! and p is 0-2;
R16 is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, carboxy, carbamoyl, mercapto, sulphamoyl, methyl, ethyl, ethenyl, ethynyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, iV-methyl-N-ethylamino, acetylamino, N-methylcarbamoyl, iV-ethylcarbamoyl, N, N-dimethylcarbamoyl, N, N-diethylcarbamoyl, N-methyl-N-ethylcarbamoyl, methylthio, ethylthio, methylsulphinyl, ethylsulphinyl, mesyl, ethylsulphonyl, methoxycarbonyl, ethoxy carbonyl, iV-methylsulphamoyl, N-ethylsulphamoyl, N, N-dimethylsulphamoyl, N, N-diethylsulphamoyl or N-methyl-N-ethylsulphamoyl; or a pharmaceutically acceptable salt thereof.
The present invention also provides a compound of formula (IA):
Figure imgf000006_0001
(IA) wherein:
R1 is selected from hydrogen, nitro, hydroxy, halo, cyano, Q^alkyl, C1-4alkoxy, C2-4alkenyl, C2-4alkynyl, C1-4alkanoyl, C1-4alkylS(O)a wherein a is 0 to 2 and C3-6cycloalkyl; wherein R1 may be optionally substituted on carbon by one or more halo or cyclopropyl; R2 is selected from hydrogen, nitro, hydroxy, halo, cyano, C1-4alkyl, C1-4alkoxy,
C2-4alkenyl, C2-4alkynyl, C1-4alkanoyl, C1-4alkylS(O)a wherein a is 0 to 2 and C3-6cycloalkyl; wherein R2 may be optionally substituted on carbon by one or more halo or C3-6cycloalkyl; R3 is selected from hydrogen, nitro, hydroxy, halo, cyano, -C=N-OR' wherein R' is H or Ci-4alkyl, C1-4alkyl,
Figure imgf000007_0001
C2-4alkenyl, C2-4alkynyl, Ci-4alkanoyl, C1-4alkylS(O)a wherein a is 0 to 2 and C3-6cycloalkyl; wherein R3 may be optionally substituted on carbon by one or more halo or C3-6cycloalkyl; X is a direct bond, -CH2-, -C(O)- or S(O)q- (wherein q is 1 or
2);
Ring A is carbocyclyl or heterocyclyl; wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R9; R4 and R5 are substituents on carbon and are independently selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, sulfo, formyl, ureido, hydroxyiminomethyl, N-hydroxyformamido, hydrazinocarbonyl, JV-hydroxyethanimidoyl, amino(hydroxyimino)methyl, C1-4alkyl, C2-4alkenyl, C2-4alkynyl, C1-4alkoxy, Ci-4alkanoyl, C1-4alkanoyloxy, 7V-(C1-4alkyl)amino, ^^-(Cmalkyl^amino,
Figure imgf000007_0002
JV-(C 1-4alkyl)carbamoyl, iV;N-(C1-4alkyl)2carbamoyl, N-(C1 -4alkoxy)carbamoyl, N-(C1 -4alky l)ureido, JV' JV-(C i -4alkyl)2ureido, N-(C1-4alkyl)-N-(C1-4alkoxy)carbamoyl, Ci.4alkylS(0)a wherein a is 0 to 2, C i -4alkoxycarbonyl, C i -4alkoxycarbony lamino, N-(Ci -4alky 1) sulphamoyl, N1N-(Ci -4alky l)2sulphamoy 1, C \ _4alkylsulphony lamino, C i -4alkylsulphony laminocarbony 1, JV-(C1-4alkyl)hydrazinocarbonyl, N',N'-(Ci-4alkyl)2hydrazinocarbonyl, carbocyclyl-R10- or heterocyclyl-R11-; wherein R4 and R5 independently of each other may be optionally substituted on carbon by one or more R12; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R13; R6, R7 and R8 are independently selected from hydrogen or C^alkyl; n is 1-4; wherein the values of R4 may be the same or different; m is 0-4; wherein the values of R5 may be the same or different; R is selected from azido, halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C1-4alkyl, C2-4alkenyl, C2-4alkynyl, C1-4alkoxy, Ci-4alkanoyl, Ci-4alkanoyloxy, N-(Ci-4alkyl)amino, N,N-(C1-4alkyl)2amino, C1-4alkanoylamino, N-(C1-4alkyl)carbamoyl, N5N-(C i-4alkyl)2carbamoyl, C1-4alkylS(O)a wherein a is 0 to 2, C1-4alkoxycarbonyl, N-(C1-4alkyl)sulphamoyl, N,N-(C1-4alkyl)2sulphamoyl, C1-4alkylsulphonylamino, Ci-4alkoxycarbonylamino, carbocyclyl-R14- or heterocyclyl-R15-; wherein R12 independently of each other may be optionally substituted on carbon by one or more R16; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R17;
R9, R13 and R17 are independently selected from Ci-4alkyl, C1-4alkanoyl, C1-4alkylsulphonyl, Ci-4alkoxycarbonyl, carbamoyl, JV-(C1 -4alkyl)carbamoyl,
Figure imgf000008_0001
benzyl, benzyloxycarbonyl, benzoyl and phenylsulphonyl;
R10, R11, R14 and R15 are independently selected from a direct bond, -O-, -N(R18)-, -C(O)-, -N(R19)C(O)-, -C(O)N(R20)-, -S(O)P-, -SO2N(R21)- or -N(R22)SO2-; wherein R18, R19, R20, R21 and R22 are independently selected from hydrogen or C1-4alkyl and p is 0-2;
R16 is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, carboxy, carbamoyl, mercapto, sulphamoyl, methyl, ethyl, ethenyl, ethynyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, iV-methyl-iV-ethylamino, acetylamino, iV-methylcarbamoyl, iV-ethylcarbamoyl, N, iV-dimethylcarbamoyl, λζiV-diethylcarbamoyl, iV-methyl-iV-ethylcarbamoyl, methylthio, ethylthio, methylsulphinyl, ethylsulphinyl, mesyl, ethylsulphonyl, methoxycarbonyl, ethoxycarbonyl, N-methylsulphamoyl, iV-ethylsulphamoyl, ΛζiV-dimethylsulphamoyl, AζiV-diethylsulphamoyl or iV-methyl-N-ethylsulphamoyl; or a pharmaceutically acceptable salt thereof.
The present invention also provides a compound of formula (IB):
Figure imgf000008_0002
(IB) wherein:
R1 is selected from hydrogen, nitro, hydroxy, halo, cyano, Ci-4alkyl, C1-4alkoxy, C2-4alkenyl, C2-4alkynyl, C1-4alkanoyl, C1-4alkylS(O)a wherein a is 0 to 2 and C3-6cycloalkyl; wherein R1 may be optionally substituted on carbon by one or more halo or cyclopropyl; R2 is selected from hydrogen, nitro, hydroxy, halo, cyano, C1-4alkyl, C1-4alkoxy,
C2-4alkenyl, C2-4alkynyl, C1-4alkanoyl, C1-4alkylS(O)a wherein a is 0 to 2 and C3-6cycloalkyl; wherein R2 may be optionally substituted on carbon by one or more halo or C3-6cycloalkyl;
R3 is selected from hydrogen, nitro, hydroxy, halo, cyano, -C=N-OR' wherein R' is H or C1-4alkyl, C1-4alkyl, C^alkoxy, C2-4alkenyl, C2-4alkynyl, C1-4alkanoyl, C1-4alkylS(O)a wherein a is 0 to 2 and C3-6Cy cloalkyl; wherein R3 may be optionally substituted on carbon by one or more halo or C3-6cycloalkyl;
Ring A is carbocyclyl or heterocyclyl; wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R ;
R and R5 are substituents on carbon and are independently selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, sulfo, formyl, ureido, hydroxyiminomethyl, JV-hydroxyformamido, hydrazinocarbonyl, N-hydroxyethanimidoyl, amino(hydroxyimino)methyl, C1-4alkyl, C2-4alkenyl, C2-4alkynyl, C1-4alkoxy, C1-4alkanoyl, Ci-4alkanoyloxy, iV-(C1-4alkyl)amino, ΛζN-(C1-4alkyl)2amino, C 1-4alkanoylamino, N-(Ci -4alkyl)carbamoyl, N, N-(C i .4alkyl)2carbamoyl, N-(Ci-4alkoxy)carbamoyl, JV-(C1.4alkyl)ureido, N',N'-(CI-4alkyl)2ureido, N-(C1-4alkyl)-N-(Ci.4alkoxy)carbamoyl, C1-4alkylS(O)a wherein a is 0 to 2, C1-4alkoxycarbonyl, C1-4alkoxycarbonylamino, N-(C 1-4alkyl) sulphamoyl, N,N-(C1-4alkyl)2sulphamoyl, C 1-4alkylsulphonylamino, C^alkylsulphonylaminocarbonyl, N'-(C1-4alkyl)hydrazinocarbonyl, N',N'-(C1-4alkyl)2hydrazinocarbonyl, carbocyclyl-R10- or heterocyclyl-R1 '-; wherein R4 and R5 independently of each other may be optionally substituted on carbon by one or more R12; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R13;
R6, R7 and R8 are independently selected from hydrogen or C1-4alkyl; n is 1-4; wherein the values of R4 may be the same or different; m is 0-4; wherein the values of R5 may be the same or different;
R12 is selected from azido, halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, Q^alkyl, C2-4alkenyl, C2-4alkynyl, C1-4alkoxy, C1-4alkanoyl, Ci-4alkanoyloxy, N-(C1-4alkyl)amino, N,N-(Ci-4alkyl)2amino, C1-4alkanoylamino, N-(Ci-4alkyl)carbamoyl, N,N-(Ci-4alkyl)2carbamoyl, C1-4alkylS(O)a wherein a is 0 to 2, Ci-4alkoxycarbonyl, N-(Ci_4alkyl)sulphamoyl, N5N-(C i -4alky l)2sulphamoy 1, C i-4alky lsulphony lamino, C i -4alkoxy carbonylamino, carbocyclyl-R14- or heterocyclyl-R15-; wherein R12 independently of each other may be optionally substituted on carbon by one or more R16; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R17;
R9, R13 and R17 are independently selected from Chalky I5 C1-4alkanoyl, C1-4alkylsulphonyl, C1-4alkoxycarbonyl, carbamoyl, JV-(C 1-4alkyl)carbamoyl, AζiV-(C1-4alkyl)carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulphonyl; R10, R11, R14 and R15 are independently selected from a direct bond, -O-, -N(R18)-,
-C(O)-, -N(R19)C(O)-, -C(O)N(R20)-, -S(O)P-, -SO2N(R21)- or -N(R22)SO2-; wherein R18, R19, R20, R21 and R22 are independently selected from hydrogen or C1-4alkyl and p is 0-2;
R16 is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, carboxy, carbamoyl, mercapto, sulphamoyl, methyl, ethyl, ethenyl, ethynyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, iV-methyl-iV-ethylamino, acetylamino, iV-methylcarbamoyl, iV-ethylcarbamoyl, ΛζiV-dimethylcarbamoyl, i\ζiV-diethylcarbamoyl, iV-methyl-iV-ethylcarbamoyl, methylthio, ethylthio, methylsulphinyl, ethylsulphinyl, mesyl, ethylsulphonyl, methoxycarbonyl, ethoxycarbonyl, iV-methylsulphamoyl, JV-ethylsulphamoyl, ΛζN-dimethylsulphamoyl, AζiV-diethylsulphamoyl or N-methyl-JV-ethylsurphamoyl; or a pharmaceutically acceptable salt thereof.
The present invention also provides a compound of formula (IC):
Figure imgf000010_0001
(IC) wherein:
R1 is selected from hydrogen, nitro, hydroxy, halo, cyano, Ci-4alkyl, Ci-4alkoxy, C2-4alkenyl, C2-4alkynyl, C1-4alkanoyl, C1-4alkylS(O)a wherein a is 0 to 2 and C3-6cycloalkyl; wherein R1 may be optionally substituted on carbon by one or more halo or cyclopropyl; R2 is selected from hydrogen, nitro, hydroxy, halo, cyano, Ci-4alkyl, Ci-4alkoxy, C2-4alkenyl, C2-4alkynyl,
Figure imgf000011_0001
Ci-4alkylS(O)a wherein a is 0 to 2 and C3-6cycloalkyl; wherein R2 may be optionally substituted on carbon by one or more halo or C3-6cycloalkyl;
R3 is selected from hydrogen, nitro, hydroxy, halo, cyano, -C=N-OR' wherein R' is H or C^alkyl, C1-4alkyl, C1-4alkoxy, C2-4alkenyl, C2-4alkynyl, C1-4alkanoyl, C1-4alkylS(0)a wherein a is 0 to 2 and C3-6cycloalkyl; wherein R3 may be optionally substituted on carbon by one or more halo or C3-6cycloalkyl;
Ring A is carbocyclyl or heterocyclyl; wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R9; R4 and R5 are substituents on carbon and are independently selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, sulfo, formyl, ureido, hydroxyiminomethyl, N-hydroxyformamido, hydrazinocarbonyl, N-hydroxyethanimidoyl, amino(hydroxyimino)methyl, Ci.4alkyl, C2-4alkenyl, C2-4alkynyl, C1-4alkoxy, C1-4alkanoyl, C1-4alkanoyloxy, N-(C1-4alkyl)amino, N,N-(C1-4alkyl)2amino, C1-4alkanoylamino, N-(C1-4alkyl)carbamoyl, N, N-(C1-4alkyl)2carbamoyl, N-(C1 -4alkoxy)carbamoyl, N-(C1 -4alky l)ureido, N', N-(C1 -4alkyl)2ureido, N-(C1-4alkyl)-N-(C1-4alkoxy)carbamoyl, C1-4alkylS(O)a wherein a is 0 to 2, C1-4alkoxycarbonyl, C1-4alkoxycarbonylamino, N-(C1-4alkyl)sulphamoyl, N,N-(C1-4alkyl)2sulphamoyl, Ci-4alkylsulphonylamino, C1-4alkylsulphonylaminocarbonyl, N'-(C1-4alkyl)hydrazinocarbonyl, N'N'-(Ci-4alkyl)2hydrazinocarbonyl, carbocyclyl-R10- or heterocyclyl-R11-; wherein R and R5 independently of each other may be optionally substituted on carbon by one or more R12; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R13; R6, R7 and R8 are independently selected from hydrogen or Ci^alkyl; m is 0-4; wherein the values of R5 may be the same or different;
R12 is selected from azido, halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, Ci-4alkyl, C2-4alkenyl, C2-4alkynyl, C1-4alkoxy, Ci-4alkanoyl, C1-4alkanoyloxy, N-(Ci-4alkyl)amino, N,N-(Ci-4alkyl)2amino, Ci^alkanoylamino, N-(C1-4alkyl)carbamoyl, N,N-(C1-4alkyl)2carbamoyl, Ci-4alkylS(O)a wherein a is 0 to 2, Ci-4alkoxycarbonyl, N-(C1-4alkyl)sulphamoyl,
N,N-(Ci-4alkyl)2sulphamoyl, Ci-4alkylsulphonylamino, Ci-4alkoxycarbonylamino, carbocyclyl-R14- or heterocyclyl-R15-; wherein R12 independently of each other may be optionally substituted on carbon by one or more R16; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R17;
R9, R13 and R17 are independently selected from C1-4alkyl, C1-4alkanoyl, C1-4alkylsulphonyl, C1-4alkoxycarbonyl, carbamoyl, iV-(C1-4alkyl)carbamoyl, N,JV-(C1-4alkyi)carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulphonyl;
R10, R11, R14 and R15 are independently selected from a direct bond, -O-, -N(R18)-, -C(O)-, -N(R19)C(0)-, -C(O)N(R20)-, -S(0)p-, -SO2N(R21)- or -N(R22)SO2-; wherein R18, R19, R20, R21 and R22 are independently selected from hydrogen or C1-4alkyl and p is 0-2;
R16 is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, carboxy, carbamoyl, mercapto, sulphamoyl, methyl, ethyl, ethenyl, ethynyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, N-methyl-JV-ethylamino, acetylamino, iV-methylcarbamoyl, iV-ethylcarbamoyl, N,iV-dimethylcarbamoyl, λζiV-diethylcarbamoyl, iV-methyl-JV-ethylcarbamoyl, methylthio, ethylthio, methylsulphinyl, ethylsulphinyl, mesyl, ethylsulphonyl, methoxycarbonyl, ethoxy carbonyl, JV-methylsulphamoyl, iV-ethylsulphamoyl, N, iV-dimethylsulphamoyl, N,iV-diethylsurphamoyl or N-methyl-7V-ethylsulphamoyl; or a pharmaceutically acceptable salt thereof.
The present invention also provides a compound of formula (ID):
Figure imgf000012_0001
(ID) wherein:
R1 is selected from hydrogen, nitro, hydroxy, halo, cyano, C1-4alkyl, Ci-4alkoxy, C2-4alkenyl, C2-4alkynyl, C1-4alkanoyl, C1-4alkylS(0)a wherein a is 0 to 2 and C3-6cycloalkyl; wherein R1 may be optionally substituted on carbon by one or more halo or cyclopropyl;
R2 is selected from hydrogen, nitro, hydroxy, halo, cyano, Ci-4alkyl, C1-4alkoxy, C2-4alkenyl, C2-4alkynyl, Ci-4alkanoyl, Ci-4alkylS(O)a wherein a is 0 to 2 and C3-6cycloalkyl; wherein R2 may be optionally substituted on carbon by one or more halo or C3-6cycloalkyl; R3 is selected from hydrogen, nitro, hydroxy, halo, cyano, -C=N-OR' wherein R' is H or C1-4alkyl, Ci-4alkyl, C1-4alkoxy, C2-4alkenyl, C2-4alkynyl, C1-4alkanoyl, C1-4alkylS(0)a wherein a is 0 to 2 and C3-6cycloalkyl; wherein R3 may be optionally substituted on carbon by one or more halo or C3-6cycloalkyl; Ring A is heterocyclyl; wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R9;
R and R5 are substituents on carbon and are independently selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, sulfo, formyl, ureido, hydroxyiminomethyl, N-hydroxyformamido, hydrazinocarbonyl, iV-hydroxyethanimidoyl, amino(hydroxyimino)methyl, C1-4alkyl, C2-4alkenyl, C2-4alkynyl, C1-4alkoxy, C1-4alkanoyl, C1-4alkanoyloxy, N-(C1-4alkyl)amino, N,N-(C1-4alkyl)2amino, C i -4alkanoylamino, N-(Cj -4alkyl)carbamoy 1, N, N-(C i -4alkyl)2carbamoy 1, N-(C1-4alkoxy)carbamoyl, N'-(C1-4alkyl)ureido, N'N'-(Ci-4alkyl)2ureido, N-(C1-4alkyl)-N-(C1-4alkoxy)carbamoyl, C1-4alkylS(O)a wherein a is 0 to 2, C 1-4alkoxycarbonyl, C i -4alkoxycarbonylamino, N-(C i -4alkyl)sulphamoyl, N,N-(Ci-4alkyl)2sulphamoyl, C1-4alkylsulphonylamino, d^alkylsulphonylaminocarbonyl, N-(C1-4alkyl)hydrazinocarbonyl, N'.NHCMalkyrhhydrazinocarbonyl, carbocyclyl-R10- or heterocyclyl-R11-; wherein R4 and R5 independently of each other may be optionally substituted on carbon by one or more R12; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R13; R , R and R are independently selected from hydrogen or C1-4alkyl; m is 0-4; wherein the values of R5 may be the same or different; R12 is selected from azido, halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, Ci-4alkyl, C2-4alkenyl, C2-4alkynyl, Ci-4alkoxy, C1-4alkanoyl, C1-4alkanoyloxy, N-(Ci.4alkyl)amino, N,N-(Ci.4alkyl)2amino, Ci-4alkanoylamino, N-(C1-4alkyl)carbamoyl, N,N-(C1-4alkyl)2carbamoyl, C1-4alkylS(O)a wherein a is 0 to 2, C1-4alkoxycarbonyl, N-(Ci-4alkyl)sulphamoyl, N5N-(C i -4alky l)2sulphamoyl, C i -4alkylsulphonylamino, C i -4alkoxycarbonylamino, carbocyclyl-R14- or heterocyclyl-R15-; wherein R12 independently of each other may be optionally substituted on carbon by one or more R16; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R17; R9, R13 and R17 are independently selected from Ci-4alkyl, C1-4alkanoyl, Ci-4alkylsulphonyl, C1-4alkoxycarbonyl, carbamoyl, iV-(Ci-4alkyl)carbamoyl, N,N-(C1-4alkyl)carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulphonyl;
R10, R11, R14 and R15 are independently selected from a direct bond, -O-, -N(R18)-, -C(O)-, -N(R19)C(O)-, -C(O)N(R20)-, -S(0)p-, -SO2N(R21)- or -N(R22)SO2-; wherein R18, R19, R , R and R are independently selected from hydrogen or C1-4alkyl and p is 0-2;
R16 is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, carboxy, carbamoyl, mercapto, sulphamoyl, methyl, ethyl, ethenyl, ethynyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, iV-methyl-iV-ethylamino, acetylamino, JV-methylcarbamoyl, iV-ethylcarbamoyl,
ΛζiV-dimethylcarbamoyl, N,iV-diethylcarbamoyl, N-methyl-JV-ethylcarbamoyl, methylthio, ethylthio, methylsulphinyl, ethylsulphinyl, mesyl, ethylsulphonyl, methoxycarbonyl, ethoxycarbonyl, iV-methylsulphanioyl, N-ethylsulphamoyl, iV,N-dimethylsulphamoyl, AζN-diethylsulphamoyl or iV-methyl-N-ethylsulphamoyl; or a pharmaceutically acceptable salt thereof.
The present invention also provides a compound of formula (IE):
Figure imgf000014_0001
(IE) wherein:Y is NH, N(Ci-4alkyl) or S;
R1 is selected from hydrogen, nitro, hydroxy, halo, cyano, Ci-4alkyl, Q^alkoxy, C2-4alkenyl, C2-4alkynyl, C1-4alkanoyl, C1-4alkylS(O)a wherein a is 0 to 2 and C3-6cycloalkyl; wherein R1 may be optionally substituted on carbon by one or more halo or cyclopropyl; R2 is selected from hydrogen, nitro, hydroxy, halo, cyano, C]-4alkyl, Ci-4alkoxy, C2-4alkenyl, C2-4alkynyl, Ci-4alkanoyl, C1-4alkylS(O)a wherein a is 0 to 2 and C3-6cycloalkyl; wherein R2 may be optionally substituted on carbon by one or more halo or C3-6cycloalkyl;
R3 is selected from hydrogen, nitro, hydroxy, halo, cyano, -C=N-OR' wherein R' is H or C1-4alkyl, Chalky!, Q^alkoxy, C2-4alkenyl, C2-4alkynyl, C1-4alkanoyl, C1-4alkylS(O)a wherein a is 0 to 2 and C3-6cycloalkyl; wherein R3 may be optionally substituted on carbon by one or more halo or C3-6cycloalkyl;
X is a direct bond, -CH2-, -C(O)- or S(O)q- (wherein q is 1 or 2); Ring A is heterocyclyl; wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R9;
R4 is a substitutent on carbon selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, sulfo, formyl, ureido, hydroxyiminomethyl, N-hydroxyformamido, hydrazinocarbonyl, N-hydroxyethanimidoyl, amino(hydroxyimino)methyl, Q^alkyl, C2-4alkenyl, C2-4alkynyl, C1-4alkoxy, Ci-4alkanoyl, C1-4alkanoyloxy, N-(C1 -4alkyl)amino, N",N-(C1-4alkyl)2amino, C1-4alkanoylamino, N-(C1-4alkyl)carbamoyl, N,N-(Ci-4alkyl)2carbamoyl, N-(C1-4alkoxy)carbamoyl, N'-(C1-4alkyl)ureido, N',N'-(C1-4alkyl)2ureido, N-(C1-4alkyl)-N-(Ci-4alkoxy)carbamoyl, C1-4alkylS(O)a wherein a is 0 to 2, C1-4alkoxycarbonyl, C1-4alkoxycarbonylamino, N-(C1-4alkyl)sulphamoyl, N, N-(C 1-4alkyl)2 sulphamoyl, C1-4alkylsulphonylamino, C1 -4alky lsulphonylaminocarbony 1, N-(C \ -4alkyl)hy drazinocarbonyl,
N'N'-(Ci-4alkyl)2hydrazinocarbonyl, carbocyclyl-R10 — or heterocyclyl-Ru — ; wherein R4 and R5 independently of each other may be optionally substituted on carbon by one or more R12; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R13; R5a and R5b are substituents as defined for R4 or taken together with the carbons to which they are attached form a 6-membered carbocyclyl ring substituted by one or two groups which may be the same or different and which are selected from R14;
R6, R7 and R8 are independently selected from hydrogen or C1-4alkyl;
R12 is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C1-4alkyl, C2-4alkenyl, C2-4alkynyl, Ci-4alkoxy, C1-4alkanoyl, C1-4alkanoyloxy, N-(C1-4alkyl)amino, N,N-(C1-4alkyl)2amino, C1-4alkanoylamino, N-(C1-4alkyl)carbamoyl, N,N-(C1-4alkyl)2carbamoyl, C1-4alkylS(O)a wherein a is 0 to 2, C1-4alkoxycarbonyl, N-(Ci-4alkyl)sulphamoyl, N5N-(C i-4alkyl)2sulphamoyl, C1-4alkylsulphonylamino, C1-4alkoxycarbonylamino, carbocyclyl-R14 — or heterocyclyl-R15 — ; wherein R12 independently of each other may be optionally substituted on carbon by one or more R16; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R17; R9, R13 and R17 are independently selected from Ci-4alkyl, Ci-4alkanoyl, C1-4alkylsulphonyl, C1-4alkoxycarbonyl, carbamoyl, iV-(C1-4alkyl)carbamoyl, ΛζiV-(Ci-4alkyl)carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulphonyl;
R10, R11, R14 and R15 are independently selected from a direct bond, -O-, -N(R18)-, -C(O)-, -N(R19)C(O>, -C(O)N(R20)-, -S(0)p-, -SO2N(R21)- or -N(R22)SO2-; wherein R18, R19, R20, R21 and R22 are independently selected from hydrogen or C1-4alkyl and p is 0-2;
R16 is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, carboxy, carbamoyl, mercapto, sulphamoyl, methyl, ethyl, ethenyl, ethynyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, Af-methyl-JV-ethylamino, acetylamino, iV-methylcarbamoyl, iV-ethylcarbamoyl,
ΛζiV-dimethylcarbamoyl, iVjiV-diethylcarbamoyl, N-methyl-iV-ethylcarbamoyl, methylthio, ethylthio, methylsulphinyl, ethylsulphinyl, mesyl, ethylsulphonyl, methoxycarbonyl, ethoxycarbonyl, iV-methylsulphamoyl, iV-ethylsulphamoyl, N,iV-dimethylsulphamoyl, ΛζiV-diethylsulphamoyl or N-methyl-N-ethylsulphamoyl; or a pharmaceutically acceptable salt thereof.
The present invention also provides a compound of formula (IF):
Figure imgf000016_0001
wherein:
R1 is selected from hydrogen, nitro, hydroxy, halo, cyano, Ci-4alkyl, Ci-4alkoxy, C2-4alkenyl, C2-4alkynyl, C1-4alkanoyl, C1-4alkylS(O)a wherein a is 0 to 2 and C3-6cycloalkyl; wherein R1 may be optionally substituted on carbon by one or more halo or cyclopropyl; R2 is selected from hydrogen, nitro, hydroxy, halo, cyano, C]-4alkyl, Ci-4alkoxy, C2-4alkenyl, C2-4alkynyl, d^alkanoyl, Ci-4alkylS(O)a wherein a is 0 to 2 and C3-6cycloalkyl; wherein R2 may be optionally substituted on carbon by one or more halo or C3-6Cy cloalkyl;
R3 is selected from hydrogen, nitro, hydroxy, halo, cyano, -C=N-OR' wherein R' is H or Ci-4alkyl, C1-4alkyl, Ci-4alkoxy, C2-4alkenyl, C2-4alkynyl, Ci-4alkanoyl, Ci-4alkylS(O)a wherein a is 0 to 2 and C3-6cycloalkyl; wherein R3 may be optionally substituted on carbon by one or more halo or C3-6Cy cloalkyl;
X is a direct bond, -CH2-, -C(O)- or S(O),- (wherein q is 1 or T); R4 is a substitutent on carbon selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, sulfo, formyl, ureido, hydroxyiminomethyl, iV-hydroxyformamido, hydrazinocarbonyl, N-hydroxyethanimidoyl, amino(hydroxyimino)methyl, C^alkyl, C2-4alkenyl, C2-4alkynyl, C1-4alkoxy, Ci-4alkanoyl, C1-4alkanoyloxy, N-(C1-4alkyl)amino, 7V,7V-(C1-4alkyl)2amino, C1-4alkanoylamino, JV-(C 1-4alkyl)carbamoyl, N1N-(C Malkyl^carbamoyl, JV-(C 1-4alkoxy)carbamoy 1, JV-(C 1-4alkyl)ureido, JV',JV'-(C1-4alkyl)2ureido, N-(C Malky I)-JV-(C 1-4alkoxy)carbamoyl, Ci-4alkylS(O)a wherein a is 0 to 2, C1-4alkoxycarbonyl, d^alkoxycarbonylamino, 7V-(C1-4alkyl)sulphamoyl, JV,JV-(C1-4alkyl)2Sulphamoyl, C1-4alkylsulphonylamino, Ci^alkylsulphonylaminocarbonyl, JV'-(C1-4alkyl)hydrazinocarbonyl, JV' JV'-(Ci-4alkyl)2hydrazinocarbonyl, carbocyclyl-R10 — or heterocyclyl-R11 — ; wherein R4 and R5 independently of each other may be optionally substituted on carbon by one or more R12; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R 3;
R5a and R5b are substituents as defined for R4 or taken together with the carbons to which they are attached form a 6-membered carbocyclyl ring substituted by one or two groups which may be the same or different and which are selected from R14;
R6, R7 and R8 are independently selected from hydrogen or C1-4alkyl; R12 is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C1-4alkyl, C2-4alkenyl, C2-4alkynyl, C1-4alkoxy, C^alkanoyl, C1-4alkanoyloxy, N-(C1-4alkyl)amino, N,N-(C1-4alkyl)2amino, C1-4alkanoylamino, N-(CMalkyl)carbamoyl, N,N-(C1-4alkyl)2carbamoyl, C1-4alkylS(0)a wherein a is 0 to 2, Ci-4alkoxycarbonyl, N-(Ci-4alkyl)sulphamoyl, N,N-(Ci4alkyl)2Sulphamoyl, Ct^alkylsulphonylamino, Ci-4alkoxycarbonylamino, carbocyclyl-R14 — or heterocyclyl-R15 — ; wherein R12 independently of each other may be optionally substituted on carbon by one or more R16; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R17;
R9, R13 and R17 are independently selected from C^alkyl, d^alkanoyl,
Figure imgf000017_0002
C1_4alkoxycarbonyl, carbamoyl,
Figure imgf000017_0001
JV,JV-(C1.4alkyl)carbamoyl5 benzyl, benzyloxycarbonyl, benzoyl and phenylsulphonyl; B2006/000529
- 17 -
R10, R11, R14 and R15 are independently selected from a direct bond, -0-, -N(R18)-, -C(O)-, -N(R19)C(O)-, -C(O)N(R20)-, -S(0)p-, -SO2N(R21)- or -N(R22)SO2-; wherein R18, R19, R20, R21 and R22 are independently selected from hydrogen or C1-4alkyl and p is 0-2;
R16 is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, cafboxy, carbamoyl, mercapto, sulphamoyl, methyl, ethyl, ethenyl, ethynyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, JV-methyl-iV-ethylamino, acetylamino, iV-methylcarbamoyl, TV-ethylcarbamoyl, ΛζΛ^dimethylcarbamoyl, N,iV"-diethylcarbamoyl, 7V-methyl-iV-ethylcarbamoyl, methylthio, ethylthio, methylsulphinyl, ethylsulphinyl, mesyl, ethylsulphonyl, methoxycarbonyl, ethoxycarbonyl, N-methylsulphamoyl, -V-ethylsulphamoyl, iV,iV-dimethylsulphamoyl, iV, N-diemylsulpharnoyl or N-methyl-TV-ethylsulphamoyl; or a pharmaceutically acceptable salt thereof.
The invention also provides a compound which is 2-((3^4i?)-4-{[(3,4-dichloro-5-memyl-lH-ρyrrol-2-yl)carbonyl]amino}-3- fluoropiperidin-l-yl)-l,3-thiazole-5-carboxylic acid;
2-((3lS',4i?)-4-{[(3,4-dichloro-5-methyl-lif-pyrrol-2-yl)carbonyl]amino}-3- methoxypiperidm-l-yl)-4-{[(2-memoxyemyl)amino]carbonyl}-l,3-thiazole-5-carboxyhc acid; 2-((35',4i?)-4-{[(3,4-dichloro-5-memyl-lH-pyrrol-2-yl)carbonyl]amino}-3- methoxypiperidin- 1 -yl)-4-( { [(I iS)-2-methoxy- 1 -methylethyl] amino } carbonyl)- 1 ,3 -thiazole-5 - carboxylic acid;
2-((3S,4i?)-4-{[(3,4-dicruoro-5-memyl-lH-ρyrrol-2-yl)carbonyl]arnino}-3- methoxypiperidm-l-yl)-4-[(memylamino)carbonyl]-l,3-thiazole-5-carboxylic acid; 2-((35,4R)-4- {[(3,4-Dichloro-5-methyl-lH-pyrrol-2-yl)carbonyl]amino} -3- methoxypiperidin-1 -yl)-4-methyl-l,3-thiazole-5-carboxylic acid;
2-((3S',4i()-4- {[(3,4-dichloro-5-methyl- lff-ρyrrol-2-yl)carbonyl]amino} -3- methoxypiperidin-l-yl)-l,3-thiazole-5-carboxylic acid;
4-acetyl-2-((3,S',4JR)-4-{[(354-dichloro-5-methyl-lH-pyrrol-2-yl)carbonyl]amino}-3- methoxypiperidin-l-y^-l^-thiazole-S-carboxylic acid;
2-((36',4i?)-4-{[(3J4-dichloro-5-memyl-liϊ-ρyrrol-2-yl)carbonyl]arnino}-3- methoxypiperidin-1 -yl)-4-( {[(li?)-2-methoxy- 1 -methylethyl] amino} carbonyl)- 1 ,3 -thiazole-5- carboxylic acid; 2-((3Sl,4i?)-4-{[(3,4-dichloro-5-methyl-lH-pyrrol-2-yl)carbonyl]amino}-3- methoxypiperidin-l-yl)-4-({[(25)-2-methoxyρropyl]amino}carbonyl)-l,3-thiazole-5- carboxylic acid;
2-((3S,4i?)-4-{[(3,4-dichloro-5-methyl-lH-ρyrrol-2-yl)carbonyl]amino}-3- methoxypiperidin- 1 -yl)-4-( { [(2i?)-2-methoxypropy l]amino } carbony I)- 1 ,3 -thiazole-5 - carboxylic acid;
2-((35r,4i?)-4-{[(3,4-dichloro-5-metliyl-lH"-pyrrol-2-yl)carbonyl]amino}-3- methoxypiperidin-l-yl)-4-({[(li?,2iS)-2-fluorocyclopropyl]amino}carbonyl)-l,3-thiazole-5- carboxylic acid; Cis(±)2-(4-{[(3,4-dichloro-5-methyl-lH-pyrrol-2-yl)carbonyl]amino}-3- methoxypiperidin-1 -yl)-l ,3-benzothiazole-7-carboxylic acid;
Cis(±)2-(4-{[(3,4-dichloro-5-methyl-lH-pyrrol-2-yl)carbonyl]amino}-3- methoxypiperidin-l-yl)-4-(metlioxymethyl)-l,3-thiazole-5-carboxy lie acid;
Cis(±)2-(4-{[(3,4-dichloro-5-metb.yl-lH-pyrrol-2-yl)carbonyl]amino}-3- methoxypiperidin- 1 -yl)isonicotinic acid;
2-((3iS',4i?)-4- { [(4-chloro-5-methyl- lH-pyrrol-2-yl)carbonyl]amino} -3- methoxypiperidin- 1 -yl)-l ,3 -benzothiazole-7-carboxylic acid;
Cis(±)-2-(3-chloro-4-{ [(3,4-dichloro-5-methyl- lH-pyrrol-2- yl)carbonyl]amino} piperidin- 1 -yl)-4-(methoxymethyl)- 1 ,3 -thiazole-5 -carboxylic acid; 2-((3(Sr, 4i?)-4-{[(3,4-Dichloro-5-methyl-li/-pyrrol-2-yl)carbonyl]amino}-3- fluoropiperidin- 1 -yl)-4-methyl- 1 ,3 -thiazole-5 -carboxylic acid;
Cis(±)-2- [4- { [(3 ,4-dichloro-5 -methyl- 1 if-pyrrol-2-y l)carbony 1] amino } -3 -(prop-2-yn- 1 -yloxy)piρeridin-l -yl]-l ,3-thiazole-5-carboxylic acid;
Cis(±)2-((3S,4i?)-4- { [(3 ,4-dichloro-5-methyl- lH-pyrrol-2-yl)carbonyl]amino} -3- fluoropiperidin- 1 -y I)- 1 ,3 -thiazole-4-carboxylic acid; or
2-((3iS',4i?)-4-{[(3,4-dichloro-5-methyl-lH-pyrrol-2-yl)carbonyl]amino}-3- methoxypiperidin- l-yl)-4-({ [2-methoxy-l -(methoxymethyl)ethyl]amino}carbonyl)-l ,3- thiazole-5-carboxylic acid; or a pharmaceutically acceptable salt thereof.
The invention also provides a pharmaceutical composition that comprises a compound of formula I, IA, IB, IC, ID, or IE or a pharmaceutically-acceptable salt thereof, and a pharmaceutically-acceptable diluent or carrier. The invention also provides a method of treating a bacterial infection in a warm-blooded animal, such as a human being, in need of such treatment, which comprises administering to said animal an effective amount of a compound of formula I, IA, IB, IC, ID, or IE, or a pharmaceutically-acceptable salt thereof.
The invention also provides a method for inhibiting bacterial DNA gyrase in a warm-blooded animal, such as a human being, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula I, IA, IB, IC, ID, or IE or a pharmaceutically acceptable salt.
The invention also provides a compound of formula I, IA, IB, IC, ID, or IE and pharmaceutically acceptable salts thereof for use as a medicament.
Theinvention also provides the use of a compound of formula I, IA, IB, IC, ID, or IE, or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for use in the production of an anti-bacterial effect in a warm-blooded animal such as a human being.
The invention also provides the use of a compound of formula I, IA, IB, IC, ID, or IE, or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for use in the treatment of a bacterial infection in a warm-blooded animal such as a human being.
The present invention also provides a process for preparing compounds of formula (I) or pharmaceutically-acceptable salts thereof, comprising:
Process a) for compounds of formula (I) wherein W is -C(R7)(R8)-; converting a compound of formula (II):
Figure imgf000020_0001
(H) wherein Ra is cyano and Rb is dimethyamino or diethylamino; or Ra and Rb are independently selected from Q-4alkylthio; or Ra and Rb together form 1,3-dithianyl or 1,3-dithiolanyl; into a compound of formula (I) ; Process b) for compounds of formula (I) wherein W is -O-; reacting a compound of formula (III):
Figure imgf000021_0001
(HI) with a compound of formula (IV):
Figure imgf000021_0002
(IV)
Process c) for compounds of formula (I) wherein W is -N(R6)-; reacting a compound of formula (V):
Figure imgf000021_0003
(V) with a compound of formula (IV) or an activated acid derivative thereof;
Process ά) for compounds of formula (I) wherein W is -C(R7)(R8)-; reacting a compound of formula (VI):
Figure imgf000021_0004
(VI) wherein L is a displaceable group; with a compound of formula (VII):
Figure imgf000021_0005
(VII) Process e.) for compounds of formula (I) wherein W is -C(R7)(R8)-; reacting a compound of formula (VIII):
Figure imgf000022_0001
(VIII) wherein M is an organometallic group; with a compound of formula (IX):
Figure imgf000022_0002
(IX) wherein L is a displaceable group; Process J) reacting a compound of formula (X):
Figure imgf000022_0003
(X) with a compound of formula (XI):
Figure imgf000022_0004
(XI) wherein D is a displaceable group;
Process g) for compounds of formula (I) wherein X is -C(O)-; reacting a compound of formula (X) with a compound of formula (XII):
Figure imgf000022_0005
(XII) and thereafter if necessary: i) converting a compound of the formula (I) into another compound of the formula (I); ii) removing any protecting groups; iii) forming a pharmaceutically acceptable salt.
DETAILED DESCRIPTION OF THE INVENTION
DEFINITIONS
In this specification the term alkyl includes both straight and branched chain alkyl groups. For example, "Ci-4alkyl" includes methyl, ethyl, propyl, isopropyl and t-butyl. However references to individual alkyl groups such as propyl are specific for the straight chain version only. An analogous convention applies to other generic terms.
Where optional substituents are chosen from one or more groups it is to be understood that this definition includes all substituents being chosen from one of the specified groups or the substituents being chosen from two or more of the specified groups.
A "heterocyclyl" is a saturated, partially saturated or unsaturated, mono or bicyclic ring containing 4-12 atoms of which at least one atom is chosen from nitrogen, sulphur or oxygen, which may, unless otherwise specified, be carbon or nitrogen linked, wherein a -CH2- group can optionally be replaced by a -C(O)- and a ring nitrogen and / or a ring sulphur atom may be optionally oxidised to form the N- or S-oxide(s). In one aspect of the invention a "heterocyclyl" is a saturated, partially saturated or unsaturated, monocyclic ring containing 5 or 6 atoms of which at least one atom is chosen from nitrogen, sulphur or oxygen, it may, unless otherwise specified, be carbon or nitrogen linked, a -CH2- group can optionally be replaced by a -C(O)-and a ring sulphur atom may be optionally oxidised to form the S-oxides. In a further aspect of the invention a "heterocyclyl" is an unsaturated, carbon-linked, monocyclic ring containing 5 or 6 atoms of which at least one atom is chosen from nitrogen, sulphur or oxygen. Examples and suitable values of the term "heterocyclyl" are morpholino, piperidyl, pyridyl, pyranyl, pyrrolyl, pyrazolyl, isothiazolyl, indolyl, quinolyl, thienyl, 1,3-benzodioxolyl, thiadiazolyl, piperazinyl, thiazolidinyl, pyrrolidinyl, thiomorpholino, pyrrolinyl, homopiperazinyl, 3,5-dioxapiperidinyl, tetrahydropyranyl, imidazolyl, pyrimidyl, pyrazinyl, pyridazinyl, isoxazolyl, iV-methylpyrrolyl, 4-pyridone, 1-isoquinolone, 2-pyrrolidone, 4-thiazolidone, pyridine-iV-oxide and quinoline-iV-oxide. Further examples and suitable values of the term "heterocyclyl" are thiazolyl, quinolinyl, benzothiazolyl, pyrimidinyl and pyridinyl.
A "carbocyclyl" is a saturated, partially saturated or unsaturated, mono or bicycHc carbon ring that contains 3-12 atoms; wherein a -CH2- group can optionally be replaced by a -C(O)-. Particularly "carbocyclyl" is a monocyclic ring containing 5 or 6 atoms or a bicyclic ring containing 9 or 10 atoms. Suitable values for "carbocyclyl" include cyclopropyl, cyclobutyl, 1-oxocyclopentyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, phenyl, naphthyl, tetralinyl, indanyl or 1-oxoindanyl. A particular example of "carbocyclyl" is phenyl. An example of "C1-4alkanoyloxy" is acetoxy. Examples of "C1-4alkoxycarbonyl" include methoxycarbonyl, ethoxycarbonyl, n- and t-butoxycarbonyl. Examples of
"Ci-4alkoxycarbonylamino" include methoxycarbonylamino, ethoxycarbonylamino, n- and t-butoxycarbonylamino. Examples of "C^alkoxy" include methoxy, ethoxy and propoxy. Examples of "C^alkanoylamino" include formamido, acetamido and propionylamino. Examples of "C1-4alkylS(O)a wherein a is 0 to 2" include methylthio, ethylthio, methylsulphinyl, ethylsulphinyl, mesyl and ethylsulphonyl. Examples of "C1-4alkanoyl" include propionyl and acetyl. Examples of 'W-(Ci -4alkyl)amino" include methylamino and ethylamino. Examples of "N1N-(Ci -4alkyl)2amino" include diW-methylamino, di-(7V-ethyi)amino and W-ethyl-N-methylamino. Examples of "C2-4alkenyl" are vinyl, allyl and 1-propenyl. Examples of "C2-4alkynyl" are ethynyl, 1-propynyl and 2-propynyl. Examples of 'W-(C1-4alkyl)sulphamoyl" are N-(methyl)sulphamoyl and W-(ethyl)sulphamoyl. Examples of "AζN-(Ci-4alkyl)2Sulphamoyl" are W,N-(dimethyl)sulphamoyl and N-(methyl)-W-(ethyl)sulphamoyl. Examples of "W-(Ci-4alkyl)carbamoyl" are methylaminocarbonyl and ethylaminocarbonyl. Examples of "NW-(C1 -4alkyl)2carbamoyl" are dimethylaminocarbonyl and methylethylaminocarbonyl. Examples of "JV-(C 1-4alkoxy)carbamoyl" are methoxyaminocarbonyl and isopropoxyaminocarbonyl. Examples of 'W-(C1 ^alky I)-JV-(C i-4alkoxy)carbamoyl" are W-methyl-N- methoxyaminocarbonyl and N-methyl-N-ethoxyaminocarbonyl. Examples of "C3-6cycloalkyl" are cyclopropyl, cyclobutyl, cyclopropyl and cyclohexyl. Examples of "W-(Ci -4alkyl)ureido" are JV'-methylureido and W'-isopropylureido. Examples of "W, W'-(C1.4alkyl)2ureido" are N1N'- dimethylureido and iV'-methyl-W'-isopropylureido. Examples of
'W'-(Ci.4alkyl)hydrazinocarbonyl" are W-methylhydrazinocarbonyl and N- isopropylhydrazinocarbonyl. Examples of "W',iV-(C1,4alkyl)2hydrazinocarbonyr' are N1N'- dimethylhydrazinocarbonyl and N'-methyl-W-isopropylhydrazinocarbonyl. Examples of
Figure imgf000025_0001
include methylsulphonylamino, isopropylsulphonylamino and t-butylsulphonylamino. Examples of "Ci^alkylsulphonylaminocarbonyl" include methylsulphonylaminocarbonyl, isopropylsulphonylaminocarbonyl and t-butylsulphonylaminocarbonyl. Examples of "Ci-4alkylsulphonyl" include methylsulphonyl, isopropylsulphonyl and t-butylsulphonyl.
A compound of formula (I) may form stable acid or basic salts, and in such cases administration of a compound as a salt may be appropriate, and pharmaceutically acceptable salts may be made by conventional methods such as those described following.
Suitable pharmaceutically-acceptable salts include acid addition salts such as methanesulfonate, tosylate, α-glycerophosphate, fumarate, hydrochloride, citrate, maleate, tartrate and (less preferably) hydrobromide. Also suitable are salts formed with phosphoric and sulfuric acid. In another aspect suitable salts are base salts such as an alkali metal salt for example sodium or potassium, an alkaline earth metal salt for example calcium or magnesium, an organic amine salt for example triethylamine, morpholine, iV-methylpiperidine, iV-ethylpiperidine, procaine, dibenzylamine, Aζ/V-dibenzylethylamine, tris-(2-hydroxyethyl)amine, tromethamine, TV-methyl d-glucamine and amino acids such as glycine or lysine. There may be more than one cation or anion depending on the number of charged functions and the valency of the cations or anions. A preferred pharmaceutically-acceptable salt is the sodium salt. However, to facilitate isolation of the salt during preparation, salts which are less soluble in the chosen solvent may be preferred whether pharmaceutically-acceptable or not.
Within the present invention it is to be understood that a compound of the formula (I) or a salt thereof may exhibit the phenomenon of tautomerism and that the formulae drawings within this specification can represent only one of the possible tautomeric forms. It is to be understood that the invention encompasses any tautomeric form which inhibits DNA gyrase and/or topoisomeraseIV and is not to be limited merely to any one tautomeric form utilised within the formulae drawings. The formulae drawings within this specification can represent only one of the possible tautomeric forms and it is to be understood that the specification encompasses all possible tautomeric forms of the compounds drawn not just those forms which it has been possible to show graphically herein. The same applies to compound names. It will be appreciated by those skilled in the art that certain compounds of formula (I) contain an asymmetrically substituted carbon and/or sulphur atom, and accordingly may exist in, and be isolated in, optically-active and racemic forms. Some compounds may exhibit polymorphism. It is to be understood that the present invention encompasses any racemic, optically-active, polymorphic or stereoisomeric form, or mixtures thereof, which form possesses properties useful in the inhibition of DNA gyrase and/or topoisomeraselV, it being well known in the art how to prepare optically-active forms (for example, by resolution of the racemic form by recrystallization techniques, by synthesis from optically-active starting materials, by chiral synthesis, by enzymatic resolution, by biotransformation, or by chromatographic separation using a chiral stationary phase) and how to determine efficacy for the inhibition of DNA gyrase and/or topoisomeraselV by the standard tests described hereinafter. It is also to be understood that certain compounds of the formula (I) and salts thereof can exist in solvated as well as unsolvated forms such as, for example, hydrated forms. It is to be understood that the invention encompasses all such solvated forms which inhibit DNA gyrase and/or topoisomeraselV.
Particular and suitable values for certain substituents and groups referred to in this specification are listed below. These values may be used where appropriate with any of the definitions and embodiments disclosed herein. Each stated species represents a particular and independent aspect of the invention.
Referring to a compound of formula I, R1 is Ci -4alkyl. R1 is methyl. R1 is halo. R1 is hydrogen.
R2 is C1-4alkyl. R2 is methyl. R2 is halo. R2 is fluoro or chloro. R2 is hydrogen. R2 is chloro.
R3 is C1-4alkyl. R3 is methyl. R3 is halo. R3 is fluoro or chloro. R3 is hydrogen. R3 is
CN. R3 is C=N-OH. R3 is chloro.
W is -O-. W is -N(R6)-. W is -NH-. W is -C(R7)(R8)-.
X is a direct bond. X is -CH2-. X is -C(O)-. X is S(O)q- (wherein q is 1 or 2).
Ring A is carbocyclyl. Ring A is heterocyclyl; wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R9. Ring A is heterocyclyl. Ring A is thiazolyl, quinolinyl, benzothiazolyl, pyrimidinyl or pyridinyl. Ring A is thiazol-2-yl, quinolin-4-yl, benzothiazol-2-yl, pyrimidin-4-yl, pyridin-2- yl or pyridin-4-yl.
R is a substituent on carbon and is selected from halo, hydroxy, carboxy, Ci-4alkyl,
Figure imgf000027_0001
JV-(C14alky I)-N-(C i-4alkoxy)carbamoyl, C1-4alkoxycarbonyl or heterocyclyl-Ru-; wherein R4 may be optionally substituted on carbon by one or more R12. R12 is selected from hydroxy, C2-4alkenyl, C1-4alkoxy, N-(C1-4alkyl)amino
Figure imgf000027_0002
and R11 is -C(O)-.
Alternatively, R4 is a substituent on carbon and is selected from fluoro, hydroxy, carboxy, methyl, methoxy, propoxy, iV-ethylcarbamoyl, N,N-dimethylcarbamoyl, iV-methyl-iV-methoxy carbamoyl, methoxycarbonyl or morpholino-R11-; wherein R4 may be optionally substituted on carbon by one or more R12. R12 is selected from hydroxy, ethenyl, methoxy, Ν-methylamino or Ν,Ν-dimethylamino; and R11 is -C(O)-.
Alternatively, R4 is a substituent on carbon and is selected from methoxy, hydroxy, methoxycarbonyl, fluoro, allyloxy, propoxy, N, JV-dimethylcarbamoyl, morpholinocarbonyl, iV-ethylcarbamoyl, N-(2-hydroxyethyl)carbamoyl, dimethylaminomethyl, N-methyl-N-methoxycarbamoyl, methoxymethyl, methylaminomethyl and carboxy.
Alternatively, R4 is a substituent on carbon and is selected from methoxy, hydroxy, methoxycarbonyl, fluoro, allyloxy, propoxy, ΛζN-dimethylcarbamoyl, morpholinocarbonyl, iV-ethylcarbamoyl, N-(2-hydroxyethyl)carbamoyl, dimethylaminomethyl, iV-methyl-N-methoxycarbamoyl, methoxymethyl, methylaminomethyl, carboxy, N-methyl-N- methoxyxcarbamoyl, Ν-hydroxyethylcarbamoyl, hydroxymethyl, (methylthio)methyl, (methylsulfmyl)methyl, (methylsulfonyl)methyl, benzyloxy, propynyloxy, methoxyethoxy, methoxypropoxy, chloro, methyl, cyclopropylmethoxy, thiazolylmethoxy, ethoxy, oxyacetic acid, ethylaminocarbonyloxy, allylaminocarbonyloxy, pyridinylmethoxy, hydroxypropoxy, methoxy(methyl)amino, and azido.
Alternatively R4 is halo, particularly fluoro. R5 is a substituent on carbon and is selected from halo, carboxy, carbamoyl, d.4alkyl, Ci-4alkoxy, TV-(C 1-4alkyl)carbamoyl, TV-(C 1-4alkoxy)carbamoyl or C1-4alkoxycarbonyl; wherein R5 may be optionally substituted on carbon by one or more R12. R12 is selected from C1-4alkoxy or carbocyclyl-R14-; and R14 is a direct bond.
Alternatively, R5 is a substituent on carbon and is selected from chloro, carboxy, carbamoyl, methyl, methoxy, TV-(isopropyl)carbamoyl, TV-(methoxy)carbamoyl, methoxycarbonyl or ethoxycarbonyl; wherein R5 may be optionally substituted on carbon by one or more R12. R12 is selected from methoxy or phenyl-R14-; and R14 is a direct bond.
Alternatively, R5 is a substituent on carbon and is selected from chloro, carboxy, carbamoyl, methyl, methoxymethyl, methoxy, TV-(I -methyl- l-phenylethyl)carbamoyl, TV-(methoxy)carbamoyl, methoxycarbonyl or ethoxycarbonyl.
Alternatively, R5 is a substituent on carbon and is selected from chloro, carboxy, carbamoyl, methyl, methoxymethyl, methoxy, TV-(I -methyl- 1 -phenylethyl)carbamoyl,
TV-(methoxy)carbamoyl, methoxycarbonyl or ethoxycarbonyl, TV-methoxycarbamoyl, formyl, (methoxy imino)methyl, isopropoxycarbonyl, ethoxy, morpholinocarbonyl, hydroxy- 1- methylethyl, amino, methoxycarbonylamino, methylsulfonylamino, TV-(I -methyl- 1- phenylethyl)carbamoyl, TV-2-morpholin-4-ylethylcarbamoyl, piperidinocarbonyl, N- methylcarbamoyl, TV-2-hydroxyethylcarbamoyl, TV-2-methoxyethylcarbamoyl, TV-2- hydroxypropylcarbamoyl, TV-2-hydroxy-l-methylethylcarbamoyl, TV-isoxazolylcarbamoyl, TV- 2,2-difluoroethylcarbamoyl, TV-tetrahydrofuran-3-ylcarbamoyl, TV-cyclopropylcarbamoyl, TV-I- cyanocyclopropylcarbamoyl, TV-2-fluorocyclopropylcarbamoyl, TV-2-hydroxy-l ,1 - dimethylethylcarbamoyl, TV- 1 -cyano- 1 -methylethylcarbamoyl, TV- 1 -(hydroxymethyl-2- methoxy-2-oxoethylcarbamoyl, TV-l,3-dioxolan-2-ylmethylcarbamoyl, TV-3-(2~oxopyrrolidin- 1-ylpropylcarbamoyl, TV-pyridin-2-ylmethylcarbamoyl, TV-2-(methylthio)ethylcarbamoyl, TV- 1 ,3-oxazol-2-ylmethylcarbamoyl, TV-2-fluoroethylcarbamoyl, TV-(2-hydroxy-2- methylpropyl)carbamoyl, morpholin-4-ylmethyl, fert-butylaminomethyl, piperidine-1- ylmethyl, (3-hydroxypyrrolidin-l-yl)methyl, (hydroxyimino)methyl, 1,1-difluoromethyl, azidomethyl, cyano(morpholin-4-yl)methyl, TV-2-(methylsulfonyl)ethylcarbamoyl, cyano, 1- hydroxy-1-methylethyl, cyclopropylmethyl, TV-methylcarbamoyl, TV-I- carboxycycloproylcarbamoyl, TV-isoxazol-3-ylcarbamoyl, TV-prop-2-yn-lylcarbamoyl, TV-I- carboxy-2-hydroxyrnethylcarbamoyl, TV-[3-(2-oxopyrrolidin-l -yl)propyl]carbamoyl, TV-(2- hydroxy-2-methylpropyl)carbamoyl, N-methoxy-iV-methylcarbamoyl, N-2- (methylsulfonyl)ethylcarbamoyl, TV-methoxypropylcarbamoyl, and methoxymethyl)ethyl]amino}carbamoyl.
Alternatively R5 is carboxy.
R6 is hydrogen.
n is 1.
m is 1 or 2; wherein the values of R5 may be the same or different, m is 1. m is 2.
In a further aspect of the invention there is provided a compound of formula (I) (as depicted above) wherein: R1 is selected from C1-4alkyl;
R2 is selected from halo.
R3 is selected from hydrogen or halo;
W is -N(R6)-;
X is a direct bond; Ring A is heterocyclyl;
R4 is a substituent on carbon and is selected from halo, hydroxy, carboxy, C1-4alkyl, C1-4alkoxy, iV-(C1-4alkyl)carbamoyl, ΛζiV-(C1-4alkyl)2carbamoyl, iV-(C1-4alkyl)-iV-(Ci-4alkoxy)carbamoyl, C1-4alkoxycarbonyl or heterocyclyl-R11-; wherein R4 may be optionally substituted on carbon by one or more R12; R5 is a substituent on carbon and is selected from halo, carboxy, carbamoyl, C^alkyl,
C1-4alkoxy,
Figure imgf000029_0001
iV-(Ci.4alkoxy)carbamoyl or C1-4alkoxycarbonyl; wherein R5 may be optionally substituted on carbon by one or more R12;
R6 is hydrogen;
R11 is -C(O)-; R12 is selected from hydroxy, C2-4alkenyl, Ci-4alkoxy, N-(C1-4alkyl)amino,
N,N-(Ci-4alkyl)2amino or carbocyclyl-R14-;
R14 is a direct bond; n is 1 ; and m is 1 or 2; wherein the values of R5 may be the same or different; or a pharmaceutically acceptable salt thereof.
In a further aspect of the invention there is provided a compound of formula (I) (as depicted above) wherein:
R1 is selected from methyl; R is fluoro or chloro;
R3 is selected from hydrogen, fluoro or chloro; W is -NH-; X is a direct bond;
Ring A is thiazolyl, quinolinyl, benzothiazolyl, pyrimidinyl or pyridinyl; R4 is a substituent on carbon and is selected from methoxy, hydroxy, methoxycarbonyl, fluoro, allyloxy, propoxy, ΛζiV-dimethylcarbamoyl, morpholinocarbonyl, iV-ethylcarbamoyl, JV-(2-hydroxyethyi)carbamoyl, dimethylaminomethyl, iV-methyl-iV-methoxy carbamoyl, methoxymethyl, methylamhiomethyl and carboxy;
R5 is a substituent on carbon and is selected from chloro, carboxy, carbamoyl, methyl, methoxymethyl, methoxy, N-(I -methyl- l-phenylethyl)carbamoyl, iV-(methoxy)carbamoyl, methoxymethyl)ethyl]amino}carbamoyl, methoxycarbonyl or ethoxycarbonyl; n is 1 ; and m is 1 or 2; wherein the values of R5 may be the same or different; or a pharmaceutically acceptable salt thereof.
In a further aspect of the invention there is provided a compound of formula (I) (as depicted above) wherein: R1 is selected from hydrogen or methyl;
R2 is hydrogen, bromo, fluoro, chloro, CN5 or -C=NOMe;
R3 is selected from hydrogen, fluoro or chloro;
W is -NH-;
X is a direct bond; Ring A is thiazolyl, quinolinyl, benzothiazolyl, pyrimidinyl or pyridinyl;
R4 is a substituent on carbon and is selected from methoxy, hydroxy, methoxycarbonyl, fluoro, allyloxy, propoxy, N,N-dimethylcarbamoyl, morpholinocarbonyl, iV-ethylcarbamoyl, iV-(2-hydroxyethyl)carbamoyl, dimethylaminomethyl, JV-methyl-JV-methoxycarbamoyl, methoxymethyl, methylaminomethyl, carboxy, JV~methyl-JV- methoxyxcarbamoyl, N-hydroxyethylcarbamoyl, hydroxymethyl, (methylthio)methyl, (methylsulfmyl)methyl, (methylsulfonyl)methyl, benzyloxy, propynyloxy, methoxyethoxy, methoxypropoxy, chloro, methyl, cyclopropylmethoxy, thiazolylmethoxy, ethoxy, oxyacetic acid, ethylaminocarbonyloxy, allylaminocarbonyloxy, pyridinylmethoxy, hydroxypropoxy, methoxy(methyl)amino, and azido;
R5 is a substituent on carbon and is selected from chloro, carboxy, carbamoyl, methyl, methoxymethyl, methoxy, JV-(I -methyl- l-phenylethyl)carbamoyl, JV-(methoxy)carbamoyl, methoxycarbonyl or ethoxycarbonyl, JV-methoxycarbamoyl, formyl, (methoxyimino)methyl, isopropoxycarbonyl, ethoxy, morpholinocarbonyl, hydroxy- 1-methylethyl, amino, methoxy carbonylamino, methylsulfonylamino, JV-(I -methyl- l-phenylethyl)carbamoyl, JV-2- morpholin-4-ylethylcarbamoyl, piperidinocarbonyl, N-methylcarbamoyl, JV-2- hydroxyethylcarbamoyl, JV-2-methoxyethylcarbamoyl, iV-2-hydroxypropylcarbamoyl, JV-2- hydroxy-1-methylethylcarbamoyl, JV-isoxazolylcarbamoyl, JV2,2-difluoroethylcarbamoyl, JV- tetrahydrofuran-3-ylcarbamoyl, JV-cyclopropylcarbamoyl, JV- 1 -cyanocyclopropylcarbamoyl, 7V-2-fluorocy clopropylcarbamoyl, JV-2 -hydroxy- 1 , 1 -dimethylethylcarbamoyl, JV- 1 -cyano- 1 - methylethylcarbamoyl, JV- 1 -(hy droxymethyl-2-methoxy-2-oxoethylcarbamoyl, JV- 1 ,3 - dioxolan-2-ylmethylcarbamoyl, JV-3-(2-oxopyrrolidin-l-ylpropylcarbamoyl, JV-pyridin-2- ylmethylcarbamoyl, JV-2-(methylthio)ethylcarbamoyl, JV-l,3-oxazol-2-ylmethylcarbamoyl, JV- 2-fluoroethylcarbamoyl, JV-(2-hydroxy-2-methylpropyl)carbamoyl, morpholin-4-ylmethyl, /e/t-butylaminomethyl, piperidine- 1 -ylmethy 1, (3 -hy droxypyrrolidin- 1 -y l)methy 1, (hydroxyimino)methyl, 1,1-difluoromethyl, azidomethyl, cyano(morpholin-4-yl)methyl, JV-2- (methylsulfonyl)ethylcarbamoyl, cyano, 1 -hydroxy- 1-methylethyl, cyclopropylmethyl, JV-methylcarbamoyl, JV-1-carboxycycloproylcarbamoyl, JV-isoxazol-3-ylcarbamoyl, JV-prop-2- yn-lylcarbamoyl, JV-l-carboxy-2-hydroxymethylcarbamoyl, JV-[3-(2-oxopyrrolidin-l- yl)propyl]carbamoyl, JV-(2-hydroxy-2-methylρropyl)carbamoyl, JV-methoxy- JV-methylcarbamoyl, JV-2-(methylsulfonyl)ethylcarbamoyl, JV-methoxypropylcarbamoyl, and methoxymethy l)ethyl] amino } carbamoyl ; n is 1; and m is 1 or 2; wherein the values of R5 may be the same or different; or a pharmaceutically acceptable salt thereof. In a further aspect of the invention, there is provided a compound of the invention which is a compound of formula (IA)
Figure imgf000032_0001
(IA) wherein:
R1 is selected from hydrogen, halo, cyano, or C1-4alkyl; R2 is selected from hydrogen, halo, cyano, or C1-4alkyl; R3 is selected from hydrogen, halo, cyano, C^alkyl, or -C=N-OH; X is a direct bond, -CH2-, -C(O)- or S(0)q- (wherein q is 1 or 2); Ring A is carbocyclyl or heterocyclyl; wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R9;
R4 and R5 are substituents on carbon and are independently selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, sulfo, formyl, ureido, hydroxyiminomethyl, CMalkoxyiminomethyl, iV-hydroxyformamido, C1-4hydrazino, hydrazinocarbonyl, JV-hydroxyethanimidoyl, amino(hydroxyimino)methyl, C1-4alkyl, C2-4alkenyl, C2-4alkynyl, C1-4alkoxy, d-4alkanoyl, C1-4alkanoyloxy, iV-(Cj-4alkyl)amino, ΛζiV-(Ci-4alkyl)2amino, C1-4alkanoylamino, iV-(C1-4alkyl)carbamoyl, iV,iV-(C1-4alkyl)2carbamoyl, JV-(C 1-4alkoxy)carbamoyl, iV-(C1-4alkyl)ureido, iV'iV-(C1-4alkyl)2ureido, iV-(Ci-4alkyl)-Λ''-(Ci-4alkoxy)carbamoyl, C1-4alkylS(O)a wherein a is 0 to 2, C1-4alkoxycarbonyl, C1-4alkoxycarbonylamino, 7V-(C1-4alkyl)sulphamoyl,
N, N-(C i -4alky l)2sulphamoy 1, C i -4alkylsulphony lamino , C1 -4alky lsulphony laminocarbonyl, ΪV'-(Ci-4alkyl)hydrazinocarbonyl, iV' AP-(C1 -4alkyl)2hydrazinocarbonyl, carbocyclyl-R10- or heterocyclyl-R11 — ; wherein R4 and R5 independently of each other may be optionally substituted on carbon by one or more R 2; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R13; R6 is hydrogen or Ci-4alkyl; n is 1-4; wherein the values of R4 may be the same or different; m is 0-4; wherein the values of R5 may be the same or different; R12 is selected from azido, halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, Ci-4alkyl, C2-4alkenyl, C2-4alkynyl, Cj^alkoxy, B2006/000529
- 32 -
Ci.4aIkarLoyl, C1-4alkanoyloxy, N-(Ci-4alkyl)ainino, N5N-(C1-4alkyl)2ainino,
Figure imgf000033_0001
wherein a is 0 to 2, C1-4alkoxycarbonyl, N-tCMalkyOsulphamoyl, N,N-(Ci-4aIkyl)2Sulphamoyl5 C1-4alkylsulphonylamino, CMalkoxycarbonylamino, carbocyclyl-R14- or heterocyclyl-R1?-; wherein R12 independently of each other may be optionally substituted on carbon by one or more R16; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R17;
R9, R13 and R17 are independently selected from C1-4alkyl, C1-4alkanoyl, C1-4alkylsulphonyl,
Figure imgf000033_0002
carbamoyl, iV-(C1-4alkyl)carbamoyl, JV,JV-(C1-4alkyl)carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulphonyl;
R10, R11, R14 and R15 are independently selected from a direct bond, -O-, -N(R18)-, -C(O)-, -N(R19)C(O)-, -C(O)N(R20)-, -S(O)P-, -SO2N(R21)- or -N(R22)SO2-; wherein R18, R19, R , R and R are independently selected from hydrogen or C^alkyl and p is 0-2;
R16 is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, carboxy, carbamoyl, mercapto, sulphamoyl, methyl, ethyl, ethenyl, ethynyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, iV-methyl-N-ethylamino, acetylamino, JV-methylcarbamoyl, JV~eth.ylcarbam.oyl, Λ^N-dmethylcarbamoyl, N,iV-diethylcarbamoyl, iV-methyl-iV-ethylcarbamoyl, methylthio, ethylthio, methylsulphinyl, ethylsulphinyl, mesyl, ethylsulphonyl, methoxycarbonyl, ethoxycarbonyl, iV-methylsulphamoyl, iV-ethylsulphamoyl, ΛζiV-dimethylsulphamoyl, JSζN-diethylsulphamoyl or iV-methyl-N-ethylsulphamoyl; or a pharmaceutically acceptable salt thereof.
In a further aspect of the invention, there is provided a compound of formula (IA) which is a compound of formula (XB):
Figure imgf000033_0003
(IB) wherein: R4 is a substituent on carbon and is selected from methoxy, hydroxy, methoxycarbonyl, fluoro, allyloxy, propoxy, JV, JV-dimethy lcarbamoy 1, morpholinocarbonyl, N-ethylcarbamoyl, JV-(2-hydroxyethyl)carbamoyl, dimethylaminornethyl, JV-methyl-JV-methoxycarbamoyl, methoxymethyl, methylaminomethyl, carboxy , JV-methyl-JV- methoxyxcarbamoyl, N-hydroxyethylcarbamoyl, hydroxymethyl, (methylthio)methyl, (methylsulfinyl)methyl, (methylsulfonyl)methyl, benzyloxy, propynyloxy, methoxyethoxy, methoxypropoxy, chloro, methyl, cyclopropylmethoxy, thiazolylmethoxy, ethoxy, oxyacetic acid, ethylaminocarbonyloxy, allylaminocarbonyloxy, pyridinylmethoxy, hydroxypropoxy, methoxy(methyl)amino, and azido; R5 is a substituent on carbon and is selected from chloro, carboxy, carbamoyl, methyl, methoxymethyl, methoxy, JV-(I -methyl- l-phenylethyl)carbamoyl, JV-(methoxy)carbamoyl, methoxycarbonyl or ethoxycarbonyl, JV-methoxycarbamoyl, formyl, (methoxyimino)methyl, isopropoxycarbonyl, ethoxy, morpholinocarbonyl, hydroxy- 1-methylethyl, amino, methoxycarbonylamino, methylsulfonylamino, JV-(I -methyl- 1 -phenylethyl)carbamoyl, JV-2- morpholin-4-ylethylcarbamoyl, piperidinocarbonyl, N-methylcarbamoyl, JV-2- hydroxyethylcarbamoyl, iV-2-methoxyethylcarbamoyl, iV-2-hydroxypropylcarbamoyl, JV-2- hydroxy-1-methylethylcarbamoyl, iV-isoxazolylcarbamoyl, Λ^^-difluoroethylcarbamoyl, JV- tetrahydrofuran-3-ylcarbamoyl, JV-cyclopropylcarbamoyl, N- 1 -cyanocyclopropylcarbamoyl, JV-2-fluorocy clopropy lcarbamoy 1, JV-2-hydroxy- 1 , 1 -dimethylethylcarbamoy 1, N- 1 -cy ano- 1 - methylethylcarbamoyl, JV-l-(hydroxymethyl-2-methoxy-2-oxoethylcarbamoyl, iV-1,3- dioxolan-2-ylmethylcarbamoyl, 7V-3-(2-oxopyrrolidin-l-ylpropylcarbamoyl, iV-pyridin-2- ylmethylcarbamoyl, iV-2-(methylthio)ethylcarbamoyl, N-l,3-oxazol-2-ylmethylcarbamoyl, TV- 2-fluoroethylcarbamoyl, iV-(2-hydroxy-2-methylpropyl)carbamoyl, morpholin-4-ylmethyl, ϊert-butylaminomethyl, piperidine- 1 -ylmethyl, (3 -hydroxypyrrolidin- 1 -yl)methyl, (hydroxyimino)methyl, 1,1-difluoromethyl, azidomethyl, cyano(morpholin-4-yl)methyl, N-I- (methylsulfonyl)ethylcarbamoyl, cyano, 1 -hydroxy- 1-methylethyl, cy clopropy lmethyl, 7V-rnethylcarbamoyl, JV-I -carboxy cycloproylcarbamoyl, JV-isoxazol-3-y lcarbamoy 1, JV-prop-2- yn- 1 ylcarbamoyl, JV- 1 -carboxy -2 -hydroxymethylcarbamoyl, JV-[3-(2-oxopyrrolidin- 1 - yl)propyl]carbamoyl, JV-(2-hydroxy-2-methylpropyl)carbamoyl, JV-methoxy- JV-methylcarbamoyl, JV-2-(methylsulfonyl)ethylcarbamoyl, JV-methoxypropylcarbamoyl, and methoxymethyl)ethyl]amino}carbamoyl; n is 1; wherein the values of R4 may be the same or different; and m is 1 or 2; wherein the values of R may be the same or different. In a further aspect of the invention, there is provided a compound of formula (IB) which is a compound of formula (IC).
Figure imgf000035_0001
(IC)
In a further aspect of the invention, there is provided a compound of formula (IC) which is a compound of formula (ID):
Figure imgf000035_0002
(ID) wherein:
Ring A is heterocyclyl; wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from C1-4alkyl,
Figure imgf000035_0003
C1-4alkylsulphonyl, C1-4alkoxycarbonyl, carbamoyl, N-(C1-4alkyl)carbamoyl,
Figure imgf000035_0004
benzyl, benzyloxycarbonyl, benzoyl and phenylsulphonyl.
In a further aspect of the invention, there is provided a compound of formula (ID) which is a compound of formula (IE):
Figure imgf000035_0005
wherein:
Y is N-H, N-Ci-4alkyl, S, or O;
R5a is H or as defined for R5;
R5b is H or as defined for R5; or R5a and R5b taken together with the carbons to which they are attached form a 6- membered carbocyclyl ring substituted by one or two groups selected from R1 which may be the same or different;
R14 is selected from a direct bond, -O-, -N(R18)-, -C(O)-, -N(R19)C(O)-, -C(O)N(R20)-, -S(O)p-, -SO2N(R21)- or -N(R22)SO2-; wherein R18, R19, R20, R21 and R22 are independently selected from hydrogen or C1-4alkyl and p is 0-2.
In a further aspect of the invention, there is provided a compound of formula (IE) which is a compound of formula (IF):
Figure imgf000036_0001
(IF)
Particular compounds of the invention are the compounds of the Examples, each of which provides a further independent aspect of the invention. In further aspects, the present invention also comprises any two or more compounds of the Examples.
In one embodiment of the invention are provided compounds of formula (I), in an alternative embodiment are provided pharmaceutically-acceptable salts of compounds of formula (I).
In a further aspect the present invention provides a process for preparing a compound of formula (I) or a pharmaceutically-acceptable salt thereof. Thus, the present invention also provides that the compounds of the formula (I) and pharmaceutically-acceptable salts thereof, can be prepared by a process as follows (wherein the variables are as defined above unless otherwise stated)
Process a) for compounds of formula (I) wherein W is -C(R7)(R8)-; converting a compound of formula (II):
Figure imgf000037_0001
(II) wherein Ra is cyano and Rb is dimethyamino or diethylamino; or Ra and Rb are independently selected from C1-4alkylthio; or Ra and Rb together form 1,3-dithianyl or 1,3-dithiolanyl; into a compound of formula (I) ;
Process b) for compounds of formula (I) wherein W is -O-; reacting a compound of formula (HI):
Figure imgf000037_0002
with a compound of formula (IV) :
Figure imgf000037_0003
(IV)
Process c) for compounds of formula (I) wherein W is -N(R6)-; reacting a compound of formula (V):
Figure imgf000037_0004
with a compound of formula (IV) or an activated acid derivative thereof;
Process d) for compounds of formula (I) wherein W is -C(R7)(R8)-; reacting a compound of formula (VI):
Figure imgf000038_0001
(VI) wherein L is a displaceable group; with a compound of formula (VII):
Figure imgf000038_0002
(VII)
Process e) for compounds of formula (I) wherein W is -C(R7)(R8)-; reacting a compound of formula (VIII):
Figure imgf000038_0003
(VIII) wherein M is an organometallic group; with a compound of formula (IX):
Figure imgf000038_0004
(IX) wherein L is a displaceable group; Process/) reacting a compound of formula (X):
Figure imgf000038_0005
(X) with a compound of formula (XI):
Figure imgf000039_0001
(XI) wherein D is a displaceable group; Process g) for compounds of formula (I) wherein X is -C(O)-; reacting a compound of formula (X) with a compound of formula (XII):
Figure imgf000039_0002
(XII) and thereafter if necessary: i) converting a compound of the formula (I) into another compound of the formula (I); ii) removing any protecting groups; iii) forming a pharmaceutically acceptable salt.
L is a displaceable group. Suitable values for L include halo, for example chloro and bromo, pentafluorophenoxy and 2,5-oxopyrrolidin-l-yloxy. D is a displaceable group. Suitable values for D include halo, for example chloro, bromo and iodo, tosylate and mesylate.
M is an organometallic group, suitable values for M include organocuprates, for example CuLi, organozincs, Zn, or a Grignard reagent for example MgG where G is halo for example chloro. Specific reaction conditions for the above reaction are as follows.
Process a) Compounds of formula (II) may be converted into compounds of formula (I):
(i) where Ra is cyano and Rb is dimethyamino or diethylamino; in the presence of a base for example sodium hydroxide, in a suitable solvent for example aqueous methanol at room temperature. (ii) wherein or Ra and Rb are independently selected from Ci-4alkylthio; or Ra and Rb together form 1,3-dithianyl or 1,3-dithiolanyl; in the presence of a reagent such as a mercury, copper or silver salt for example Hg(C104)2, CuCl2 or AgNO3ZAg2O in the presence of a suitable solvent for example methanol, acetone or ethanol from a temperature ranging from room temperature to reflux. Compounds of formula (II) may be prepared according to Scheme 1:
Conditions of
Figure imgf000040_0001
Figure imgf000040_0002
i) Deprotection ii) FGI
Figure imgf000040_0003
wherein Pg is a hydroxy protecting group as defined hereinbelow; and D is a displaceable group as defined hereinabove.
Deprotection of hydroxy protecting groups are well known in the art. Examples of such deprotections are given hereinbelow.
FGI stands for Functional Group Interconversion. In the above scheme such conversions between a hydroxy group and a D group are well known in the art and are well within the capabilities of a person skilled in the art.
Compounds of formula (Ha) and (lid) are known in the literature, or they are prepared by standard processes known in the art.
Process b) Compounds of formula (III) and (IV) may be reacted together may be reacted together in the presence of a coupling reagent, for example dicyclohexylcarbodiimide or EDC, in a suitable solvent, for example dichloromethane, THF or diethylether. Compounds of formula (III) may be prepared according to Scheme 2: i) Conditions of Process f)
+ (XI) ii) Deprotection
(HI)
(Ilia) <R4>"
Scheme 2 wherein Pg is a hydroxy protecting group as defined hereinbelow. Deprotection of hydroxy protecting groups are well known in the art. Examples of such deprotections are given hereinbelow. Compounds of formula (Ilia) and (IV) are commercially available compounds, or they are known in the literature, or they are prepared by standard processes known in the art. Process c) Compounds of formula (V) and (IV) may be coupled together in the presence of a suitable coupling reagent. Standard peptide coupling reagents known in the art can be employed as suitable coupling reagents, or for example carbonyldiimidazole and dicyclohexyl-carbodiimide, optionally in the presence of a catalyst such as dimethylaminopyridine or 4-pyrrolidinopyridine, optionally in the presence of a base for example triethylamine, pyridine, or 2,6-di-α/&y/-pyridines such as 2,6-lutidine or 2,6-di-/er/-butylpyridine. Suitable solvents include dimethylacetamide, dichloromethane, benzene, tetrahydrofuran and dimethylformamide. The coupling reaction may conveniently be performed at a temperature in the range of -40 to 40°C.
Suitable activated acid derivatives include acid halides, for example acid chlorides, and active esters, for example pentafluorophenyl esters. The reaction of these types of compounds with amines is well known in the art, for example they may be reacted in the presence of a base, such as those described above, and in a suitable solvent, such as those described above. The reaction may conveniently be performed at a temperature in the range of -40 to 4O0C.
Compounds of formula (V) may be prepared according to Scheme 3: i) Conditions of Process f) + (XI) ϋ) Deprotection (m)
Figure imgf000041_0001
Scheme 3 wherein Pg is a amino protecting group as defined hereinbelow. The skilled reader will appreciate that where R6 is hydrogen, this hydrogen also needs protecting by way of a suitable protecting group.
Deprotection of amino protecting groups are well known in the art. Examples of such deprotections are given hereinbelow.
Compounds of formula (Va) are commercially available compounds, or they are known in the literature, or they are prepared by standard processes known in the art. Process d) Compounds of formula (VI) and (VII) may be reacted in a suitable solvent such a DCM or 1,2-dichloroethane, optionally in the presence of a Lewis acid, for example AlCl3, from 0 °C to room temperature. Compounds of formula (VI) may be prepared according to Scheme 4:
Figure imgf000042_0001
Scheme 4 wherein RaOC(O) is an ester group. Suitable values for Ra include C1-6alkyl. Deprotection of the Ra carboxy protecting group may be achieved under standard conditions, for example acid or base hydrolysis, such as those conditions give hereinbelow.
FGI stands for Functional Group Interconversion. In the above scheme such conversions between an acid group and a -C(O)L group are well known in the art and are well within the capabilities of a person skilled in the art.
Compounds of formula (Via) and (VII) are commercially available compounds, or they are known in the literature, or they are prepared by standard processes known in the art. Process e) Compounds of formula (VIII) and (IX) may be reacted in a suitable aprotic solvent such as THF or ether, at temperatures in the range of -78 °C to 0 0C. Compounds of formula (VIII) may be prepared from compounds of formula (lie) under standard conditions known in the art. For example where M is an organocuprous reagent such compounds could be prepared according to Scheme 5: i) n-BuLi , THF, -780C ii) CuI
(lie) (VIII)
Scheme 5 Compounds of formula (IX) are commercially available compounds, or they are known in the literature, or they are prepared by standard processes known in the art. Processf) Compounds of formula (X) and (XI) may be reacted in a suitable solvent such as DMF, iV-methylpyrrolidinone or dimethylacetamide in the presence of a base such as triethylamine or diisopropylethylamine under thermal conditions or a microwave reactor. Compounds of formula (X) may be prepared according to Scheme 6:
Conditions of Process
Figure imgf000043_0001
(Xb)
Scheme 6 wherein M is an organometallic group as defined hereinabove.
Compounds of formula (Xa), (Xb) and (XI) are commercially available compounds, or they are known in the literature, or they are prepared by standard processes known in the art.
Process g) Compounds of formula (X) and (XII) may be coupled together under the conditions outlined in Process c).
Compounds of formula (XII) are commercially available compounds, or they are known in the literature, or they are prepared by standard processes known in the art. The formation of a pharmaceutically-acceptable salt is within the skill of an ordinary organic chemist using standard techniques.
It will be appreciated that certain of the various ring substituents in the compounds of the present invention may be introduced by standard aromatic substitution reactions or generated by conventional functional group modifications either prior to or immediately following the processes mentioned above, and as such are included in the process aspect of the invention. The reagents used to introduce such ring substituents are either commercially available or are made by processes known in the art.
Introduction of substituents into a ring may convert one compound of the formula (I) into another compound of the formula (I). Such reactions and modifications include, for example, introduction of a substituent by means of an aromatic substitution reaction, reduction of substituents, alkylation of substituents , oxidation of substituents, esterification of substituents, amidation of substituents, formation of heteroaryl rings. The reagents and reaction conditions for such procedures are well known in the chemical art. Particular examples of aromatic substitution reactions include the introduction of alkoxides, diazotization reactions followed by introduction of thiol group, alcohol group, halogen group. Examples of modifications include; oxidation of alkylthio to alkylsulphinyl or alkylsulphonyl.
The skilled organic chemist will be able to use and adapt the information contained and referenced within the above references, and accompanying Examples therein and also the Examples herein, to obtain necessary starting materials, and products. If not commercially available, the necessary starting materials for the procedures such as those described above may be made by procedures which are selected from standard organic chemical techniques, techniques which are analogous to the synthesis of known, structurally similar compounds, or techniques which are analogous to the above described procedure or the procedures described in the examples. It is noted that many of the starting materials for synthetic methods as described above are commercially available and/or widely reported in the scientific literature, or could be made from commercially available compounds using adaptations of processes reported in the scientific literature. The reader is further referred to Advanced Organic Chemistry, 4th Edition, by Jerry March, published by John Wiley & Sons 1992, for general guidance on reaction conditions and reagents.
It will also be appreciated that in some of the reactions mentioned herein it may be necessary/desirable to protect any sensitive groups in compounds. The instances where protection is necessary or desirable are known to those skilled in the art, as are suitable methods for such protection. Conventional protecting groups may be used in accordance with standard practice (for illustration see T.W. Greene, Protective Groups in Organic Synthesis, John Wiley and Sons, 1991). Examples of a suitable protecting group for a hydroxy group is, for example, an acyl group, for example an alkanoyl group such as acetyl, an aroyl group, for example benzoyl, a silyl group such as trimethylsilyl or an arylmethyl group, for example benzyl. The deprotection conditions for the above protecting groups will necessarily vary with the choice of protecting group. Thus, for example, an acyl group such as an alkanoyl or an aroyl group may be removed, for example, by hydrolysis with a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide. Alternatively a silyl group such as trimethylsilyl may be removed, for example, by fluoride or by aqueous acid; or an arylmethyl group such as a benzyl group may be removed, for example, by hydrogenation in the presence of a catalyst such as palladium-on-carbon.
A suitable protecting group for an amino group is, for example, an acyl group, for example an alkanoyl group such as acetyl, an alkoxycarbonyl group, for example a methoxycarbonyl, ethoxycarbonyl or t-butoxycarbonyl group, an arylmethoxycarbonyl group, for example benzyloxycarbonyl, or an aroyl group, for example benzoyl. The deprotection conditions for the above protecting groups necessarily vary with the choice of protecting group. Thus, for example, an acyl group such as an alkanoyl or alkoxycarbonyl group or an aroyl group may be removed for example, by hydrolysis with a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide. Alternatively an acyl group such as a t-butoxycarbonyl group may be removed, for example, by treatment with a suitable acid as hydrochloric, sulphuric or phosphoric acid or trifluoroacetic acid and an arylmethoxycarbonyl group such as a benzyloxycarbonyl group may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon, or by treatment with a Lewis acid for example boron tris(trifluoroacetate). A suitable alternative protecting group for a primary amino group is, for example, a phthaloyl group which may be removed by treatment with an alkylamine, for example dimethylaminopropylamine or 2-hydroxyethylamine, or with hydrazine.
A suitable protecting group for a carboxy group is, for example, an esterifying group, for example a methyl or an ethyl group which may be removed, for example, by hydrolysis with a base such as sodium hydroxide, or for example a ^-butyl group which may be removed, for example, by treatment with an acid, for example an organic acid such as trifluoroacetic acid, or for example a benzyl group which may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon. The protecting groups may be removed at any convenient stage in the synthesis using conventional techniques well known in the chemical art, or they may be removed during a later reaction step or work-up.
When an optically active form of a compound of the invention is required, it may be obtained by carrying out one of the above procedures using an optically active starting material (formed, for example, by asymmetric induction of a suitable reaction step), or by resolution of a racemic form of the compound or intermediate using a standard procedure, or by chromatographic separation of diastereoisomers (when produced). Enzymatic techniques may also be useful for the preparation of optically active compounds and/or intermediates. Similarly, when a pure regioisomer of a compound of the invention is required, it may be obtained by carrying out one of the above procedures using a pure regioisomer as a starting material, or by resolution of a mixture of the regioisomers or intermediates using a standard procedure.
Enzyme Potency Testing Methods
Compounds were tested for inhibition of GyrB ATPase activity using an ammonium molybdate/malachite green-based phosphate detection assay (Lanzetta, P. A., L. J. Alvarez, P. S. Reinach, and O. A. Candia, 1979, 100: 95-97). Assays were performed in multiwell plates in lOOμl reactions containing: 50 mM TRIS buffer pH 7.5, 75 mM ammonium acetate, 5.5 mM magnesium chloride, 0.5 mM ethylenediaminetetraacetic acid, 5% glycerol, 1 mM 1,4-Dithio-DL-threitol, 200 nM bovine serum albumin, 16 μg/ml sheared salmon sperm DNA, 4 nM E. coli GyrA, 4 nM E. coli GyrB, 250 μM ATP, and compound in dimethylsulfoxide. Reactions were quenched with 150 μl of ammonium molybdate/malachite green detection reagent containing 1.2 mM malachite green hydrochloride, 8.5 mM ammonium molybdate tetrahydrate, and 1 M hydrochloric acid. Plates were read in an absorbance plate reader at 625 nm and percent inhibition values were calculated using dimethylsulfoxide (2%)-containing reactions as 0% inhibition and novobiocin-containing (2 μM) reactions as 100% inhibition controls. Compounds were tested for inhibition of topoisomeraseIV ATPase activity as described above for GyrB except the 1 OOμl reactions contained the following: 20 mM TRIS buffer pH 8, 50 mM ammonium acetate, 8 mM magnesium chloride, 5% glycerol, 5 mM 1,4-Dithio-DL-threitol, 0.005% Brij-35, 5 μg/ml sheared salmon sperm DNA, 10 nM E. coli GyrA, 10 nM E. coli GyrB, 160 μM ATP, and compound in dimethylsulfoxide. Compound potency was based on IC50 measurements determined from reactions performed in the presence of 10 different compound concentrations.
Compounds of the Examples generally have IC5O values of <20μg/ml.
Bacterial Susceptibility Testing Methods Compounds were tested for antimicrobial activity by susceptibility testing in liquid media. Compounds were dissolved in dimethylsulfoxide and tested in 10 doubling dilutions in the susceptibility assays. The organisms used in the assay were grown overnight on suitable agar media and then suspended in a liquid medium appropriate for the growth of the organism. The suspension was a 0.5 McFarland and a further 1 in 10 dilution was made into the same liquid medium to prepare the final organism suspension in 100 μL. Plates were incubated under appropriate conditions at 37 degrees C for 24 hrs prior to reading. The Minimum Inhibitory Concentration was determined as the lowest drug concentration able to reduce growth by 80% or more.
Example 48 had an MIC of 0.13μg/ml against Streptococcus pneumoniae. Other examples areprovided in the following table.
αple No. MIC HIN446 MIC MCA445 MIC SPN548 MIC SAU516 MIC EF]V
333 4 0.13 0.063 2 0.5
60 4 0.25 2 2 8
315 2 0.13 0.5 4 4
345 0.25 0.031 0.03 0.5 0.13
294 0.031 0.001 0.0039 0.031 0.016
According to a further feature of the invention there is provided a compound of the formula (I), or a pharmaceutically-acceptable salt thereof for use in a method of treatment of the human or animal body by therapy.
We have found that compounds of the present invention inhibit bacterial DNA gyrase and topoisomeraseIV and are therefore of interest for their antibacterial effects.
According to a further feature of the present invention there is provided a method for producing an antibacterial effect in a warm blooded animal, such as man, in need of such treatment, which comprises administering to said animal an effective amount of a compound of the present invention, or a pharmaceutically-acceptable salt thereof.
According to a further feature of the invention there is provided a method for inhibition of bacterial DNA gyrase and/or topoisomeraseIV in a warm-blooded animal, such as a human being, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof as defined hereinbefore.
According to a further feature of the invention there is provided a method of treating a bacterial infection in a warm-blooded animal, such as a human being, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof as defined hereinbefore.
A further feature of the present invention is a compound of formula (I) and pharmaceutically acceptable salts thereof for use as a medicament. Suitably the medicament is an antibacterial agent.
According to a further aspect of the invention there is provided the use of a compound of formula (I), or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for use in the production of an anti-bacterial effect in a warm-blooded animal such as a human being.
According to a further aspect of the invention there is provided the use of a compound of formula (I), or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for use in inhibition of bacterial DNA gyrase and/or topoisomeraseIV in a warm-blooded animal such as a human being.
Thus according to a further aspect of the invention there is provided the use of a compound of formula (I), or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for use in the treatment of a bacterial infection in a warm-blooded animal such as a human being.
According to a further aspect of the invention there is provided a compound of formula (I), or a pharmaceutically acceptable salt thereof for use in the production of an anti- bacterial effect in a warm-blooded animal such as a human being.
According to a further aspect of the invention there is provided a compound of formula (I), or a pharmaceutically acceptable salt thereof for use in inhibition of bacterial DNA gyraseand/or topoisomeraseIV in a warm-blooded animal such as a human being.
Thus according to a further aspect of the invention there is provided a compound of formula (I), or a pharmaceutically acceptable salt thereof for use in the treatment of a bacterial infection in a warm-blooded animal such as a human being. In order to use a compound of the formula (I) or a pharmaceutically-acceptable salt thereof, (hereinafter in this section relating to pharmaceutical composition "a compound of this invention") for the therapeutic (including prophylactic) treatment of mammals including humans, in particular in treating infection, it is normally formulated in accordance with standard pharmaceutical practice as a pharmaceutical composition.
Therefore in another aspect the present invention provides a pharmaceutical composition that comprises a compound of the formula (I) or a pharmaceutically-acceptable salt thereof, and a pharmaceutically-acceptable diluent or carrier.
According to a further aspect of the invention there is provided a pharmaceutical composition that comprises a compound of formula (I) as defined hereinbefore or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable excipient or carrier for use in producing an anti-bacterial effect in an warm-blooded animal, such as a human being.
According to a further aspect of the invention there is provided a pharmaceutical composition that comprises a compound of formula (I) as defined hereinbefore or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable excipient or carrier for use in inhibition of bacterial DNA gyrase and/or topoisomeraseIV in an warm-blooded animal, such as a human being.
According to a further aspect of the invention there is provided a pharmaceutical composition that comprises a compound of formula (I) as defined hereinbefore or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable excipient or carrier for use in the treatment of a bacterial infection in an warm-blooded animal, such as a human being.
The compositions of the invention may be in a form suitable for oral use (for example as tablets, lozenges, hard or soft capsules, aqueous or oily suspensions, emulsions, dispersible powders or granules, syrups or elixirs), for topical use (for example as creams, ointments, gels, or aqueous or oily solutions or suspensions), for administration by inhalation (for example as a finely divided powder or a liquid aerosol), for administration by insufflation (for example as a finely divided powder) or for parenteral administration (for example as a sterile aqueous or oily solution for intravenous, subcutaneous, intramuscular or intramuscular dosing or as a suppository for rectal dosing).
The compositions of the invention may be obtained by conventional procedures using conventional pharmaceutical excipients, well known in the art. Thus, compositions intended for oral use may contain, for example, one or more colouring, sweetening, flavouring and/or preservative agents.
Suitable pharmaceutically acceptable excipients for a tablet formulation include, for example, inert diluents such as lactose, sodium carbonate, calcium phosphate or calcium carbonate, granulating and disintegrating agents such as corn starch or algenic acid; binding agents such as starch; lubricating agents such as magnesium stearate, stearic acid or talc; preservative agents such as ethyl or propyl p-hydroxybenzoate, and anti-oxidants, such as ascorbic acid. Tablet formulations may be uncoated or coated either to modify their disintegration and the subsequent absorption of the active ingredient within the gastrointestinal tract, or to improve their stability and/or appearance, in either case, using conventional coating agents and procedures well known in the art.
Compositions for oral use may be in the form of hard gelatin capsules in which the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules in which the active ingredient is mixed with water or an oil such as peanut oil, liquid paraffin, or olive oil.
Aqueous suspensions generally contain the active ingredient in finely powdered form together with one or more suspending agents, such as sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethylcellulose, sodium alginate, polyvinyl-pyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents such as lecithin or condensation products of an alkylene oxide with fatty acids (for example polyoxethylene stearate), or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example polyethylene sorbitan monooleate. The aqueous suspensions may also contain one or more preservatives (such as ethyl or propyl p-hydroxybenzoate, anti-oxidants (such as ascorbic acid), colouring agents, flavouring agents, and/or sweetening agents (such as sucrose, saccharine or aspartame).
Oily suspensions may be formulated by suspending the active ingredient in a vegetable oil (such as arachis oil, olive oil, sesame oil or coconut oil) or in a mineral oil (such as liquid paraffin). The oily suspensions may also contain a thickening agent such as beeswax, hard paraffin or cetyl alcohol. Sweetening agents such as those set out above, and flavouring agents may be added to provide a palatable oral preparation. These compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid. Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water generally contain the active ingredient together with a dispersing or wetting agent, suspending agent and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above. Additional excipients such as sweetening, flavouring and colouring agents, may also be present. The pharmaceutical compositions of the invention may also be in the form of oil-in-water emulsions. The oily phase may be a vegetable oil, such as olive oil or arachis oil, or a mineral oil, such as for example liquid paraffin or a mixture of any of these. Suitable emulsifying agents may be, for example, naturally-occurring gums such as gum acacia or gum tragacanth, naturally-occurring phosphatides such as soya bean, lecithin, an esters or partial esters derived from fatty acids and hexitol anhydrides (for example sorbitan monooleate) and condensation products of the said partial esters with ethylene oxide such as polyoxyethylene sorbitan monooleate. The emulsions may also contain sweetening, flavouring and preservative agents.
Syrups and elixirs may be formulated with sweetening agents such as glycerol, propylene glycol, sorbitol, aspartame or sucrose, and may also contain a demulcent, preservative, flavouring and/or colouring agent.
The pharmaceutical compositions may also be in the form of a sterile injectable aqueous or oily suspension, which may be formulated according to known procedures using one or more of the appropriate dispersing or wetting agents and suspending agents, which have been mentioned above. A sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example a solution in 1,3-butanediol. Compositions for administration by inhalation may be in the form of a conventional pressurised aerosol arranged to dispense the active ingredient either as an aerosol containing finely divided solid or liquid droplets. Conventional aerosol propellants such as volatile fluorinated hydrocarbons or hydrocarbons may be used and the aerosol device is conveniently arranged to dispense a metered quantity of active ingredient.
For further information on formulation the reader is referred to Chapter 25.2 in Volume 5 of Comprehensive Medicinal Chemistry (Corwin Hansch; Chairman of Editorial Board), Pergamon Press 1990.
The amount of active ingredient that is combined with one or more excipients to produce a single dosage form will necessarily vary depending upon the host treated and the particular route of administration. For example, a formulation intended for oral administration to humans will generally contain, for example, from 0.5 mg to 2 g of active agent compounded with an appropriate and convenient amount of excipients which may vary from about 5 to about 98 percent by weight of the total composition. Dosage unit forms will generally contain about 1 mg to about 500 mg of an active ingredient. For further information on Routes of Administration and Dosage Regimes the reader is referred to Chapter 25.3 in Volume 5 of Comprehensive Medicinal Chemistry (Corwin Hansch; Chairman of Editorial Board), Pergamon Press 1990.
In addition to the compounds of the present invention the pharmaceutical composition of this invention may also contain or be co-administered (simultaneously, sequentially or separately) with one or more known drugs selected from other clinically useful antibacterial agents (for example, macrolides, quinolones, β-lactams or aminoglycosides) and/or other anti-infective agents (for example, an antifungal triazole or amphotericin). These may include carbapenems, for example meropenem or imipenem, to broaden the therapeutic effectiveness. Compounds of this invention may also contain or be co-administered with bactericidal/permeability-increasing protein (BPI) products or efflux pump inhibitors to improve activity against gram negative bacteria and bacteria resistant to antimicrobial agents.
As stated above the size of the dose required for the therapeutic or prophylactic treatment of a particular disease state will necessarily be varied depending on the host treated, the route of administration and the severity of the illness being treated. Preferably a daily dose in the range of 1-50 mg/kg is employed. However the daily dose will necessarily be varied depending upon the host treated, the particular route of administration, and the severity of the illness being treated. Accordingly the optimum dosage may be determined by the practitioner who is treating any particular patient.
In addition to its use in therapeutic medicine, compounds of formula (I) and their pharmaceutically acceptable salts are also useful as pharmacological tools in the development and standardisation of in- vitro and in- vivo test systems for the evaluation of the effects of inhibitors of DNA gyrase in laboratory animals such as cats, dogs, rabbits, monkeys, rats and mice, as part of the search for new therapeutic agents.
In the above other, pharmaceutical composition, process, method, use and medicament manufacture features, the alternative and particular embodiments of the compounds of the invention described herein also apply .
Examples
The invention is now illustrated but not limited by the following Examples in which unless otherwise stated :- (i) evaporations were carried out by rotary evaporation in- vacuo and work-up procedures were carried out after removal of residual solids by filtration;
(ii) operations were carried out at ambient temperature, that is typically in the range 18-26 0C and without exclusion of air unless otherwise stated, or unless the skilled person would otherwise work under an inert atmosphere; (iii) column chromatography (by the flash procedure) was used to purify compounds and was performed on Merck Kieselgel silica (Art. 9385) unless otherwise stated; (iv) yields are given for illustration only and are not necessarily the maximum attainable; (v) the structure of the end-products of the invention were generally confirmed by NMR and mass spectral techniques [proton magnetic resonance spectra is quoted and was generally determined in DMSO-d6 unless otherwise stated using a Bruker DRX-300 spectrometer operating at a field strength of 300 MHz. Chemical shifts are reported in parts per million downfield from tetramethysilane as an internal standard (δ scale) and peak multiplicities are shown thus: s, singlet; d, doublet; AB or dd, doublet of doublets; dt, doublet of triplets; dm, doublet of multiplets; t, triplet, m, multiplet; br, broad; fast-atom bombardment (FAB) mass spectral data were generally obtained using a Platform spectrometer (supplied by Micromass) run in electrospray and, where appropriate, either positive ion data or negative ion data were collected]or using Agilent 1 lOOseries LC/MSD equipped with Sedex 75ELSD, run in APCI mode and, where appropriate, either positive ion data or negative ion data were collected; optical rotations were determined at 589 nm at 20 °C using a Perkin Elmer Polarimeter 341; reverse phase HPLC was carried out using YMC Pack ODS-AQ(100x20 mmID, S-5μ particle size, 12 nm pore size);
(vi) each intermediate was purified to the standard required for the subsequent stage and was characterised in sufficient detail to confirm that the assigned structure was correct; purity was assessed by HPLC, TLC, or NMR and identity was determined by infra-red spectroscopy
(IR), mass spectroscopy or NMR spectroscopy as appropriate;
(vii) in which the following abbreviations may be used :-
DMF is N,N-dimethylformamide; DMA is N,N-dimethylacetamide; TLC is thin layer chromatography; HPLC is high pressure liquid chromatography; DMSO is dimethylsulfoxide;
CDCl3 is deuterated chloroform; MS is mass spectroscopy; APCI is atmospheric pressure chemical ionisation; EtOAc is ethyl acetate; MeOH is methanol; DIEA is diisopropylethlamine; TFA is trifluoroacetic acid; HATU is
N-[(dimethylamino)-lH,2,3-triazolo[4,5-b-]pyridin-l-ylmethylene]-N-methylmethanaminium hexafluorophosphate N-oxide; HOAT is l-hydroxy-7-azabenzotriazole; NMP is
N-methylpyrrolidinone; THF is tetrahydrofuran; EtOH is ethanol; LCMS is liquid chromatography/mass spectrometry; DCM is dichloromethane;
(viii) temperatures are quoted as 0C;
(ix) Smith Microwave Synthesizer refers to an equipment that uses microwave energy to heat organic reactions in a short period of time; it was used according to the manufacturers instruction and was obtained from Personal Chemistry Uppsala AB;
(x) Kugelrohr distillation refers to a piece of equipment that distils liquids and heats sensitive compounds using air-bath oven temperature; it was used according to the manufacturers instruction and was obtained from Buchi, Switzerland or Aldrich, Milwaukee, USA; (xi) Where cis(±) or trans(±) is used it is to be understood that this refers to a racemic mixture of the cis or the trans isomers, (-) or (+) refers to the single enantiomer as does R,R or S5S where quoted. Rotations were measured for the first chiral compound in the synthetic scheme
(see for example Intermediates 57 and 58) by measuring the rotation of the effluent from the chiral column, using a Perkin Elmer Polarimeter 341, at the point at which the enantiomer eluted, the nomenclature cis(-) or cis (+) was then continued for all the compounds in the synthesis (for example, Example 42 is the Final compound in the synthesis which started from
Intermediate 57); and (xii) GCMS is Gas phase chromatography (model 6890N) with Mass Spectrometer(model 5973) manufactured by Agilent and was used according to manufacturers instructions.
Example 1 Cisfj-tøethyl 2-(4- i 1T3.,4-dichloro-5-methyl- 1 H-pyrrol-2-vncarbonyll amino I -3 - methoxypiperidin- 1 -yl*)- 1 ,3 -thiazole-5-carboxylate
Figure imgf000055_0001
Method 1
Cis(±)3,4-dichloro-N-(3-methoxypiperidin-4-yl)-5-methyl-lH-pyrrole-2-carboxamide (Intermediate 50; 380 mg), methyl 2-bromo-l,3-thiazole-5-carboxylate (276 mg), were dissolved in anhydrous DMA (5 ml). DIEA (216 μl) was added and the mixture was heated at 120 0C for 7 hours (h). The mixture was diluted with EtOAc, washed well with citrate buffer, water, brine, and dried over Na2SO4. The organic phase was concentrated in vacuo to give the title compound as a brown solid (337 mg).
Method 2
Alternatively the title compounds were prepared using a Smith Microwave Synthesizer by subjecting the reaction mixture to single-mode microwave at 150 0C for 30 minutes (min.) or until the reaction is complete as judged by LCMS5 using polar aprotic solvent such as DMA, NMP or l-butyl-3 -methyl imidazolium-tetrafluoroborate as reaction solvents. MS (ES) MH+: 447 for C17H20Cl2N4O4S; NMR: 1.65 (m, 2H), 2.09 (s, 3H), 3.07 (m, 3H)5 3.48 (m, IH), 3.63 (s, 3H), 3.86 (m, IH), 4.15 (m, 2H), 6.91 (d, IH)5 7.45 (s, IH)5 11.19 (S, IH).
Examples 2-33
The following Examples were prepared by the procedure described in Example 1 from the starting materials (SM) indicated.
Figure imgf000056_0001
Figure imgf000057_0001
Figure imgf000058_0001
Figure imgf000059_0001
Figure imgf000060_0001
Figure imgf000061_0001
Figure imgf000062_0001
Figure imgf000063_0001
Example 34
Cis('±')methyl 4-(aminocarbonyl)-2-('4-{[r4-chloro-5-methyl-lH-pyrrol-2-yl')carbonyl]amino>- 3-methoxypiperidin-l-ylV13-thiazole-5-carboxylate Cis(±)methyl-2-(4-{[(4-chloro-5-methyl-l//-pyrrol-2-yl)carbonyl]amino}-3- methoxypiperidin- 1 -yl)-4- { [( 1 -methyl- 1 -phenylethyl)amino]carbonyl } - 1 ,3 -thiazole-5- carboxylate (Example 21; 0.058 g, 0.1 mmol) was dissolved in equal volumes of TFA and DCM. The reaction was heated in a sealed tube to an external temperature of 85 °C overnight. The reaction mixture was concentrated to remove the DCM and excess TFA. The residue was partitioned with EtOAc and NaHCO3 and the organic extracts were dried with MgSO4 and concentrated to a yellow solid (0.050 g, 100%). MS (ES) MH+: 456 for Ci8H22ClN5O5S. Example 35
Cisf±^-f 4- { [(3 ,4-dichloro-5 -methyl- 1 H-pyrrol-2-y Dcarbonyl] amino > -3 -methoxypiperidin- 1 - vD-1 ^-thiazole-S-carboxylic acid
Figure imgf000064_0001
Cis(±)methyl 2-(4-{[(3,4-dichloro-5-methyl-lH-ρyrrol-2-yl)carbonyl]amino}-3- methoxypiperidin-l-yl)-l,3-thiazole-5-carboxylate (Example 1; 200 mg) was dissolved in THF (50 ml). 2N LiOH (100 ml) was added and the mixture was heated at 50 0C for 18 h. The reaction mixture was cooled to ambient and acidified with 20% aqueous citric acid. The aqueous phase was extracted with EtOAc and the organic phase was washed with water, brine, dried over Na2SO4. The organic phase was concentrated in vacuo and triturated with diethyl ether to give the title compound as an off white solid. (164 mg). MS (ES) MH+: 433, 431 for C16H18Cl2N4O4S; NMR: 1.87 (m, 2H), 2.28 (s, 3H), 3.32 (m, 6H), 3.63 (s, IH), 3.87 (m, IH), 4.45 (m, 2H), 7.04 (d, IH), 7.90 (s, IH), 11.97 (s, IH), 12.30 (s, IH).
Examples 36-71
The following Examples were synthesized by an analogous method to Example 35 from the starting materials (SM) given in the table below.
Figure imgf000064_0002
Figure imgf000065_0001
Figure imgf000066_0001
Figure imgf000067_0001
Figure imgf000068_0001
Figure imgf000069_0001
Figure imgf000070_0001
Figure imgf000071_0001
Example 72
Cis(±)2-(4- { IY3 ,4-dichloro-5-methyl- 1 H-pyrrol-2-yl)carbonyllamino } -3-methoxypiperidin- 1 - ylVN-methoxy-U-thiazole-S-carboxamide Cis(±)2-(4-{[(3,4-dichloro-5-methyl-lH-ρyrrol-2-yl)carbonyl]amino}-3- methoxypiperidin-l-yl)-l,3-thiazole-5-carboxylic acid (Example 35; 100 mg) was dissolved in anhydrous DMA (2 ml). HATU (97 mg), HOAT (31 mg), DIEA (41 μl) were added and the mixture was stirred for 30 min. vV-Methoxyamine hydrochloride (19.3 mg) was added followed by DIEA (41 μl), and the mixture was stirred at room temperature for 16 h. The reaction mixture was diluted with EtOAc, washed with H20, 20% citric acid solution, H2O5 sat. NaHCO3, H2O, brine and dried over Na2SO4. The organic phase was concentrated in vacuo to give the title compound as an off-white solid (82 mg). MS (ES)(MH+): 462, 460 for Ci7H2ICl2N5O4S; NMR: 1.64 (m, 2H), 1.85 (m, IH), 2.05 (s, 3H)5 2.83 (m, IH)5 3.33 (m, 5H)5 3.73 (s, 3H)5 4.07 (m, IH)5 4.38 (m, 2H), 7.24 (d, IH)5 7.74 (s, IH)5 11.39 (s, IH), 12.05 (s, IH). Example 73
The following Example was prepared by the procedure described in Example 72 from the starting material (SM) indicated.
Figure imgf000072_0001
Example 74
Cis(±)2-(4- 1 [(3 ,4-dichloro-5-methyl- lH-pyrrol-2-v0carbonyl"|aminol -3-hvdroxypiperidin- 1 - vD-1 ^-thiazole-S-carboxylic acid
Cis(±)2-(4- { [(3 ,4-dichloro-5-methyl- 1 H-pyrrol-2-yl)carbonyl]amino } -3 - methoxypiperidin-l-yl)-l,3-thiazole-5-carboxylic acid (Example 35; 100 mg) was suspended in anhydrous DCM. BBr3/ DCM (15 ml) was added and the mixture was heated at 40 0C for 18 h. The reaction mixture was cooled to -50 °C and water was added. The mixture was extracted with EtOAc and the organic phase was washed with water, dried over Na2SO4. The organic phase was concentrated in vacuo to yield a pale brown solid which was dissolved in acetonitrile/water mixture and was lyophilized (46 mg). MS (ES) MH+: 419 for C15H16Cl2N4O4S; NMR: 1.87 (m, 2H), 2.20 (s, 3H), 3-4 (brm, 6H), 6.9 (d, IH), 7.51 (s, IH)5 12.19 (s, IH).
Example 75
The following Example was prepared by the procedure described in Example 74 from the starting material (SM) indicated.
Figure imgf000073_0001
Example 76
Cis(±M-f 4- { [(3 ,4-dichloro-5 -methyl- 1 H-pyrrol-2-vDcarbony 11 amino } -3 -methoxypiperidin- 1 - vOquinoline-2-carboxylic acid
Cis(±)3,4-dicholoro-N-[3-methoxy-l-(2-methylquinolin-4-yl)piperidin-4-yl]-5- methyl-lH-pyrrole-2-carboxamide (Example 29; 170 mg) was dissolved in pyridine (5 ml). Selenium dioxide (211 mg) was added and the mixture was heated at 130 °C for 3 h. The brown solution was cooled to room temperature, diluted with water and filtered through a bed of celite. The filtrate was extracted with EtOAc, washed with water and dried over Na2SO4, concentrated in vacuo. The brown solid that separated was triturated with Et2O, filtered, washed well with n-hexanes and dried in vacuo to give the title compound as a brown solid (176 mg). MS (ES) MH+: 477 for C22H22Cl2N4O4; NMR: 1.34 (m, IH), 2.01 (m, IH), 2.28 (s, 3H)5 3.10 (s, 3H), 3.42 (m, 3H)5 3.72 (m, 2H), 4.23 (m, IH), 7.36 (d, IH), 7.63 (s, IH), 7.78 (m, IH), 7.92 (m, IH)5 8.30 (m, 2H), 12.30 (brs, IH).
Example 77
Cisf±H- ( IY3 ,4-Dichloro-5 -methyl- 1 H-pyrrol-2- vDcarbonv 11 amino 1 - 1 - [5 -(methoxycarbonylV 1 ,3-thiazol-2-yl1piperidine-3-carboxylic acid Cis(±)4-{[(3,4-Dichloro-5-methyl-lH-pyrrol-2-yl)carbonyl]amino}piperidine-3- carboxylic acid hydrochloride (Intermediate 79; 1.84 g) was dissolved in anhydrous DMF (20 ml) under an argon atmosphere in a 100-ml round bottom flask. Methyl 2-bromothiazole-5- carboxylate (1.43 g) was added followed by N,N-diisopropylethylamine (3.6 ml) at room temperature. The reaction was heated to 55 °C for 14 h cooled to room temperature. The reaction mixture was diluted with EtOAc (250 ml) and washed with a saturated aqueous ammonium chloride solution (125 ml), followed by a saturated aqueous sodium chloride solution (100 ml). The EtOAc solution was dried over anhydrous MgSO4 and concentrated in vacuo. The crude product was purified by silica gel chromatography using 0-10% CH3OH in DCM. The recovered product was recrystallised from EtOAc to further enhance the diastereomeric excess, increasing it from a 90:10 cis:trans mixture to a 96:4 cis:trans mixture (by HPLC analysis). The recrystallised product was carried on to the next reaction (2 g). MS (ES - (M+H)+): 461, 463 for C17H18Cl2N4O5S; NMR: 1.71 (m, IH), 1.91 (m, IH), 2.16 (s, 3H), 2.81 (dt, IH), 3.42 (m, 2H), 3.74 (s, 3H), 3.86 (m, IH), 4.34 (m, 2H), 7.43 (d, IH), 7.88 (s, IH), 8.50 (brs, IH), 12.06 (s, IH).
Example 78
Cisr±)methyl 2-r4-|[('3,4-dichloro-5-methyl-liJ'-pyrrol-2-vDcarbonyl1amino}-3-('morpholin- 4-ylcarbonyl)piperidin- 1 -yl]- 1 ,3-thiazole-5-carboxylate
The title compound was prepared in a manner analogous to (Intermediate 37) starting from cis(±)4- { [(3 ,4-dichloro-5-methyl- 1 H-pyrrol-2-yl)carbonyl]arnino } - 1 - [5 -
(methoxycarbonyl)-l,3-thiazol-2-yl]piperidine-3-carboxylic acid (Example 77) and morpholine. MS (ES+): 530, 532 for C21H25Cl2N5O5S.
Examples 79-82 The following compounds were synthesized by an analogous method to Example 78 from Example 77 and the starting materials given in the table below.
Figure imgf000074_0001
Figure imgf000075_0001
Example 83
Cis(±)6-(4- { [f 4-chloro-5-methyl- lH-pyiTOl-2-yl)carbonyl]amino I -3 -methoxypiperidin- 1 -ylV 2-methoxypyrimidine-4-carboxylic acid Cis(±)methyl 2-chloro-6-(4- { [(4-chloro-5-methyl- lH-pyrrol-2-yl)carbonyl]amino } -3 - methoxypiperidin-l-yl)ρyrimidine-4-carboxylate (Example 23; 0.12g, 0.27 mmol) was dissolved in 0.5 M sodium methoxide in MeOH (5.4 ml, 2.7 mmol) and heated in the microwave for 1.5 h at 85 °C. The reaction mixture was acidified with IN HCl and the product was extracted with EtOAc, dried with MgSO4 and concentrated to a solid which was purified by reverse phase chromatography (gradient elution from 20-50% CH3CN in water with 0.5%TFA). Freeze drying yielded product as a white solid. MS (ES) MH+: 424 for Ci8H22ClN5O5; NMR: 1.62 (s, IH), 1.75 (s, IH), 2.14 (s, 3H), 3.26 (s, 3H), 3.53 (m, 3H), 3.87 (s, 3H), 4.22 (s, 2H), 6.88 (d, J=2.64 Hz, IH), 7.07 (s, IH), 7.66 (d, J=7.91 Hz, IH), 11.63 (s, IH). Example 84
The following compound was prepared by the procedure of Example 83 from the starting material (SM) indicated.
Figure imgf000076_0001
Examples 85-86
The following compounds were prepared by the procedure of Intermediate 37 using the starting materials (SM) indicated.
Figure imgf000076_0002
Preparation of starting materials for Examples 1-86 Intermediate 1
3.4-Dichloro-5-methyl-liJ-pyrrole-2-carboxylic acid
Figure imgf000077_0001
Ethyl 3,4-dichloro-5-methyl-lH-pyrrole-2-carboxylate (Intermediate 2; 7.765 g,
0.03496 mol) was dissolved in MeOH (80 ml) and DCM (10 ml) and slowly added to a 70 °C solution of 2 N LiOH (105 ml, 0.21 mol). After 2 h, the reaction mixture was cooled to room temperature and then in an ice bath, followed by acidification with 2 N HCl. The mixture was stirred at 0 °C for 1 h, and a purple solid was filtered, washed with water and lyophilized overnight to give 4.314 g (0.0222 mol, 64% yield) of the desired product. MS (ES'): 192.13, 194.13 for C6H5Cl2NO2; NMR: 2.17 (s, 3H).
Intermediate 2
Ethyl 3,4-dichloro-5-methyl-liJr-pyrrole-2-carboxylate Method 1
A solution of ethyl 5-methyl-lif-pyrrole-2-carboxylate (Intermediate 3; 7.00 g, 0.0457 mol) in tetrachloromethane (30 ml) was cooled to 0 °C under nitrogen. The rubber septum used in the apparatus was pierced with a needle, and SO2Cl2 (7.8 ml, 0.096 mol) was then added dropwise over 25 min. Within 1 h, the reaction mixture had formed a slurry. The solid was collected by suction filtration, washed with cold tetrachloromethane, and dried under vacuum overnight to give the title product as a peach coloured solid (7.84 g, 0.0353 mol, 77% yield). MS (ES"): 222.00, 224.00 for C8H9Cl2NO2; NMR: 1.34-1.40 (t, 3H), 2.28 (s, 3H), 4.32-4.38 (m, 2H).
Method 2
A 4-neck 22L round bottom flask equipped with an overhead stirrer, reflux condenser, nitrogen inlet and an internal temperature probe was charged with (Intermediate 253, 1000 g, 3.9 mol), l-methyl-2-pyrrolidinone (10 L) and sodium cyanoborohydride (382 g, 6.1 mol, 1.56 eq). The resulting solution was heated at 75-80 0C for 6 h and allowed to cool to ambient overnight. Reaction solution was poured into water (20 L) resulting in a light brown suspension and product was extracted with methyl tert-butyl ether (2 x 10 L). Organic layer was dried with sodium sulfate and concentrated under reduced pressure to a thick slurry, which was filtered and solid dried in convection oven yielding 4 (518 g, 60 %) as a light brown solid.
Intermediate 3
Ethyl 5-methyl- 1 H-pyrrole-2-carboxylate
Sodium (2.79 g, 0.121 mmol) was dissolved in anhydrous EtOH (100 ml), then 2,2,2- trichloro-1 -(5-methyl- lH-pyrrol-2-yl)ethanone (Intermediate 4; 22.5 g, 0.099 mmol) was added in small portions. The dark brown solution was stirred at room temperature for 30 min then concentrated under vacuum to a small volume. The mixture was cooled in an ice bath and 3 N HCl was added slowly then extracted with diethyl ether (3 x 100 ml). The ether extracts were washed with 10% NaHCO3, water and brine, dried over Na2SO4 and concentrated in vacuo to give the title compound as a brown solid. (15.04 g). NMR: 1.32 (t, 3H), 2.1 (s, 3H), 4.371 (q, 2H), 5.96 (dd, IH), 6.78 (dd, IH), 11.67 (s, IH).
Intermediate 4
2,2,2-Trichloro- 1 -f 5-methyl- 1 H-pyrrol-2-yl)ethanone
2-Methyl-lH-pyrrole (Intermediate 5; 10 g, 0.123 mmol) in anhydrous diethyl ether (30 ml) was added dropwise over 1 h to a stirred solution of triacetyl chloride (29 g, 0.16 mmol) in anhydrous Et2O (100 ml). The mixture was stirred for a further 1 h then K2CO3 (10 g/30 ml) was added slowly through a dropping funnel. The organic phase was dried over Na2SO4 and treated with decolourizing charcoal (3 g) for 30 min at room temperature. The resulting purple solution was concentrated and triturated with n-hexanes to give the title compound as a purple solid. (16.72 g). NMR (CDCl3): 2.36 (s, 3H), 6.04 (dd, IH), 7.45 (dd, IH), 10.344 (s, IH).
Intermediate 5 2-Methyl- 1 H-pyrrole
Potassium hydroxide (50 g, 0.89 mmol) was added to a solution of ethylene glycol (750 ml) and lH-pyrrole-2-carbaldehyde (50 g,0.53 mmol). Hydrazine hydrate (37 ml, 0.745 mmol) was added slowly over 15 min. The reaction mixture was refluxed at 90 0C for 90 min. The mixture was cooled to room temperature and cold water (250 ml) was added. The aqueous mixture was extracted with DCM (250 ml). The organic phase was washed with water (250 ml), dried over Na2SO4 and concentrated in vacuo. Kugelrohr distillation gave the title compound as a clear colourless liquid (29.75 g). NMR: 2.1 (s, 3H), 5.77 (s, IH), 5.9 (dd, IH), 6.25 (dd, IH), 10.54 (s, IH).
Intermediate 6
4-Chloro-5-methyl-lH~-pyrrole-2-carboxylic acid
Figure imgf000079_0001
Lithium hydroxide (2 M, 4 ml) was warmed to 50 0C and a solution of ethyl 4-chloro- 5-methyl-li7-pyrrole-2-carboxylate (Intermediate 7; 0.30 g, 1.60 mmol) in MeOH was added to it. The reaction was heated to 80 0C and stirred for two hours. The MeOH was removed and the aqueous solution was cooled to 0 0C and acidified with 30% HCl. The precipitated product (0.23 g, 92%) was filtered and dried. MS (ES): 160 (M+l) for C6H6ClNO2; NMR (CDCl3): 2.25 (s, 3H), 6.85 (s, IH), 8.98 (brs, IH).
Intermediate 7
Ethyl 4-chloro-5-methyl- li7-pyrrole-2-carboxylate
N-Chlorosuccinimide (0.67 g, 5.08 mmol) was added to a solution of ethyl 5-methyl- lH-pyrrole-2-carboxylate (Intermediate 3; 0.65 g, 4.23 mmol) in chloroform (20 ml). The reaction was warmed to 40 0C and stirred for 4 h, then poured to a beaker containing 2 N NaOH (20 ml) at 0 0C. The layers were separated and the aqueous layer was extracted with chloroform (x3). The combined organic extracts were dried over magnesium sulfate and concentrated. The resultant off-white solid was purified by flash chromatography (hexanes/EtOAc, 16:1) to give the title product as a white solid (0.3 g, 38%). MS (ES): 188 (M+l) for C8H10ClNO2; NMR (CDCl3): 1.34 (t, 3H), 2.27 (s, 3H), 4.30 (q, 2H), 6.76 (s, IH), 9.07 (brs, IH)
Intermediate 8
3,4-Difluoro-2-methyl-lH-pyrrole
BH3THF (400 ml, IM in THF) was added dropwise to a solution of 3,4-difluoro-lH- pyrrole-2-carbaldehyde (Intermediate 19; 3.82 g) in THF (50 ml) cooled in an ice-water bath under N2. The reaction mixture was stirred at room temperature for 3 days. MeOH was added slowly to quench excess of BH3 and then the solvent was removed in vacuo at 0 °C. The resulting yellow oil was triturated with hexanes/DCM and the yellow precipitate was removed by filtration. The filtrate was washed with NaHCO3, H2O and brine, dried over Na2SO4, filtered and concentrated at O °C in vacuo to give a pale yellow oil (3.8 g). MS (ES) MH+: 116 for C5H5F2N; NMR (CDCl3): 2.15 (s, 3H), 6.22 (m, IH).
Intermediate 9
1 -fert-Butyl-3-methyl-4-hvdroxy-5,6-dihydropyridine- 1 ,3-f2H)-dicarboxylate
Methyl-4-hydroxy-l,2,5,6-tetrahydropyridine-3-carboxylate-hydrochloride (25 g) was suspended in DCM (250 ml). DIEA (41.6 g) was added in a single portion and the resultant homogeneous solution was cooled to 0 0C. A DCM solution of di-tert-butyl dicarbonate (29.5 g, 1.05 moles) was added dropwise over a 1 h period. After the addition, the reaction was warmed to room temperature and stirred overnight. The reaction mixture was concentrated to one-half the volume and washed with water, brine, dried over Na2SO4, filtered and concentrated in vacuo to an oil. The crude product was purified by flash column chromatography eluting with (20% EtOAc / 80% hexanes) to give the title product (33 g). NMR (CDCl3): 1.48 (s, 9Η), 2.37 (m, 2H), 3.57 (t, 2H), 3.78 (s, 3H), 4.06 (brs, 2H), 11.9 (s, IH).
Intermediate 10
Ethyl 4-chloroquinoline-2-carboxylate
Figure imgf000080_0001
Phosphorous oxychloride (5ml) was added to ethyl 4-hydroxyquinoline-2-carboxylate (l.Olg). The reaction mixture was subjected to single-mode microwave at 100 0C for 30 min using a Smith Microwave Synthesizer. The solvent was removed in vacuo and recrystallized with acetone to gave the title compound as a white solid (1.9Og). MS (ES) MH+: 235, 237 for C12Hi0ClNO2; NMR (CDCl3): 1.44 (t, 3H, J = 7.16), 4.51 (q, 2H, J = 7.16), 7.19 (s, IH), 7.71 (m, IH), 7.81 (m, IH), 8.22 (m, IH), 8.36 (d, IH, J = 8.29). Intermediate 11
2-(Methylthio)-l ,3-thiazole-4-carboxylic acid
Ethyl 2-(methylthio)-l,3-thiazole-4-carboxylate (5.0 g) (Sinha, Subhash C et ύ.Tet.Lett. 2000, 41 (43), 8243-8246) was dissolved in MeOH (50 ml) and 2N LiOH (74 ml) was added. After stirring at room temperature for five minutes the reaction mixture was concentrated to remove MeOH and the residue was suspended in water and acidified with cone. HCl to pH 3. The white precipitate was filtered and dried to yield the title compound (3.42 g). NMR: 2.72 (s, 3H), 8.35 (s, IH).
Intermediate 12
2-(MethylthioV4-thiazolecarbonyl chloride
2-(Methy ItWo)-1, 3 -thiazole-4-carboxylic acid (Intermediate 11; 1.0 g) in thionyl chloride (10 ml) was heated to reflux for 30 min. The solution was cooled to room temperature and concentrated in vacuo. The residue was washed with anhydrous THF and concentrated to yield a black solid which was dried and stored cold under nitrogen (1.2 g). NMR (CDCl3): 2.76 (s, 3H), 8.32 (s, IH).
Intermediate 13
N-(I -Methyl- 1 -phenylethyl)-2-(methylthioV 1 ,3-thiazole-4-carboxamide Triethylamine (2.24 ml) was added to a solution of cumylamine (3.2 ml) in anhydrous
THF (30 ml). After stirring for 15 min, a solution of 2-(methylthio)-4-thiazolecarbonyl chloride (Intermediate 12; 3.1 g) in anhydrous THF was added and the reaction mixture was concentrated in vacuo after 15 min. The residue was partitioned with EtOAc and water, dried with MgSO4, and concentrated to an orange oil. Flash purification on silica gel with isocratic elution of DCM yielded the product as a yellow oil (3.7 g). MS (ES) MH+: 293 for
C14H16N2OS2; NMR: 1.68 (s, 6H), 2.76 (s, 3H), 7.20 (d, J=7.16 Hz, IH), 7.29 (t, J=7.54 Hz, 2H), 7.36 - 7.41 (m, 2H), 8.04 (s, IH), 8.08 (s, IH).
Intermediate 14 4- { [(I -Methyl- 1 -phenylethyl)aminolcarbonyl|-2-(methylthio)- 1 ,3-thiazole-5-carboxylic acid
Diisopropylamine (4.2 ml) was dissolve in anhydrous THF (100 ml) was cooled to - 78°C and to this was added n-butyl lithium (12 ml) slowly. The solution was slowly warmed to 0 °C and then cooled back to -78°C. A solution of TV-(I -methyl- 1 -phenylethyl)-2- (methylthio)-l,3-thiazole-4-carboxamide (Intermediate 13; 2.8 g) in anhydrous THF was added slowly maintaining the temperature below -70°C. After stirring for 30 min, a solution of methyl cyano formate (1.6 ml) in anhydrous THF was added in one portion and the reaction was stirred at -780C for 30 min followed by slow warming to room temperature. The reaction mixture was diluted with water and extracted with ether. The aqueous portion was acidified with cone. HCl, extracted with EtOAc, dried with MgSO4 and concentrated to an orange solid (0.9 g). MS (ES) MH+: 337 for Ci5H16N2O3S2; NMR: 1.66 - 1.74 (m, 6H), 2.80 (s, 3H), 7.23 (d, J=7.16 Hz, IH), 7.33 (t, J=7.54 Hz, 2H), 7.45 (s, 2H), 9.07 (s, IH).
Intermediate 15
Methyl 4- { I'd -methyl- 1 -phenylethyl)arnino"|carbonyl) -2-("methylthio)- 1 ,3-thiazole-5- carboxylate
Figure imgf000082_0001
Potassium carbonate (0.37 g) and iodomethane (0.17 ml) were added to a solution of 4- { [(I -methyl- 1 -phenylethyl)amino]carbonyl} -2-(methylthio)- 1 ,3 -thiazole-5-carboxylic acid (Intermediate 14; 0.9 g) in DMF (20 ml) and heated in a sealed tube at an external temperature of 85°C for 30 min. The reaction mixture was concentrated to remove DMF and partitioned with EtOAc and water. The combined organic extracts were washed with water, dried with MgSO4, and concentrated to an orange solid (0.63 g). NMR: 1.60 - 1.65 (m, 6H), 2.76 (s, 3H), 3.78 - 3.83 (m, 3H), 7.22 (d, J=7.16 Hz, IH), 7.33 (t, J-7.63 Hz, 2H), 7.46 (d, J=7.35 Hz, 2H), 8.75 (s, IH).
Intermediate 16
Methyl 4- { [Y 1 -methyl- 1 -phenylethyl)amino]carbonyl } -2-fmethylsulfonyl)- 1 ,3 -thiazole-5- carboxylate
3-Chloroperbenzoic acid (0.89 g) was added to a solution of methyl 4- { [(I -methyl- 1 - phenylethyl)amino]carbonyl}-2-(methylthio)-l,3-thiazole-5-carboxylate (Intermediate 15;
0.63 g) in DCM (25 ml). After stirring overnight the reaction was complete. Aqueous sodium bisulfite was added to quench any unreacted peroxides and the solution was washed with sat. NaHCθ3. The organic portion was dried with MgSO4 and concentrated to a yellow solid (0.6 I
- 82 -
g). NMR: 1.63 - 1.68 (m, 6H), 3.58 (s, 3H), 3.89 (s, 3H), 7.23 (d, J=7.16 Hz, IH), 7.34 (t, J=7.63 Hz, 2H), 7.47 (d, J=7.54 Hz, 2H), 8.91 (s, IH).
Intermediate 17 Methyl-2-chloro-4-fmethoxymethylVl,3-thiazole-5-carboxylate tert-Butyl nitrite (2.2 ml, 18.6 mmol) and cuprous chloride (1.5 g) were suspended in anhydrous CH3CN (100 ml). Methyl 2-amino-4-(methoxymethyl)-l,3-thiazole-5-carboxylate (2.5 g) prepared as described in (Kennedy, Alan R. et al. Acta Crystallographica, Section C: Crystal Structure Communications (1999, C55 (7) 2) was added in one portion. The mixture was stirred at room temperature for 2 h and the temperature was raised to 70 °C for 1 h. The mixture was cooled to room temperature and filtered. The filtrate was poured into 6 N HCl, extracted with EtOAc, dried with MgSO4 and concentrated to a black oil. Flash purification on silica gel with gradient elution (hexane to EtOAc) yielded product as a yellow liquid (0.82 g). NMR: 3.31 (s, 3H), 3.85 (s, 3H), 4.71 (s, 2H).
Intermediate 18 3,4-Difluoro-liJl-pyrrole
3,4-Difluoro-lH-pyrrole was prepared as described in Eric K. Woller et al., J Org. Chem., 1998 63(16), 5706-5707) and references therein. Thus, to a solution of 3,3,4,4- tetrafluoro-pyrrolidine hydrochloride (30.2 g) in dry DMSO (250 ml) cooled in an ice-water bath, A-BuOK was added (100 g) under N2. After the addition was complete (~0.5 h), the reaction mixture was stirred at room temperature for another 0.5 h. It was cooled to 0 °C and quenched with ice water (300 ml). After the solid dissolved, the mixture was diluted to —1.5 1 with water, neutralized to pH 7 with HCl, and extracted with DCM. The combined DCM extracts were washed with water, brine, dried over MgSO4 and filtered. DCM was removed in vacuo at 0 °C, and the resulting orange oil was dissolved in pentane at room temperature, cooled to -20 °C overnight and filtered under N2 to give the title compound as golden crystals (4.6 g). NMR (CDCl3): 6.38 (d, IH), 6.41 (d, IH).
Intermediate 19
3,4-Difluoro-lH-pyrrole-2-carbaldehyde
DMF (4.3 ml) was cooled in ice-water bath under N2 and POCl3 (5.2 ml) was added dropwise. The mixture was stirred at room temperature for 10 min. The ice- water bath was replaced, and the mixture was diluted with DCM (45 ml). A solution of 3,4-difluoro-lH- pyrrole (Intermediate 18; 4.57 g) in DCM (45 ml) was added dropwise. The mixture was refluxed for 30 min, cooled to room temperature and a solution of NaOAc (23 g) in water (60 ml) was added slowly. The resulting mixture was refluxed for 30 min, organic phase was 5 separated and aqueous phase was extracted with DCM. The combined organic phase was washed with NaHCO3, dried over Na2SO4, and concentrated in vacuo. The crude solid was triturated with DCM (20 ml)/pentane (100 ml), and then cooled to -20 °C to give the title compound as pale brown needles (4.73 g). NMR (CDCl3): 6.87 (m, IH), 9.6 (m, IH).
10 Intermediate 20
3 ,4-Difluoro-5-methyl- 1 H-pyrrole-2-carboxylic acid
Figure imgf000084_0001
2,2,2-Trichloro-l-(3,4-difluoro-5-methyl-lH-pyrrol-2-yl)ethanone (Intermediate 80; 1.03 g) was added to an aqueous solution of NaOH (18 ml) at 0 °C under N2. The mixture was
15 stirred at room temperature for a further 2 h, cooled to 0 0C and acidified with HCl to ~pH 2. A brown precipitate of product was collected by filtration. The crude product was purified by column chromatography on silica gel elution with EtOAc/hexanes (1 :1). Trituration with DCM (1 ml)/pentane (6 ml) gave the title compound as a pale brown solid (306 mg). M.p. 140 0C (dec). MS (ES) MH+: 160, 161 for C6H5F2NO2; NMR (CDCl3): 2.15 (s, 3H), 11.5 (s,
20 IH), 12.8 (brs, IH).
Intermediate 21
Cisf±)ethyl 4-amino-3-methoxypiperidine-l-carboxylate hydrochloride salt
The title compound can be prepared as described in Lee, C. et al. Synth. Comm. 2001, 25 31(7), 10881-10890 and / or WO 94/12494or from Intermediate 157 by the following procedure;
To a stirred solution of the benzylamine (36.45 g, 125 mmol) and 10% palladium on activated carbon (50% wet; approximately 4 g) in methanol (250 mL), at room temperature and under an atmosphere of N2, was added ammonium formate (31.50 g, 500 mmol) as a 30 solid. Temperature was increased to 70 °C; the reaction was stirred overnight at this temperature, under an atmosphere of N2. Complete conversion was suggested by TLC (6% methanol in ethyl acetate; Rf ~ 0.06 in a solution of 15 % methanol and 30% acetone in methylene chloride) in the morning. The reaction mixture was filtered through Celite and concentrated under vacuum. To the residue was added approximately 50 mL water; from this mixture was extracted the crude product with a solution of ~3% methanol in chloroform (4 X 5 300 mL). Organic layers were combined, dried over magnesium sulfate, and concentrated. Obtained 24.18 g (96%) of an off-white solid. MS (ES) MH+: 202 for C9H18N2O3.
Intermediate 22 0 Cis(±)ethyl 4- { [Ybenzyloxytearbonyl] amino > -3 -methoxypiperidine- 1 -carboxylate
Benzyl chloroformate (3.3 ml) was added dropwise to a cold solution of Cis(±)ethyl 4- amino-3 -methoxypiperidine- 1 -carboxylate hydrochloride salt (Intermediate 21; 5 g) in saturated NaHCO3. The mixture was stirred at room temperature for 14 h. The white precipitate was filtered, washed well with water, dried in vacuo to give the title compound as 5 a white solid (6.66 g). MS (ES) MH+: 336 for C17H24N2O5; NMR: 1.21 (t, 3H), 1.52-1.67 (m, 2H), 3.08 (m, 2H), 3.28 (s, 3H), 3.41 (s, 2H), 3.74-3.92 (m, 2H), 3.96 (m, 2H), 4.14 (m, IH), 5.10 (s, 2H), 7.24 (d, IH), 7.44 (m, 5H).
Intermediate 23 and Intermediate 24 0 ethyl (3i?,45)-4- { [(benzyloxy)carbonyl]amino } -3 -methoxypiperidine- 1 -carboxylateand ethyl (3S,4R)-4- { [(benzyloxy)carbonyl]amino } -3 -methoxypiperidine- 1 -carboxylate
Cis(±)ethyl 4-{[(benzyloxy)carbonyl]amino}-3-methoxypiperidine-l -carboxylate (Intermediate 22; 6.2 g) were separated into its enantiomers by chiral chromatography over a Chiralcel OJ column (eluant: hexanes/MeOH/EtOH;70/15/15;0.1% diethylamine). The 5 fractions corresponding to the first chromatographic peak (Cis(-)isomer) were collected and evaporated yielding the title compound as a white solid (2.62 g). The fractions corresponding to the second chromatographic peak (Cis(+)isomer) were collected and evaporated yielding the title compound as a white solid (2.71 g). MS (ES) (M+Na)+: 360 for Cj7H24N2O5; NMR: 1.21 (t, 3H), 1.52-1.67 (m, 2H), 3.08 (m, 2H), 3.28 (s, 3H), 3.41 (s, 2H), 3.74-3.92 (m, 2H), 0 3.96 (m, 2H), 4.14 (m, IH), 5.10 (s, 2H), 7.24 (d, IH), 7.44 (m, 5H). Intermediate 25 ethyl (3ιS,4i?)-4-amino-3-methoxypiperidine-l -carboxylate
Figure imgf000086_0001
Cis(+)ethyl 4- { [(benzyloxy)carbonyl] amino } -3 -methoxypiperidine- 1 -carboxylate (Intermediate 24; 3.98 g) was dissolved in MeOH (100 ml) and IN HCl (50 ml). 10% Pd- charcoal (600 mg) was added, degassed and hydrogenolysed under an atmosphere of H2 gas at room temperature for 3 h. The catalyst was filtered through a bed of celite, concentrated in vacuo and lyophilized giving the title compound (2.8 g). MS (ES) MH+: 202 for C9Hi8N2O3. Intermediate 26 The title compound was prepared in a manner analogous to Intermediate 25 from the starting material indicated.
Figure imgf000086_0002
Intermediate 27
Cis(±)ethyl-3 -( aHyloxy)-4- [(fert-butoxycarbonyPaminolpiperidine- 1 -carboxylate A 50% aqueous solution of sodium hydroxide (3 ml) was added to a suspension of allyl bromide (693 mg, 5.70 mmol), cis(±)ethyl 4-[(tert-butoxycarbonyl)amino]-3- hydroxypiperidine-1 -carboxylate (reference: C. H. Lee et al. Syn. Commun., 2001, 31, 1081.), (750 mg, 2.6 mmol), benzyltriethylammonium chloride (4 mg, cat.) and toluene (8 ml). The resultant mixture was stirred overnight at room temperature. The reaction mixture was diluted with EtOAc (150 ml) and water (35 ml). The organic phase was separated and the aqueous phase was back extracted with EtOAc (2 x 30 ml). The combined organic phase was washed with brine, dried over sodium sulfate, filtered and concentrated. The crude residue was purified by flash column chromatography (hexane/EtOAc, 3:2) to yield 734 mg of the title compound. MS (ES)(M+H): 329.for Ci6H28N2O5; NMR: 1.28 (t, 3H)5 1.47 (s, 9H), 1.68 (m, 2H), 2.88 (brt, 2H), 3.50 (m, IH), 3.68 (m, IH), 3.90 (m, IH), 4.00-4.45 (m, 3H), 4.10 (q, 2H), 4.92 (brs, IH), 5.20 (m, 2H), 5.86 (m, IH). Intermediate 28
Cis( ±)ethyl-3 -(ally loxy)-4-amino] piperidine- 1 -carboxylate hydrochloride salt 4N HCl/dioxane (20 ml) was added to cis(±)ethyl-3-(allyloxy)-4-[(ført- butoxycarbonyl)amino]piperidine-l -carboxylate (Intermediate 27; 572 mg). The mixture was stirred at room temperature for 90 min. The solvent was removed in vacuo, dried in vacuo to give the title compound as an oily foam which was used without further purification (449 mg). MS (ES)(M+H): 228.for CnH20N2O3.
Intermediates 29-36 The following compounds were prepared in a manner analogous to Intermediate 28 from the starting material (SM) indicated.
Figure imgf000087_0001
Figure imgf000088_0001
Intermediate 37
Cis(±*)ethyl 4- { ϊ(3 Λ-dichloro-S-methyl- lH-pyrrol-2-yl)carbonyl1amino} -3- methoxypiperidine- 1 -carboxylate 3,4-Dichloro-5-methyl-lH-pyrrole-2-carboxylic acid (Intermediate 1; 304 mg) was dissolved in anhydrous DMF. HATU (596 mg), HOAT (213 mg) and DIEA (274 μl) were added and stirred at ambient for 15 min. Cis(±) ethyl 4-amino-3-methoxypiperidine-l- carboxylate (Intermediate 21; 317 mg) was added and the mixture was stirred at ambient for 18 h. The mixture was diluted with EtOAc and washed with water, IN HCl, bicarbonate buffer, water, brine and dried over Na2SO4. The solution was concentrated in vacuo to give the title compound as a brown solid (503 mg). MS (ES) MH+: 378, 380 for Ci5H2ICl2N3O4; NMR: 1.29 (t, 3H), 1.79 (m, 2H), 2.27 (s, 3H)5 3.12 (m, 2H), 3.30 (s, 3H)5 3.37 (m, IH), 3.83- 4.16 (m, 5H), 7.25 (d, IH)5 12.23 (s, IH). Intermediates 38-49
The following compounds were prepared in a manner analogous to Intermediate 37 from the starting material (SM) indicated.
Figure imgf000089_0001
Figure imgf000090_0001
Figure imgf000091_0002
Intermediate 50
Cis(±)3.4-dichloro-N-('3-methoxypiperidin-4-ylV5-methyl-lH-pyrrole-2-carboxamide
Figure imgf000091_0001
The title compound was prepared by the methods described below: Method A
Cis(±)ethyl 4- { [(3 ,4-dichloro-5-methyl- 1 H-pyrrol-2-yl)carbonyl]amino} -3 - methoxypiperidine-1-carboxylate (Intermediate 37; 503 mg) was dissolved in MeOH (30 ml). 1 M NaOH was added and the mixture was heated at 100 0C for 12 h. The reaction mixture was cooled to ambient and extracted with EtOAc, washed with water, dried over Na2SO4 and concentrated in vacuo to give the title compound as a brown oily gum which was used without further purification (336 mg).
Method B
Cis(±)ethyl-4-{[(3,4-dichloro-5-methyl-lH-pyrrol-2-yl)carbonyl]amino}-3- methoxypiperidine-1-carboxylate (Intermediate 37; 3.85 g) was suspended in anhydrous CH3CN. Iodotrimethylsilane (2.2 ml) was added slowly. The reaction was heated to reflux for several hours until complete by LCMS. The crude reaction mixture was diluted with water and acidified with IN HCl to pH 3. The solution was extracted with EtOAc. The aqueous layer was basified with 50% NaOH to pH 10. The aqueous layer as saturated with sodium chloride and extracted with THF, dried with MgSO4 and concentrated to a tan solid (2.1 g). MH+: 306 for C12Hi7Cl2N3O2; NMR: 1.61 (d, J=3.77 Hz, 2H), 1.76 (dt, J=6.50, 3.16 Hz, IH), 2.16 - 2.20 (m, 3H), 2.56 - 2.69 (m, 2H), 2.90 (d, J=13.19 Hz, IH), 3.18 (dd, J=13.75, 3.01 Hz, IH), 3.30 - 3.35 (m, 3H), 3.56 - 3.64 (m, IH), 4.04 - 4.15 (m, J=8.10, 7.72, 7.72, 3.01 Hz, lH), 7.14 (d, J=8.29 Hz, IH).
Intermediates 51-56
The following Intermediates were prepared as described by the general methods described in Intermediate 50 from the starting materials (SM) indicated.
Figure imgf000092_0001
Figure imgf000093_0002
Intermediate 57 and Intermediate 58 fer/-Butyl-(3)S,4ig)-4-(benzylaminoV3-fluoropiperidine-l -carboxylate and tert-Buty\-(3R,4S)- 4-(benzylaminoV3-fluoropiperidine- 1 -carboxylate
Figure imgf000093_0001
Cis(±)tert-butyl-4-(benzylamino)-3-fluoropiperidine- 1 -carboxylate (Intermediate 82; 2.2 g) was separated into the title compounds using chiral HPLC, in a manner analogous to Intermediate 23 and Intermediate 24 over a Chiralpak AD column (eluent: hexanes / MeOH / EtOH; 90 / 2.5 / 2.5; 0.1% diethylamine). The fractions corresponding to the first chromatographic peak (Cis(+) isomer; Intermediate 57) were collected and evaporated yielding the title compound as a white solid (942 mg). The fractions corresponding to the second chromatographic peak (Cis(-) isomer; Intermediate 58) were collected and evaporated yielding the title compound as a white solid (980 mg). NMR (CDCl3): 1.40 (s, 9H), 1.88 (m, 2H), 3.01 (m, 2H), 3.55 (m, 2H), 3.77 (m, IH), 4.66 (d, IH). Intermediate 59
Cis(±Vgrt-butyl-4-amino-3-fluoropiperidine- 1 -carboxylate
Cis(±)tert-butyl-4-(benzylamino)-3-fluoropiperidine-l-carboxy late (Intermediate 82; 711 mg), ammonium formate (582 mg), and 10% Pd/C (200 mg) in MeOH (10 ml) was heated to 50 °C for 1 h. The reaction mixture was cooled to room temperature, filtered through diatomaceous earth and concentrated under reduced pressure to give the title compound (503 mg, quantitative). NMR (CDCl3): 1.40 (s, 9H), 1.88 (m, 2H), 3.01 (m, 2H), 3.55 (m, 2H), 3.77 (m, IH), 4.66 (d, IH).
Intermediates 60-64
The following Intermediates were prepared by the procedure described in Intermediate 59 from the starting materials (SM) indicated.
Figure imgf000094_0001
Figure imgf000095_0002
Intermediate 65
Trans(±~)tg;-t-butyl 4-(benzylamino)-3 -fluoropiperidine- 1 -carboxylate
Figure imgf000095_0001
The title compound was prepared as described in Monique B. van Neil et al. J Med.
Chem., 1999, 42, 2087-2104 and the references therein. NMR (CDCl3): 1.40 (s, 9H), 1.88 (m, 2H), 3.01 (m, 2H), 3.55 (m. 2H), 3.77 (m, IH), 4.66 (d, IH).
Intermediate 66 tert-Butyl |"(3R,4R)- 1 -benzyl-3-methoxypiperidin-4-yl"|carbamate
The title compound (150 mg) was prepared from tert-butyl [(3i-,4i?)-l-benzyl-3- hydroxypiperidin-4-yl]carbamate by the procedure described (for similar compounds) in Synth. Commun., 2001, 31, 1081-1089. NMR (CDCl3): 1.44 (s, 9H), 1.97-2.11 (m, 3H), 2.68 (d, IH), 3.07-3.12 (m, 2H), 3.36 (s, 3H), 3.41 (m, IH), 3.52 (m, 2H), 4.51 (m, IH), 7.23-7.32 (m, 5H).
Intermediate 67 tert-Butyl r(3S,4S)-l-benzyl-3-methoxypiperidin-4-yl"lcarbarnate
The title compound (426 mg) was prepared from tert-butyl [(?>S,AS)-l-'h&azy\-3- hydroxypiperidin-4-yl] carbamate by the procedure described (for similar compounds) in Synth Commun., 2001, 31, 1081-1089. NMR (CDCl3): 1.44 (s, 9H), 1.97-2.11 (m, 3H), 2.68 (d, IH), 3.07-3.12 (m, 2H), 3.36 (s, 3H), 3.41 (m, IH)5 3.52 (m, 2H), 4.51 (m, IH), 7.23-7.32 (m, 5H). Intermediates 68-69
The following Intermediates were prepared by the procedure described in Example 1 from the starting materials (SM) indicated.
Figure imgf000096_0002
Intermediate 70 l-tert-Butyl-3-methyl-4-aminopiperidine-l,3-dicarboxylate
Figure imgf000096_0001
The title compound was prepared according to (Cordero, F.M et al. Gazz. Chim. Ital. 1997, 127, 25-29). Thus, l-ter^butyl-3-methyl-4-hydroxy-5,6-dihydropyridine-l,3-(2#)- dicarboxylate (Intermediate 9; 33 g) and NH4OAc (100 g) were dissolved in dry MeOH (250 ml). NaCNBH3 (8.1 g) was added in three equal portions at 1 h intervals. The reaction mixture was stirred at room temperature overnight. The reaction was monitored by GC/MS and additional NH4OAc (2.5 equiv.) and NaCNBH3 (0.25 equiv.) were added until reaction was completed. The reaction was cooled to -10 0C and acidified to pH = 2 with concentrated HCl and solvent was removed in vacuo. The solid residue was dissolved in water, and extracted with Et2O. The pH of the aqueous phase was adjusted to 8-9 with solid KOH, solution W
- 96 -
saturated with NaCl and extracted with EtOAc. The organic layer was dried over K2CO3, filtered and concentrate to an oil (25 g). GC/MS: 258 for Ci2H22N2O4.
Intermediate 71 Cis(±)fer/-butyl-4-{['('3.4-dichloro-5-methyl-l/f-pyrrol-2-yl)carbonyl]amino}-3- ("hydroxymethvDpiperidine- 1 -carboxylate
Cis(d=)l-fert-butyl-3-methyl-4-{[(3,4-dichloro-5-methyl-l/f-pyrrol-2- yl)carbonyl]amino}-piperidine-l,3-dicarboxylate (Intermediate 46; 4.26 g) and LiBPI4 (321 mg) were combined in dry THF (20 ml). MeOH (600 μl) was added in a single portion. The reaction was heated to reflux for 1 h. The mixture was cooled to room temperature, diluted with EtOAc and washed with 0.5% HCl. The organic layer was dried over Na2SO4, filtered and concentrated to a solid which was purified by flash column chromatography eluting with (60% EtOAc / 40% hexanes), to yield title compound (3.11 g). MS (ES) (MH+): 406 for C17H25Cl2N3O4; NMR (CDCl3): 1.47 (s, 9H), 1.56 (m, IH), 1.96 (m, IH), 2.27 (s, 3H), 2.84 (m, IH), 2.9 (m, IH), 3.49 (m, IH), 3.71 (m, IH), 4.16 (m, 5H), 6.58 (d, IH), 10.1 (brs, IH).
Intermediate 72
Cisf±Vert-butyl-4- { \(3 ,4-dichloro-5-methyl- lH-ρyrrol-2-yncarbonyl~l amino } -3-(U(4- methylphenvDsulfonylloxy }methyl)piρeridine- 1 -carboxylate. Cis(±)tert-butyl-4-{[(3,4-dichloro-5-methyl-li/-pyrrol-2-yl)carbonyl]amino}-3-
(hydroxymethyl)piperidine-l -carboxylate (Intermediate 71; 1.46 g) was dissolved in dry pyridine (20 ml) and cooled to 0 0C. Tosylchloride (822 mg) was added in a single portion. The reaction was allowed to slowly warm to room temperature and stirred overnight. The mixture was diluted with EtOAc and washed with water, dried over Na2SO4, filtered and concentrated in vacuo. The foam was purified by flash column chromatography eluting with (40% EtOAc / 60% hexanes) to give title compound (1.58 g). MS (ES) (MH+): 560 for C24H31Cl2N3O6S; NMR (CDCl3): 1.46 (brs, HH), 1.89 (m, IH), 1.98 (m, IH), 2.31 (s, 3H), 2.35 (s, 3H), 2.8 (m, 2H), 3.96-4.23 (m, 4H), 6.4 (d, IH)5 7.19 (d, 2H), 7.68 (d, 2H), 10.3 (brs, IH). Intermediate 73
Cis(±H-r(3,4-Dichloro-5-methyl-lH-pyrrole-2-carbonylVaminol-3-methoxymethyl- piperidine-1-carboxylic acid tert-butyl ester.
Cis-te^bu1yl-4-{[(3,4-dicWoro-5-methyl-lH'-pyrrol-2-yl)carbonyl]amino}-3-({[(4- methylphenyl) sulfonyl] oxy } methy l)piperidine- 1 -carboxylate (Intermediate 72 ; 325 mg) was dissolved in 5 ml of a 30wt% MeOH solution containing NaOMe and an additional 5 ml of dry MeOH. The homogeneous reaction was stirred at room temperature for 2 days. Upon reacting, solids began to precipitate from solution. The reaction was concentrated to a solid residue, re-dissolved in EtOAc and washed with saturated NH4Cl (2x10 ml). The organic layer was dried over Na2SO4, filtered and concentrated. The residual material was purified by flash column chromatography eluting with (1:1 EtOAc / hexanes) to give the title compound (192 mg). MS (ES) (MH+): 420 for Ci9H27Cl2N3O4.
Intermediate 74 Cis(-fc)3,4-dichloro-iV-[3-(methoxymethyl>)piperidin-4-yl1-5-methyl-lH-pyrrole-2- carboxamide hydrochloride
Cis(±)tert-butyl4- { [(3 ,4-dichloro- 5 -methy 1- 1 H-pyrrol-2-y l)carbony 1] amino } -3 -
(methoxymethyl)piperidine-l -carboxylate (Intermediate 73; 192 mg, 0.45 mmol) was dissolved in 4N HCl in dioxane (10 ml) and 10 ml of MeOH. The mixture was stirred at room temperature for 3 h, concentrated to dryness and azeotroped with MeOH to remove excess
HCl (5 x 20 ml) to yield the title compound which was used without purification, (crude mixture 195 mg). MS (ES) (MH+): 320 for C13Hi9Cl2N3O2.
Intermediates 75-76 The following Intermediates were prepared by the procedure described in Intermediate
74 from the starting materials (SM) indicated.
Figure imgf000099_0001
Intermediate 77
Cis(±)4- IY3 ^-Dichloro-S-methyl- 1 H-pyrrole-2-carbonylVammo] -3 -methylaminomethyl- piperidine-1-carboxylic acid tert-butyl ester Cis(±)te7*t-butyl-4- { [(3 ,4-dichloro-5 -methyl- 1 H-ρyrrol-2-yl)carbonyl] amino } -3 -( { [(4- methylphenyl)sulfonyl]oxy}methyl)-piperidine-l-carboxylate (Intermediate 72; 500 mg, 0.89 mmol) was dissolved in 5 ml of a 2.0 M THF solution containing MeNH2. The reaction vessel was sealed and heated to 100 0C for 2 h. The mixture was cooled to room temperature and diluted with EtOAc, then washed with water. The organic layer was dried over Na2SO4, filtered and concentrated to a crude solid foam which was used without further purification. MS (ES)MH+: 419 for C18H28Cl2N4O3.
Intermediate 78
The title compound was prepared in a manner analogous to Intermediate 77 from the starting material indicated.
Figure imgf000099_0002
Intermediate 79
Cis(±)4-{[(3,4-Dichloro-5-methyl-liJr-pyrrol-2-yπcarbonyl]ammolpiperidine-3-carboxylic acid hydrochloride
THF (10 ml) and MeOH (8 ml) were added to cis(±)l-ferf-butyl 3-methyl 4-{[(3,4- dichloro-5-methyl-lH-pyrrol-2-yl)carbonyl]amino}piperidine-l,3-dicarboxylate (Intermediate 46; 2.24 g). The resultant mixture was cooled to O0C, and a solution of lithium hydroxide (0.37 g) in water (5 ml) at 0°C was added dropwise via pipette, producing a clear, lightly yellow solution. The reaction was stirred at 0 0C for 2 h, stored overnight in a freezer without stirring, then stirred again at O0C for six hours. The reaction was acidified to pH 3 with 2N HCl 9~7 ml), and was concentrated in vacuo. The resultant mixture was dissolved in EtOAc (125 ml) and a saturated aqueous sodium chloride solution (40 ml), followed by the addition of 2N HCl (~ 1 ml) to acidify the aqueous layer to pH 1. The phases were separated and the aqueous layer was washed with EtOAc (2 x 60 ml). The combined EtOAc layers were dried over anhydrous MgSO4 and concentrated in vacuo. The resultant white solid was suspended in anhydrous THF (35 ml) under an argon atmosphere, cooled to 00C, followed by the addition of 4 M HCl in 1,4-dioxane (10 ml, 40 mmol). The reaction was warmed to room temperature, producing a clear orange-red solution. The reaction was stirred overnight at room temperature, followed by the addition of 5 ml of 4 M HCl in 1 ,4-dioxane. The reaction was stirred for two days at room temperature, then heated to 50°C for two hours, and allowed to slowly cool to room temperature overnight. The reaction was concentrated in vacuo, and carried on to the next reaction without further purification (5.16 mmol). MS (ES)(M+H)+): 320, 322 for C12H15Cl2N3O3.
Intermediate 80 2.2.2-Trichloro- 1 -(3.4-difluoro-5 -methyl- 1.H-pyrrol-2-vDethanone
Figure imgf000100_0001
3, 4-Difluoro-2 -methyl- lH-pyrrole (Intermediate 8; 3.8 g) was dissolved in anhydrous diethyl ether (100 ml). Anhydrous K2CO3 (12.5 g) was added followed by trichloroacetyl chloride (10 ml). The mixture was stirred at room temperature under N2 for 2 h, poured into a cold saturated solution OfNaHCO3, stirred for 10 min, and extracted with ether. The combined organic layers were dried over Na2SO4 and concentrated in vacuo to give a red brown oil. Trituration with pentane (50 ml)/DCM (2 ml), at -20 °C overnight to gave the title compound as a brown powder (1.3 g). MS (ES) MH+: 262 for C7H4Cl3 F2NO; NMR (CDCl3): 2.35 (d, 3H), 9.0 (brs, IH).
Intermediate 81
Cis(±)ethyl-4-[("fert-butoxycarbonyl)amino]-3-rpropyoxypiperidine-l-carboxylate
Cis(±)ethyl-3 -(allyloxy)-4- [(fert-butoxycarbonyl)amino]piperidine- 1 -carboxylate (Intermediate 27; 528 mg) was dissolved in MeOH (20 ml). 10% Pd-C (100 mg) was added and the mixture was evacuated and replaced with H2 gas twice. The mixture was stirred under an atmosphere of H2 gas for 12 h. The catalyst was removed over a bed of celite and solvent was removed in vacuo to give the title compound as an oil (445 mg). NMR: 0.94 (m, 3H), 1.25 (m, 3H), 1.43 (s, 9H), 1.53 (m, 2H), 1.71 (m, IH), 3.04 (m, 2H), 3.37 (m, 2H), 3.50 (m, 2H), 3.69 (m, IH), 3.89 (m, IH), 4.15 (m, 2H), 6.5 (d, IH).
Intermediate 82
Cisf±Vert-butyl 4-(benzylaminoV 3-fluoropiperidine- 1 -carboxylate
The title compound was prepared as described in Monique B. van Neil et al. J Med. Chem., 1999, 42, 2087-2104 and the references therein. NMR (CDCl3): 1.40 (s, 9H), 1.88 (m, 2H), 3.01 (m, 2H), 3.55 (m, 2H), 3.77 (m, IH), 4.66 (d, IH).
Examples 87-193
The following Examples were prepared by the procedure described in Example 1 from the starting materials (SM) indicated.
Figure imgf000101_0001
Figure imgf000102_0001
Figure imgf000103_0001
Figure imgf000104_0001
Figure imgf000105_0001
Figure imgf000106_0001
Figure imgf000107_0001
Figure imgf000108_0001
Figure imgf000109_0001
Figure imgf000110_0001
Figure imgf000111_0001
Figure imgf000112_0001
Figure imgf000113_0001
Figure imgf000114_0001
Figure imgf000115_0001
Figure imgf000116_0001
Figure imgf000117_0001
Figure imgf000118_0001
Figure imgf000119_0001
Figure imgf000120_0001
Figure imgf000121_0001
Figure imgf000122_0001
Figure imgf000123_0001
Figure imgf000124_0001
Example 194
CisC±Vethyl 5-amino-2-(4-{[r3,4-dichloro-5-methyl-lH-pyrrol-2-yl)carbonyllamino>-3- methoxypiperidin- 1 -vDisonicotinate A solution of SnCl2 dihydrate (870 mg, 3.8 mmol) in 5 ml concentrated HCl was added to a solution of 436 mg (0.87 mmol) of Cis(±)-ethyl 2-(4-{[(3,4-dichloro-5-methyl-lH- pyrrol-2-yl)carbonyl]amino}-3-methoxypiperidin-l-yl)-5-nitroisonicotinate (Example 308) in 30 ml acetic acid. The mixture was stirred at room temperature overnight. Solvent was removed and the residue was partitioned between water and EtOAc. The EtOAc was separated and washed with brine. Drying (MgSO4), removal of solvent and chromatography on silica gel (100% CH2Cl2 followed by gradient elution to 100% EtOAc and then to 10% MeOH in EtOAc) gave 230 mg of product. MS (ES) (MH+): 470 for C20H25Cl2N5O4; NMR (CDCl3): 1.5 (t, 3H), 2.1 (m, 2H) 2.4 (s, 3H), 3.2 (m, 2H), 3.6 (s, 3H), 3.65 (m, IH), 4.0 (m, IH), 4.4 (m, IH), 4.5 (q, 2H)5 7.3 (s, IH), 8.0 (s, IH), 9.5 (s, IH). Example 195
Cisr±Vethyl 2-(4-(r(3,4-dichloro-5-methyl-lH-pyrrol-2-vDcarbonyllaminol-3- methoxypiperidin-l-yl)-5-|"(methoxycarbonyl)aminolisonicotinate
Figure imgf000125_0001
Methylchlorofomate (15 μl, 0.19 mmol) was added to a solution of 60 mg (0.13 mmol) of Cis(±)-ethyl 5 -amino-2-(4- { [(3 ,4-dichloro-5-methyl- 1 H-pyrrol-2-yl)carbonyl] amino} -3 - methoxypiperidin-l-yl)isonicotinate (Example 194) in 3 ml pyridine. After stirring at room temperature overnight, 7 μl more methylchloroformate was added. Solvent was removed and the residue was partitioned between EtOAc and NaHCO3 (aqueous). The EtOAc was separated and washed with water and brine. Drying (MgSO4) and removal of solvent gave 43 mg of product. NMR (d6-DMSO): 1.3 (t, 3H), 1.7 (m, 2H) 2.2 (s, 3H), 3.1 (m, 2H), 3.3 (s, 3H), 3.5 (m, IH), 3.6 (s, 3H), 4.0-4.3 (m, 4H), 4.6 (m, IH), 7.05 (m, IH), 7.15 (m, IH), 8.2 (s, IH), 9.1 (s, IH), 12.2 (s, IH).
Example 196
Cisr±Vethyl 2-(4-(["(3.4-dichloro-5-methyl-lH-ρyrrol-2-yl)carbonyllamino>-3- methoxypiperidin- 1 -vD-5 - [YmethylsulfonvDamino] isonicotinate
Methanesulfonyl chloride (16 μl, 21 mmol) was added to 66 mg (0.14 mmol) of Cis(±)-ethyl 5-amino-2-(4-{[(3,4-dichloro-5-methyl-lH-ρyrrol-2-yl)carbonyl]amino}-3- methoxypiperidin-l-yi)isonicotinate (Example 194) in 3 ml pyridine. After stirring for 1 h, 5 μl more methanesulfonyl chloride was added. Stirred at room temperature overnight. Solvent was removed, and the residue was partitioned between EtOAc and Na2CO3 (aqueous). The EtOAc was separated and washed with water and brine. Drying (MgSO4) and removal of solvent gave 63 mg of product. MS (ES) (MH+): 534 for C21H27Cl2N5O6S. NMR (dδ-DMSO): 1.4 (t, 3H), 1.8 (m, 2H) 2.2 (s, 3H), 2.9 (s, 3H), 3.1-3.2 (m, 2H), 3.3 -3.5 (m), 3.6 (m, IH), 4.2-4.3 (m, 2H), 4.4 (q, 2H), 4.7 (m, IH), 7.1 (s, IH), 7.2 (d, IH), 8.2 (s, IH), 12.2 (s, IH). Example 197
Cis(±)-6-(4- { \(3.Λ-dichloro-S-methyl- lH-pyrrol-2-yl)carbonyll amino) -3-methoxypiperidin- 1 - vD-4-(ethoxycarbonyl)nicotinic acid
A solution of 133 mg (0.84 mmol) KMnO4 in 5 ml water was added to a solution of Cis(±)-ethyl 2-(4-{[(3,4-dichloro-5-methyl-lH-pyrrol-2-yl)carbonyl]amino}-3- methoxypiperidin-l-yl)-5-formylisonicotinate (Example 154) in 20 ml acetone, and the mixture was stirred at room temperature for 4 h. After quenching with aqueous NaHSO3, the mixture was acidified to about pH = 4 with IN HCl and extracted twice with EtOAc. The EtOAc extracts were washed with brine, dried (MgSO4) and concentrated to give a solid that was triturated with MeOH to give 175 mg of product. MS (ES) MH+: 499 for C21H24Cl2N4O6; NMR: 1.25 (t, 3H), 1.5-1.8, (m, 3H), 2.1 (s, 3H), 3.1 (m, 3H), 3.3 (s, 3H), 3.5 (m, IH), 4.2 (m, 2H), 4.4 (m, IH), 4.9 (m, IH), 6.9 (s, IH), 7.1 (d, IH), 8.6 (s, IH), 12.1 (s, IH), 13.3 (s, IH).
Example 198 Cisf±Vethyl 2-(4-{r(3,4-dichloro-5-methyl-lH-pyrrol-2-yl)carbonyllamino>-3- methoxypiperidin- 1 -vD-5- { [Y 1 -methyl- 1 -phenylethvDamino'lcarbonvUisonicotinate
ΗATU (87 mg, 24 mmol) was added to a solution of 118 mg (0.24 mmol) Cis(±)-6-(4- {[(3,4-dichloro-5-methyl-lH-pyrrol-2-yl)carbonyl]amino}-3-methoxypiperidin-l-yl)-4- (ethoxycarbonyl)nicotinic acid (Example 197), 0.040 ml (28 mmol) Et3N and 33 mg (0.24 mmol) cumylamine in 3 ml DMF. After stirring at room temperature overnight, the mixture was diluted with water and extracted with EtOAc. The EtOAc was washed 2 times with water and once with brine before being dried (MgSO4) and concentrated to give 103 mg of a solid. MS (ES) MH+: 616 for C30H35Cl2N5O5.
Examples 199-200
The following Examples were prepared by the procedure described in Example 198 from the starting materials (SM) indicated.
Figure imgf000127_0001
Example 201
Cisf±Vethyl 5-raminocarbonylV2-(4-{rf3,4-dichloro-5-methyl-lH-pyrrol-2- γl*)carbonyl]amino) -3-methoxypiperidin- 1 -vDisonicotinate
A solution of 103 mg (0.17 mmol) of Cis(±)-ethyl 2-(4- {[(3, 4-dichloro-5 -methyl- IH- pyrrol-2-yl)carbonyl] amino } -3 -methoxypiperidin- 1 -y l)-5 - { [( 1 -methyl- 1 - phenylethyl)amino]carbonyl}isonicotinate (Example 198) in 10 ml TFA was heated at 40 0C overnight and at 50 0C for 6 h. Solvent was removed and the residue was triturated with MeOH to give 62 mg of a white solid. MS (ES) MH+: 498 for C2IH25Cl2N5O5.
Example 202
The following Examples were prepared by the procedure described in Example 201 from the starting materials (SM) indicated.
Figure imgf000128_0001
Example 203
Cisf±Vethyl 2-r4-fr('3,4-dichloro-5-methyl-lH-pyrrol-2-vncarbonyllamino>-3- methoxypiperidin-l-ylV4-[(dimethylamino)carbonyl]-L3-tb.iazole-5-carboxylate A solution of Cis(±)-2-((35,4i?)-4-{[(3,4-dichloro-5-methyl-lH"-pyrrol-2- yl)carbonyl]amino} -3-methoxypiperidin- 1 -yl)-5-(ethoxycarbonyl)- 1 ,3-thiazole-4-carboxylic acid (0.062g, 0.12mmol, Example 188), dimethylamine (O.OόmL, 2M solution in THF5 Aldrich), HATU (0.05g, 0.13mmol) and triethylamine (0.018mL, 0.13mmol) was stirred at room temperature until complete by LCMS (about 30 min). The crude reaction mixture was slowly poured into water and the resulting white precipitate was filtered, washed with water and dried under vacuum to yield pure product (0.028g). MS (ES) MH+: 532 for C2IH27Cl2N5O5S; NMR: 1.20 (t, 3 H) 1.76 (s, 2 H) 2.18 (s, 3 H) 2.78 (s, 3 H) 2.93 (s, 3 H) 3.29 (d,l H) 3.36 (s, 3 H) 3.39 - 3.43 (m, 1 H) 3.55 (s, 1 H) 3.91 (s, 1 H) 4.15 (q, 2 H) 4.29 (s, 2 H) 7.15 (d, I H) 12.14 (s, I H)
Examples 204-241
The following Examples were prepared by the procedure described in Example 203 from the starting materials (SM) indicated
Figure imgf000128_0002
Figure imgf000129_0001
Figure imgf000130_0001
Figure imgf000131_0001
Figure imgf000132_0001
Figure imgf000133_0001
Figure imgf000134_0001
Figure imgf000135_0001
Figure imgf000136_0001
Figure imgf000137_0001
Ex Compound Data SM
241 ethyl 2-((3S,4i?)-4-{[(3,4- MS (ES) MH+: 576 for Example 191 and 1- dichloro-5-methyl- lH-pyrrol-2- C23H31Cl2N5O6S; amino-2- yl)carbonyl]amino } -3 - NMR: l.l l (s, 6 ] H) 1.22 (d, 3 methylpropan-2-ol methoxypiperidin- 1 -yl)-4- { [(2- H) 1.75 (s, 2 H) 2 18 (s, 3 H) hydroxy-2- 3.14 (s, 3 H) 3.38 (S5 3 H) 3.55 methylpropyl)amino]carbonyl } - (s, 1 H) 3.95 (s, 1 H) 4.17 (s, 2
1 ,3-thiazole-5-carboxylate H) 4.27 (s, 2 H) 4 .39 (S5 1 H)
7.14 (s, l H) 8.28 (s, 1 H)
12.17 (s, 1 H)
Examples 242-245
The following Examples were prepared by the procedure described in Example 34 from the starting materials (SM) indicated.
Figure imgf000138_0001
Figure imgf000139_0001
Example 246
Cis(±)-ethyl 2-(4-{r(3.4-dicMoro-5-metQyl-l//-pyrrol-2-yl>)carbonyllamino>-3- methoxypiperidin-l-ylV4-(morpholin-4-ylmethyl)-l,3-thiazole-5-carboxylate To a solution of ethyl 2-(4-{[(3,4-dichloro-5-methyl-177-pyrrol-2-yl)carbonyl]amino}-
3 -methoxypiperidin- l-yl)-4-formyl-l, 3 -thiazole-5-carboxylate (0.15g, 0.31mmol, Example 252) in methylene chloride (2OmL) was added sodium triacetoxyborohydride (O.lg, 0.47mmol) and morpholine (0.03mL, 0.34mmol). Reaction was stirred at room temperature and monitored by LCMS. Upon completion, the reaction mixture was diluted with IN HCl and then partitioned with EtO Ac/sat, sodium bicarbonate. Washing with brine, drying with MgSO4 and concentrating yielded a solid. Purification by silica gel flash column (gradient elution 70-100% EtOAc/CH2Cl2) afforded pure product (0.09Ig) MS (ES) M+H÷: 560 for C23H3ICl2N5O5S; NMR: 1.24 (t, 3 H) 1.75 (s, 2 H) 2.18 (s, 3 H) 3.32 (s, 2 H) 3.36 (s, 3 H) 3.52 (s, 2 H) 3.54 (d, 4 H) 3.65 - 3.75 (m, 2 H) 3.76 - 3.86 (m, 2 H) 3.93 (s, 1 H) 4.18 (q, 2 H) 4.27 (s, 1 H) 7.16 (d, 1 H) 12.16 (s, 1 H)
Examples 247-249
The following Intermediate was prepared by the procedure described in Example 246 from the starting materials (SM) indicated.
Figure imgf000140_0002
Example 250
Cis(±Vethyl 2-(4-[r('3,4-dichloro-5-methyl-lH-pyrrol-2-vncarbonvnamino>-3- methoxypiperidin- 1 - ylV4- f(ff)-f hvdroxyimino*)methyri - 1.3 -thiazole- 5 -carboxylate
Figure imgf000140_0001
A solution of Cis(±)-ethyl 2-(4-{[(3,4-dichloro-5-methyl-l#-pyrrol-2- yl)carbonyl]amino}-3-methoxypiperidin-l-yl)-4-formyl-l,3-thiazole-5-carboxylate (0.10g, 0.2mmol, Example 252), sodium acetate (0.04Ig5 0.5mmol) and hydroxylamine hydrochloride (0.028g, 0.4mmol) were heated to reflux in absolute ethanol for 3 hours. After cooling to room temperature the ethanol was removed under reduced pressure followed by EtOAcZH2O partitioning, drying with MgSO4 and concentrating to a yellow solid (0.08Ig) MS (ES): 504 NMR: 1.25 (t, 3H) 1.75 (s, 2 H) 2.18 (s, 3 H) 3.31 (s, 3 H) 3.36 (s, 3 H) 3.55 (s, 1 H) 3.95 (s, 1 H) 4.18 - 4.26 (m, 2 H) 4.26 (d, 2 H) 7.16 (d, 1 H) 8.61 (s, 1 H) 11.72 (s, 1 H) 12.16 (s, 1 H) Examples 251
The following Intermediate was prepared by the procedure described in Example 250 from the starting materials (SM) indicated.
Figure imgf000141_0001
Example 252
Cis(±)-ethyl 2-(4-(rr3.4-dichloro-5-methyl-lH-r)yrrol-2-yl>)carbonyllamino>-3- methoxypiperidin- 1 -yl>4-formy 1- 1 ,3 -thiazole-5 -carboxylate
To a solution of Cis(±)-ethyl 2-(4-{[(3,4-dichloro-5-methyl-lH-pyrrol-2- yl)carbonyl]amino } -3 -methoxypiperidin- 1 -yl)-4-(hydroxymethyl)- 1 ,3 -thiazole-5 -carboxylate (0.63g, 1.3mmol, Example 143) in methylene chloride was added Dess-Martin periodinane (0.61g, 1.4mmol). After lhr stirring at room temperature the reaction was complete. The crude reaction mixture was washed with water (x2) and brine, followed by drying with MgSO4 and concentrating to a minimal volume of methylene chloride after which it was directly deposited on a silica gel flash column (gradient elution to 1 : 1 EtOAc in CH2C12). Pure fractions concentrated to clean, yellow solid (0.56g). NMR: 1.29 (t, 3 H) 1.75 (s, 2 H) 2.18 (s, 3 H) 3.38 (s, 4 H) 3.44 (s, 1 H) 3.57 (s, 1 H) 4.03 (d, IH) 4.22 - 4.35 (m, 4 H) 7.15 (d, I H) 10.31 (s, I H) 12.16 (s, l H).
Example 253 ethyl 2-(r35',4i?V4-fr(3.4-dichloro-5-methyl-lH-pyrrol-2-ylN)carbonyl1amino}-3- methoxypiperidin-l-yl')-4-(difluoromethyl')-l,3-thiazole-5-carboxylate
Diethylaminosulfurtrifluoride (0.03mL, 0.22mmol) was added to a solution of ethyl 2- ((35',4i?)-4-{[(3,4-dichloro-5-methyl-lH-pyrrol-2-yl)carbonyl]amino}-3-methoxypiperidin-l- yl)-4-formyl-l,3-thiazole-5-carboxylate (O.lOg, 0.2mmol, Example 252) in methylene chloride. The reaction was complete after heating at reflux overnight. Upon cooling to room temperature, the reaction was washed with water (x3) and brine (xl), dried with MgSO4 and concentrated to a yellow solid which, upon trituration, yielded a clean white solid (0.02Ig). MS (ES) M+H: 511 for Ci9H22Cl2F2N4O4S; NMR: 1.26 (t, 3 H) 1.75 (s, 2 H) 2.18 (s, 3 H) 3.37 (s, 3 H) 3.43 (s, 1 H) 3.56 (s, 1 H) 3.96 (s, 1 H) 4.25 (s, 1 H) 4.36 (s, 2 H) 7.16 (s, 1 H) 7.31 (s, I H) 12.17 (s, I H).
Example 254 ethyl 4-CazidomethylV2-('r3>S.4i;V4-{r('3.4-dichloro-5-methyl-lH-pyrrol-2- vDcarbonyliamino } -3 -methoxypiperidin- 1 -yP)- 1 ,3 -thiazole-5-carboxylate
To a suspension of ethyl 2-((3S,4R)-4-{[(3,4-dichloro-5-methyl-lH-pyrrol-2- yl)carbonyl]amino} -3-methoxypiperidin- 1 -yl)-4-(hydroxymethyl)- 1 ,3-thiazole-5-carboxylate (0.1 Og, 0.2mmol, Example 143) in anhydrous toluene was added diphenylphosphorylazide (0.053mL, 0.24mmol). The reaction was cooled to Odeg and DBU was added slowly. After stirring at Odeg for 30min the reaction was warmed to room temperature and stirred overnight. The biphasic reaction mixture was washed with water (x3), INHCl (xl), brine (xl), dried with MgSO4 and concentrated (0.048g). MS (ES) M+H: 516 for C19H23Cl2N7O4S.
Example 255
Cisr±)-ethyl 4-rcyano(morpholin-4-yl)methyl1-2-(4-{|"(3,4-dichloro-5-methyl-lij-pyrrol-2- yl)carbonyl]amino I -3-methoxypiperidin- 1 -vD- 1 ,3-thiazole-5 -carboxylate
Figure imgf000142_0001
A solution of sodium cyanide (0.01 Ig, 0.22mmol) and morpholine (0.018mL, 0.21mmol) in water (5mL) was cooled to Odeg. IN HCl (0.22mL, 0.22mmol) was added slowly. After warming to room temperature, a solution of Cis(±)-ethyl 2-(4-{[(3,4-dichloro- 5-methyl-lH-pyrrol-2-yl)carbonyl]amino}-3-methoxypiperidin-l-yl)-4-formyl-l,3-thiazole-5- carboxylate (0.1 Og, 0.2mmol, Example 252) in methanol (1OmL) was added. After stirring at room temperature for six weeks the reaction was complete. The reaction mixture was concentrated to remove methanol and the residue was diluted with water and extracted with EtOAc (x3), washed with brine (xl), dried with MgSO4 and concentrated to a pink solid (0.055g). MS (ES) M+Η: 585 for C24H30Cl2N6O5S. Example 256 ethyl 2-f(3S.4JgM-(r(3.4-dicMoro-5-me1fayl4.¥-pyrrol-2-vπcarbonyl1amino>-3- methoxypiperidin- 1 -yl)-4-({ [2-(methylsulfonyl')etriyl'| amino } carbonylV 1 ,3-thiazole-5- carboxylate m-CPBA (0.091g, 0.37mmol) was added to a cold solution of ethyl 2-((3S',4i?)-4-
{[(3,4-dichloro-5-methyl-lH-pyrrol-2-yl)carbonyl]ammo}-3-niethoxypiperidin-l-yl)-4-({[2- (methylthio)ethyl]amino}carbonyl)-l,3-thiazole-5-carboxylate (0.107g, O.lδmmol, Example 238) in methylene chloride. After stirring at room temperature for 2 hours, the reaction mixture was washed with sat. sodium bicarbonate (x3), dried with MgSO4, and concentrated to a white solid (0.092g). MS (ES) M+H: 610 for C22H29Cl2N5O7S2; NMR: 1.21 (q, 3 H) 1.66 - 1.80 (m, 2 H) 2.18 (s, 3 H) 3.04 (s, 3 H) 3.29 (s, 4 H) 3.36 (s, 3 H) 3.51 - 3.62 (m, 3 H) 3.99 (s, 1 H) 4.17 (q, 2 H) 4.28 (s, 2 H) 7.15 (d, 1 H) 8.72 (t, 1 H) 12.17 (s, 1 H).
Examples 257-381 The following Examples were synthesized by an analogous method to Example 35 from the starting materials (SM) given in the table below.
Figure imgf000143_0001
Figure imgf000144_0001
Figure imgf000145_0001
Figure imgf000146_0001
Figure imgf000147_0001
Figure imgf000148_0001
Figure imgf000149_0001
Figure imgf000150_0001
Figure imgf000151_0001
Figure imgf000152_0001
Figure imgf000153_0001
Figure imgf000154_0001
Figure imgf000155_0001
Figure imgf000156_0001
Figure imgf000157_0001
Figure imgf000158_0001
Figure imgf000159_0001
Figure imgf000160_0001
Figure imgf000161_0001
Figure imgf000162_0001
Figure imgf000163_0001
Figure imgf000164_0001
Figure imgf000165_0001
Figure imgf000166_0001
Example 382
Cis(±)-5-(aminocarbonylV2-(4- { \(3 Λ-dichloro-S-methyl- lH-pyrrol-2-yl)carbonyl]amino } -3- methoxypiperidin- 1 -vD- 1 ,3 -thiazole-4-carboxylic acid A solution of 55 mg (23 mmol) of Cis(±)- 3,4-dichloro-7V-[3~methoxypiperidin-4-yl]-
5-methyl-li7-pyrrole-2-carboxamide (Intermediate 50), 55 mg (0.23 mmol) of ethyl 5- (aminocarbonyl)-2-chloro-l,3-thiazole-4-carboxylate (Intermediate 220) and 33 mg (0.23 mmol) K2CO3 in 3 ml NMP was heated at 150 0C for 1 h in a microwave reactor. Water (0.1 ml) was added and the mixture was heated at 150 0C for another hour. The solution was diluted with water and acidified with IN HCl before being extracted 2 times with EtOAc. The EtOAc extracts were washed with brine, dried (MgSO4) and concentrated to give a solid that was triturated with MeOH to give 41 mg of a white solid. MS (ES) MH+: 479 for C17Hi9Cl2N5O5S; NMR: 1.75 (m, 2H), 2.2 (s, 3H), 3.3 (s), 3.5 (s, IH), 3.9 (m, IH), 4.2 (m, 2H), 7.15 (d IH), 7.8 (s, IH), 8.9 (s, IH), 12.2 (s, IH). Example 383
Cis(±)-5-(aniinocarbonyl')-2-(4-{r(3.,4-dicliloro-5-methyl-lH-pyrrol-2-vDcarbonyllamino>-3- methoxypiperidin- 1 -vDisonicotinic acid
A mixture of 85 mg (0.17 mmol) of Cis(±)-ethyl 5-(aminocarbonyl)-2-(4-{[(3,4- dichloro-5 -methyl- lH-pyrrol-2-yl)carbonyl]arnino} -3-methoxypiperidin- 1 -yl)isonicotinate (Example 198) and 86 mg (0.50 mmol) Ba(OH)2 in 3 ml MeOH and 2 ml water was heated at 120 0C for 1 h. The mixture was acidified to about pH = 4 with IN HCl and extracted 4 times with EtOAc. The EtOAc was concentrated and the residue was purified by reverse phase HPLC (20-40% CH3CN gradient in water with 0.1% TFA) to afford 8 mg of product as a white solid. MS (ES) MH+: 470 for C19H21Cl2N5O5; NMR: 1.5-1.8, (m, 3H), 2.2 (s, 3H), 3.0- 3.2 (m, 2H), 3.3 (s, 3H), 3.5 (m, 2H), 4.2-4.5 (m, 2H), 4.9 (d, IH), 6.9 (s, IH), 7.1-7.3 (m, 2H), 7.8 (s, IH), 8.4 (s, IH), 12.1 (s, IH), 13.1 (s, IH).
Examples 384-385 The following Examples were synthesized by an analogous method to Example 383 ; -'' from the starting materials (SM) given in the table below.
Figure imgf000167_0001
Example 386
2-(Y3iS',4i?y4- ( [(3 Λ-dichloro-S-methyl- lH-pyrrol-2-vDcarbonyliaminol -3-methoxypiperidin-
1 -yl)-4- rdnethylamino)carbonyll- 1 ,3 -thiazole-5 -carboxylic acid
To a suspension/solution of ethyl 2-((35r,4i?)-4-{[(3,4-dichloro-5-methyl-lH-pyrrol-2- yl)carbonyl]amino}-3-methoxypiperidin-l-yl)-4-[(methylammo)carbonyl]-l,3-thiazole-5- carboxylate (0.078g, 0.15mmol, Example 218) in methanol (2mL) was added barium hydroxide (0.052g, 0.30mmol) and water (0.5mL). After stirring several hours the reaction was complete. The reaction was acidified with IN HCl and then concentrated to remove methanol. The residue was extracted with EtOAc (x3), dried with MgSO4 and concentrated to a white solid (0.059g). MS (ES) M+H+: 490 for C18H21Cl2N5O5S; NMR: 1.76 (s, 2 H) 2.18 (s, 3 H) 2.86 (s, 3 H) 3.38 (s, 3 H) 3.56 (s, 2 H) 4.02 (s, 1 H) 4.27 (s, 2 H) 4.40 (s, 1 H) 7.15 (s, I H) 9.38 (s, I H) 12.15 (s, l H)
Examples 387-412 The following Intermediate was prepared by the procedure described in Example 386 from the starting materials (SM) indicated.
Figure imgf000168_0001
Figure imgf000169_0001
Figure imgf000170_0001
Figure imgf000171_0001
Figure imgf000172_0001
Figure imgf000173_0001
Example 413
4- { [Y 1 -cyanocyclopropyQaminolcarbonvU -2-(Y3£4i?>4- ( IY3.,4-dichloro-5-methyl- lH"-pyrrol- 2-vDcarbonyr| aminol -3 -methoxypiperidin- 1 -ylV 1.3 -thiazole-5-carboxylic acid To a solution of ethyl 4-{[(l-cyanocyclopropyl)amino]carbonyl}-2-((3δ',4i?)-4-{[(354- dichloro-5-methyl-lH-pyrrol-2-yl)carbonyl]amino}-3-methoxypiperidin-l-yl)-l,3-thiazole-5- carboxylate (0.09g, O.lόmmol, Example 230) in methanol (2mL) was added potassium carbonate (0.022g, O.lόmmol) and water (0.5mL). After heating in the microwave for 30min at 80°, reaction was complete by LCMS analysis. The reaction mixture was diluted with water and acidified withlN HCl. After concentrating to remove methanol, the resulting white precipitate was filtered, washed with water and dried (0.07Ig). MS (ES) M+H+: 541 for C2IH22Cl2N6O5S; NMR: 1.33 - 1.41 (m, 2 H) 1.64 (s, 2 H) 1.75 (s, 2 H) 2.19 (s, 3 H) 3.37 (s, 3H) 3.43 (s, 1 H) 3.57 (s, 1 H) 4.08 (s, 1 H) 4.27 (d, 2 H) 4.40 (s, 1 H) 7.16 (d, 1 H) 9.87 (s, 1 H) 12.17 (s, 1 H)
The following Intermediate was prepared by the procedure described in Example 413 from the starting materials (SM) indicated.
Figure imgf000174_0002
Example 415 2-(Y3 S.4RV4- ( r(3.4-dichloro-5-methyl- 1 H-pyrrol-2-yl)carbonyllamino> -3-fluoropiperidin- 1 - vD-N-methoxy-N-methyl- 1 ,3 -thiazole-5-carboxamide
Figure imgf000174_0001
2-((35r,4i?)-4- { [(354-dichloro-5-methyl- lH-pyrrol-2-yl)carbonyl] amino} -3 - fluoropiperidin-l-yl)-l,3-thiazole-5-carboxylic acid (lOmg, 0.024mmol) was dissolved in dry DMF (10ml), HATU (9.1mg5 0.024mmol), triethylamine (7.27mg5 0.072mmol) and N5O- dimethylhydroxyamine (4.65mg5 0.048mmol) were added. The mixture was stirred at room temperature for 30 minutes, then was poured into cold water (3OmI)5 the precipitate was filtered, washed with water and collected as the desired product (off white solid, lOmg).
MS (ESP): 465 (MH+) for Ci7H20Cl2FN5O3S NMR (CDCl3) δ: 1.87 (m, 2H); 2.19 (s, 3H); 3.07 (m, 2H); 3.21 (s, 3H); 3.72 (s, 3H); 4.01 (m, IH); 4.30 (m, 2H); 4.96 (d, br, IH); 7.28 (d, IH); 7.85 (s, IH); 12.09 (s, IH).
The following compound was produced following the procedure described for Example 415 from Example 334 and N-methoxy amine hydrochloride.
Example 416
2-(('3)$',4i?)-4-{r('3,4-Dichloro-5-methyl-lH-pyrrol-2-yl)carbonyl1amino}-3-methoxypiperidin- l-ylV7V-methoxy-4-methyl-l,3-thiazole-5-carboxamide MS (ES) MH+: 476 for Ci8H23Cl2N5O4S; NMR: 1.66-1.79 (m, IH), 2.17(s, 3H), 2.37
(s, 3H), 3.20-3.35 (m, buried under water peak), 3.35 (s, 3H), 33.50-3.55 (m, IH), 3.61 (s, 3H), 3.82-3.91 (m, IH), 4.15-4.31 (m, 2H), 7.14 (d, IH), 10.79 (s, IH), 12.14 (s, IH)
Example 417 sodium 2-((3lS'.4i?V4-([f3.4-dichloro-5-methyl-lH-pyrrol-2-vncarbonyllaminol-3- methoxypiperidin-l-ylV4--{'r(2-methoxyethyl)amino]carbonvU-l,3-thiazole-5-carboxylate
Sodium hydroxide (0.056mL, 0.056mmol, Acros IN) was added to a suspension of 2- ((3S,4R)-4- { [(3 ,4-dichloro-5-methy 1- lH-pyrrol-2-yl)carbonyl]amino } -3 -methoxypiperidin- 1 - yl)-4-{[(2-methoxyethyl)amino]carbonyl}-l,3-thiazole-5-carboxylic acid (0.03g, 0.056mmol, Example 387) in methanol (5mL). After stirring five minutes the reaction was homogeneous. The reaction mixture was concentrated and the resulting white solid was dried overnight (0.03Og). MS (ES) MH+: 534 for C20H24Cl2N5O6SNa; NMR: 1.73 (s, 2 H) 2.19 (s, 3 H) 3.24 (s, 3 H) 3.32 (s, 2 H) 3.36 (s, 3 H) 3.51 (s, 1 H) 3.84 (s, 1 H) 4.22 (d, 2 H) 7.17 (d, 1 H) 12.17 (s. 1 H) 13.26 (s, 1 H)
Examples 419-423
The following Examples were prepared by the procedure described in Example 417 from the starting materials (SM) indicated.
Figure imgf000176_0001
Example 424
N-ethylethanaminium 2-((35l.4i?V4-(rr3,4-dichloro-5-methyl-lH'-pyrrol-2- yDcarbonyliaminol-B-meliioxypiperidin-l-yD^-irQ-niethoxyethvDaniinoicarbonvU-l.S- thiazole-5-carboxylate Diethylamine (0.0058mL, 0.056mmol, Aldrich) was added to a suspension of 2-
((35r,4i?)-4- { [(3 ,4-dichloro-5-methyl- lH-pyrrol-2-yl)carbonyl]amino } -3 -methoxypiperidin- 1 - yl)-4-{[(2-methoxyethyl)amino]carbonyl}-l,3-thiazole-5-carboxylic acid (0.03g, 0.056mmol, Example 387) in methanol (5mL). After stirring five minutes, methylene chloride was added until solution was homogeneous. The reaction was concentrated and the resulting solid was dried overnight (0.024g). MS (ES) MH+: 534 for C24H37Cl2N6O6S; NMR: 1.16 (t, 3 H) 1.74 (s, 2 H) 2.19 (s, 3 H) 2.91 (q, 3 H) 3.25 (s, 3 H) 3.32 (s, 4 H) 3.37 (s, 3 H) 3.42 (d, 2 H) 3.53 (s, 1 H) 3.94 (s, 1 H) 4.22 (s, 2 H) 7.17 (d, 1 H)
The following compound was synthesized according to the procedure described for Example 424.
Figure imgf000177_0001
Example 426
Potassium 2-(T3.S'.4i-V4-{rr3.4-dichloro-5-methyl-lH-pyrrol-2-vncarbonynamino)-3- fluoropiperidin- 1 -yP- 1 ,3-thiazole-5-carboxylate An aqueous solution of potassium hydroxide (0.1 M, 4.75 ml, 0.475 mmol) was added to a solution of 2-((35r,4i?)-4-{[(3,4-dichloro-5-methyl-lH-pyrrol-2-yl)carbonyl]amino}-3- fluoropiperidin-l-yl)-l,3-thiazole-5-carboxylic acid (Example 42, 200 mg, 0.475 mmol) in methanol (35 ml). The mixture was stirred for 1 h and then concentrated under reduced pressure to provide the crude salt (230 mg). The salt was dissolved in acetone/water (50 ml; 48:2) and acetone was added slowly to the stirred mixture until it became cloudy. Stirring was continued and more acetone was added very slowly over 20 min. The mixture was stored at 4 °C overnight. The solid was collected by filtration and air dried for 24 h to provide the salt (160 mg).
MS (ESP): 421 (M+H) for C15H15Cl2FN4O3S
1H NMR (300 MHz, DMSOd6) δ: 1.75 (d, IH); 2.04 (m, IH); 2.24 (s, 3H); 3.34 (m, 2H);
3.75 (d, IH); 4.20 (m, IH); 4.39 (t, IH); 4.83 (d, IH); 7.17 (s, IH); 8.18 (s, IH); 14.12 (s,
IH).
Example 427
1 ,3-Dihvdroxy-2-(hvdroxymethyl)propan-2-aminium 2-((3SΛR)-4-{ |Y3,4-dichloro-5-methyl- li/-Pyrrol-2-yl)carbonyllamino> -3-fluoropiperidm- 1 -yP)- 1 ,3-thiazole-5-carboxylate
Tromethamine (43 mg, 0.36 mmol), 2-((35',4i?)-4-{[(3,4-dichloro-5-methyl-lH-pyrrol- 2-yl)carbonyl]amino}-3-fluoropiperidin-l-yl)-l,3-thiazole-5-carboxylic acid (Example 42, 150 mg, 0.36 mmol), methanol (50 ml) and water (5 ml) were combined and stirred at 60 °C until the mixture was a homogeneous solution (30 min). The mixture was cooled to room temperature and concentrated under reduced pressure. The crude salt (80 mg) was dissolved in ethyl acetate/ methanol (8 ml; 50:50) and ethyl acetate was added slowly to the stirred solution until it became cloudy. Stirring was continued and additional ethyl acetate (-15 ml) was added slowly to the mixture. The mixture was stored at 4 °C overnight. The solid was collected by filtration and air dried for 24 h to provide the salt (64 mg). MS (ESP): 421 (M+H) for C15Hi5Cl2FN4O3S 1H NMR (300 MHz, Methanol-d4) δ: 2.00 (m, 2H); 2.25 (s, 3H); 3.33 (m, 2H); 3.30-3.55 (m, 2H); 3.67 (s, 6H); 4.10 (d, IH); 4.35 (m, 2H); 4.90 (d, IH); 7.57 (s, IH).
The following Examples were prepared by the procedure described in Example 1 from the starting materials (SM) indicated in the table below.
Figure imgf000179_0001
The following Examples were synthesized by an analogous method to Example 35 from the starting materials (SM) given in the table below.
Figure imgf000179_0002
Example 430-433
The following Examples were prepared by the procedure described in Example 1 from the starting materials (SM) indicated in the table below.
Figure imgf000179_0003
Figure imgf000180_0001
Examples 434-437
The following Examples were synthesized by an analogous method to Example 35 from the starting materials (SM) given in the table below.
Figure imgf000180_0002
Figure imgf000181_0001
Examples 438-440
The following Examples were prepared by the procedure described in Example 417 from the starting materials (SM) indicated
Figure imgf000181_0002
Figure imgf000182_0001
Preparation of Starting Materials Intermediate 83
Cisr±Vethyl (4-{rG.4-dichloro-5-methyl-liJr-pyrrol-2-vπcarbonyllamino>-3- methylpiperidine- 1 -carboxylate
A solution of 167 mg (0.9 mmol) of Cis(±)-ethyl (4-amino-3-methylpiperidine-l- carboxylate (Intermediate 152), 235 μl (1.25 mmol) diisopropylethylamine and 280 mg (1.35) of 3,4-dichloro-5-methyl-lH-pyrrole-2-carbonyl chloride (Intermediate 202) was stirred at room temperature for 1 h. The mixture was diluted with EtOAc and washed with aqueous Na2CO3 and brine. Drying MgSO4 and removal of solvent gave an oil that was purified by chromatography (100% CH2Cl2 followed by gradient elution to 100% EtOAc) to afford 145 mg of product. MS (ES) (MH+): 362 for C15H21Cl2N3O3; NMR (d6-DMSO): 0.8 (d, 3H), 1.2 (t, 3H), 1.65 (m, 2H), 1.9 (m, IH), 2.2 (s, 3H), 3.5 (m, IH), 4.0 (m, 2H), 4.1 (m, IH), 7.1 (d, IH), 12.0 (s, IH). Intermediates 84-114
The following Intermediates were synthesized by an analogous method to Intermediate 37 or Intermediate 83 from the starting materials (SM) given in the table below.
Figure imgf000183_0001
Figure imgf000184_0001
Figure imgf000185_0001
Figure imgf000186_0001
Figure imgf000187_0001
Figure imgf000188_0001
Figure imgf000189_0001
Figure imgf000190_0001
Intermediates 115-144
The following Intermediates were synthesized by an analogous method to Intermediate 50 or Intermediate 74 from the starting materials (SM) given in the table below.
Figure imgf000190_0002
Figure imgf000191_0001
Figure imgf000192_0001
Figure imgf000193_0001
Figure imgf000194_0001
Figure imgf000195_0001
Intermediates 145-157
The following Intermediates were synthesized by an analogous method to Intermediate 59 from the starting materials (SM) given in the table below.
Figure imgf000196_0001
Figure imgf000197_0001
Figure imgf000198_0001
Intermediates 158-167
The following Intermediates were synthesized by an analogous method to Intermediate 28 or Intermediate 59 from the starting materials (SM) given in the table below.
Figure imgf000198_0002
Figure imgf000199_0001
Figure imgf000200_0001
Intermediate 168 ethyl 3 -methoxy-4-oxopiperidine- 1 -carboxylate
To a stirred solution of the methoxyketal (Intermediate 173, 55.15 g, 223 mmol, crude) in dry THF (30 mL), at room temperature and under ambient atmosphere, was added an aqueous solution OfH2SO4 (5%, v/v, 190 mL). Temperature was increased to 60 0C; the reaction was stirred at this temperature. Complete conversion was suggested after 2 hours by TLC (50% ethyl acetate in hexanes; Hanessian's stain; Rf- 0.43). The reaction mixture was allowed to come to room temperature. THF was removed under vacuum. To the aqueous solution was added solid sodium bicarbonate until basic, and solid sodium chloride until saturated, with the addition of more water necessary. Crude product was extracted with methylene chloride (3 X 300 mL); the organic layers were combined, dried over magnesium sulfate, and concentrated. The crude material was used without further purification; yield was assumed quantitative. MS (ESI) M: 201 for C9Hi5NO4. 1H NMR (CDCl3): 1.28 (t, 3H), 2.38-2.60 (m, 2H), 3.30- 3.41 (m, 2H), 3.45 (s, 3H), 3.69 (m, IH), 4.05 (m, 2H), 4.17 (q, 2H).
Intermediates 169-172 The following Intermediates were synthesized by an analogous method to
Intermediate 168 from the starting materials (SM) given in the table below.
Figure imgf000201_0001
Intermediate 173 ethyl 3.4,4-trimethoxypiperidine-l -carboxylate
To a stirred solution of sodium hydride (6.96 g, 290 mmol) in dry THF (100 mL), at 0 °C and under an atmosphere of N2, was added a solution of the hydroxyketal (Intermediate 255, 223 mmol) in THF (125 mL) over approximately 30 minutes, via addition funnel. The resulting solution was stirred at 0 °C under an atmosphere of N2 for approximately 15 minutes; to it was then added methyl iodide (18.0 mL, 41.O g, 290 mmol) portionwise, via syringe, over approximately 5 minutes. The reaction was stirred overnight under an atmosphere of N2, gradually reaching room temperature. Complete conversion was suggested by TLC (50% ethyl acetate in hexanes; Hanessian's stain; Rf ~ 0.57) in the morning. The reaction was quenched with a small volume of water, then concentrated under vacuum. To the residue was added approximately 50 mL of water; from this mixture was extracted the crude product with ethyl acetate (3 X 150 mL). The organic layers were combined, dried over magnesium sulfate, and concentrated. The crude material was used without further purification; yield was assumed quantitative.
MS (ESI) M: 247 for C11H21NO5. 1H NMR (CDCl3): 1.24 (t, 3H), 1.72-1.83 (m, 2H), 2.82 (m, 2H), 2.98 (t, IH), 3.20 (s, 3H), 3.21 (s, 3H), 3.41 (s, 3H), 4.10 (q, 2H), 4.20-4.37 (m, 2H).
Intermediates 174-175
The following Intermediates were synthesized by an analogous method to Intermediate 173 from the starting materials (SM) given in the table below.
Figure imgf000202_0001
Intermediate 176
Ethyl 2-oxobutanoate
Diethyl oxalate (10 g; 68 mmol) was dissolved in Et2O (100 ml) and cooled to -78 C. Ethyl magnesium bromide (1.0 M in THF; 72 ml; 71.8 mmol; 1.05 equiv.) was added slowly via syringe. The dry ice / acetone bath was allowed to melt and warm to 10 C. Monitored the reaction by 1H NMR. The reaction was cooled to 0 C and quenched with saturated NH4Cl. Dilute with H2O and separate phases. The organic layer was dried over Na2SO4, filtered and concentrated. Isolation gave 7.6 g of a crude yellow oil in 86% yield. No further purification.
Intermediate 177 Ethyl 3-bromo-2-oxobutanoate
CuBr2 (39.3 g; 176 mmol; 3 equiv.) was suspended in EtOAc (160 ml). A CHCl3 solution containing ethyl 2-oxobutanoate (Intermediate 176, 7.6 g; 58.7 mmol) was added dropwise. The suspension was then heated to reflux for 6 hours and monitored by 1H NMR. The solids were filtered through a pad of Celite and the mother liquor was concentrated. The crude oil was passed through a short plug of silica gel and eluted with a 1:1 mixture of EtOAc / hexanes. The yellow band was collected and concentrated to give 12.2 g of product. No further purification.
Intermediate 178
Ethyl 2-amino-5-methyl- 1 ,3-thiazole-4-carboxylate
Ethyl 3-bromo-2-oxobutanoate (Intermediate 177, 12.2 g; 58.7 mmol) and thiourea (4.46 g; 76.1; 58.7 mmol) were combined and heated to reflux. The solution was allowed to cool to room temperature and stir for 12 hours. The reaction was monitored by LC/MS. The base was precipitated with 20% NH4OH (10 ml) and then redissolved with IN HCl (100 ml) and then finally reprecipitated with 20% NH4OH. The precipitate was collected and washed with H2O. The crude product was then crystallized from 9:1 ethanol / water to give 5.95 g of product in 55% yield. MS (ES) MH+: 187 for C7H10N2O2S.
Intermediate 179
Ethyl 2-chloro-5-methyl- 1 ,3-thiazole-4-carboxylate
Ethyl 2-amino-5-methyl-l,3-thiazole-4-carboxylate (Intermediate 178, 3 g; 16.1 mmol) and anhydrous CuCl2 (3.25 g; 24.2 mmol; 1.5 equiv.) were combined in dry acetonitrile (28 ml), t-butyl nitrite (90% tech; 2.77 g; 24.2 mmol; 1.5 equiv.) was added drop wise. The suspension was stirered at room temperature for 12 hours and monitored by LC/MS. The acetonitrile was removed in vacou and the solid was redissolved in CHCl3 and H2O. The aqueous layer was acidified with 2N HCl and the phases were separated. Back extracted the aqueous with CHCl3. The organic extracts were combined, dried over Na2SO4 and decolorizing carbon for 1 hour. Filtered through a pad of Celite and concentrated to an oil. Isolation gave 2.62 g of the title compound in 80% yield. The compound can be further purified via flash column chromatography and crystallization. MS (ES) MH+: 206, 208 for C7H8ClNO2S. Intermediate 180
Ethyl 5-(bromomethyl)-2-chloro-l .,3-thiazole-4-carboxylate
Ethyl 2-chloro-5-methyl-l,3-thiazole-4-carboxylate (Intermediate 179, 2.8 g; 13.6 mmol) was dissolved in CCl4 (25 ml). NBS (2.3 g; 13 mmol) and AIBN (2.12 g; 13 mmol) were added in a single portion and the resultant reaction mixture was heated to reflux for 24 hours. Additional NBS (690 mg; 0.3 equiv.) and AIBN (636 mg; 0.3 mmol) were added to push the reaction to completion. Continued to heat for another 4 hours. Cooled to room temperature, filtered and concentrated the mother liquor. Redissolved in minimal DMSO (7 ml) and purified by Gilson HPLC (5-95% ACN / 0.1% TFA; run time = 35 min). Isolated 1.15 g of desired product in 29% yield MS (ES) MH+: 284, 286, 288 for C7H7BrClNO2S.
Intermediate 181
Ethyl 2-chloro-5-formyl-l,3-thiazole-4-carboxylate
Ethyl 5-(bromomethyl)-2-chloro-l,3-thiazole-4-carboxylate (Intermediate 180, 920 mg; 3.2 mmol) was dissolved in acetonitrile dried over moleculare sieves. The solution was cooled to 0 C and NMO (570 mg; 1.5 equiv.) was added in a single portion. The reaction was monitored by LC/MS. An additional 1.5 equivalents of NMO was added in two portions over two hours. The reaction was concentrated to a solid residue, redissolved in EtOAc and washed with H2O. Dried the organic over Na2SO4, filtered and concentrated. No further purification. MS (ES) MH+: 220,222 for C7H6ClNO3S.
Intermediate 182 tert-Butyl 3 -bromo-4-oxopiperidine- 1 -carboxylate
Chlorotrimethylsilane (5.6 ml, 44 mmol) was added slowly to a solution of før/-butyl 4-oxopiperidine-l -carboxylate (commercial, 8 g, 40 mmol), triethylamine (12.3 ml, 88 mmol) and DMF (40 ml) at room temperature. The resultant solution was heated to 75 °C and stirred overnight under nitrogen. The reaction mixture was cooled to room temperature and then in an ice bath. Cold hexane (250 ml) was added slowly to the reaction mixture followed by cold (saturated) aqueous sodium bicarbonate (50 ml). The organic phase was separated and washed with brine, dried over sodium sulfate, filtered and concentrated under reduced pressure. The crude silyl enolether was dissolved in THF (15 ml) and cooled to 0 °C. N-
Bromosuccinimide (7.1 g, 40 mmol) was dissolved in THF (120 ml) and added slowly (45 min.) to the reaction mixture. The resultant mixture was allowed to slowly warm to room temperature and stirred overnight. The reaction mixture was concentrated under reduced pressure. The crude residue was purified by flash chromatography (hexanes/ethyl acetate,
5:1) to provide the title compound as a white solid (11 g).
MS (ESP): 222.1 (M- tBu) for C10H16BrNO3
1H NMR (300 MHz, DMSOd6) δ: 1.25 (s, 9H); 2.30 (m, IH); 2.55 (m, IH); 3.42-3.80 (m,
3H); 3.93 (m, IH); 4.60 (m, IH).
Intermediate 183 tert-Butyl 3-(methylthioV4-oxopiperidine- 1 -carboxylate
Sodium thiomethoxide (805 mg, 11.5 mmol) was added to a solution of tert-bntyl 3- bromo-4-oxopiperidine-l -carboxylate (Intermediate 182, 3.20 g, 11.5 mmol) and THF (15 ml) at 0 °C. The resultant mixture was allowed to slowly warm to room temperature and stirred overnight. The reaction was quenched with water (15 ml) and diluted with ethyl acetate (150 ml). The organic phase was separated and washed with brine. The combined aqueous phase was back extracted with ethyl acetate (50 ml). The combined organic layer was dried over magnesium sulfate, filtered, and concentrated under reduced pressure. The crude residue was purified by flash chromatography (hexanes/ethyl acetate, 7: 1) to provide the title compound
(2-4 g).
MS (ESP): 190.2 (M- tBu) for C11H19NO3S
1H NMR (300 MHz, CDCl3) δ: 1.43 (s, 9H); 2.02 (s, 3H); 2.23 (dt, IH); 2.95 (m, IH); 3.20-
3.40 (m, 2H); 3.65 (m, IH); 3.90-4.20 (m, 2H).
Intermediate 184
Cis(+)-fert-butyl-4-amino-3 -(methylthio)piperidine- 1 -carboxylate
Sodium cyanoborohydride (344 mg, 5.48 mmol) was added to a solution of tert-buty\
3 -(methylthio)-4-oxopiperidine-l -carboxylate (Intermediate 183, 1.07 g, 4.40 mmol), ammonium acetate (3.24 g, 42 mmol) and methanol (15 ml). The resultant mixture was stirred for 4 h. The reaction was quenched by addition of IN HCl (3 ml). Aqueous sodium bicarbonate (saturated, 50 ml) was added slowly to the reaction mixture followed by extraction with ethyl acetate (3 x 75 ml). The combined organic phase was dried over sodium sulfate, filtered and concentrated under reduced pressure to yield the crude amine. MS (ESP): 247.3 (M+H) for CnH22N2O2S.
Intermediate 185
Trans(±Vert-butyl 4-amino-3 -hvdroxypiperidine- 1 -carboxylate
Figure imgf000206_0001
The title compound was prepared as described in Marquis R. W. et al. J. Med. Chem. 1998, 41,3563-3567 and / or WO 9805336. MS (ES) MYt:2\l for C10H20N2O3; NMR: 1.45 (s, 9H), 1.80 (m, IH)5 1.95 (m, IH), 2.21 (m, IH), 2.62 (m, IH), 2.75 (m, IH), 3.28 (m, IH), 3.47 (m, IH), 3.81 (m, IH), 4.11 (m, IH), 4.28 (m, IH), 8.20 (m, IH)
Intermediate 186
Ethyl 3-chloro-5-methyl-lH-pyrrole-2-carboxylate The compound was prepared by the procedure described for Intermediate 2.
MS (ESP): 188 (MH+) for C8H10ClNO2 1H-NMR (CDCl3) δ: 1.37 (t, 3H); 2.26 (s, 3H); 4.32 (q, 2H); 5.96 (s, IH); 8.81 (br, IH).
Intermediate 187 Ethyl 4-bromo-5-methyl- 1 H-pyrrole-2-carboxylate
The compound was prepared by the procedure described for Intermediate 2. MS (ESP): 234 (MH+) for C8H10BrNO2 1H-NMR δ: 1.27 (t, 3H); 2.17 (s, 3H); 4.22 (q, 2H); 6.74 (s, IH); 12.10 (s, br, IH).
Intermediate 188
4 Ethyl 4-bromo-3-chloro-5 -methyl- lH-pyrrole-2-carboxylate
Ethyl 4-bromo-5-methyl-lH-pyrrole-2-carboxylate (Intermediate 187, 2.87g, 12.4mmol) was dissolved in dry DMF (30ml), N-chlorosuccinimide(1.66g, 12.4mmol) was added and resulting mixture was stirred at room temperature over night, more N- chlorosuccinimide (0.83g, 6.2mmol) was added and the reaction temperature was increased to 35oC, stirred for 4 hours. The mixture was poured into cold sodium hydroxide aqueous solution (2M) (50ml), extracted with diethyl ether (2x5 OmI). The organic phase was then washed with water (20ml) and brine (20ml), dried over anhydrous sodium sulfate and purified by column chromatography(hexanes/ethyl acetate, gradient) to give the desired product as a white crystal.(1.2g).
MS (ESP): 268 (MH+) for C8H9BrClNO2
1H-NMR (CDCh) δ: 1.38 (t, 3H); 2.30 (s, 3H); 4.34 (q, 2H); 9.0 (br, IH)
Intermediate 189 ethyl 4-chloro-3.5 -dimethyl- lH-pyrrole-2-carboxylate
N-Chlorosuccinimide (1.77 g, 13.25 mmol) was added to a solution of ethyl 3,5- dimethyl-2-pyrrole carboxylate (2.11 g, 12.62 mmol) in chloroform (45 mL). The reaction mixture was stirred at room temperature for 24 h and then poured into 2 N NaOH. The organic layer was washed with water and brine, dried over sodium sulfate, filtered, and concentrated under reduced pressure to give a crude solid. The crude solid was dissolved in hot MeOH, cooled to room temperature, and the precipitate was collected by filtration (493 mg, 19%). MS (ES) MH+: 174 for C9H12ClNO2.
Intermediate 190 ethyl 4-chloro-3-r(E)-(methoxyimino)methyll-5-methyl-lH-pyrrole-2-carboxylate
Figure imgf000207_0001
A solution of Intermediate 191 (300 mg, 1.39 mmol) in MeOH (5 mL) and pyridine (1.5 mL) with methylamine hydrochloride (255 mg, 3.06 mmol) was heated to 60 °C overnight. The reaction was cooled to room temperature and then partitioned between methylene chloride and 10% HCl. The organic layer was dried over sodium sulfate, filtered, and concentrated under reduced pressure to give an off-white solid. MS (ES) MH+: 245 for CI 0HI3CIN2O3;
NMR (DMSO-^): 1.29 (t, 3H)5 2.36 (s, 3H), 3.83 (s, 3H), 4.27 (q, 2H), 8.03 (s, IH), 12.31 (s, IH). Intermediate 191 ethyl 4-chloro-3-formyl-5-memyl-lH-pyrrole-2-carboxylate
POCl3 in 1,2-dichloroethane (14 mL) was slowly added to a solution of DMF (4.37 niL, 59.79 mmol) in 1,2-dichloroethane (10 mL). The reaction mixture was stirred for 15 min and then Intermediate 7 (2.04 g, 10.87 mmol) was added. The reaction mixture was heated at reflux for 3 h and then cooled to room temperature. The reaction mixture was treated with sodium acetate (10 g) in water (25 mL) and stirred for 1 h. The mixture was extracted with methylene chloride, wshed with water, dried over sodium sulfate, filtered, and concentrated under reduced pressure. Purification by flash column chromatography (silica, 2:1 hexanes/ethyl acetate) gave the desired compound (720 mg). MS (ES) MH+: 216 for C9H10ClNO3.
Intermediate 192 ethyl 3-bromo-4-chloro-5-methyl- lH-pyrrole-2-carboxylate Bromine (0.56 ml, 11 mmol) was added to a solution of 1 g (5.3 mmol) of ethyl 4- chloro-5 -methyl- lH-pyrrole-2-carboxy late (Intermediate 7) and 0.8 ml (5.7 mmol) Et3N in CH2Cl2. After stirring at room temperature for 2 h, aqueous NaHSO3 was added and the CH2Cl2 was removed and the aqueous residue was partitioned between water and EtOAc. The EtOAc was separated and washed with brine. Drying (MgSO4) and removal of solvent gave 1.5 g of product as a solid. MS (ES) (MH+): 240 for C8H9BrClNO2; NMR (d6-DMSO): 1.3 (t, 3H), 2.2 (s, 3H), 4.2 (q, 2H), 12.3 (s, IH).
Intermediate 193 ethyl 4-chloro-3-cyano-5 -methyl- l/7-pyrrole-2-carboxylate Nitrogen gas was bubbled through a mixture of 1.4 g (5.25 mmol) of ethyl 3-bromo-4- chloro-5-methyl-lH-ρyrrole-2-carboxylate (Intermediate 192), 470 g (4 mol) Zn(CN)2, 250 mg (0.26 mmol) Pd2(dba)3 and 302 mg (0.26 mmol) dppf in 15 ml DMF for 15 min. The mixture was heated at 130 0C for 1 h. Additional Zn(CN)2 (1 g), Pd2(dba)3 (500 mg) and dppf (604 mg) were added. After bubbling through N2 for 15 min and heating at 130 "C for 2 h, additional Zn(CN)2 (0.5 g), Pd2(dba)3 (250 mg) and dppf (302 mg) were added. Heating was continued at 130 0C for 2h. Solvent was removed and the residue was partitioned between EtOAc and water. The EtOAc was separated and washed with brine. Combined aqueous layers were extracted again with EtOAc, which was washed with brine. Combined EtOAc extracts were dried (MgSO4) and concentrated. The residue was purified by silica gel chromatography (100% CH2Cl2 followed by gradient elution to 5% MeOH in CH2Cl2) to afford 750 mg of product as a solid. MS (ES) (MH+): 213 for C9H9ClN2O2; NMR (d6- DMSO): 1.3 (t, 3H), 2.2 (s, 3H), 4.3 (q, 2H), 13.1 (s, IH).
Intermediate 194 ethyl 3.5 -dichloro-4-methyl- 1 H-pyrrole-2-carboxylate
Et3N (5.5 ml, 39 mmol) was added slowly to a solution of 2.0 g (13 mmol) of ethyl A- methyl-l/J-pyrrole-2-carboxylate and 3.1 ml SO2Cl2 in 30 ml CH2Cl2 cooled in an ice water bath. The mixture was warmed to room temperature with stirring overnight. After treatment with aqueous NaHSO3, the CH2Cl2 was removed and the aqueous residue was diluted with water and extracted twice with EtOAc. The EtOAc extracts were washed with brine, dried (MgSO4) and concentrated. The solid residue was twice recrystallized from 50% aqueous EtOH to afford 1.38 g of product as a white solid. MS (ES) (M-H'): 222 for C8H9Cl2NO2; NMR (d6-DMSO): 1.3 (t, 3H), 1.9 (s, 3H), 4.25 (q, 2H), 12.8 (s, IH).
Intermediate 195
4-chloro-3,5-dimethyl- liJr-pyrrole-2-carboxylic acid
Figure imgf000209_0001
Prepared using the procedure described for Intermediate 1 using Intermediate 189 as the starting material. MS (ES) MH+: 174 for C7H8ClNO2
Intermediate 196 3-chloro-5-methyl-lH-pyrrole-2-carboxylic acid
Prepared using the procedure described for Inteπnediate 1 using Intermediate 186 as the starting material.
MS (ESP): 160 (MH+) for C6H6ClNO2
1H-NMR (CDCl3) δ: 2.29 (s, 3H); 6.02 (s, IH); 8.83 (br, IH). Intermediate 197
4-bromo-5 -methyl- lH-pyrrole-2-carboxylic acid
Prepared by the procedure described for Intermediate 1 usingjntermediate 187 as the starting material. MS (ESP): 206 (MH+) for C6H6BrNO2
NMR (CDCl3) δ: 2.31 (s, 3H); 6.97 (s, IH); 9.08 (s, br, IH).
Intermediate 198
4-bromo-3-chloro-5-methyl-lH-pyrrole-2-carboxylic acid Prepared using the procedure described for Intermediate 1 and Intermediate 188. MS
(ESP): 240 (MH+) for C6H5BrClNO2
Intermediate 199
4-chloro-3-r(E)-(methoxyimino)methyll-5-methyl-lH-pyrrole-2-carboxylic acid Synthesized as described for Intermediate 1 from Intermediate 190.
MS (ES) MH+: 217 for C9H9ClN2O3.
Intermediate 200
4-chloro-3-cyano-5-methyl-lH-pyrrole-2-carboxylic acid
Figure imgf000210_0001
A solution of 670 mg (3.2 mmol) of ethyl 4-chloro-3-cyano-5-methyl-lH-pyrrole-2- carboxylate (Intermediate 193) and 3.2 ml (3.2 mmol) IN NaOH in 20 ml MeOH was heated at 100 0C in a microwave reactor for 2 h. The mixture was diluted with water and extracted with EtOAc. The EtOAc was washed with IN NaOH. The combined aqueous layers were acidified with concentrated HCl and extracted 2 times with EtOAc, each extract being washed with brine. Drying (MgSO4) and removal of solvent gave 535 mg of product as a solid. MS (ES) (M-H-): 183 for C7H5ClN2O2; NMR (d6-DMSO): 2.2 (s, 3H), 12.9 (s, IH), 13.3 (s, IH).
Intermediate 201 3 , 5 -dichloro-4-methyl- 1 H-pyrrole-2-carboxylic acid
A solution of 1.1 gm (4.95 mmol) of ethyl 3,5-dichloro-4-methyl-lH-pyrrole-2- carboxylate (Intermediate 194) and 1.7 g (9.9 mmol) OfBa(OH)2 in 50 ml 1 :1 EtOH-H2O was heated at 85 0C for 9 h. The mixture was diluted with water, acidified with 20 ml IN HCl and extracted 3 times with ether. The ether was washed with water, dried (MgSO4) and concentrated to give 1.0 g of product as a solid. MS (ES) (M-H'): 194 for C6H5Cl2NO2; NMR (d6-DMS0): 1.9 (s, 3H), 12.7 (s, IH), 12.8 (s, IH).
Intermediate 202
3,4-dichloro-5-methyl-liJr-pyrrole-2-carbonyl chloride
A solution of 10.4 g (54 mmol) of 3,4-Dichloro-5-methyl-lH-pyrrole-2-carboxylic acid (Intermediate 1) in 100 ml SOCl2 was heated at reflux for 30 min. Solvent was removed to afford product. NMR (CDCl3): 2.3 (s, IH), 8.8 (s, IH).
Intermediate 203
2.2.2-trichloro- 1 -C4.5-dichloro- lH-pyrrol-2-yl)ethanone
To a solution of 2,2,2-trichloro-l-(l/f-pyrrol-2-yl)ethanone (1.0Og, 47.06 mmol) in dichloromethane (8 mL), sulfuryl chloride (1.60 mL, 0.188 mol) was added slowly at room temperature. The reaction was stirred overnight and quenched with water and extracted with dichloromethane. The extract was washed with saturated sodium bicarbonate, water and brine.
Then it was dried over magnesium sulfate and concentrated to give the desired product as a white solid (0.90 g). MS (ES) M': 279 for C6H2NCl5O
Intermediate 204 ethyl 2-bromori.31thiazolor4,5-61pyridine-7-carboxylate
To a 0 °C mixture Of CuBr2 (229 mg, 1.02 mmol) in acetonitrile (3 mL) was slowly added t-Butyl nitrite (0.15 mL, 1.28 mmol). The reaction mixture was stirred for 15 min and then added Intermediate 205 (250 mg, 0.85 mmol). The reaction mixture was stirred for 2 h, partitioned between diethyl ether and water, and filtered through diatomaceous earth. The organic layer was washed with water and brine, dried over sodium sulfate, filtered, and concentrated under reduced pressure. Purification by flash column chromatography (silica, 1:1 hexanes/ethyl acetate) gave the desired product (38 mg, 16%). MS (ES) MH+: 174 for C9H7BrN2O2S. Intermediate 205 ethyl 2-amino|"l ,31thiazolor4,5-άlpyridine-7-carboxylate
To a solution of Intermediate 206 (944 mg, 4.20 mmol) in acetic acid (12 mL) was added benzyltrimethyl ammonium tribromide (1.67 g, 4.28 mmol). The reaction mixture was stirred at room temperature for 2 h and the solid that formed was collected by filtration to provide the desired compound as the acetic acid salt (1.20 g). MS (ES) MH+: 224 for C9H9N3O2S.
Intermediate 206 ethyl 2- [YaminocarbonothioyDaminol isonicotinate
A solution of Intermediate 207 (2.10 g, 6.38 mmol) in ethanol (20 mL) and potassium carbonate (882 mg, 6.38 mmol) was heated to 80 0C for 2 h. The reaction mixture was cooled to room temperature and the solid that formed was collected by filtration to give the desired compound. MS (ES) MH+: 226 for C9H11N3O2S;
NMR (DMSO-cfc): 1.17 (t, 3H), 4.18 (q, 2H), 7.29 (m, IH), 7.59 (s, IH), 8.25 (m, IH), 8.87
(s, IH), 10.24 (s, IH), 10.63 (s, IH).
Intermediate 207 ethyl 2- { [ (benzoylamino^carbonothioyllaminoHsonicotinate
To a 0 °C solution of benzyl isothiocyanate (1.25 mL, 9.27 mmol) in acetone (15 mL) was slowly added ethyl 2-aminoisonicotinate (1.4 g, 8.43 mmol). The reaction mixture was stirred for 1 h and then poured onto ice. The solid that formed was collected by filtration and washed with water to give the desired product (2.10 g). MS (ES) MH+: 330 for Ci6Hi5N3O3S.
Intermediate 208
2-chloro-5-nitroisonicotinic acid
A solution of 13.7 g (46 mmol) OfNa2Cr2O3 in 100 ml concentrated H2SO4 was added slowly to a solution of 3.0 g (17.4 mmol) of 2-chloro-4-methyl-5-nitropyridine dissolved in 100 ml concentrated H2SO4 while cooling in ice water. Allowed to warm to room temperature and stir overnight. The solution was poured onto 600 ml ice and extracted twice with EtOAc, each extract being washed with brine. The combined organic extracts were dried (MgSO4) and concentrated to afford product as a gummy oil. MS (ES) MH+: 203 for C6H3ClN2O4.
Intermediate 209 ethyl 2-amino-4-(hydroxymethyl)- 1 ,3-thiazole-5-carboxylate
A solution of 5.0 g (37 mmol) of 3-chlorofuran-2,4(3#,5H)-dione and 3.3 g (43 mmol) of thiourea in 50 ml EtOH was heated at reflux for 4 h. Solvent was removed and the residue was dissolved in water with IN HCl added. The aqueous solution was basified with aqueous Na2CO3. Thick solids that formed were filtered, rinsed with water and dried in vacuo. NMR: 1.2 (t, 3H), 4.2 (q, 2H), 4.6 (s, 2H), 4.9 (s, broad, IH), 7.8 (s, 2H).
Intermediate 210 ethyl 2-amino-4-({rfert-butyl(dimethyDsilylloxy>methylVl,3-thiazole-5-carboxylate
Figure imgf000213_0001
To a solution of 2.0 g (9.8 mmol) of ethyl 2-amino-4-(hydroxymethyl)-l,3-thiazole-5- carboxylate (Intermediate 209) and 1.3 g (19.4 mmol) of imidazole in 20 ml DMF was added 1.6 g (10.6 mmol) of t-butyldimethylsilyl chloride. After stirring for 2 h, solvent was removed and the residue was taken up in water. Insoluble solids were collected, ground up, washed with water and dried in vacuo to afford 2.95 g of product. MS (ES) (MH+): 317 for CnH24N2O3SSi; NMR (d6-DMSO): 0.03 (s, 6H), 0.86 (s, 9H), 1.2 (t, 3H), 4.1 (q, 2H), 4.8 (s, 2H), 7.8 (s, 2H).
Intermediate 211 ethyl 4-( { [tert-buty l(dimethy 1) silyl] oxy } methyl)~2-chloro- 1 ,3 -thiazole-5 -carboxylate t-Butylnitrite (1.8 ml (14 mmol) was added slowly to a mixture of 2.9 g (9.2 mmol) of ethyl 2-amino-4-({[tert-butyl(dimethyl)silyl]oxy}methyl)-l,3-thiazole-5-carboxylate (Intermediate 210) and 1.95 g (14 mmol) CuCl2 in CH3CN. After stirring at room temperature for 2 h, solvent was removed and the residue was taken up in EtOAc, which was washed 2 times with INHCl and once with brine. Drying (MgSO4) and removal of solvent gave 2.95 g of product as an oil. NMR (CDCl3): 0.1 (s, 6H), 0.9 (s, 9H), 1.35 (t, 3H), 4.3 (q, 2H), 5.0 (s, 2H).
Intermediates 212 The following Intermediates were synthesized by an analogous method to
Intermediate 211 from the starting materials (SM) given in the table below
Figure imgf000214_0002
Intermediate 214 methyl 2-chloro-4-(l-hydroxy-l-methylethyl)-l,3-thiazole-5-carboxylate A solution of 5.6 ml (11.2 mmol) 2N AlMe3 in toluene was added to a dry ice-acetone bath of 1.14 g (5.2 mol) of methyl 4-acetyl-2-chloro-l,3-thiazole-5-carboxylate (Intermediate 212) in 20 ml dry CH2Cl2. The mixture was allowed to warm to room temperature slowly before being quenched with MeOH. After stirring at room temperature overnight, the mixture was diluted with IN HCl and stirred 15 min before being diluted with water and extracted twice with EtOAc. The EtOAc was washed with brine, dried (MgSO4) and concentrated to give an oil that was purified by chromatography (50% hexanes in CH2Cl2 with gradient elution to 100% CH2Cl2) affording 720 mg of product as an oil. NMR (CDCl3): 1.5 (s, 6H), 3.8 (s, 3H), 5.7 (s, broad, IH).
Intermediate 215 ethyl 2-chloro-4-(hydroxymethyl)-l,3-thiazole-5-carboxylate
Figure imgf000214_0001
A solution of 17.7 g (53 mmol) of ethyl 4-({[ført-butyl(dimethyl)silyl]oxy}methyl)-2- chloro-1 ,3-thiazole-5-carboxylate (Intermediate 211) and 53 ml (53 mmol) of IN HCl in dioxane was stirred at room temperature for 1 h. The mixture was extracted 3 times with EtOAc, which was dried (MgSO4) and concentrated to give 11.3 g of an orange oil. Purification by silica gel chromatography affords a solid. NMR (CDCl3): 1.2 (t, 3H), 3.1 (s, broad, IH), 4.2 (q, 2H), 4.8 (s, 2H).
Intermediate 216 4- ( [4-q rfert-butyl(dimetliylN)silylloxy>methylV2-chloro-l .3-thiazol-5- yl"|carbonyl)morpholine
A solution of 2N Me3Al in hexanes (0.91 ml, 1.82 mmol) was added slowly to a solution of 0.16 ml (1.8 mmol) of morpholine in 4 ml CH2Cl2. After stirring for 15 min, a solution of 0.5 g (1.5 mmol) of ethyl 4-({[tert-butyl(dimethyl)silyl]oxy}methyl)-2-chloro-l,3- thiazole-5-carboxylate (Intermediate 218) in 4 ml CH2Cl2 was added. The solution was heated at 80 0C in a microwave reactor for 1 hour before pouring into dilute aqueous HCl. The mixture was extracted 3 times with CH2Cl2, which was washed with brine, dried (MgSO4) and concentrated. The residue was purified by silica gel chromatography (100% CH2Cl2 followed by gradient elution to 30% EtOAc in CH2Cl2 to give 315 mg of product. MS (ES) (MH+): 377 for Ci5H25ClN2O3SSi; NMR (d6-DMSO): 0.1 (s, 6H), 0.9 (s, 9H), 3.6 (m, 4H), 3.7 (m, 4H), 4.1 (q, 2H), 4.75 (s, 2H).
The following Examples were synthesized by an analogous method to Intermediate 216 from the starting materials (SM) given in the table below.
Figure imgf000215_0001
Intermediate 218
2-chloro-5-(morpholin-4-ylcarbonylN)-l,3-thiazole-4-carboxylic acid
A solution of 173 mg (1.7 mmol) CrO3 in 1 ml of 4:1 water/H2SO4 was added to as solution of 310 mg (0.82 mmol) of 4-{ [4-({ [tert-butyl(dimethyl)silyl]oxy}methyl)-2-chloro- l,3-thiazol~5-yl]carbonyl}morpholine (Intermediate 216) in 3 ml acetone cooled in an ice water bath. The mixture was stirred with warming room temperature over 90 min. A few drops of isopropanol were added, and the mixture was diluted with water and extracted 2 times with EtOAc. The EtOAc extracts were washed with brine, dried (MgSO4) and concentrated to give 190 mg of a white solid. MS (ES) (MH+): 277 for C9H9ClN2O4S; NMR (d6-DMS0): 3.3 (m, 4H), 3.6 (m, 4H), 13.7 (s, IH).
The following Examples were synthesized by an analogous method to Intermediate 5 218 from the starting materials (SM) given in the table below.
Figure imgf000216_0002
Intermediate 220 ethyl 5-(aminocarbonyl)-2-chloro-l,3-thiazole-4-carboxylate
o
Figure imgf000216_0001
A solution of 210 mg of ethyl 2-chloro-5-{[(l-methyl-l- phenylethyl)amino]carbonyl}-l,3-thiazole-4-carboxylate (Intermediate 233) in 5 ml TFA was stirred at room temperature overnight. Solvent was removed and the residue was dissolved in 5 ml MeOH. Solvent was again removed and the residue was triturated with ether to give 57 5 mg of a white solid. NMR (d6-DMSO): 1.3 (t, 3H), 4.3 (q, 2H), 8.2 (s, IH), 8.8 (s, IH).
Intermediate 221 methyl 2-chloro-4,4-dimethoxy-3-oxopentanoate
SO2Cl2 (2.2 ml, 27 mmol) was added slowly to a solution of 5.0 g (26 mmol) of 0 methyl 4,4-dimethoxy-3-oxopentanoate in 30 ml CH2Cl2 cooled in an ice water bath. The solution was warmed to room temperature and stirred for 1 h. Solvent was removed and the residue was taken up in EtOAc, which was washed with water and brine. Drying (MgSO4) and removal of solvent gave 6.1 g of an oil. NMR: (CDCl3): 1.5 (s, 3H), 3.25 (2s, 6H), 4.8 (s, 3H), 5.3 (s, IH). Intermediate 222 methyl 4-acetyl-2-amino- 1 ,3-thiazole-5-carboxylate
A solution of 4.37 g (19 mmol) methyl 2-chloro-4,4-dimethoxy-3-oxopentanoate (Intermediate 221) and 1.8 g (24 mmol) thiourea in 50 ml EtOH was heated at reflux for 3 h. Solvent was removed and the residue was dissolved in 1 : 1 acetone-5N HCl and the solution was heated at reflux for 4 h. Acetone was removed and the aqueous residue was neutralized with 50% NaOH and then basified with aqueous Na2CO3. Precipitated solids were filtered, washed with water and dried in vacuo. NMR (d6-DMSO): 2.4 (s, 3H), 3.7 (s, 3H), 8.0 (s, 2H).
Intermediate 223 isopropyl 4-chloropyridine-2-carboxylate 1 -oxide
A solution of 2.55 g (14 mmol) of isopropyl 4-chloropyridine-2-carboxylate (Intermediate 232) and 1.4 g (26 mmol) of m-CPBA in 30 ml CH2Cl2 was stirred at room temperature for 2 d. The mixture was quenched with aqueous NaHSO3 and CH2Cl2 was removed. The aqueous residue was basified with aqueous Na2CO3, saturated with NaCl and extracted repeatedly with EtOAc. The EtOAc was dried (MgSO4) and concentrated. The residue was taken up in ether and insoluble material was filtered off. The filtrate was concentrated and the residue was chromatographed on silica gel (100% CH2Cl2 with gradient elution to 100% EtOAc) to afford 2.1 g of product as an oil. NMR (d6-DMSO): 1.3 (d, 6H), 5.3 (septet, IH), 7.25 (m, IH), 7.5 (d, IH), 8.1 (d, IH).
Intermediate 224 isopropyl 4-chloro-6-cyanopyridine-2-carboxylate
A solution of 200 mg (0.86 mmol) of isopropyl 4-chloropyridine-2-carboxylate 1- oxide (Intermediate 223), 0.14 ml (1 mmol) Et3N and 0.36 ml (2.7 mmol) of trimethylsilylcyanide in 3 ml CH3CN was heated at 90 0C overnight. The solution was diluted with EtOAc and washed with water and brine. Drying (MgSO4) and removal of solvent gave an oil that was purified by chromatography on silica gel (100% CH2Cl2 followed by gradient elution to 10% EtOAc in CH2Cl2) to afford 130 mg of product as a white solid. MS (ES) (MH+): 224 for Ci9H9ClN2O2; NMR (d6-DMSO): 1.35 (d, 6H), 5.2 (septet, IH), 8.4 (s, IH), 8.6 (s, IH). Intermediate 225 ethyl 2-chloro-5-formylisonicotinate
Figure imgf000218_0001
A solution of 51 ml (128 mmol) of 2.5 N «-butyllithium in hexanes was added slowly to a THF solution of 16 ml (95 mmol) of tetramethylpiperidine cooled in a dry ice-acetone bath. The solution was warmed to -30 0C and cooled to -60 0C before 5.0 g (32 mmol) of 6- chloronicotinic acid was added portion wise. The mixture was warmed to -25 0C and stirred for 30 min. It was then cooled to —70 0C and 10 ml (129 mmol) DMF was added quickly. After quenching with IN HCl, the solution was warmed to room temperature. The pH was brought to about 4 with additional IN HCl and the solution was continuously extracted with EtOAc overnight. The EtOAc was dried (MgSO4) and concentrated. The residue was dissolved in 100 ml EtOH and 2 ml concentrated H2SO4 was added. The solution was heated at reflux for 24 h. The mixture was brought to about pH = 4 with 50% NaOH and was extracted twice with ether. The ether was dried (MgSO4) and concentrated to gave an oil that was chromatographed on silica gel (50% hexanes in CH2Cl2 with gradient elution to 100% CH2Cl2) to afford 1 g of product as an oil that slowly solidified. NMR (CDCl3): 1.4 (t, 3H), 4.5 (q, 2H), 7.7 (s, IH), 9.1 (s, IH), 10.7 (s, IH).
Intermediate 226 ethyl 2-chloro-5 -nitroisonicotinate
A mixture of 2-chloro-5-nitroisonicotinic acid (Intermediate 208) and 16 ml triethylorthoacetate in 100 ml toluene was heated at reflux for 2 h. The mixture as stirred with IN HCl for 30 min before being partitioned between EtOAc and water. The EtOAc was separated, washed with water and brine, dried (MgSO4) and concentrated. Chromatographed on silica gel (100% hexanes with gradient elution to 100% CH2Cl2 to give product as an oil. MS (ES) (MH+): 231 for C8H7ClN2O4; NMR (d6-DMSO): 1.3 (t, 3H), 4.4 (m, 2H), 8.1 (s, IH), 9.2 (s, IH). Intermediates 227-233
The following compounds were prepared in a manner analogous to Intermediate 226 from the starting material (SM) indicated.
Figure imgf000219_0001
Intermediate 234
1.3-thiazol-2-ylmethanol
To a stirred solution of commercially available l,3-thiazole-2-carbaldehyde (5.36 g,
47 mmol) in dry methanol (100 mL), at 0 0C and under an atmosphere of N2, was added sodium borohydride (2.15 g, 57 mmol) as a solid over approximately 20 minutes. The reaction was stirred for an hour at ambient temperature, under an atmosphere of N2.
Complete conversion was suggested by TLC (50% ethyl acetate in hexanes; Rf- 0.23). The reaction was concentrated under vacuum. To the residue was added 15 mL of an aqueous solution of ammonium chloride, and 15 mL of an aqueous solution of sodium chloride; from this mixture was extracted the crude product with ethyl acetate (4 X 50 mL). The organic layers were combined, dried over magnesium sulfate, and concentrated. The crude material was used without further purification.
MS (ES) MH+: 116 for C4H5NOS. 1H NMR (DMSO): 4.72 (d, 2H), 6.03 (t, IH), 7.61
(d, IH), 7.71 (d, IH).
Intermediate 235
2-(bromomethvD- 1 ,3 -thiazole
Figure imgf000220_0001
This compound was synthesized from Intermediate 234 above, using the procedure described in Tetrahedron 61 (2005), p. 137. The crude material was purified by column chromatography (silica gel, 15% ethyl acetate in hexanes). A pale orange liquid (57% yield) was obtained; this material decomposed rapidly, and was used immediately in the next step.
MS (ES) MH+: 179 for C4H4BrNS. 1H NMR (CDCl3): 4.75 (s, 2H), 7.37 (d, IH), 7.74
(d, IH).
Intermediate 236
Ethyl 2-chloro-4-methyl-l .3-thiazole-5-carboxylate
Syntheisized according to the procedure described for Intermediate 17. MS (ES)
MH+: 206, 208 for C7H8ClNO2S; 1H-NMR (300 MHz; DMSO-d6) δ: 1.28 (t, 3H); 2.60 (s, 3H); 4.28 (q, 2 H). Intermediate 237
1 -tgrt-butyl 3 -methyl 4-hvdroxy-5,6-dihvdropyridine- 1 ,3 (2HVdicarboxylate
Methyl 4-oxopiperidine-3-carboxylate hydrochloride (13.0 g) was suspended in anhydrous DCM (100 niL) under an argon atmosphere. DIEA (29.2 mL) was added slowly via syringe, producing a slightly cloudy solution. The reaction was cooled to O0C, and άi-tert- butyl dicarboxylate (16.1 g) was added, resulting in an exothermic reaction. The reaction mixture was left stirring overnight , slowly warming to room temperature. The reaction mixture was then concentrated in vacuo and partitioned between EtOAc (500 mL) and saturated aqueous NH4Cl (350 mL). The EtOAc layer was washed with brine (125 mL), dried over anhydrous MgSO4 and concentrated in vacuo, producing a yellow oil. The product was purified by silica gel chromatography (1-25% EtOAc in hexanes), producing the title compound as a clear, colourless oil (14.7 g, 85.1%). MS (ES)[(M-H)"]: 256 for Ci2H19NO5; NMR (CDCl3): 1.46 (s, 9H), 2.36 (t, 2H), 3.55 (t, 2H), 3.76 (s, 3H) 4.04 (s, 2H), 11.97 (s, IH).
Intermediate 238
Ethyl 4-azido-3 -hy droxypiperidine- 1 -carboxylate
Ethyl 4-bromo-3-hy droxypiperidine- 1 -carboxylate (Preparation: Izamanishi, T. et al; 1982, Chem. Pharm. Bull, 30: 3617-3623) (5.1 g) was dissolved in anhydrous DMF (20 mL) under an argon atmosphere, followed by the addition of 18-crown-6 (0.27 g) and sodium azide (2.89 g). The reaction was heated at 90°C for twenty-three hours, then stirred overnight, slowly cooling to room temperature. The reaction was then added to deionised water (150 mL) to quench it, saturated with solid sodium chloride, and extracted with EtOAc (2 x 200 mL). The combined EtOAc layers were washed with brine (100 mL), dried over anhydrous MgSO4 and concentrated in vacuo, yielding the title compound (4.3 g, 100%). MS (GC-EI) [(M-N2)+]: 186 for C8Hi4BrN4O3.
Intermediate 239
Ethyl 4-azido-3 -(2-tgrt-butoxy-2-oxoethoxy)piperidine- 1 -carboxylate Ethyl 4-azido-3-hy droxypiperidine- 1 -carboxylate (Intermediate 238, 1.71 g) was dissolved in anhydrous THF (15 mL) and cooled to 0°C. Sodium hydride (60% in mineral oil) (0.42 g) was added as a shot, stirred for twenty minutes at 0°C, followed by the slow addition of tert-butyl bromo acetate (0.86 mL) via syringe, and stirred for an additional two hours at O0C. The reaction was partitioned between EtOAc (250 mL) and saturated aqueous NaHCO3 (200 mL), and the aqueous layer was washed with EtOAc (200 mL). The combined EtOAc layers were washed with brine (50 mL), dried over anhydrous MgSO4 and concentrated in vacuo, yielding the title compound as a crude product (1.78 g, 103%). MS 5 (GC-EI)[(M-N2)+]: 300 for C14H24N4O5.
Intermediate 240
Ethyl 4-amino-3 -(2-fert-butoxy-2-oxoethoxy)piperidine- 1 -carboxylate
Figure imgf000222_0001
10 Ethyl 4-azido-3 -(2-tert-butoxy-2-oxoethoxy)piperidine- 1 -carboxylate (Intermediate
239, 1.75 g) was dissolved in THF (60 mL), followed by the addition of deionised water (5 mL) and PS-triphenylphosphine resin (10.6 g), and stirred at room temperature over the weekend. The reaction mixture was filtered, and the resin was rinsed repeatedly with MeOH and a 1:5 MeOH:DCM mixture, and the filtrate was concentrated in vacuo, yielding the title 15 compound (1.20 g, 75%). MS (GC-EI) [(M)+]: 302 for C14H26N2O5.
Intermediate 241
Ethyl 4-bromo-3-([tgrt-butyl(dimethyl)silyl]oxy>piperidine-l-carboxylate
Ethyl 4-bromo-3-hydroxypiperidine-l -carboxylate (Preparation: Izamanishi, T. et al;
20 1982, Chem. Pharm. Bull., 30: 3617-3623) (10.17 g) was dissolved in anhydrous DCM (100 mL) under an argon atmosphere and cooled to 0°C. fert-Butyldimethylsilyl trifluoromethylsulfonate (10.2 mL) was added dropwise via syringe, followed by 2,6-lutidine (4.7 mL), also added dropwise via syringe. The reaction was stirred overnight, slowly warming to room temperature, then diluted with DCM (200 mL) and washed with saturated
25 aqueous NaHCO3 (150 mL), saturated aqueous NH4Cl ((150 mL), brine (100 mL), dried over anhydrous MgSO4 and concentrated in vacuo, yielding the title compound as a crude product (15.1 g, 102%). MS (GC-EIX(M-C4H7)"1"]: 310, 312 for C14H28BrNO3Si; NMR (CDCl3): 0.10 (s, 3H), 0.12 (s, 3H), 0.88 (s, 9H), 1.24 (t, 3H), 1.87 (m, IH)5 2.34 (m, IH), 2.84-3.40 (m, 2H), 3.69 (m, 2H), 3.93 (m, 2H), 4.13 (q, 2H).
30 Intermediate 242
Ethyl 4-azido-3 - { rtgrt-butyl(dimethyl)silyll oxylpiperidine- 1 -carboxylate
The title compound was prepared in a manner analogous to (Intermediate 238) starting with ethyl 4-bromo-3-{[fert-butyl(dimethyl)silyl]oxy}piperidine-l-carboxylate (Intermediate 5 241). MS (GC-EI)[(M-N2)+]: 300 for Ci4H28N4O3Si.
Intermediate 243
Ethyl 4-amino-3-{[tert-butyl(dimethyl)silylloxylpiperidine-l-carboxylate
The title compound was prepared in a manner analogous to (Intermediate 240) starting 10 with ethyl 4-azido-3-{[tert-butyl(dimethyl)silyl]oxy}piperidine-l-carboxylate (Intermediate 242). MS (GC-EI)KM)+]: 302 for C14H30N2O3Si.
Intermediate 244
3,4-dichloro-N-(3-hydroxypiperidin-4-yl)-5-methyl-l/i-pyrrole-2-carboxamide 15 Ethyl 3-{[tert-butyl(dimethyl)silyl]oxy}-4-{[(3,4-dichloro-5-methyl-lH-pyrrol-2- yl)carbonyl] amino }piperidine-l -carboxylate (Intermediate 114, 0.805 g) was dissolved in a mixture of MeOH (10 mL) and 1,4-dioxane (15 niL), to which was added IN NaOH (10 niL) and heated to reflux for twenty-four hours. An additional 5 mL of IN NaOH was added, with 5 mL of 1,4-dioxane, and the reaction was heated for an additional forty-two hours, then 20 cooled to O0C and acidified to ~ pH 9 with 2N HCl (6 mL). The cold mixture was filtered and washed with deionised water, yielding the title compound as a crude product. MS (ES) MH+: 292, 294 for C11H15Cl2N3O2.
The following Intermediate was prepared by the procedure described in Intermediate 25 16 from the starting materials (SM) indicated.
Figure imgf000223_0001
Intermediate 246 ethyl 4-{[(l-methyl-l-phenylethyl)amino]carbonyl}-2-(methylthio)-l,3-thiazole-5- carboxylate
Diisopropylamine (5.3 ml) was dissolve in anhydrous THF (100 ml) was cooled to - 5 780C and to this was added n-butyl lithium (15 ml) slowly. The solution was slowly warmed to 0 °C and then cooled back to -780C. A solution of TV-(I -methyl- 1-pheny lethyl)-2- (methy ItMo)-1, 3 -thiazole-4-carboxamide (Intermediate 13; 3.7 g) in anhydrous THF was added slowly maintaining the temperature below -700C. After stirring for 30 min, a solution of ethyl cyano formate (2.5 ml) in anhydrous THF was added in one portion and the reaction 0 was stirred at -78°C for 30 min followed by slow warming to room temperature. The reaction mixture was diluted with water and extracted with ethyl acetate (X3), dried with MgSO4 and concentrated to a black oil (0.84g) NMR: 1.22 - 1.29 (m, 3 H) 1.63 (s, 6 H) 2.76 (s, 3 H) 4.28 (q, 2 H) 7.20 (t, 1 H) 7.32 (t,2 H) 7.46 (d, 2 H) 8.75 (s, 1 H)
5 Intermediate 247 diethyl 2-chloro-l ,3-thiazole-4,5-dicarboxylate
To a solution of tert-butyl nitrite (3.4mL, 28 mmol) and copper (II) chloride (3.7g,
28mmol) in acetonitrile (5OmL) was added diethyl 2-amino-l,3-thiazole-4,5-dicarboxylate
(4.6g, 19mmol, Intermediate 248) all in one portion. Gas evolution was observed. After 45 0 min of stirring at room temperature LCMS indicated complete product formation. After concentrating to remove acetonitrile the residue was partitioned with chloroform and IN HCl
(Fisher), washed with chloroform, dried with MgSO4 and concentrated to an orange oil.
Purification by flash column yielded a pale yellow oil (4.2g, 85%). MS (ES): 264; NMR:
1.25 - 1.29 (t, 3 H) 1.29 - 1.33 (t, 3 H) 4.28 - 4.33 (q, 2 H) 4.33 - 4.39 (q, 2 H) 5
Intermediate 248 diethyl 2-amino-l,3-thiazole-4,5-dicarboxylate
A solution of thiourea (1.7g, 22 mmol) and diethyl 2-chloro-3-oxosuccinate (5.Og, 22 mmol) in absolute ethanol (5OmL) was heated at reflux for one hour. After cooling to room 0 temperature the solvent was removed leaving a white solid. The solid was dissolved in water
(10OmL) and the resulting precipitate was filtered and dried (4.6g, 87%). MS (ES): 245;
NMR: 1.21 (t, 3 H) 1.26 (t, 3 H) 4.16 (q, 2 H) 4.26 (q, 2 H) 8.04 (s, 2 H) 06 000529
- 224 -
Intermediate 249 isopropyl 4-chloro-6-(morpholin-4-ylcarbonyl)pyridine-2-carboxylate n-butyllithium (1.92niL, 2.5M in hexanes) was added dropwise to a -78°C solution of morpholine (0.42mL, 4.8mmol) in anhydrous THF followed by slow warming to room temperature. The solution was transferred to an addition funnel via cannulation and then added dropwise to a solution of dimethyl 4-chloropyridine-2,6-dicarboxylate (1.Og, 4.4mmol, Intermediate 251) in anhydrous THF. A slight precipitate was observed during the addition. After stirring two hrs at room temperature an additional 0.5 equivalence of the morpholino- lithium reagent was added to the reaction and after an additional two hrs of stirring another 0.5 equivalence was added followed by stirring one hour to reach completion. The solvent was removed under reduced pressure and the residue was suspended in methylene chloride and the product was extracted with a sat. sodium bicarbonate solution (x3). The sodium bicarbonate portion was acidified with cone. HCl to pH 3 and then extracted with EtOAc (xlO), followed by drying with MgSO4 and concentrating to a solid (0.8g, 70%). MS (ES) MH+:271 for C11H11ClN2O4. The solid was suspended in anhydrous toluene (75mL) and to this was added triisopropylorthoformate (1.97mL, 8.9mmol) slowly followed by heating to reflux for 12 hours. After cooling to room temperature the solvent was removed under reduced pressure and the residue was suspended in IN HCl. Basification to pH8 with saturated sodium bicarbonate followed by extraction with EtOAc (x3), drying with MgSO4 and removal of solvent yielded a tan solid. Purification by silica gel flash column (gradient elution to 3:1 EtOAc:CH2Cl2) yielded a white solid (0.23g) MS (ES) MH+-JD for C14Hi7ClN2O4; NMR: 1.33 (s, 3 H) 1.35 (s, 3 H) 3.41 (s, 2 H) 3.44 (d, 2 H) 3.58 (d, 2 H) 3.68 (s, 4 H) 5.17 (dt, 1 H) 8.01 (d, IH) 8.13 (d,l H).
The following Intermediate was prepared by the procedure described in Intermediate
249 from the starting materials (SM) indicated.
Figure imgf000225_0001
Intermediate 251 dimethyl 4-chloropyridine-2,6-dicarboxylate
Phophorus pentachloride (45.5g, 218mmol) was weighed into a closed flask and suspended in chloroform. 4-hydroxypyridine-2,6-dicarboxylic acid (10. Og, 55 mmol) was added and after heating at a gentle reflux for 3 days the reaction was complete (60% conversion). After cooling to O0C anhydrous methanol (15OmL) was added dropwise. Once the exotherm subsided the solvent was removed under reduced pressureand the residue was partitioned with EtOAc and water and the insoluble material was filtered, washed with EtOAc and dried (6.7g). The EtOAc layer was washed with water, dried with MgSO4 and concentrated. Recrystallization with methanol yielded additional pure product (0.64g). MS (ES) MH+: 230 for C9H8ClNO4; NMR: 3.94 (s, 3 H) 8.32 (s, 1 H).
Intermediate 252
2-chloro-5-(ethoxycarbonyl)-l .3-thiazole-4-carboxylic acid To a solution of ethyl 2-chloro-4-(hydroxymethyl)-l,3-thiazole-5-carboxylate (2.5g,
1 lmmol, Intermediate 211) in acetone at O0C was slowly added a solution of chromium trioxide (2.26g, 22mmol) in 20% cone. Sulfuric acid in water (2OmL). After stirring at room temperature for 2 hrs, isopropanol (ImL) was added to quench unreacted chromium trioxide.
The reaction was diluted with water and the acetone was removed. Partitioning with methylene chloride (x3), drying with MgSO4 and concentrating yielded a white solid (2.3g,
90%). MS (ES) MH+: 236 for C7H6ClNO4S; NMR: 1.26 (t, 3 H) 4.31 (q, 2 H) 13.99 - 14.15 (m, I H).
Intermediate 253 3,4-Dichloro-5-chloromethyl-lH-pyrrole-2-carboxylic acid ethyl ester
To a 4-neck 22L round bottom flask equipped with an overhead stirrer, liquid addition funnel, nitrogen inlet and an internal temperature probe was charged (Intermediate 254, 2000 g, 13.6 mol) and carbon tetrachloride (12 L). The reaction mixture was cooled to -5 0C and sulfuryl chloride was added at a rate that the temperature did not exceed 0 °C (1 h). Resulting reaction mixture became very thick (as precipitate becomes heavy, significant gas evolution was observed) and was allowed to stir at 0 0C for a total of 4 h after addition. Precipitate was filtered and solid azeotroped with toluene to remove excess sulfuryl chloride. The solid was and dried in convection oven at 50 °C yielding 3 (2077 g, 62 %) as a dark purple solid. Intermediate 254
5 -Methyl- lH-pyrrole-2-carboxylic acid ethyl ester
To a 4-neck 22L round bottom flask equipped with an overhead stirrer, liquid addition runnel, nitrogen inlet and an internal temperature probe was charged ethyl 3-oxobutanoate (1952 g, 15.0 mol) and glacial acetic acid (5 L). The resulting solution was cooled to 0 0C with an ice water bath and an aqueous solution of sodium nitrite (1242 g, 18.0 mol, 1.2 eq, in 1875 ml of water) was added slowly (4.5 h) not allowing the internal temperature above 10 °C. The homogeneous red solution was allowed to warm to ambient and stirred for 48 h. The solution color changed from light red to yellow. Reaction vessel was then placed in a heating mantle, fitted with a reflux condenser and acetylacetaldehyde dimethyl acetal (1982 g, 15.0 mol, 1 eq) was added in one portion (the top of the reflux condenser was left open to air to allow for the rapid gas evolution during the addition of the zinc). Zinc (dust, 2156 g, 33 mol, 2.2 eq) was added in portions (at a rate such that gas evolution was controlled) over 4 h. The addition of zinc brought the reaction to reflux and after addition the dark red solution was heated at reflux for an additional 1.5 h. Contents of the reaction were poured hot into a 50 L container with 20 kg of ice and allowed to stir for 16 h. Resulting suspension was filtered, dried in convection oven and recrystallized with hot heptane yielding a light yellow splid (312 g, 13.6% yield).
Intermediate 255 ethyl 3 -hydroxy-4,4-dimethoxypiperidine- 1 -carboxylate
Figure imgf000227_0001
To a stirred solution of potassium hydroxide (42 g, 752 mmol) in dry methanol (100 mL), at 0 0C and under an atmosphere of N2, was added a solution of ethyl 4-oxopiperidine-l- carboxylate (26.4 mL, 29.96 g, 175 mmol) in dry methanol (75 mL) via syringe. The resulting solution was stirred for an additional 30 minutes under an atmosphere of N2 at 0 °C. To it, in small portions over approximately 90 minutes, was added iodobenzene diacetate (84.6 g, 262 mmol). Temperature was kept near 0 0C throughout this time. The reaction was stirred overnight under an atmosphere of N2, gradually reaching room temperature. Complete conversion was suggested by TLC (50% ethyl acetate in hexanes; Hanessian's stain; Rf- 0.25) in the morning. The reaction was concentrated under vacuum. To the residue was added approximately 50 mL water; from this mixture was extracted the crude product with ethyl acetate (3 X 200 mL). The organic layers were combined, dried over magnesium sulfate, and concentrated. The crude product was purified using column chromatography (silica gel; 10-65% ethyl acetate in hexanes), yielding 26.74 g (66%) of a pale yellow oil.
MS (ESI) M: 233 for C10Hi9NO5. 1H NMR (CDCl3): 1.22 (t, 3H), 1.69-1.86 (m, 2H), 2.20 (m, 2H), 2.86 (t, IH), 3.22 (s, 3H), 3.23 (s, 3H), 3.74 (m, IH), 3.95 (m, 2H), 4.11 (q, 2H).
The following Intermediates were synthesized by an analogous method to Intermediate 28 or Intermediate 59 from the starting materials (SM) given in the table below.
Figure imgf000228_0001
The following Intermediates were synthesized by an analogous method to
Intermediate 37 or Intermediate 83 from the starting materials (SM) given in the table below.
Figure imgf000228_0002
Figure imgf000229_0001
The following Intermediates were synthesized by an analogous method to Intermediate 50 or Intermediate 74 from the starting materials (SM) given in the table below.
Figure imgf000229_0002
Intermediate 262 fert-butyl (3>S'.4i?)-4-(r(4-chloro-3-fluoro-5-methyl-lH-pyrrol-2-yl)carbonyllaminol-3- fluoropiperidine- 1 -carboxylate tert-butyl (35r,4i2)-4- { [(4-chloro-3-fluoro-5 -methyl- 1 - { [2- (trimethy lsily l)ethoxy]methy 1 } - 1 H-pyrrol-2-yl)carbonyl] amino } -3 -fluoropiperidine- 1 - carboxylate (Intermediate 259, 80mg, 0.16mmol) was dissolved in anhydrous THF (6ml), followed by the addition of tetra-butyl ammonium fluoride (1ml, IM in THF) and ethylene diamine ( lmmol), the mixture was then stirred at 50oC over night. After cooling down to room temperature, the reaction mixture was diluted with ethyl acetate (20ml) and washed with saturated aqueous sodium bicarbonate (10ml) and brine (10ml), dried over anhydrous sodium sulfate, concentrated and purified by column chromatography (100%~70%hexanes/ethyl acetate) to give the desired product (55mg). MS (ESP): 378 (MNa+) for Ci6H22ClF2N3O3
1H-NMR (CDClO δ: 1.46 (s, 9H); 1.84 (m, 2H); 2.24 (s, 3H); 2.89 (m, 2H); 4.28 (m, 2H);
4.50 (m, IH); 4.70 (m, br, IH); 6.32 (m, IH); 9.36 (br, IH).
Intermediate 263
4-chloro-3-fluoro-5-methyl-l-{[2-(trimethylsilyl')ethoxy]methvU-lH-pyrrole-2-carboxylic acid tert-butyl 4-chloro-3-fluoro-5-methyl- 1 - { [2-(trimethylsilyl)ethoxy]methyl} - IH- pyrrole-2-carboxylate (Intermediate 264, lOOmg) was dissolved in N-methyl pyrolidinone (10ml), heated to 2000C for 30 minutes. The resulting solution was carried on to the next step without further purification. MS (ESP): 307 (M') for C12H19ClFNO3Si
Intermediate 264 tert-butyl 4-chloro-3-fluoro-5-methyl- 1 - { [2-(trimethylsilyl)ethoxy1methyl} - lH-pyrrole-2- carboxylate tert-butyl 3-bromo-4-chloro-5-methyl-l-{[2-(trimethylsilyl)ethoxy]methyl}-lH- pyrrole-2-carboxylate (Intennediate 265, 480mg, 1.13mmol) was dissolved in dry TΗF(8ml), cooled down to -780C, n-BuLi (2.5M in Hexane, 3.39mmol) was added dropwise into the mixture via syringe and the mixture was stirred at -780C for 30min followed by a quick addition of N-Fluorobenzensulfonimide(1.25g, 3.96mmol in 5 ml of THF/Toluene 1:1), the resulting mixture was then stirred at -780C for 30min and slowly warmed up to room temperature during a period of 12hrs. The reaction was quenched at O0C with drops of saturated NH4Cl solution and further diluted with EtOAc (50ml). The organic phase was washed with brine and dried over anhydrous MgSO4, concentrated to an oil and purified by flash column chromatography eluted with 10% EtOAc in Hexanses. The desired product was obtained as an oil (125mg). MS (ESP): 364 (MH+) for Ci6H27ClFNO3Si 1H-NMR (CDClO δ: 0.00 (s, 9H); 0.90 (t, 2H); 1.58 (s, 9H); 2.31 (s, 3H); 3.52 (t, 2H); 5.70 (s, 2H).
19F-NMR (CDCl3) δ: -148.85 Intermediate 265 fert-butyl 3-bromo-4-chloro-5-methyl-l-{r2-('trimethylsilyl')ethoxylnietlivU-lH-pyrrole-2- carboxylate
Figure imgf000231_0001
Ethyl 3-bromo-4-chloro-5-methyl-l-{[2-(trimethylsilyl)etlioxy]methyl}-lH-pyrrole-2- carboxylate (Intermediate 266, 564mg, 1.42mmol), t-Butylacetate (330mg, 2.84mmol) and potassium t-butoxide ( 0.14mmol) were mixed together and stirred at room temperature for 10 minutes, concentrated to an oil under vacuum. t-Butylacetate (330mg, 2.84mmol) and potassium t-butoxide ( 0.14mmol) were added again into the reaction mixture, repeated the same procedure again. The resulting reaction crude was filtered through a short pass silica gel, washed with ethyl acetate, the combined filtrate was concentrated to an oil and purified by column chromatography (2% ethyl acetate in hexanses) to give the desired product as an oil (485mg). 1H-NMR (CDClO δ: 0.00 (s, 9H); 0.90 (t, 2H); 1.58 (s, 9H); 2.33 (s, 3H); 3.52 (t, 2H); 5.75 (s, 2H)
Intermediate 266
Ethyl 3-bromo-4-chloro-5-methyl-l-{[2-(trimethylsilyl')ethoχy1methvU-l/f-pyrrole-2- carboxylate To a suspension of sodium hydride (76mg, 3.16mmol) in dry DMF (5ml), solution of ethyl 3-bromo-4-chloro-5-methyl-lH-pyrrole-2-carboxylate (Intermediate 267, 420mg, 1.58mg) was added, the resulting mixture was stirred at O0C for 30 minutes until gas evolution seized. Trimethylsilyl-ethoylmethyl chloride (315mg, 1.89mmol) was added drop wise and stirred over night while allowing the reaction mixture warmed up to room temperature slowly. The reaction was quenched with cold water, diluted with ether (20ml), washed with water and brine, the organic layer was dried over anhydrous sodium sulfate, concentrated and purified by column chromatography (95%hexanes in ethyl acetate) to give the desired product as an oil (624mg). MS (ESP): 397 (MH+) for C14H23BrClNO3Si
1H-NMR fCDCh) δ: 0.00 (s, 9H); 0.90 (t, 2H); 1.43 (t, 3H); 2.38 (s, 3H); 3.55 (t, 2H); 4.34
(q, 2H); 5.75 (s, 2H).
Intermediate 267
Ethyl 3 -bromo-4-chloro-5 -methyl- 1 H-pyrrole-2-carboxylate
Ethyl 4-chloro-5-methyl-lH-pyrrole-2-carboxylate (Intermediate 7, 300mg, l.όmmol) was dissolved in dry dichloromethane (10ml), N-bromosuccinimide(285mg, l.όmmol) was added at O0C and resulting mixture was stirred at room temperature over night. The mixture was poured into cold sodium hydroxide aqueous solution (2M) (20ml), extracted with diethyl ether (2x20ml). The organic phase was then washed with water (20ml) and brine (20ml), dried over anhydrous sodium sulfate, concentrated and purified by column chromatography (hexanes/ethyl acetate, gradient) to give the desired product as a yellowish solid. (424mg). MS (ESP): 266 (MH+) for C8H9BrClNO2
1H-NMR fCDClO δ: 1.39 (t, 3H); 2.32 (s, 3H); 4.34 (q, 2H); 9.04 (s, br, IH).
Intermediate 268
Trans(+Vtgrt-butyl-4- [(diphenylmethylene)amino] -3 -hvdroxypiperidine- 1 -carboxylate tert-butyl-4-amino-3-hydroxypiperidine-l -carboxylate (11.9 g; 55 mmol) and benzophenone imine (1Og; 59 mmol; 1.05 eq.) were dissolved in anhydrous toluene and heated to reflux for 18 hrs. Monitored the reaction by TLC (30% EtOAc / hexanes with 0.1% triethylamine). The crude reaction was concentrated and purified by flash column chromatography. Isolation gave 18.4 g of the title compound in an 86% yield. LC/MS (ES+)[(M+H)+]: 381 for C23H28N2O3.
Intermediate 269
Cis(+Vfert-butyl-3-azido-4-r(diphenylmethylene)aminolpiperidine-l-carboxylate
In a flame-dried flask triphenylphosphine (3.86 g; 14.7 mmol; 2 eq.) was dissolved in anhydrous THF (15 ml) and cooled to 0 C. DIAD (2.97 g; 14.7 mmol; 2 eq.) was slowly added dropwise. Upon addition a white precipitate formed. A THF solution containing tert- butyl-4-[(diphenylmethylene)amino]-3-hydroxypiperidine- 1 -carboxylate (Intermediate 268, 2.8 g; 7.36 mmol) was added (amount of THF added was such that the final concentration of alcohol was ca. 0.5 - IM). The resultant reaction slurry was stirred at 0 C for 30 minutes. (PhO)2PON3 (4.05 g; 14.7 mmol; 2eq.) was then added and the reaction was allowed to warm to RT and stirred for 12 hrs. Monitored by LC/MS. The reaction was concentrated and purified by flash column chromatography (0 - 30% EtOAc / hexanes with 0.1% triethylamine). Isolation gave 2.13 g of the title compound in 71% yield. LC/MS 5 (ES+)[(M+H)+]: 406 for C23H27N5O2.
Intermediate 270
Cis(+)fert-butyl-4-amino-3 -azidopiperidine- 1 -carboxylate
Figure imgf000233_0001
tert-butyl-3-azido-4-[(diphenylmethylene)amino]piperidine-l-carboxylate (Intermediate 269, 1.36 g; 3.3 mmol) was dissolved in 10 mi's of aqueous THF (5% H2O). PPTS (850 mg; 3.4 mmol; 1.03 eq.) was added in a single portion. The initial cloudy solution 15 became clear within minutes. Upon completion (as determined by LC/MS analysis) the reaction was concentrated and azeotropically dried with acetonitrile. No further purification. (LC/MS: see disappearance of starting material and formation OfPh2C=O. Product is not observable due to lack of chromophore).
20 Intermediate 271
Cis(±Vert-butyl-3 -azido-4- ( IT 3.4-dichloro-S-methyl- 1 H-pyrrol-2- vDcarbonyl] amino > piperidine- 1 -carboxylate
Crude tert-butyl-4-amino-3-azidopiperidine-l-carboxylate (Intermediate 270, 3.3 mmol) was dissolved in anhydrous CH2Cl2 (10 ml) and DIEA (1.27 g; 1.6 ml; 9.9 mmol; 3 25 eq.). The solution was cooled to 0 C and 3, 4-dichloro-5 -methyl- lH-pyrrole-2-carbonyl chloride (736 mg; 3.5 mmol; 1.05 eq.) was added. The reaction was complete within 30 minutes. Dilute with CH2Cl2 and wash with H2O (x2), brine and dried over Na2SO4. Filter and concentrate. Purify by flash column chromatography (0 - 60% EtOAc / hexanes).
Isolation gave 967 mg in 69% yield over the two-step sequence. LC/MS (ES") [(M-H)"]: 415, 30 417 for Ci6H22Cl2N6O3. Intermediate 272
Cis(+)N-('-3-azidopiperidin-4-yl)-3.4-dichloro-5-niethyl-lH-pynOle-2-carboxamide hydrochloride. ført-butyl-3-azido-4-{[(3,4-dichloro-5-methyl-l/f-pyrrol-2- 5 yl)carbonyl]amino}piperidine-l-carboxylate (Intermediate 271, 967 mg; 2.3 mmol) was dissolved in 4N HCl in dioxanes (20 ml) and methanol (10 ml). The solution was stirred for 2 hours and monitored by LC/MS. Upon completion the solvent was removed and the crude reaction mixture was azeotroped with methanol to remove excess HCl. No further purification. LC/MS (ES+) [(M+H)+]: 317, 319 for CnH14Cl2N6O. 10
Intermediate 273
(2i?V2-Methoχyproρan-l -amine hydrochloride ("1725-162) tert-Butyl [(2i?)-2-methoxypropyl]carbamate (Intermediate 277, 0.33 g, 1.74 mmol) and Hydrochloric acid (4 M, 1.5 mL) were combined and stirred at room temperature for two 15 hours. Then it was concentrated and triturated with diethyl ether to give white crystalline solid
(0.20 g) as the product.
NMR: 1.14 (d, 3H), 3.30 (s, 3H), 3.35- 3.45 (m, 2H), 7.99 (brs, 3H)
The following compounds were produced according to the procedure for Intermediate 20 273 or by hydrogenation using the starting materials listed.
Figure imgf000234_0001
Intermediate 276
Benzyl IY 1 i?V2-methoxy- 1 -methylethyll carbamate
To a solution of benzyl [(li?)-2-hydroxy-l-methylethyl]carbamate (0.5 g, 2.38 mmol) 25 in acetonitrile (20 mL), silver oxide( 3.8 g, 13.09 mmol) is added followed by the addition of methyl iodide (1.94 mL, 23.8 mmol). The resultant mixture was stirred overnight at room temperature. The insoluble salt was filtered off and the filtrate was concentrated. The residue was flashed using silica and Ethyl acetate/hexanes system as eluent to give the desired product as clear oil (0.38 g). MS (ES) MH+Na: 246 for C12HnNO3; NMR: 1.01 (d, 3H), 3.12- 3.17 (m, IH), 3.22 (s, 3H), 3.25-3.26 (m, IH), 3.60-3.75 (m, IH), 5.00 (s, 2H), 7.16 (d, IH), 7.29-7.36 (m, 5H)
Intermediate 277 tert-Butyl |Y2 J?)-2-methoxypropyl1 carbamate To a solution of tert-butyl [(2i?)-2-hydroxypropyl]carbamate (0.4 g, 2.28 mmol) in
THF (5mL), sodium hydride (0.06 g, 2.51 mmol) was added at 0°C . The resulting solution was stirred for 30 minutes at that temperature and then methyl iodide (0.14 mL, 2.28 mmol) was added. The reaction was warmed to room temperature slowly and allowed to stir for an additional two hours. The reaction was quenched by adding water and extracted with ethyl acetate. The extract was washed with sodium bicarbonate solution, water and brine. It was dried over magnesium sulfate and concentrated. The desired product was obtained as clear oil
(0.31 g) and it did not need any further purification.
NMR (CDCl3): 1.15 (d, 3H), 1.43 (s, 9H), 3.31- 3.33 (m, 2H), 3.34 (s, 3H), 3.77-3.81 (m,
IH), 4.66 (brs, IH)
Interemediate 278 tert-Bntyl r(2,SV2-methoxypropyl1carbamate( 1725- 160^)
The title compound was synthesized by using the method analogous to the synthesis of
Intermediate 277 starting with fert-butyl [(25)-2-hydroxypropyl]carbamate and alkylating it with methyl iodide.
NMR (CDCl3): 1.15 (d, 3H), 1.43 (s, 9H), 3.31- 3.33 (m, 2H), 3.34 (s, 3H), 3.77-3.81 (m,
IH), 4.66 (brs, IH) The following Intermediate was prepared by the procedure described in Example 203 from the starting materials (SM) indicated
Figure imgf000236_0001
The following Intermediate was prepared by the procedure described in Example 383 from the starting materials (SM) indicated
Figure imgf000236_0002
The following Examples were prepared by the procedure described in Example 417 from the starting materials (SM) indicated
Figure imgf000237_0001

Claims

What is claimed is:
1. A compound of formula (I) :
Figure imgf000238_0001
(I) wherein:
R1 is selected from hydrogen, nitro, hydroxy, halo, cyano, C1-4alkyl, C1-4alkoxy, C2-4alkenyl, C2-4alkynyl, C1-4alkanoyl, C1-4alkylS(O)a wherein a is 0 to 2 and C3-6cycloalkyl; wherein R1 may be optionally substituted on carbon by one or more halo or cyclopropyl; R2 is selected from hydrogen, nitro, hydroxy, halo, cyano, C1-4alkyl, C1-4alkoxy,
C2-4alkenyl, C2-4alkynyl, C1-4alkanoyl, C1-4alkylS(O)a wherein a is 0 to 2 and C3-6cycloalkyl; wherein R2 may be optionally substituted on carbon by one or more halo or C3-6cycloalkyl;
R3 is selected from hydrogen, nitro, hydroxy, halo, cyano, -C=N-OR' wherein R' is H or C1-4alkyl, C^alkyl, C1-4alkoxy, C2-4alkenyl, C2-4alkynyl, C1-4alkanoyl, C1-4alkylS(O)a wherein a is 0 to 2 and C3-6cycloalkyl; wherein R3 may be optionally substituted on carbon by one or more halo or C3-6cycloalkyl;
W is -O-, -N(R6)- or -C(R7)(R8)-;
X is a direct bond, -CH2-, -C(O)- or S(O)q- (wherein q is 1 or 2);
Ring A is carbocyclyl or heterocyclyl; wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R9;
R and R5 are substituents on carbon and are independently selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, sulfo, formyl, ureido, hydroxyiminomethyl, C1-4alkoxyiminomethyl, N-hydroxyformamido, C1-4hydrazino, hydrazinocarbonyl, iV-hydroxyethanimidoyl, amino(hydroxyimino)methyl, Ci-4alkyl, C2-4alkenyl, C2-4alkynyl, Ci-4alkoxy, C1-4alkanoyl, Ci_4alkanoyloxy,
N-(Ci_4alkyl)amino, N,N-(Ci-4alkyl)2amino, Ci-4alkanoylamino, N-(Ci-4alkyl)carbamoyl,
Figure imgf000238_0002
iV-(Ci-4alkoxy)carbamoyl, iV'-(Ci-4alkyl)ureido, N'N-(Ci-4alkyl)2ureido, N~(C1-4alkyl)-N-(C1-4alkoxy)carbamoyl, C 1-4alkylS(O)a wherein a is 0 to 2, C1-4alkoxycarbonyl, Ci-4alkoxycarbonylamino, N-(C 1-4alkyl) sulphamoyl, N, N-(C i -4alkyl)2sulphamoyl, C i -4alkylsulphonylamino, C i -4alkylsulphonylaminocarbonyl,
Figure imgf000239_0001
N'iV'-(Ci-4alkyl)2hydrazinocarbonyl, carbocyclyl-R10- or heterocyclyl-R1 ' — ; wherein R4 and R5 independently of each other may be optionally substituted on carbon by one or more R ; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R ; R 5 R and R are independently selected from hydrogen or C1-4alkyl; n is 1-4; wherein the values of R4 may be the same or different; m is 0-4; wherein the values of R5 may be the same or different; R12 is selected from azido, halo, nitro, cyano, hydroxy, trifiuoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C1-4alkyl, C2-4alkenyl, C2-4alkynyl, C1-4alkoxy, C1-4alkanoyl, C1-4alkanoyloxy, N-(C1-4alkyl)ammo, N5N-(C 1-4alkyl)2amino,
C1-4alkanoylamino, N-(C1-4alkyl)carbamoyl, N,N-(C1-4alkyl)2carbamoyl, C1-4alkylS(O)a wherein a is 0 to 2, C1-4alkoxycarbonyl, N-(C 1-4alkyl) sulphamoyl, N5N-(C 1-4alkyl)2sulphamoyl, C1-4alkylsulphonylamino, C1-4alkoxycarbonylamino, carbocyclyl-R14 — or heterocyclyl-R 5— -; wherein R12 independently of each other may be optionally substituted on carbon by one or more R16; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R17;
R9, R13 and R17 are independently selected from C1-4alkyl, C1-4alkanoyl, C^alkylsulphonyl, C1-4alkoxycarbonyl5 carbamoyl, iV-(C1-4alkyl)carbamoyl, AζiV^CMalkytycarbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulphonyl; R10, R11, R14 and R15 are independently selected from a direct bond, -O-, -N(R18)-,
-C(O)-, -N(R19)C(O)-, -C(O)N(R20)-, -S(O)P-, -SO2N(R21)- or -N(R22)SO2-; wherein R18, R19, R20, R21 and R22 are independently selected from hydrogen or C1-4alkyl and p is 0-2;
R16 is selected from halo, nitro, cyano, hydroxy, trifiuoromethoxy, trifluoromethyl, amino, carboxy, carbamoyl, mercapto, sulphamoyl, methyl, ethyl, ethenyl, ethynyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, iV-methyl-iV-ethylamino, acetylamino, iV-methylcarbamoyl, JV-ethylcarbamoyl, AζiV-dimethylcarbamoyl, AζiV-diethylcarbamoyl, N-methyl-JV-ethylcarbamoyl, methylthio, ethylthio, methylsulphinyl, ethylsulphinyl, mesyl, ethylsulphonyl, methoxycarbonyl, ethoxy carbonyl, iV-methylsulphamoyl, iV-ethylsulphamoyl, ΛζN-dimethylsulphamoyl, N, TV-diethylsulphamoyl or N-methyl-iV-ethylsulphamoyl; or a pharmaceutically acceptable salt thereof.
2. The compound of claim 1 , or a pharmaceutically acceptable salt thereof which is a compound of formula (IA).
Figure imgf000240_0001
(IA)
3. The compound of claims 1-2, or a pharmaceutically acceptable salt thereof which is a compound of formula (IB).
Figure imgf000240_0002
(IB)
4. The compound of claims 1-3, or a pharmaceutically acceptable salt thereof which is a compound of formula (IC).
Figure imgf000240_0003
(IC)
5. The compound of claims 1-4, or a pharmaceutically acceptable salt thereof which is a compound of formula (ID):
Figure imgf000240_0004
(ID) wherein Ring A is heterocyclyl; wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from C1-4alkyl, C1-4alkanoyl, C1-4alkylsulphonyl, C1-4alkoxycarbonyl, carbamoyl,
Figure imgf000241_0001
N,iV-(C1-4alkyl)carbamoyl, benzyl, benzyloxycarbon}'!, benzoyl and phenylsulphonyl.
6. The compound of claims 1-5, or a pharmaceutically acceptable salt thereof which is a compound of formula (IE):
Figure imgf000241_0002
(IE) wherein:
Y is NH, N(C1-4alkyl) or S; wherein R5a and R5b are substituents as defined for R5 or taken together with the carbons to which they are attached form a 6-membered carbocyclyl ring substituted by one or two groups which may be the same or different and which are selected from R14;
7. The compound of claims 1-6, or a pharmaceutically acceptable salt thereof which is a compound of formula (IF).
Figure imgf000241_0003
(IF)
8. A compound which is
2-((3^4i?)-4-{[(3,4-dicMoro-5-methyl-liY-pyirol-2-yl)carbonyl]aniino}-3- fluoropiρeridin-l-yl)-l,3-thiazole-5-carboxylic acid; 2-((35r,4i?)-4-{[(3,4-dichloro-5-methyl-lH-pyrrol-2-yl)carbonyl]amino}-3- methoxypiperidin- 1 -yl)-4- { [(2-methoxyethyl)amino]carbonyl} - 1 ,3 -thiazole-5-carboxylic acid;
2-((3»S',4i?)-4-{[(3,4-dichloro-5-methyl-lH-pyrrol-2-yl)carbonyl]amino}-3- methoxypiperidin- 1 -yl)-4-( { [( 15)-2-methoxy- 1 -methylethyl] amino } carbonyl)- 1 ,3 -thiazole-5- carboxylic acid;
2-((3»S',4i?)-4-{[(3,4-dicliloro-5-methyl-lH-pyrrol-2-yl)carbonyl]amino}-3- methoxypiperidin-l-yl)-4-[(methylamino)carbonyl]-l,3-thiazole-5-carboxy lie acid;
2-((35',4i?)-4-{[(3,4-Dichloro-5-methyl-lH-pyrrol-2-yl)carbonyl]aniino}-3- methoxypiperidin- 1 -yl)-4-methyl- 1 ,3-thiazole-5-carboxylic acid;
2-((3,S',4i?)-4-{[(3,4-dichloro-5-metliyl-lH-pyrrol-2-yl)carbonyl]amino}-3- methoxypiperidin- 1 -yl)- 1 ,3 -thiazole-5-carboxylic acid;
4-acetyl-2-((35',4i?)-4-{[(3,4-dichloro-5-methyl-lH-pyrrol-2-yl)carbonyl]amino}-3- methoxypiperidin- 1 -yl)- 1 ,3-thiazole-5 -carboxylic acid; 2-((35',4i?)-4-{[(3,4-dichloro-5-methyl-li/-pyrrol-2-yl)carbonyl]amino}-3- methoxypiperidin- 1 -yl)-4-( { [( 1 i-)-2-methoxy- 1 -methylethyl] amino } carbonyl)- 1 ,3 -thiazole-5- carboxylic acid;
2-((31S',4i-)-4-{[(3,4-dichloro-5-methyl-lH-pyrrol-2-yl)carbonyl]amino}-3- methoxypiperidin- 1 -yl)-4-( { [(25)-2-methoxypropyl]amino } carbonyl)- 1 ,3 -thiazole-5- carboxylic acid;
2-((35',4i?)-4-{[(3,4-dichloro-5-methyl-lH-pyrrol-2-yl)carbonyl]amino}-3- methoxypiperidin-l-yl)-4-({[(2i?)-2-methoxypropyl]amino}carbonyl)-l,3-thiazole-5- carboxylic acid;
2-((35,4i?)-4-{[(3,4-dichloro-5-methyl-l/f-ρyrrol-2-yl)carbonyl]amino}-3- methoxypiperidin-l-y^^-d^liJ^^^-fluorocyclopropylJaminoJcarbony^-l^-thiazole-S- carboxylic acid;
Cis(±)2-(4-{[(3,4-dichloro-5-methyl-lH-pyrrol-2-yl)carbonyl]amino}-3- methoxypiperidin- 1 -yl)- 1 ,3 -benzothiazole-7-carboxylic acid;
Cis(±)2-(4-{[(3,4-dichloro-5-methyl-lH-pyrrol-2-yl)carbonyl]amino}-3- methoxypiperidin-l-yl)-4-(methoxymethyl)-l,3-thiazole-5-carboxylic acid;
Cis(±)2-(4- { [(3 ,4-dichloro-5-methyl- 1 H-pyrrol-2-yl)carbonyl] amino } -3 - methoxypiperidin- 1 -yl)isonicotinic acid; 2-((3S,422)-4- { [(4-chloro-5-methyl- lH-pyrrol-2-yl)carbonyl] amino} -3- methoxypiperidin- 1 -yl)- 1 ,3-benzothiazole-7-carboxylic acid;
Cis(±)-2-(3-chloro-4-{[(3,4-dichloro-5-methyl-lH-pyrrol-2- yl)carbonyl]amino}piperidin-l-yl)-4-(methoxymethyl)-l,3-thiazole-5-carboxylic acid; 5 2-((3JS, 4i?)-4-{[(3,4-Dichloro-5-methyl-lH-pyrrol-2-yl)carbonyl]amino}-3- fluoropiperidin- 1 -yl)-4-methyl-l ,3-thiazole-5-carboxylic acid;
Cis(+)-2- [4- { [(3 ,4-dichloro-5-methyl- 1 H-pyrrol-2-yl)carbonyl]amino } -3 -(prop-2-yn- 1 -yloxy)piperidin- 1 -yl]- 1 ,3-thiazole-5-carboxylic acid;
Cis(±)2-((35',4i-)-4- { [(3 ,4-dichloro-5-methyl- 1 H-pyrrol-2-yl)carbonyl] amino } -3 - 10 fluoropiperidin-l-yl)-l,3-thiazole-4-carboxylic acid; or
2-((35',4i?)-4-{[(3,4-dichloro-5-methyl-lH"-pyrrol-2-yl)carbonyl]amino}-3- methoxypiperidin- 1 -yl)-4-( { [2-methoxy- 1 -(methoxymethyl)ethyl]amino} carbonyl)- 1,3- thiazole-5-carboxylic acid; or a pharmaceutically acceptable salt thereof. 15
9. A pharmaceutical composition that comprises a compound of claims 1-8 or a pharmaceutically-acceptable salt thereof, and a pharmaceutically-acceptable diluent or carrier.
10. A method of treating a bacterial infection in a warm-blooded animal, such as a human 20 being, in need of such treatment, which comprises administering to said animal an effective amount of a compound of claims 1-8, or a pharmaceutically-acceptable salt thereof.
11. A method for inhibiting bacterial DNA gyrase in a warm-blooded animal, such as a human being, in need of such treatment which comprises administering to said animal an
25 effective amount of a compound of claims 1-8 or a pharmaceutically acceptable salt.
12. A compound of claims 1-8 and pharmaceutically acceptable salts thereof for use as a medicament.
30 13. The use of a compound of claims 1-8 formula (I), or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for use in the production of an anti-bacterial effect in a warm-blooded animal such as a human being.
14. The use of a compound of claims 1-8 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for use in the treatment of a bacterial infection in a warm-blooded animal such as a human being.
15. A process for preparing compounds of formula (I) or pharmaceutically-acceptable salts thereof, comprising:
Process a) for compounds of formula (I) wherein W is -C(R )(R )-; converting a compound of formula (II):
Figure imgf000244_0001
(II) wherein Ra is cyano and Rb is dimethy amino or diethylamino; or Ra and Rb are independently selected from C1-4alkylthio; or Ra and Rb together form 1,3-dithianyl or 1,3-dithiolanyl; into a compound of formula (I);
Process b) for compounds of formula (I) wherein W is -O- ; reacting a compound of formula (III):
Figure imgf000244_0002
(III) with a compound of formula (IV):
Figure imgf000244_0003
(IV) Process c) for compounds of formula (I) wherein W is -N(R )-; reacting a compound of formula (V):
Figure imgf000245_0001
(V) with a compound of formula (IV) or an activated acid derivative thereof;
Process d) for compounds of formula (I) wherein W is -C(R7)(R8)-; reacting a compound of formula (VI):
(VI) wherein L is a displaceable group; with a compound of formula (VII):
Figure imgf000245_0003
(VII)
Process e) for compounds of formula (I) wherein W is ~C(R7)(R8)-; reacting a compound of formula (VIII):
Figure imgf000245_0004
(VIII) wherein M is an organometallic group; with a compound of formula (IX):
Figure imgf000245_0005
wherein L is a displaceable group;
Process/) reacting a compound of formula (X):
Figure imgf000246_0001
(X) with a compound of formula (XI) :
Figure imgf000246_0002
(XI) wherein D is a displaceable group;
Process g) for compounds of formula (I) wherein X is -C(O)-; reacting a compound of formula (X) with a compound of formula (XII) :
Figure imgf000246_0003
(XII) and thereafter if necessary: i) converting a compound of the formula (I) into another compound of the formula (I); ii) removing any protecting groups; iii) forming a pharmaceutically acceptable salt.
PCT/GB2006/000529 2005-02-18 2006-02-16 Antibacterial piperidine derivatives WO2006087543A1 (en)

Priority Applications (15)

Application Number Priority Date Filing Date Title
CN2006800130583A CN101163693B (en) 2005-02-18 2006-02-16 Antibacterial piperidine derivatives
BRPI0607756-0A BRPI0607756A2 (en) 2005-02-18 2006-02-16 compound or a pharmaceutically acceptable salt thereof, pharmaceutical composition, method for inhibiting bacterial DNA gyrase and / or topoisomerase iv in a warm-blooded animal, use of a compound or a pharmaceutically acceptable salt thereof, and process for preparing compounds or pharmaceutically acceptable salts thereof
MX2007010072A MX2007010072A (en) 2005-02-18 2006-02-16 Antibacterial piperidine derivatives.
ES06709766T ES2430569T3 (en) 2005-02-18 2006-02-16 Piperidine-derived antibacterial compounds
NZ561613A NZ561613A (en) 2005-02-18 2006-02-16 Antibacterial piperidine derivatives
US11/816,612 US8399489B2 (en) 2005-02-18 2006-02-16 Antibacterial piperdine derivatives
EP06709766.7A EP1853586B1 (en) 2005-02-18 2006-02-16 Antibacterial piperidine derivatives
KR1020137019849A KR101422432B1 (en) 2005-02-18 2006-02-16 Antibacterial piperidine derivatives
JP2007514146A JP4058106B2 (en) 2005-02-18 2006-02-16 Antibacterial piperidine derivatives
AU2006215399A AU2006215399B2 (en) 2005-02-18 2006-02-16 Antibacterial piperidine derivatives
CA2598423A CA2598423C (en) 2005-02-18 2006-02-16 Antibacterial piperidine derivatives
IL185306A IL185306A (en) 2005-02-18 2007-08-15 Antibacterial piperidine derivatives
NO20074703A NO20074703L (en) 2005-02-18 2007-09-14 Antibacterial piperidine derivatives
HK08102716.1A HK1114376A1 (en) 2005-02-18 2008-03-07 Antibacterial piperidine derivatives
US13/759,323 US20130150366A1 (en) 2005-02-18 2013-02-05 Chemical compounds

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65467005P 2005-02-18 2005-02-18
US60/654,670 2005-02-18

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/759,323 Continuation US20130150366A1 (en) 2005-02-18 2013-02-05 Chemical compounds

Publications (2)

Publication Number Publication Date
WO2006087543A1 true WO2006087543A1 (en) 2006-08-24
WO2006087543A8 WO2006087543A8 (en) 2007-10-18

Family

ID=36218455

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2006/000529 WO2006087543A1 (en) 2005-02-18 2006-02-16 Antibacterial piperidine derivatives

Country Status (22)

Country Link
US (2) US8399489B2 (en)
EP (1) EP1853586B1 (en)
JP (4) JP4058106B2 (en)
KR (2) KR101422432B1 (en)
CN (1) CN101163693B (en)
AR (1) AR053683A1 (en)
AU (1) AU2006215399B2 (en)
BR (1) BRPI0607756A2 (en)
CA (1) CA2598423C (en)
ES (1) ES2430569T3 (en)
HK (1) HK1114376A1 (en)
IL (1) IL185306A (en)
MX (1) MX2007010072A (en)
NO (1) NO20074703L (en)
NZ (1) NZ561613A (en)
RU (1) RU2424240C2 (en)
SA (1) SA06270020B1 (en)
TW (1) TWI402263B (en)
UA (1) UA94901C2 (en)
UY (1) UY29384A1 (en)
WO (1) WO2006087543A1 (en)
ZA (1) ZA200706920B (en)

Cited By (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008020229A2 (en) * 2006-08-17 2008-02-21 Astrazeneca Ab Antibacterial pyrrolecarboxamides
WO2008020222A1 (en) * 2006-08-17 2008-02-21 Astrazeneca Ab Pyrrole derivatives with antibacterial activity
WO2008020227A2 (en) * 2006-08-17 2008-02-21 Astrazeneca Ab Antibacterial pyrrolecarboxamides
WO2008084861A1 (en) 2007-01-12 2008-07-17 Astellas Pharma Inc. Condensed pyridine compound
WO2008152418A1 (en) * 2007-06-12 2008-12-18 Astrazeneca Ab Piperidine compounds and uses thereof
WO2009084614A1 (en) 2007-12-27 2009-07-09 Daiichi Sankyo Company, Limited Imidazole carbonyl compound
WO2010013222A1 (en) * 2008-07-30 2010-02-04 Ranbaxy Laboratories Limited Pyrrole carboxylic acid derivatives as antibacterial agents
US7709503B2 (en) 2003-09-13 2010-05-04 Astrazeneca Ab Pyrrol derivatives with antibacterial activity
WO2010067125A1 (en) 2008-12-12 2010-06-17 Astrazeneca Ab 2- (piperidin-1-yl) -4-azolyl-thiazole-5-carboxylic acid derivatives against bacterial infections
WO2010067123A1 (en) 2008-12-12 2010-06-17 Astrazeneca Ab 2- (piperidin-1-yl) -4-heterocyclyl-thiazole-5-carboxylic acid derivatives against bacterial infections
WO2010136817A1 (en) 2009-05-29 2010-12-02 Astrazeneca Ab Heterocyclic urea derivatives and methods of use thereof
WO2011024004A1 (en) 2009-08-26 2011-03-03 Astrazeneca Ab Heterocyclic urea derivatives useful for treatment of bacterial infection
US8124807B2 (en) * 2007-12-26 2012-02-28 Msd K.K. Sulfonyl-substituted 6-membered ring derivative
US8124602B2 (en) 2005-06-16 2012-02-28 Astrazeneca Ab Compounds for the treatment of multi-drug resistant bacterial infections
WO2012030944A2 (en) 2010-09-01 2012-03-08 Ambit Biosciences Corporation Quinoline and isoquinoline compounds and methods of use thereof
EP2511263A1 (en) 2011-04-14 2012-10-17 Phenex Pharmaceuticals AG Pyrrolo sulfonamide compounds for modulation of orphan nuclear receptor RAR-related orphan receptor-gamma (RORgamma, NR1F3) activity and for the treatment of chronic inflammatory and autoimmune diseases
WO2012143081A1 (en) 2011-04-18 2012-10-26 Merck Patent Gmbh Conjugated polymers
US8399489B2 (en) 2005-02-18 2013-03-19 Astrazeneca Ab Antibacterial piperdine derivatives
WO2013084241A1 (en) * 2011-12-09 2013-06-13 Cadila Healthcare Limited Compounds as inhibitors of renin
CN105067814A (en) * 2015-07-24 2015-11-18 中国科学院成都生物研究所 Helicase hydrolysis ATP activity determination method
WO2017056012A1 (en) 2015-09-30 2017-04-06 Daiichi Sankyo Company, Limited Hydroxyalkyl thiadiazole derivatives
WO2018019929A1 (en) 2016-07-28 2018-02-01 Idorsia Pharmaceuticals Ltd Piperidine cxcr7 receptor modulators
WO2018169092A1 (en) 2017-03-14 2018-09-20 Daiichi Sankyo Company, Limited N-phosphonoxymethyl prodrugs of hydroxyalkyl thiadiazole derivatives
WO2018174288A1 (en) 2017-03-24 2018-09-27 大正製薬株式会社 2(1h)-quinolinone derivative
WO2019145460A1 (en) 2018-01-26 2019-08-01 Idorsia Pharmaceuticals Ltd Crystalline forms of the cxcr7 receptor antagonist (3s,4s)-1-cyclopropylmethyl-4-{[5-(2,4-difluoro-phenyl)-isoxazole-3-carbonyl]-amino}-piperidine-3-carboxylic acid (1-pyrimidin-2-yl-cyclopropyl)-amide
WO2020048949A1 (en) 2018-09-03 2020-03-12 Univerza V Ljubljani New class of dna gyrase and/or topoisomerase iv inhibitors with activity against gram-positive and gram-negative bacteria
WO2022129327A1 (en) 2020-12-17 2022-06-23 Univerza V Ljubljani New n-phenylpyrrolamide inhibitors of dna gyrase and topoisomerase iv with antibacterial activity

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008531673A (en) * 2005-03-04 2008-08-14 アストラゼネカ アクチボラグ Tricyclic derivatives of azetidine and pyrrole with antibacterial activity
CA3041868C (en) * 2008-10-09 2023-03-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Bis sulfonamide piperazinyl and piperidinyl activators of human pyruvatekinase
SI2381778T1 (en) * 2008-12-22 2016-10-28 Chemocentryx, Inc. C5ar antagonists
CA2758071C (en) 2009-04-06 2018-01-09 Agios Pharmaceuticals, Inc. Pyruvate kinase m2 modulators, therapeutic compositions and related methods of use
PL2427441T3 (en) 2009-05-04 2017-06-30 Agios Pharmaceuticals, Inc. Pkm2 activators for use in the treatment of cancer
IN2012DN00471A (en) 2009-06-29 2015-06-05 Agios Pharmaceuticals Inc
JP5764555B2 (en) 2009-06-29 2015-08-19 アジオス ファーマシューティカルズ， インコーポレイテッド Therapeutic compositions and related methods of use
EP2563761A1 (en) 2010-04-29 2013-03-06 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Activators of human pyruvate kinase
DK2585064T3 (en) 2010-06-24 2017-07-24 Chemocentryx Inc C5aR antagonists
JP5837091B2 (en) 2010-12-17 2015-12-24 アジオス ファーマシューティカルズ， インコーポレイテッド Novel N- (4- (azetidine-1-carbonyl) phenyl)-(hetero-) arylsulfonamide derivatives as modulators of pyruvate kinase M2 (PKM2)
ES2569712T3 (en) 2010-12-21 2016-05-12 Agios Pharmaceuticals, Inc. PKM2 bicyclic activators
TWI549947B (en) 2010-12-29 2016-09-21 阿吉歐斯製藥公司 Therapeutic compounds and compositions
RU2675656C2 (en) 2011-05-03 2018-12-21 Аджиос Фармасьютикалз, Инк. Pyruvate kinase activators for use in therapy
CA2861020C (en) * 2012-02-02 2018-07-17 Actelion Pharmaceuticals Ltd 4-(benzoimidazol-2-yl)-thiazole compounds and related aza derivatives and their use as cxcr3 receptor modulators
ES2671323T3 (en) * 2013-07-22 2018-06-06 Idorsia Pharmaceuticals Ltd Derivatives 1¿ (piperazin¿1¿il) ¿2¿ ([1,2,4] triazol¿1¿il) ¿ethanone
ES2776395T3 (en) 2014-07-24 2020-07-30 Grace W R & Co Crystalline form of nicotinamide riboside
ES2926828T3 (en) 2014-09-29 2022-10-28 Chemocentryx Inc Processes and intermediates in the preparation of C5aR antagonists
WO2016144660A1 (en) 2015-03-09 2016-09-15 W.R. Grace & Co.-Conn. Crystalline form of nicotinamide riboside
DK3307271T3 (en) 2015-06-11 2023-10-09 Agios Pharmaceuticals Inc METHODS OF USING PYRUVATE KINASE ACTIVATORS
BR122024002810A2 (en) 2016-01-14 2024-03-12 Chemocentryx, Inc. USES OF C5AR ANTAGONIST COMPOUND
CN112020363A (en) 2017-12-22 2020-12-01 益力舒健康公司 Crystalline forms of nicotinamide riboside chloride
CN115466246B (en) * 2021-06-11 2024-02-06 中国医学科学院药物研究所 Pyrrole amide piperidine amine compound and application thereof
CN115612309B (en) * 2022-10-14 2023-07-21 浙江博澳新材料股份有限公司 Double-heterocycle diester azo disperse dye and preparation method thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004089947A2 (en) * 2003-04-08 2004-10-21 Morphochem Ag Novel compounds having an antibacterial activity
WO2005026149A1 (en) * 2003-09-13 2005-03-24 Astrazeneca Ab Pyrrol derivatives with antibacterial activity

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL23847A (en) 1964-08-07 1969-02-27 Merck & Co Inc Benzimidazoles useful as antifungals
US3963480A (en) 1973-04-11 1976-06-15 Sterling Drug Inc. Herbicidal pyrrole-2-carboxamides
US4046775A (en) 1973-04-11 1977-09-06 Sterling Drug Inc. 4,5-Dihalopyrrole-2-carboxamides
US4912109A (en) 1987-02-02 1990-03-27 Boc, Inc. N-heterocyclic-N-(4-piperidinyl) amides and pharmaceutical compositions and methods employing such compounds
US4791112A (en) 1987-02-02 1988-12-13 The Boc Group, Inc. N-heterocyclic-N-(4-piperidyl)amides and pharmaceutical compositions and methods employing such compounds
US5739135A (en) 1993-09-03 1998-04-14 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
FR2766488B1 (en) 1997-07-23 2000-02-18 Hoechst Marion Roussel Inc NOVEL AROMATIC DERIVATIVES SUBSTITUTED BY RIBOSIS, PROCESS FOR THEIR PREPARATION AND THEIR APPLICATION AS MEDICAMENTS
AU2437900A (en) * 1999-01-20 2000-08-07 Smithkline Beecham Plc Piperidinylquinolines as protein tyrosine kinase inhibitors
US7629360B2 (en) * 1999-05-07 2009-12-08 Celgene Corporation Methods for the treatment of cachexia and graft v. host disease
JP2003104971A (en) 1999-08-12 2003-04-09 Wakunaga Pharmaceut Co Ltd New anilide derivative or salt thereof, and medicine containing the same
EP1251849A1 (en) 2000-01-18 2002-10-30 Vertex Pharmaceuticals Incorporated Gyrase inhibitors and uses thereof
EP1251848B1 (en) 2000-01-18 2004-06-23 Vertex Pharmaceuticals Incorporated Gyrase inhibitors and uses thereof
TWI284639B (en) 2000-01-24 2007-08-01 Shionogi & Co A compound having thrombopoietin receptor agonistic effect
AU2001269821A1 (en) 2000-06-15 2001-12-24 Barbara Chen Cycloalkyl alkanoic acids as integrin receptor antagonists
US6964966B2 (en) 2001-04-25 2005-11-15 Wockhardt Limited Generation triple-targeting, chiral, broad-spectrum antimicrobial 7-substituted piperidino-quinolone carboxylic acid derivatives, their preparation, compositions and use as medicaments
DOP2002000386A (en) 2001-05-30 2002-12-15 Warner Lambert Co ANTIBACTERIAL AGENTS
IL160253A0 (en) 2001-08-09 2004-07-25 Ono Pharmaceutical Co Carboxylic acid derivative compounds and drugs comprising these compounds as the active ingredient
AU2002356689B2 (en) 2001-12-05 2008-05-15 Sanofi-Aventis Deutschland Gmbh Substituted 4-phenyltetrahydroisoquinolines, method for the production thereof, the use thereof as medicaments, in addition to a medicament containing same
AR038536A1 (en) 2002-02-25 2005-01-19 Upjohn Co N-ARIL-2-OXAZOLIDINONA-5- CARBOXAMIDS AND ITS DERIVATIVES
US7183276B2 (en) 2002-02-28 2007-02-27 Takeda Pharmaceutical Company Limited Azole compounds
AR040336A1 (en) 2002-06-26 2005-03-30 Glaxo Group Ltd PIPERIDINE COMPOUND, USE OF THE SAME FOR THE MANUFACTURE OF A MEDICINAL PRODUCT, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND PROCEDURE TO PREPARE SUCH COMPOUND
AP1979A (en) * 2002-09-20 2009-03-20 Lupin Ltd Pyrrole derivatives as antimycobacterial compounds
US7135469B2 (en) 2003-03-18 2006-11-14 Bristol Myers Squibb, Co. Linear chain substituted monocyclic and bicyclic derivatives as factor Xa inhibitors
JPWO2004089954A1 (en) 2003-04-08 2006-07-06 大日本住友製薬株式会社 New carbapenem compounds
SE0302116D0 (en) 2003-07-21 2003-07-21 Astrazeneca Ab Novel compounds
US7094791B2 (en) * 2003-07-31 2006-08-22 Avalon Pharmaceuticals, Inc. Derivatives of 3-hydroxy-pyrrole-2,4-dicarboxylic acid and uses thereof
GB0325956D0 (en) 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
US20050197336A1 (en) 2004-03-08 2005-09-08 Miikana Therapeutics Corporation Inhibitors of histone deacetylase
US7345043B2 (en) 2004-04-01 2008-03-18 Miikana Therapeutics Inhibitors of histone deacetylase
WO2006030975A1 (en) 2004-09-17 2006-03-23 Takeda Pharmaceutical Company Limited Piperidine derivatives and use thereof
AU2005299501B2 (en) 2004-10-22 2011-03-03 Janssen Pharmaceutica N.V. Aromatic amides as inhibitors of c-fms kinase
HUE033089T2 (en) 2004-10-22 2017-11-28 Janssen Pharmaceutica Nv Inhibitors of c-fms kinase
KR101422432B1 (en) * 2005-02-18 2014-07-22 아스트라제네카 아베 Antibacterial piperidine derivatives
EP1856103A2 (en) 2005-02-18 2007-11-21 AstraZeneca AB Pyrrole derivatives as dna gyrase and topoisomerase inhibitors
JP2008530193A (en) 2005-02-18 2008-08-07 アストラゼネカ アクチボラグ Compound
JP2008531671A (en) 2005-03-04 2008-08-14 アストラゼネカ アクチボラグ Compound
JP2008531673A (en) 2005-03-04 2008-08-14 アストラゼネカ アクチボラグ Tricyclic derivatives of azetidine and pyrrole with antibacterial activity
US8071065B2 (en) * 2005-03-31 2011-12-06 Touchstone Research Laboratory, Ltd High density carbon foam composite tooling
CA2633563A1 (en) 2005-12-23 2007-06-28 Astrazeneca Ab Antibacterial pyrrolopyridines, pyrrolopyrimidines, and pyrroloazepines
TW200819437A (en) 2006-08-17 2008-05-01 Astrazeneca Ab Chemical compounds
TW200906412A (en) * 2007-06-12 2009-02-16 Astrazeneca Ab Piperidine compounds and uses thereof
TW201026695A (en) * 2008-12-12 2010-07-16 Astrazeneca Ab Piperidine compounds and uses thereof-596

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004089947A2 (en) * 2003-04-08 2004-10-21 Morphochem Ag Novel compounds having an antibacterial activity
WO2005026149A1 (en) * 2003-09-13 2005-03-24 Astrazeneca Ab Pyrrol derivatives with antibacterial activity

Cited By (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7709503B2 (en) 2003-09-13 2010-05-04 Astrazeneca Ab Pyrrol derivatives with antibacterial activity
US8399489B2 (en) 2005-02-18 2013-03-19 Astrazeneca Ab Antibacterial piperdine derivatives
US8124602B2 (en) 2005-06-16 2012-02-28 Astrazeneca Ab Compounds for the treatment of multi-drug resistant bacterial infections
WO2008020222A1 (en) * 2006-08-17 2008-02-21 Astrazeneca Ab Pyrrole derivatives with antibacterial activity
WO2008020227A2 (en) * 2006-08-17 2008-02-21 Astrazeneca Ab Antibacterial pyrrolecarboxamides
WO2008020229A3 (en) * 2006-08-17 2008-04-03 Astrazeneca Ab Antibacterial pyrrolecarboxamides
WO2008020227A3 (en) * 2006-08-17 2008-04-24 Astrazeneca Ab Antibacterial pyrrolecarboxamides
WO2008020229A2 (en) * 2006-08-17 2008-02-21 Astrazeneca Ab Antibacterial pyrrolecarboxamides
WO2008084861A1 (en) 2007-01-12 2008-07-17 Astellas Pharma Inc. Condensed pyridine compound
JP2010529184A (en) * 2007-06-12 2010-08-26 アストラゼネカ アクチボラグ Piperidine compounds and their use
CN102648199A (en) * 2007-06-12 2012-08-22 阿斯利康(瑞典)有限公司 Piperidine compounds and uses thereof
WO2008152418A1 (en) * 2007-06-12 2008-12-18 Astrazeneca Ab Piperidine compounds and uses thereof
US8124807B2 (en) * 2007-12-26 2012-02-28 Msd K.K. Sulfonyl-substituted 6-membered ring derivative
WO2009084614A1 (en) 2007-12-27 2009-07-09 Daiichi Sankyo Company, Limited Imidazole carbonyl compound
JP5586234B2 (en) * 2007-12-27 2014-09-10 第一三共株式会社 Imidazolecarbonyl compounds
US8536197B2 (en) 2007-12-27 2013-09-17 Daiichi Sankyo Company, Limited Imidazole carbonyl compound
US8927588B2 (en) 2007-12-27 2015-01-06 Daiichi Sankyo Company, Limited Imidazole carbonyl compound
WO2010013222A1 (en) * 2008-07-30 2010-02-04 Ranbaxy Laboratories Limited Pyrrole carboxylic acid derivatives as antibacterial agents
WO2010067125A1 (en) 2008-12-12 2010-06-17 Astrazeneca Ab 2- (piperidin-1-yl) -4-azolyl-thiazole-5-carboxylic acid derivatives against bacterial infections
US8071605B2 (en) 2008-12-12 2011-12-06 Astrazeneca Ab Piperidine compounds for use in the treatment of bacterial infections
WO2010067123A1 (en) 2008-12-12 2010-06-17 Astrazeneca Ab 2- (piperidin-1-yl) -4-heterocyclyl-thiazole-5-carboxylic acid derivatives against bacterial infections
WO2010136817A1 (en) 2009-05-29 2010-12-02 Astrazeneca Ab Heterocyclic urea derivatives and methods of use thereof
WO2011024004A1 (en) 2009-08-26 2011-03-03 Astrazeneca Ab Heterocyclic urea derivatives useful for treatment of bacterial infection
WO2012030944A2 (en) 2010-09-01 2012-03-08 Ambit Biosciences Corporation Quinoline and isoquinoline compounds and methods of use thereof
WO2012139775A1 (en) 2011-04-14 2012-10-18 Phenex Pharmaceuticals Ag Pyrrolo sulfonamide compounds for modulation of orphan nuclear receptor rar-related orphan receptor-gamma (rorgamma, nr1f3) activity and for the treatment of chronic inflammatory and autoimmune diseases
EP2511263A1 (en) 2011-04-14 2012-10-17 Phenex Pharmaceuticals AG Pyrrolo sulfonamide compounds for modulation of orphan nuclear receptor RAR-related orphan receptor-gamma (RORgamma, NR1F3) activity and for the treatment of chronic inflammatory and autoimmune diseases
US8946446B2 (en) 2011-04-14 2015-02-03 Phenex Pharmaceuticals Ag Pyrrolo sulfonamide compounds for modulation of orphan nuclear receptor RAR-related orphan receptor-γ (ROR-γ, NR1F3) activity and for the treatment of chronic inflammatory and autoimmune diseases
WO2012143081A1 (en) 2011-04-18 2012-10-26 Merck Patent Gmbh Conjugated polymers
WO2013084241A1 (en) * 2011-12-09 2013-06-13 Cadila Healthcare Limited Compounds as inhibitors of renin
CN105067814A (en) * 2015-07-24 2015-11-18 中国科学院成都生物研究所 Helicase hydrolysis ATP activity determination method
WO2017056012A1 (en) 2015-09-30 2017-04-06 Daiichi Sankyo Company, Limited Hydroxyalkyl thiadiazole derivatives
US10752620B2 (en) 2016-07-28 2020-08-25 Idorsia Pharmaceuticals Ltd. Piperdine CXCR7 receptor modulators
US11306078B2 (en) 2016-07-28 2022-04-19 Idorsia Pharmaceuticals Ltd. Piperidine CXCR7 receptor modulators
CN109563085B (en) * 2016-07-28 2022-08-09 爱杜西亚药品有限公司 Piperidine CXCR7 receptor modulators
CN109563085A (en) * 2016-07-28 2019-04-02 爱杜西亚药品有限公司 Piperidines CXCR7 receptor modulators
CN110563717B (en) * 2016-07-28 2022-08-09 爱杜西亚药品有限公司 Piperidine CXCR7 receptor modulators
AU2020204578B2 (en) * 2016-07-28 2022-03-10 Idorsia Pharmaceuticals Ltd Piperidine cxcr7 receptor modulators
CN110563717A (en) * 2016-07-28 2019-12-13 爱杜西亚药品有限公司 piperidine CXCR7receptor modulators
AU2017302079B2 (en) * 2016-07-28 2021-07-22 Idorsia Pharmaceuticals Ltd Piperidine CXCR7 receptor modulators
WO2018019929A1 (en) 2016-07-28 2018-02-01 Idorsia Pharmaceuticals Ltd Piperidine cxcr7 receptor modulators
EP3798217A1 (en) 2016-07-28 2021-03-31 Idorsia Pharmaceuticals Ltd Piperidine cxcr7 receptor modulators
EA037507B1 (en) * 2016-07-28 2021-04-06 Идорсия Фармасьютиклз Лтд Piperidine cxcr7 receptor modulators
WO2018169092A1 (en) 2017-03-14 2018-09-20 Daiichi Sankyo Company, Limited N-phosphonoxymethyl prodrugs of hydroxyalkyl thiadiazole derivatives
KR20190133667A (en) 2017-03-24 2019-12-03 다이쇼 세이야꾸 가부시끼가이샤 2 (1H) -quinolinone derivative
WO2018174288A1 (en) 2017-03-24 2018-09-27 大正製薬株式会社 2(1h)-quinolinone derivative
US11339148B2 (en) 2018-01-26 2022-05-24 Idorsia Pharmaceuticals Ltd. Crystalline forms of the CXCR7 receptor antagonist (3S,4S)-1-Cyclopropylmethyl-4-{[5-(2,4-difluoro-phenyl)-isoxazole-3-carbonyl]-amino}-piperidine-3-carboxylic acid (1-pyrimidin-2-yl-cyclopropyl)-amide
WO2019145460A1 (en) 2018-01-26 2019-08-01 Idorsia Pharmaceuticals Ltd Crystalline forms of the cxcr7 receptor antagonist (3s,4s)-1-cyclopropylmethyl-4-{[5-(2,4-difluoro-phenyl)-isoxazole-3-carbonyl]-amino}-piperidine-3-carboxylic acid (1-pyrimidin-2-yl-cyclopropyl)-amide
WO2020048949A1 (en) 2018-09-03 2020-03-12 Univerza V Ljubljani New class of dna gyrase and/or topoisomerase iv inhibitors with activity against gram-positive and gram-negative bacteria
WO2022129327A1 (en) 2020-12-17 2022-06-23 Univerza V Ljubljani New n-phenylpyrrolamide inhibitors of dna gyrase and topoisomerase iv with antibacterial activity

Also Published As

Publication number Publication date
JP2008024715A (en) 2008-02-07
NO20074703L (en) 2007-11-14
US8399489B2 (en) 2013-03-19
JP2007326882A (en) 2007-12-20
BRPI0607756A2 (en) 2010-05-18
TW200640908A (en) 2006-12-01
WO2006087543A8 (en) 2007-10-18
TWI402263B (en) 2013-07-21
CA2598423A1 (en) 2006-08-24
US20100179150A1 (en) 2010-07-15
SA06270020B1 (en) 2010-10-23
IL185306A0 (en) 2008-02-09
US20130150366A1 (en) 2013-06-13
CN101163693A (en) 2008-04-16
AU2006215399B2 (en) 2010-12-09
IL185306A (en) 2012-05-31
RU2007134380A (en) 2009-03-27
JP2007326883A (en) 2007-12-20
ZA200706920B (en) 2008-06-25
UA94901C2 (en) 2011-06-25
RU2424240C2 (en) 2011-07-20
HK1114376A1 (en) 2008-10-31
AR053683A1 (en) 2007-05-16
ES2430569T3 (en) 2013-11-21
EP1853586A1 (en) 2007-11-14
JP4058106B2 (en) 2008-03-05
KR20070113233A (en) 2007-11-28
NZ561613A (en) 2010-12-24
KR101422432B1 (en) 2014-07-22
CN101163693B (en) 2013-03-06
MX2007010072A (en) 2008-01-28
KR20130093174A (en) 2013-08-21
JP2008500321A (en) 2008-01-10
AU2006215399A1 (en) 2006-08-24
CA2598423C (en) 2014-05-27
EP1853586B1 (en) 2013-07-24
UY29384A1 (en) 2006-10-02

Similar Documents

Publication Publication Date Title
AU2006215399B2 (en) Antibacterial piperidine derivatives
AU2004272338B2 (en) Pyrrol derivatives with antibacterial activity
US20080269214A1 (en) Pyrrole Derivatives as Dna Gyrase and Topoisomerase Inhibitors
NZ578159A (en) Antibacterial polycyclic urea compounds
WO2008020227A2 (en) Antibacterial pyrrolecarboxamides
EP2064209A1 (en) Pyrrole derivatives with antibacterial activity
US20080312211A1 (en) Antibacterial Pyrrolopyridines, Pyrrolopyrimidines and Pyrroloazepines-154
WO2008020229A2 (en) Antibacterial pyrrolecarboxamides
WO2009027732A1 (en) 5-6-bicyclic heteroaromatic compounds with antibacterial activity
AU2009326141A1 (en) 2- (piperidin-1-yl) -4-heterocyclyl-thiazole-5-carboxylic acid derivatives against bacterial infections
WO2006092608A1 (en) Tricyclic derivatives of azetidine and pyrrole with antibacterial activity
EP1856103A2 (en) Pyrrole derivatives as dna gyrase and topoisomerase inhibitors
EP2313402A1 (en) Heterocyclic urea derivatives and methods of use thereof

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 2007514146

Country of ref document: JP

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 185306

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2598423

Country of ref document: CA

Ref document number: 2006215399

Country of ref document: AU

Ref document number: MX/a/2007/010072

Country of ref document: MX

Ref document number: 12007501775

Country of ref document: PH

Ref document number: 2007/06920

Country of ref document: ZA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 6591/DELNP/2007

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2006709766

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2006215399

Country of ref document: AU

Date of ref document: 20060216

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2006215399

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 561613

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2007134380

Country of ref document: RU

Ref document number: 1020077021453

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 200680013058.3

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2006709766

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 11816612

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0607756

Country of ref document: BR

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 1020137019849

Country of ref document: KR